CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN L11/GTPASE ACTIVATING REGION rRNA AND USES THEREOF

Abstract: The present invention is broadly directed to methods of screening ribosomal protein L11/GTPase activating region (GAR) RNA-modulating compounds by using information from the high-resolution structure of the L11/GAR complex. The methods are useful in identifying compounds useful for anti-bacterial treatments.

Description: CRYSTAL STRUCTURE OF RIBOSOMAL PROTEIN Lll/GTPASE ACTIVATING REGION rRNA AND USES THEREOF TECHNICAL FIELD OF THE INVENTION The present invention relates to methods of screening for compounds that inhibit or activate bacterial growth by binding to the complex formed between ribosomal protein Ll l and the 23 S ribosomal RNA region that interacts with it in vivo. BACKGROUND The elongation cycle of protein synthesis is driven by two elongation factors that bind to nearly identical sites on the large (50S) ribosomal subunit (Spahn and Nierhaus, 1998; Wilson and Noller, 1998). EF-Tu delivers aminoacyl tRNAs to the ribosome, whereas EF-G catalyzes the translocation of the ribosome by one codon relative to the mRNA and the concomitant movement of the A and P site tRNAs. Both elongation factors are G proteins, and their interactions with the ribosome are coupled to the binding and hydrolysis of GTP. Like most G proteins, EF-Tu and EF-G are molecular switches that have limited inherent GTPase activity, and they rely on an accessory factor to stimulate activity at the appropriate time. This accessory factor is an integral part of the 50S ribosomal subunit and has usually been referred to as the "GTPase center," but by analogy with the functionally equivalent GAP proteins that stimulate GTPase activity in G-proteins, it seems more appropriate to refer to it as the "GTPase activating region" (hereafter abbreviated as the GAR). Early work on the identification of the molecular components of the GAR implicated a complex between ribosomal protein LI 1 and a highly conserved 58-nucleotide stretch of 23 S ribosomal RNA (rRNA), nucleotides 1051-1108 in Escherichia coli (Schmidt et al., 1981; Thompson et al., 1979). The LI 1 -RNA complex is the target for a family of thiazole antibiotics that includes thiostrepton and micrococcin. Thiostrepton binds essentially irreversibly to 5 OS subunits (Sopori and Lengyel, 1972) and inhibits hydrolysis of GTP by EF-G (Pestka, 1970; Rodnina et al., 1997), while micrococcin binds to the same complex and stimulates GTP hydrolysis by EF-G (Cundliffe and - 1- SϋBSTTTUTES Thompson, 1981). Other components of the ribosome have also been implicated in stimulation of GTP hydrolysis by elongation factors. Classical work suggested that protein L7/L12, which together with L10 forms the "stalk" of the 50S subunit that lies adjacent to Ll l, is involved in stimulation of GTPase activity in EF-Tu (Dormer et al., 1978). However, recently it has been shown that protein L7/L12, although essential for stalk formation, is not required for viability in yeast (Briones et al., 1998). The sarcin/ricin loop, a small, highly conserved stem-loop in the 23S rRNA that is known to be essential for ribosome function, has been footprinted by the elongation factors (Moazed et al., 1988), and is also considered a candidate for being part of the GAR. Therefore, it is not yet clear whether the LI 1-RNA complex er se should be considered the GAR, or whether the GAR should be defined as a more extensive region of the 50S subunit. In any event, it appears that the LI 1-RNA complex is at the heart of the GAR; the complex of LI 1 with its cognate RNA will be referred to herein as the GAR. The GAR is one of the most thoroughly characterized RNA-protein complexes. The secondary structure of the RNA was first inferred from biochemical and genetic studies (Glotz et al., 1981; Noller et al., 1981). It consists of a junction of four double-helical stems (Figure 1A). Approximately one-third of the residues in the GAR RNA are very highly conserved. The structure, thermodynamic stability, and ion-binding affinities of the RNA component have been extensively probed by a variety of biophysical and biochemical techniques; these data suggest that the 1067 and 1095 stem-loops are folded into a compact tertiary structure (Conn et al., 1998; Rosendahl and Douthwaite, 1994). Protein Ll l consists of two domains: the C-terminal domain binds tightly to the RNA tertiary structure, while the N-terminal domain is required for the cooperative interaction with thiostrepton (Xing and Draper, 1996). The structure of the C-terminal domain has been determined by NMR techniques (Hinck et al., 1997; Markus et al., 1997). Footprinting studies (Rosendahl and Douthwaite, 1993) have identified regions of RNA involved in the interaction with Ll l, while NMR chemical shift measurements (Hinck et al., 1997) have identified an RNA-binding surface on the C-terminal domain of the protein. It is an object of the invention to provide a detailed view of a functionally important protein- RNA complex in the ribosome. It is also an object of the invention to provide a high-resolution structure of a ribosomal protein-RNA complex. Yet another object of the invention is to provide new principles of RNA folding, of RNA- protein recognition, and of indirect RNA tertiary structure stabilization. Yet another object of the invention is to solve the three dimensional structure of Ll l complexed with GAR RNA and to determine its structure coordinates. SUMMARY OF THE INVENTION The present invention is broadly directed to methods of screening ribosomal protein LI 1 /GTPase activating region (GAR) RNA-modulating compounds by using information from the high-resolution structure of the LI 1/GAR complex. The invention encompasses use of the structure coordinates of an LI 1/GAR crystal to define the atomic details of regions of the LI 1/GAR complex, such as the GTPase activating region and one or more binding sites of accessory factors, which are target sites for inhibitors or activators. The invention also encompasses use of the structure coordinates and atomic details of the LI 1/GAR RNA complex or its co-complexes to design, evaluate computationally, synthesize and use inhibitors or activators of the LI 1/GAR. Structure coordinates for LI 1/GAR RNA complex according to Table II may be modified from this original set by mathematical manipulation. Such manipulations include, but are not limited to , crystallographic permutations, fractionalizations, or inversion of the raw structure coordinates, integer additions or subtractions to sets of the raw structure coordinates, and any combination of the above. The crystal structure of the GAR allows the screening and design of novel classes of GAR - 3- SUB$niuTESHEET RULE26 inhibitory or activating compounds with great medical potential, for example, to prevent or stimulate growth of certain bacteria. The invention encompasses a method for identifying a potential modulator of ribosomal protein LI 1/GAR activity, comprising the steps of: a) using a three-dimensional structure of the LI 1/GAR complex as defined by atomic coordinates of the LI 1/GAR according to FIG. 7; b) employing the three-dimensional structure to design or select the potential modulator; c) providing the potential modulator; and d) contacting the potential modulator with LI 1/GAR in the presence of an activity to determine the ability of the potential modulator to modulate the activity, for example, LI 1/GAR activity. In one embodiment of the invention, the potential modulator is designed de novo. In another embodiment of the invention, the potential modulator is designed from a known modulator. In another emdodiment of the invention, the step of employing the three-dimensional structure to design or select the compound comprises the steps of: a) identifying chemical entities or fragments capable of associating with the LI 1/GAR; and b) assembling the identified chemical entities or fragments into a single molecule to provide the structure of the potential modulator. Relative to this embodiment, the potential modulator may be designed de novo or designed from a known modulator. The invention further encompasses a method for screening LI 1/GAR-binding compounds comprising the steps of: 1) incubating in vitro one or more compounds, a known LI 1/GAR binding activity and labeled RNA comprising GAR RNA; 2) separating that fraction of the labeled RNA bound to the known LI 1/GAR binding activity from that fraction of the labeled RNA not bound to the known LI 1/GAR binding activity; and 3) detecting labeled RNA, wherein a decrease in the level of the labeled RNA bound to the known LI 1/GAR binding activity in the presence of one or more compounds indicates the binding of one or more of the compounds to LI 1/GAR. The invention further encompasses a method for screening LI 1/GAR-binding compounds - 4- SUBSTITUTE SHET(RULE26) comprising the steps of: 1) incubating in vitro one or more compounds, a labeled known LI 1/GAR binding activity and an RNA comprising GAR RNA; 2) separating that fraction of the labeled known Ll l/GAR binding activity bound to the RNA from that fraction of the labeled known Ll l/GAR binding activity not bound to the RNA; and 3) detecting labeled known Ll l/GAR binding activity wherein a decrease in the level of the labeled known Ll l/GAR binding activity bound to the RNA in the presence of one or more compounds indicates that one or more of the compounds binds LI 1/GAR. In one embodiment of the the method of screening LI 1/GAR-binding compounds, the known Ll l/GAR binding activity is an antibiotic. In another embodiment the antibiotic is micrococcin. In a prefeoed embodiment the antibiotic is thiostrepton. In another embodiment of the method of screening LI 1/GAR-binding compounds, the RNA comprising GAR RNA is contained within a ribosome. In another embodiment of the method of screening LI 1/GAR-binding compounds, a plurality of compounds is screened for LI 1/GAR binding in a plurality of separate, simultaneous assays. The invention further encompasses a method for screening LI 1/GAR-binding compounds comprising the steps of: 1) incubating in vitro one or more compounds with a translationally competent cell extract and a translatable RNA; and 2) detecting translation, wherein a decrease in the level of translation indicates binding of one or more of the compounds to LI 1/GAR. In one embodiment, the translatable RNA encodes an enzyme and the step of detecting translation comprises detecting the activity of the enzyme. In a preferred embodiment, the enzyme is luciferase. In another embodiment, the translatable RNA is poly-U, and the step of detecting transktic-n detects the incorporation of labeled phenylalanine into polyphenylalanine. In another embodiment, the translationally competent cell extract comprises isolated ribosomes. The invention further encompasses a method for screening LI 1/GAR-binding compounds comprising the steps of: 1) incubating in vitro one or more compounds, isolated 70S ribosomes, isolated EF-G and gamma-labeled GTP; and 2) detecting GTP hydrolysis wherein a decrease in GTP hydrolysis indicates one or more of the compounds binds LI 1/GAR. The invention further encompasses a method for screening anti-bacterial compounds comprising the steps of: 1) incubating in vitro one or more compounds, a known LI 1/GAR binding activity and labeled RNA comprising GAR RNA; 2) separating that fraction of the labeled RNA bound to the known LI 1/GAR binding activity from that fraction of the labeled RNA not bound to the known LI 1/GAR binding activity; and 3) detecting labeled RNA, wherein a decrease in the level of the labeled RNA bound to the known LI 1/GAR binding activity in the presence of one or more compounds indicates that one or more of the compounds has anti -bacterial properties. The invention further encompasses a method for screening anti-bacterial compounds comprising the steps of: 1) incubating in vitro one or more compounds, a labeled known LI 1/GAR binding activity and an RNA comprising GAR RNA; 2) separating that fraction of the labeled known Ll l/GAR binding activity bound to the RNA from that fraction of the labeled known Ll l/GAR binding activity not bound to the RNA; and 3) detecting labeled known Ll l/GAR binding activity wherein a decrease in the level of the labeled known Ll l/GAR binding activity bound to the RNA in the presence of one or more compounds indicates that one or more of the compounds has anti-bacterial properties. In one embodiment of the the method of screening anti-bacterial compounds, the known LI 1/GAR binding activity is an antibiotic. In another embodiment the antibiotic is micrococcin. In a preferred embodiment the antibiotic is thiostrepton. In another embodiment of the method of screening anti-bacterial compounds, the RNA comprising GAR RNA is contained within a ribosome. In another embodiment of the method of screening anti -bacterial compounds, a plurality of compounds is screened for LI 1/GAR binding in a plurality of separate, simultaneous assays. - 6- SU8SπTUTESHEET RULE26 The invention further encompasses a method for screening anti-bacterial compounds comprising the steps of: 1) incubating in vitro one or more compounds with a translationally competent cell extract and a translatable RNA; and 2) detecting translation, wherein a decrease in the level of translation indicates that one or more of the compounds has anti-bacterial properties. In one embodiment, the translatable RNA encodes an enzyme and the step of detecting translation comprises detecting the activity of the enzyme. In a preferred embodiment, the enzyme is luciferase. In another embodiment, the translatable RNA is poly-U, and the step of detecting translation detects the incorporation of labeled phenylalanine into polyphenylalanine. In another embodiment, the translationally competent cell extract comprises isolated ribosomes. The invention further encompasses a method for screening anti-bacterial compounds comprising the steps of: 1) incubating in vitro one or more compounds, isolated 70S ribosomes, isolated EF-G and gamma-labeled GTP; and 2) detecting GTP hydrolysis wherein a decrease in GTP hydrolysis indicates that one or more of the compounds has anti-bacterial properties. Further features and advantages of the invention are embodied in the following description of the invention and in the claims. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows an overview of the secondary and tertiary structure of the GTPase activating region RNA from Thermotoga maritima: a) RNA secondary structure derived from the crystal structure. Lines indicate long-range base triples and the long-range 1088-1060 base pair; b) ribbon-and-stick schematic of the RNA tertiary structure (For clarity, protein Ll l has been omitted from view); c) same as (b), but the view is down the major groove of the 1095 stem to emphasize the compactness of the RNA fold. Figures lb and lc were made with the program RIBBONS (Carson, 1991). Figure 2 shows selected details of the tertiary structure of the GTPase activating region RNA from Thermotoga maritima; in (a) and (b), the RNA backbone is represented by a ribbon and the phosphates are not shown: a) the ribose zipper that mediates the minor-groove to minor-groove association of the terminal stem and the 1082 haiφin loop (Hydrogen bonds are indicated by dotted lines); b) the major-groove to major-groove association of the 1067 and 1095 stem- loops, in a view emphasizing the high-five, S-turn, and dinucleotide platform motifs. The high-five motif consists of the long-range stacking of two bulged residues, U1061 and A1070. The S-turn comprises the inverted nucleotide U1060 and the bulged residue U1061. The dinucleotide platform motif consists of G 1089 and U1090, on which the bulged residues G1071 and C1072 rest, as part of the long-range triples G1071-(G1091-C1100) and C1072-(C1092-G1099). c) Geometries of the noncanonical base pairs and base triples. Top panel, the three major groove base triples in the core of the structure: G1089-(U1090-U1101), G1071-(G1091-C1100), and C1072- (C1092-G1099). Bottom left panel, the minor groove docking interactions (U1082-A1086)-(G1056- Al 103) and A1085-(G1054-C1104). Bottom right panel, the long-range pair A1088-U1060. Figures 2a and 2b were made with RIBBONS (Carson, 1991); 2c with MOLSCRIPT (Kraulis, 1991). Figure 3. RNA-metal ion interactions in the tertiary structure of the GTPase activating region RNA from Thermotoga maritima: a) overview of the locations of the metal ions, showing that they are primarily in the interacting major grooves of the 1067 and 1095 stems. Magnesium ions are gold, cadmium ions are magenta, and the mercury ion is rose, b) close-up of the central cadmium ion that stabilizes shaφ turns at the 1056-1057 and 1086-1087 phosphodiester linkages at the center of the 4-way junction. Direct ligation of the cadmium ion is indicated by solid lines, and second-shell ligation is indicated by dotted lines. Figure 3a was made with RIBBONS (Carson, 1991), and Figure 3b was made with MOLSCRIPT (Kraulis, 1991). Figure 4 shows the RNA-L11 complex within the GTPase activating region from Thermotoga maritima: a) alignment of four widely divergent LI 1 sequences, together with a schematic of the protein's secondary structure. The sidechains of residues colored green participate in the hydrophobic core in the crystal structure. Residues involved in RNA binding are colored blue for side-chain contacts, red for main-chain contacts, or puφle if both the side-chain and main-chain interact with RNA. Abbreviations: E. coli, Escherichia coli (eubacterium); T. marit, Thermotoga maritima (eubacterium); Sulf ac, Sulfolobus acidocaldarius (archaea) ; Sacc cer, Saccharomyces cerevisiae (eukaryote). The numbering is based on the Thermotoga maritima sequence present in the crystal structure, b) stereoview of the complex. The LI 1 N- and C-terminal domains are labeled. Note that the N-terminal domain straddles the interface of the 1067 and 1095 stem-loops, c) orthogonal stereoview of the complex. This view emphasizes the relatively loose association of the LI 1 N-terminal domain with the RNA. Figures 4b and 4c were made with RIBBONS (Carson, 1991). Figure 5 shows Protein-RNA recognition within the GTPase activating region from Thermotoga maritima: a) schematic of RNA-CTD interactions observed in the crystal structure. Unusual RNA conformational features are also indicated (see inset for key). Water molecules that mediate protein- RNA interactions are indicated by a "W". b) Detail of the recognition of the conserved long-range A1088-U1060 pair by conserved Ll l residues Glyl30 and Thrl31 from helix 5, and by the N- teoninus of helix 3. Figure 5b was made with MOLSCRIPT (Kraulis, 1991). Figure 6 shows that the sites of mutations conferring resistance to thiostrepton and micrococcin are clustered around a cleft between the RNA and the proline-rich helix in the LI 1 N-terminal domain. Residues implicated in thiostrepton binding (A1067, A1095, and Pro22) are labeled. The position of Tyrol, which is protected by thiostrepton in protein footprinting experiments, is also indicated. Other labeled residues are those that confer micrococcin resistance (see text for details). The figure was made with RIBBONS (Carson, 1991). Table II shows the atomic structure coordinates for the complex between ribosomal LI 1 protein and the GAR RNA as derived by X-ray diffraction from a crystal of LI 1 complexed with 23S rRNA nucleotides 1051-1108. DETAILED DESCRIPTION OF THE INVENTION The invention is based on the discovery of the crystal structure of the ribosomal GAR from the hyperthermophilic eubacterium Thermotoga maritima, which is disclosed herein. Definitions: As used herein, the term "binding site" or "binding pocket" refers to a region of a protein or protein/RNA complex which binds or interacts with a particular compound. It is understood that the composition of the protein or RNA residues and/or the protein or RNA backbone, as well as the interaction of such moieties with their solvent including ions defines the specificity of the binding pocket. As used herein, the term "exposed residue" refers to an amino acid or RNA residue which is located on the surface of a protein, RNA or RNA/protein complex. As used herein the term "N terminus" or "N terminal lobe" or "NTD" when used in reference to LI 1 means amino acids 1-70 of LI 1. As used herein, the term "C terminus" or "C terminal lobe" or "CTD" when used in reference to LI 1 means amino acids 76-141 of LI 1. As used herein, the term "tether" or "tether sequence" when used in reference to LI 1 means animo acids 71 to 75 of Ll l. As used herein, the term "flexible" when applied to a protein or RNA domain means that that domain allows one or more domains adjoining or flanking it to move or flex in space relative to the flexible domain. As used herein, the term "backbone" or "backbone residue" when applied to an RNA molecule refers to the sugar-phosphate moieties that are covalently linked to form an RNA polymer. When applied to a protein molecule, "backbone" or "backbone residue" refers to the alternating N- C-C-N moieties of amino acids that are covalently linked to form a peptide polymer. As used herein, the term "interface" means the point or surface at which two or more domains of one or more molecules associate with each other. As used herein, the term "GAR" refers to the region of the ribosome responsible for activating the GTPase activity of translation elongation factors. The term "GAR RNA" refers to nucleotides 1051 to 1108 of E. coli 23 S rRNA or to its functional and structurally equivalent from any other bacterial rRNA. As used herein, GAR RNA refers to the nucleotides including and limited to (i.e., an RNA molecule consisting of GAR RNA) nucleotides 1051 to 1108 of E. Coli 23 S rRNA (or the functionally and structurally equivalent region in other bacterial rRNAs); or it refers to that nucleotide region (1051 to 1108) within a longer nucleotide sequence (i.e., an RNA molecule consisting essentially of GAR RNA) where the GAR RNA (nucleotides 1051 to 1108) is the only active region in the longer sequence (in terms of binding and/or another activity), whether the extra sequence be a homologous sequence from the 23 S rRNA (short of the complete sequence) or a heterologous sequence; or it refers to the 1051 to 1108 region within a complete functional 23S rRNA (i.e., an RNA molecule comprising the GAR RNA). As used herein, the term "LI 1/GAR" refers to the portions of LI 1 and GAR RNA which, when engaged in a complex, provide the LI 1/GAR binding site and/or activity, and preferably both the binding site and the activity. The term "LI 1/GAR" refers to a complex which consists of the ribosomal protein Ll l and consists of the GAR RNA (nucleotides 1051 to 1108) in their native association; or it can refer to a complex consisting essentially of ribosomal protein Ll l and consisting of or consisting essentially of or comprising GAR RNA (i.e., including other proteins which are inactive or do not otherwise affect the activity of the LI 1/GAR complex; or it can refer to a complex comprising ribosomal protein Ll l and consisting of, consisting essentially of, or comprising GAR RNA. When ribosomal protein LI 1 is referred to, the complete protein is referred to; however, where an LI 1/GAR activity is referred to, the portion of LI 1 sufficient to provide the activity when associated in a complex with GAR ma be less than the complete Ll l protein; "portion" referring to those combined LI 1 residues which provide for LI 1/GARcomplex formation and activity, the portions being one or more of the N-terminal, C-terminal or tether regions, as defined herein, or ant combination thereof . "LI 1/GAR activity" may include one or more of the following: movement of the N-terminal lobe of LI 1 ; binding or displacement of thiostrepton or micrococcin; RNA translation, translation elongation, inhibition of amino acid addition, GTPase activity, and/or inhibition of elongation factor G (EF-G)-dependent GTP hydrolysis. As used herein, the term "known LI 1/GAR binding activity" refers to an activity known in the art to associate with the LI 1/GAR either in vitro or in vivo. Known LI 1/GAR binding activities include, but are not limited to, the binding of agents such as thiostrepton and micrococcin. As used herein, "stem loop" refers to a stretch of nucleic acid sequence on a single molecule comprising two lengths of sequence capable of forming hydrogen bonded base pairs with each other separated by a region which cannot participate in the same base pairing interaction, such that base pairing between the sequences capable of forming hydrogen bonded base pairs forms a loop of non- base paired nucleic acid consisting of the region which cannot participate in base pairing. As used herein, the term "alpha helix" refers to a secondary structure arrangement of amino acids wherein hydrogen bonding between the C=O group of one peptide and the -NH group of the peptide bond four residues further down the same peptide polymer results in a right handed twist or helix formation. As used herein, "four way junction" refers to a region in the tertiary structure of GAR RNA in which four helices interact simultaneously with each other, as defined by the crystal structure coordinates given in Table II. As used herein, the term "translationally competent cell extract" refers to any fraction of a cell lysate, including a whole cell lysate, which is capable of directing the RNA-dependent polymerization of peptide bonds. As used herein, the term "translatable RNA" refers to an RNA which, when incubated with factors necessary for translation can direct the synthesis of acid-precipitable protein. As used herein, the term "decrease" when used in reference to a level of labeled RNA, a level of known LI 1/GAR binding activity, a level of translation, or a level of GTP hydrolysis means that the detected level is reduced by at least 10%, and preferably by 20%> to 50% or more. As used herein, the term "anti-bacterial properties" refers to the ability of a particular compound to inhibit the growth of bacteria. A compound can be said to have anti-bacterial properties if the rate of bacterial cell proliferation is reduced by at least 50%>, and preferably by more than 50%i. As used herein, the term "naturally occurring amino acids" means the L-isomers of the naturally occurring amino acids. The naturally occurring amino acids are glycine (G, Gly), alanine (A, Ala), valine (V, Val), leucine (L, Leu), isoleucine (I, He), serine (S, Ser), methionine (M, Met), threonine (T, Thr), phenylalanine (F, Phe), tyrosine (Y, Tyr), tryptophan (W, Tφ), cysteine (C, Cys), proline (P, Pro), histidine (H, His), aspartic acid (D, Asp), asparagine (N, Asn), glutamic acid (E, Glu), glutamine (Q, Gin), gamma-carboxyglutamic acid, arginine (R, Arg), ornithine and lysine (K, Lys). Unless specifically indicated, all amino acids referred to in this application are in the L-form. As used herein, the term "unnatural amino acids" means amino acids that are not naturally found in proteins. Examples of unnatural amino acids used herein include racemic mixtures of selenocysteine and selenomethionine. The term "positively charged amino acid" includes any naturally occurring or unnatural amino acid having a positively charged side chain under normal physiological conditions. Examples of positively charged naturally occurring amino acids are arginine, lysine and histidine. The term "negatively charged amino acid" includes any naturally occurring or unnatural amino acid having a negatively charged side chain under normal physiological conditions. Examples of negatively charged naturally occurring amino acids are aspartic acid and glutamic acid. The term "hydrophobic amino acid" means any amino acid having an uncharged, nonpolar side chain that is relatively insoluble in water. Examples of naturally occurring hydrophobic amino acids are alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The term "hydrophilic amino acid" means any amino acid having an uncharged, polar side chain that is relatively soluble in water. Examples of naturally occurring hydrophilic amino acids are serine, threonine, tyrosine, asparagine, glutamine, and cysteine. As used herein, a "competitive" inhibitor is one that inhibits GAR activity by binding to the same kinetic form of the GAR as its accessory factors bind—thus directly competing with the accessory factors for the active site of the GAR. Competitive inhibition can be reversed completely by increasing the accessory factor concentration. As used herein, the term "kinetic form" of the GAR means the condition of the GAR when either bound to an accessory factor or not, and in either its active or inactive state. That is, a kinetic form can be any conformation the GAR can assume under physiological conditions. As used herein, the term "accessory factor" means an endogenous factor or protein that interacts with the LI 1/GAR. As used herein, EF-G is included in the term "accessory factor". As used herein, an "uncompetitive" inhibitor is one that inhibits GAR activity by binding to a different kinetic form of the GAR than do the accessory factors. Such inhibitors bind to GAR already bound with the accessory factor and not to the accessory factor-free GAR. Uncompetitive inhibition cannot be reversed completely by increasing the accessory factor concentration. As used herein, the term "co-complex" means Ll l protein in covalent or non-covalent association with GAR RNA. As used herein, a co-complex may also encompass accessory factors and/or inhibitors or activators complexed with Ll l or LI 1/GAR RNA. As used herein, the terms "associates with" or "interacts with" refers to a condition of proximity between a chemical entity or compound, or portions thereof, with another chemical entity, compound or portion thereof. The association or interaction may be non-covalent —wherein the juxtaposition is energetically favored by hydrogen bonding or van der Waals or electrostatic interactions— or it may be covalent. The term "beta-sheet" refers to the conformation of a polypeptide chain stretched into an extended zig-zig conformation. Portions of polypeptide chains that run "parallel" all run in the same direction. Polypeptide chains that are "antiparallel" run in the opposite direction from the parallel chains. As used herein, the term "target" means a region of the LI 1/GAR complex, as defined by the crystal structure coordinates of Table II, which when bound by a candidate inhibitor or activator results in inhibition or activation of LI 1/GAR function. As used herein, the term "modulate" refers to a change, either an increase or a decrease in some activity. As used herein, the term "modulator" means a compound that modulates some activity. As used herein, the term "inhibits" or "decreases" means that a candidate modulator reduces the activity of the LI 1/GAR. A candidate modulator may be said to inhibit or decrease activity if the activity of LI 1/GAR as measured by inhibition of GTP hydrolysis and/or translational activity is reduced by more than 50% in the presence of 50 uM or less of inhbitor compared to values obtained in the absence of inhibitor. Candidate modulators will preferably inhibit by more than 50% the presence of 10 uM or less of inhbitor and most preferably in the presence of 1 uM or less of inhibitor. As used herein, the term "activates" or "increases" means that a candidate modulator raises the activity of the LI 1/GAR. A candidate modulator may be said to activate or increase activity if the activity of LI 1/GAR as measured by an increase of GTP hydrolysis by more than 50% in the presence of 50 uM or less of activator compared to values obtained in the absence of activator. Candidate modulators will preferably activate by more than 50% in the presence of 10 uM or less of inhibitor and most preferably in the presence of 1 uM or less of inhibitor. As used herein, the term "structure coordinates" refers to mathematical coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of X-rays by the atoms (scattering centers) of an LI 1/GAR RNA complex in crystal form. The diffraction data are used to calculate an electron density map of the repeating unit of the crystal. The electron density maps are used to establish the positions of the individual atoms within the unit cell of the crystal. As uded herein, the term "heavy atom derivatization" refers to the method of producing a chemically modified form of a crystal of LI 1/GAR RNA. In practice, a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., methyl mercury nitrate, lead chloride, gold thiomalate, thimerosal or uranyl acetate, which can diffuse through the crystal and bind to the surface of the protein. The location(s) of the bound heavy metal atom(s) can be determined by X-ray diffraction analysis of the soaked crystal. This information, in turn, is used to generate the phase information used to construct three-dimensional structure of the protein or proteimRNA complex (Blundel, T. L. and N. L. Johnson, 1976, Protein Crystallography, Academic Press). Those of skill in the art understand that a set of structure co-ordinates determined by X-ray crystallography is not without standard error. For the puφose of this invention, any set of structure coordinates for an Ll l/GAR RNA complex that has a root mean square deviation of protein backbone atoms (N, CI, C and O) of less than 0.75 when superimposed on the structure coordinates of Table II, using backbone atoms, shall be considered identical. The term "unit cell" refers to a basic parallelipiped shaped block. The entire volume of a crystal may be constructed by regular assembly of such blocks. Each unit cell comprises a complete representation of the unit of pattern, the repetition of which builds up the crystal. Using the structure coordinates of the Ll l/GAR RNA complex provided by this invention, molecular replacement may be used to determine the structure coordinates of a crystalline mutant or homologue of the LI 1/GAR RNA complex or of a different crystal form of the LI 1/GAR RNA complex. - 16- SUBSTITUTE SHEET RULE2 Detailed Description of the High Resolution Structure of the Lll/GAR complex. The GAR RNA from the T maritima 23 S rRNA consists of nucleotides 1111-1168, which cooespond to nucleotides 1051-1108 in the E. coli sequence. Hereafter, the E. coli numbering will be used in order to facilitate comparison with the available biochemical and genetic data. As described in detail in Example 1, crystals of the GAR RNA complexed with ribosomal protein LI 1 from T. maritima were prepared and used to solve the structure to 2.6 A resolution using multi- wavelength anomalous diffraction on a mercury derivative of the crystal. Data collection, phasing and refinement statistics are shown in Table I. The asymmetric unit in the crystal consists of two 1 : 1 LI 1-RNA complexes stacked in a head-to-head manner. The two complexes are nearly identical except for a subtle bend in the terminal three base pairs of the RNA, and a difference in the degree of disorder of the two Ll l N-terminal domains. Several observations strongly suggest that the conformation observed in the crystal structure is extremely similar to the structure of the GAR in situ in the ribosome. The RNA contains all of the predicted secondary structure; the two complexes in the asymmetric unit are virtually identical; and, most significantly, the structure explains most of the large body of experimental data on this system. Structure of the GAR RNA The predicted secondary structure of the GAR RNA (Glotz et al., 1981; Noller et al., 1981) is almost identical to that derived from the crystal structure (Figure la). The RNA secondary structure contains four double-helical segments, refeoed to as the terminal stem (defined by nucleotides (nt) 1051-1056 base paired with nt 1103-1108), the 1067 stem-loop (defined by nt 1062- 1076), the 1082 haiφin (defined by nt 1082-1086) and the 1095 stem-loop (defined by nt 1090- 1101). In the tertiary structure, the terminal stem stacks on the 1095 stem-loop, and the 1067 stem- loop stacks on the 1082 haiφin. Thus the four double-helical segments stack pairwise to form two extended helical subdomains. These two subdomains have irregular yet complementary shapes, so that the entire GAR RNA folds into a single compact globular domain (Figures lb, c). The helical subdomains associate in a roughly parallel fashion, with the terminal stem packed against the 1082 haiφin, and the 1067 and 1095 stem-loops packed against each other. Bulged-out residues in the 1067 and 1095 stem-loops mediate long-range tertiary interactions between the two subdomains. The fold requires two shaφ turns in the backbone at the 1056-1057 and 1086-1087 phosphodiester linkages in the center of the junction, where the chain crosses over from one helical subdomain to the other. The molecule also contains a relatively large number of well-ordered metal ions that are integral to the structure. A ribose zipper joins the terminal stem and the 1082 hairpin The association of the terminal stem with the 1082 haiφin occurs via their minor grooves. This rather intimate packing is stabilized primarily by a dense network of hydrogen bonds between the riboses of nucleotides A1084-A1086 and CI 104-Al 106 (Figure 2a). A similar structural motif has been observed in the P4-P6 domain of the group I intron, and has been referred to as a ribose zipper (Cate et al., 1996). At the center of the four- way junction, the 2' OH of A1086 appears to be a particularly crucial component of the ribose zipper. It makes hydrogen bonds to Al 103 NI and G1056 2' OH, and also directly ligates a crucial central cadmium ion (see below). A1086 has an unusual syn conformation that is necessary for the very tight packing of its sugar against the G1056- A1103 pair, and for the reverse- Watson-Crick geometry of the U1082-A1086 pair (Figure 2c). Another noteworthy feature of the ribose zipper is a minor groove A-(G-C) triple involving nucleotides A1085, G1055 and C1104 (Figure 2c). This minor-groove triple has also been found previously in large RNA tertiary folds (Cate et al., 1996; Ferre-D'Amare et al., 1998). Intimate association of the 1067 and 1095 stem-loops by reciprocal donation of bulges The interaction between the 1067 and the 1095 stem-loops occurs primarily in their major grooves and is mediated largely by a reciprocal donation of highly conserved bulged-out bases. This unusually intimate major-groove packing is the primary reason for the compactness of the overall fold, and it requires substantial distortions from regular helical geometry. This portion of the - 18- SUBSTmUTΪ SHEET (RULE26) structure contains a large number of tertiary interactions, some of which are novel structural motifs. The 1095 stem donates a bulged-out base, A1088, to a pocket created by a distortion in the 1067 stem (Figure 1). A1088 forms a universally conserved reverse-Hoogsteen pair with U1060 (Figure 2c). Because of steric constraints, A1088 must be in the syn conformation, which together with the reverse-Hoogsteen pairing geometry requires that U1060 must be flipped over. The inversion of U 1060 is in turn facilitated by bulging out of the base of U 1061. This inversion-bulge, or S-turn motif, has an S-shaped backbone conformation that has been observed previously (Szewczak et al., 1993; Wimberly, 1994; Wimberly et al., 1993). The insertion of A1088 also requires that residues A 1077 and U1078 are unpaired and rotated out to open up the pocket. The unpaired conformation of these residues is stabilized by three hydrogen bonds to the sugar- phosphate backbone of the 1095 stem loop at A1088 and G1089. Two of these hydrogen bonds are to the base of A 1077 which explains its universal conservation. The reciprocal donation of a bulge from the 1067 stem-loop to the 1095 stem involves nucleotides G1071 and C1072, which form two novel interdomain base triples with the base pairs G1091-C1100 and C1092-G1099 respectively (Figures 2b, c). Within the 1095 stem loop, nucleotides G1089-(U1090-U1101) also form a triple (Figure 2c), with G1089 acting as a stacking platform for the other two triples (Figure 2b). The stacking of G 1071 on G1089 is further stabilized by hydrogen bonds between the 1089 2'OH and 1071 N3, and between the 1071 2' OH and the 1089 phosphate. These three base triples explain the sequence conservation of all these residues. The 1072-( 1092- 1099) triple was previously predicted and subsequently experimentally confirmed, although the geometry proposed for the triple (Conn et al, 1998) differs from that seen in the crystal structure. The 1067 and 1095 hairpin loops The highly conserved 1067 haiφin loop consists of two parts, a haiφin portion (U1066- A1069) that stacks on the sheared U1065-A1073 pair, and a three-nucleotide bulge (A1070-C1072) that participates in two different long-range tertiary interactions. The haiφin portion has a conformation commonly found in small haiφin loops, with a U-turn motif (Quigley and Rich, 1976) at U1066 and regular stacking of A1067-G1068-A1069. A1069 stacks on A1073, and its 2' OH hydrogen bonds to the N3 of U1065, thereby stabilizing the location of the 1069 sugar as well as the sheared geometry of the U1065-A1073 pair. The three-nucleotide bulge has a corkscrew-like conformation in which A 1070 is bulged to one side, and G1071 and C1072 are bulged into the major groove of the 1095 stem-loop. A 1070 makes a novel long-range stacking interaction with U1061 which will be referred to herein as a "high-five" motif (Figure 2b), while 1071 and 1072 participate in the long-range base triples described above. The high-five motif makes several hydrogen-bonding and van der Waals interactions with the 1095 haiφin loop, thereby stabilizing the relative orientations of the two haiφins. The 1095 haiφin loop is also very highly conserved, and has a regular conformation stabilized by a U-turn at U1094 and a sheared G1093-A1098 pair. Part of the base of G1093 stacks over the base of C 1072, so that the long-range base triples are tightly wedged between an overhang from the sheared G-A pair on one side, and the G1089-(U1090-U1101) triple on the other side. The structure of the 1095 haiφin loop is very similar to an NMR-derived structure of a small stem-loop containing the same haiφin loop sequence (Fountain et al., 1996). The structural basis for the very high sequence conservation of several of the residues in the 1095 haiφin loop (i.e. A1095, A1096 and U/C1097) is not completely clear, but it may arise from interactions with the N-terminal domain of LI 1 (see below) or with other components of the ribosome. Metal ion interactions with RNA Three cadmium ions and at least seven magnesium ions are visible in the experimental electron density map. One of the cadmium ions stabilizes the association of the two complexes in the asymmetric unit, but the other two are integral to the RNA structure, and these two sites are probably occupied by magnesium ions in vivo. Most of the ions mediate the close approach of phosphates in the interacting major grooves of the 1067 and 1095 stems, and five of these ions stabilize the location and conformation of the 1070-1072 bulge between the 1067 and 1095 stems (Figure 3a). A cadmium ion occupies a crucial location at the center of the four- way junction, where it makes either direct or water-mediated contacts with residues from all four double-helical stems (Figure 3b). This ion appears to stabilize both of the shaφ turns at the center of the junction, i.e. the 1056-1057 and 1086-1087 turns, and thereby plays an important role in determining the overall structure of the four- way junction. Despite the accelerating pace of RNA structure determination, extremely little is known about RNA tertiary structure because only about five RNA folds have been determined. The crystal structure of the GAR RNA reveals an unexpectedly complex and compact fold that contains both well-known and novel structural motifs. The GAR RNA is in fact the most compact RNA structure yet reported, exposing only 138 A 2 of solvent accessible surface area per nucleotide (Nicholls et al., 1991). This extreme compactness is a result of extensive tertiary interactions along the entire length of the structure, in both the major and minor grooves. The other relatively compact known RNA folds exhibit primarily minor-groove packing (e.g., the P4-P6 domain of the group I intron) or primarily major-groove packing (e.g., tRNA), and are therefore less efficiently folded. It is probable that very efficient packing of RNA will be found to be common in the ribosome. The crystal structure explains the molecular basis for a number of important mutagenesis results. In particular, the RNA residues most sensitive to mutation are involved in tertiary interactions. For example, mutation of any of the universally conserved residues within the A1085- G1055-C1104 triple, a crucial part of the ribose zipper joining the terminal stem and the 1082 haiφin, dramatically destabilizes the RNA structure and greatly reduces the affinity for LI 1 (Lu and Draper, 1995). Mutation of C1072 to U within the 1072-( 1092- 1099) triple destroys the RNA tertiary structure, which demonstrates the energetic importance of this triple. Finally, the unusual observation that U 1061 A and U1061G mutants are more stable (Lu and Draper, 1994; Lu and Draper, 1995) is explained by the 1061-1070 "high five" tertiary stacking motif, since purine stacking is more stable than pyrimidine stacking. Stabilization of the RNA tertiary structure by metal ions The crystal structure also reveals important new information about how metal ions interact with and stabilize unusual RNA structures. Biochemical experiments suggest that the GAR RNA contains relatively high affinity binding sites for two divalent cations (Bukhman and Draper, 1997) and one K+ or NH4+ ion (Wang et al., 1993). The crystal structure reveals no fewer than seven magnesium sites and two cadmium sites, most of which stabilize the close approach of phosphates in the interacting major grooves of the 1067 and 1095 stem-loops. The metal-ion stabilization of the 1070-1072 bulge conformation is qualitatively similar + though different in detail — to that seen in the A-rich bulge of the P4-P6 domain of the group I intron (Cate et al., 1996). The striking structural role played by the central cadmium ion suggests that this site corresponds to one of the thermodynamically important ions. While more experiments will be necessary to test this hypothesis, it is worth noting that this cadmium ion is one of the two sites in the structure that ligates a guanosine N7. Both Mn" and Cd" preferentially bind to guanosine N7, and it has been observed that Mn" stabilizes the tertiary structure more than other divalent cations (Bukhman and Draper, 1997). The major-groove dinucleotide platform: a generalization of the adenosine platform The crystal structure also reveals a new variant of a known tertiary structure motif, the adenosine platform. In the structure of the P4-P6 domain, two successive adenines adopt a coplanar conformation — an adenosine platform ~ that serves as a stacking platform for a long-range tertiary interaction (Cate et al., 1996). In the GAR structure, two successive nucleotides, G1089 and U1090, adopt the same conformation seen in the adenosine platform (Figure 2C). The two bases are coplanar, with a single N2-O4 hydrogen bond between them, and they also serve as a stacking platform, for the 1071-1072 bulge involved in base triples (Figure 2B). There are, however, some differences between the GU platform seen here and the AA platform. In the P4-P6 structure, the motif is displayed in the minor groove rather than in the major groove, as is seen here. Moreover, in the P4-P6 structure it is the 3' adenosine upon which the long-range stacking interaction occurs, while here G1071 rests upon the 5' residue of the motif, G1089. Finally, the tertiary stacking interaction occurs on opposite faces of the motif in the two structures. Despite these differences, the near-identity of the conformations and functions of the motifs in these two structures leads to the suggestion that the motif be referred to as a "dinucleotide platform", since it is clearly not restricted to adenosines. The few available data suggest that a GU dinucleotide platform may generally be more stable than an AA platform for major groove display. In the GAR, residues 1089 and 1090 are strictly conserved as either GU or AA, but mutation from AA to GU results in a significant stabilization of the RNA tertiary structure (Lu and Draper, 1994; Lu and Draper, 1995). The major- groove GU dinucleotide platform motif has also been found in small RNA structures lacking tertiary interactions (Szewczak et al., 1993; Wimberly et al., 1993), which suggests that in large structured RNAs, the GU dinucleotide platform may in some cases function as a pre-formed stacking platform supporting major-groove base triples. Methylmercury as a phasing vehicle for RNA crystal structures Suφrisingly, the primary mercury site used in phasing is not near a cysteine of LI 1, but is located 2.4 A from the N3 atom of U 1061, consistent with a covalent mercury-uridine N3 bond. A similar, minor mercury site at U1078 is also visible in the anomalous difference Fourier map. Although most mercury adducts of pyrimidines have been obtained at the O4 or 5 positions of the base, a mercury 1-methylthymine adduct at N3 has been obtained at alkaline pH (Kosturko et al., 1974), and methylmercury salts have been shown to denature AT-rich DNA, consistent with reaction at thymine N3 (Gruenwedel and Davidson, 1966; Gruenwedel and Davidson, 1967). Uracil is often preferred at bulge sites in RNA, so many larger RNA structures may contain solvent-accessible uracils. Therefore, methylmercury derivatization of RNA under native conditions, either prior or subsequent to crystallization, may be a generally useful method for obtaining heavy atom derivatives of RNA crystals, without the laborious incoφoration of sulfur-containing ribonucleotides. The structure of ribosomal protein Lll Ribosomal protein LI 1 consists of two globular domains connected by a linker region. The - 23- SUBSTITUTE SHEET BULE2 secondary structure and a sequence alignment of the protein are shown in Figure 4a, and the tertiary fold is shown in Figures 4b and 4c in the context of the complex. As described below, there is some flexibility between the two domains, but the linker is short and it contains two conserved prolines (73 and 74) that provide inherent rigidity. Also, the domain interface consists primarily of conserved hydrophobic residues, notably Met52, Ile53, Pro55, Pro73 and Phe77. These observations suggest that relative orientation of the two domains has not been greatly perturbed by crystal packing requirements. The structure of the Ll l N-terminal domain (NTD) has not been previously reported. It consists of two helices packed against the concave surface of a three-stranded antiparallel beta sheet, with an overall J1-I1-I2-J2-J3 topology. The N-terminal 7 residues are disordered. One of the most distinctive and conserved regions of the LI 1 molecule is the proline-rich helix 1, which appears to have a crucial functional role, as described below. The electron density for this helix was weak, and the register of the sequence in this helix may be in error by one residue. The average main-chain B-factor for the domain is 72 A 2 (for comparison, the average B-factor of the C-terminal domain (CTD) is 24 A 2 ), indicating rigid body movement of the NTD within the crystal. This flexibility is consistent with the rather limited interactions seen between the NTD and other parts of the structure, and may have functional implications (see below). The structure of the CTD is in good agreement with the previously determined NMR structures of the CTD, both in isolation (Markus et al., 1997; Xing et al., 1997) and in the context of the LI 1-RNA complex (Hinck et al., 1997). The domain consists of a three-helical bundle and a short parallel two-stranded J-ribbon, with an overall I3-J4-I4-I5-J5 topology. All five secondary structure elements contribute to a conserved hydrophobic core. The domain is characterized by two extended loops that are disordered in the absence of the RNA, but which have defined structures in the complex. The RNA-protein interaction The two domains of LI 1 are very unequally associated with RNA. The CTD-RNA interface covers over 1700 A 2 of solvent accessible surface area, while the NTD-RNA interface is less than 100 A 2 . This difference is consistent with the observation that the RNA-binding affinity of the CTD is essentially the same as that of the full-length protein (Xing and Draper, 1996). The CTD binds the minor groove of the 1067 stem (Figures 4b, c), which is bent and flatter than the minor groove of a canonical A- form double helix. The RNA-binding surface of the CTD consists of one face of helix 5, the N-terminal end of helix 3, and loops 6 and 7 that flank helix 5. Helix 5 is positioned lengthwise in the minor groove, and the flanking loops 6 and 7 extend this minor groove binding surface and .also interact with the sugar-phosphate backbones on either side of the groove. A summary of the CTD-RNA interactions observed in the crystal structure (Figure 5 a) emphasizes that the recognition of the RNA minor groove by LI 1 involves primarily interactions between the protein backbone and the RNA 2' OH moieties. Approximately half of the RNA-CTD hydrogen bonds involve a main-chain amide or carbonyl, and over half of the 2 'OH groups in the CTD footprint are hydrogen-bonded to the protein. This preponderance of protein backbone-RNA backbone interactions indicates that overall shape complementarity between the RNA and protein must be an important determinant of specificity. Although binding appears to depend less on electrostatic interactions than on shape complementarity, there are a number of important salt bridges between basic sidechains and phosphate groups: lysines 93, 126 and 133 and Arg94 interact with one side of the minor groove, and lysines 80, 87 and 112 with the other side. In the former group, the sidechains are splayed away from protein, and the hydrophobic part of the sidechain contributes to surface complementarity with the RNA. Sidechains at the N-terminus of 15 and within loop 7 make particularly intimate contact with the RNA, notably Ilel27 and Asnl 17. Asnl 17 points directly into the minor groove making a number of hydrogen bonding interactions, and is one of the few sidechains that formally "reads" the local RNA sequence. Two of the most important recognition elements in the RNA are the universally conserved long-range pair U1060-A1088 and the surrounding RNA internal loop that distorts to accommodate the insertion of A1088. Significantly, the RNA footprint of helix 5 encompasses this entire region of distorted RNA. The importance of the U1060-A1088 pair for LI 1 specificity is shown by the extremely high conservation of Glyl30 and Thrl31 to which these bases are hydrogen-bonded (Figure 5b). The NTD bridges the interface between the 1067 and 1095 stem-loops, and it makes only a few specific interactions with the RNA (Figure 4). Although its association with RNA is somewhat tenuous, which might be a result of its binding mode having been altered by crystal packing requirements, the high sequence conservation of the NTD residues interacting with RNA suggests that the binding mode observed in the crystal structure is relevant to the structure of the complex in solution. Moreover, as described above, the structure of the NTD-CTD interface also suggests that the orientation of the NTD has not been greatly perturbed by crystal packing. The NTD residues interacting with RNA include LyslO, Gin 12, Gln30 and Lys71. LyslO makes both main-chain and side-chain interactions with the RNA, and Gin 30 probably interacts specifically with A1095. There is also electron density interacting with the Watson-Crick face of C 1097, but it is not clear whether this density arises from the NTD; examination of an anomalous difference Fourier map reveals that some of this density must correspond to a mercury or cadmium site. Finally, although the proline- rich sequence in helix 1 is surface-exposed, highly conserved, and in the correct orientation for possible interactions with factors or antibiotics, it is close to but not in direct contact with RNA. The thiostrepton/micrococcin binding site A 1067 and A 1095, at the ends of their respective stem-loops, have both been implicated in the binding of the antibiotics thiostrepton and micrococcin. Modification of A 1067 by 2'-O methylation (Cundliffe and Thompson, 1979; Thompson et al., 1982) or transversion mutations at either site (Rosendahl and Douthwaite, 1994) confers thiostrepton resistance. It has also been shown that thiostrepton affects the reactivity of both A 1067 and A 1095, suggesting that these two sites are close together (Rosendahl and Douthwaite, 1994) as indeed they are in the crystal structure. As for the role of LI 1 in antibiotic binding, it is known that LI 1 is required for high affinity binding of thiostrepton to the RNA, and that binding of Ll l and thiostrepton to the RNA is cooperative. Thiostrepton has a much weaker affinity for the RNA alone (Kd = 0.4 1M), and it does not bind isolated LI 1 (Thompson et al., 1979). Two sites within the NTD of the protein have been implicated in this interaction: the mutations Pro22Ser and Pro22Thr confer thiostrepton resistance, while the antibiotic protects Tyrol (Tyr62 in E. coli) in protein footprinting experiments (Porse et al., 1998). Recently, mutations that confer resistance to micrococcin have also been mapped to the NTD of LI 1 between residues 22 and 32 (Porse et al., 1999). All of these sites are located on a small surface of the NTD, near A1067 and A1095 on the RNA (Figure 6). A prominent feature of this surface is the distinctive and highly conserved proline-rich helix, while Tyrol is over 20 A distant. The clustering of these sites of antibiotic resistance mutations, together with the cooperative binding data, strongly suggest that the antibiotics bind to the cleft between the RNA and the proline-rich helix 1 of the NTD. The structure of the C-terminal domain (CTD) was previously determined by NMR in both the free (Markus et al., 1997; Xing et al., 1997) and RNA-bound (Hinck et al., 1997) forms. Our crystal structure of the CTD is similar to that of the RNA-bound form determined by NMR, except for the conformation of the large RNA-binding loop 6 which is poorly determined in the NMR studies (Hinck et al., 1997). The mean CI root mean square difference (RMSD) for the crystal structure vs. NMR ensemble is 2.7 A overall, or 1.6 A when residues 86-97 of loop 6 are excluded. For comparison, the mean RMSD within the ensemble of NMR structures is 2.3 A for main chain atoms. Many ribosomal proteins show structural similarities to families of DNA- and RNA-binding proteins (Ramakrishnan and White, 1998). It was noted from the NMR structure that the CTD of LI 1 has a homeodomain-like fold (Markus et al., 1997; Xing et al., 1997), and further NMR studies on the complex suggested that the CTD uses the typical homeodomain helix to bind RNA (Hinck et al., 1997). Although the crystal structure reveals that this helix is indeed intimately associated with the RNA, its interaction does not bear any similarity to the base-specific recognition of a major groove by the homeodomains. Regarding the NTD, its overall I + J fold is similar to that seen in many other RNA-binding proteins (Ramakrishnan and White, 1998), but its J-I-I-J-J topology has - 27- SUBSTITUTE SHEET (RULΕ26) not yet been observed in an RNA-binding protein. RNA-protein interaction The LI 1 -GAR RNA interaction has been probed by biochemical and NMR methods, and the crystal structure is in good agreement with the results of these studies, including a rather weak interaction between the RNA and the NTD. The RNA surface covered by the CTD corresponds fairly well to the residues protected by the binding of full-length LI 1 as shown by hydroxyl radical footprinting experiments (Rosendahl and Douthwaite, 1993). The RNA-binding surface of the CTD has been mapped by NMR chemical shift changes and relaxation studies (Hinck et al., 1997), and again the agreement with the crystal structure is excellent. The observation that Ll l recognizes the RNA primarily by shape complementarity rather than by a sidechain-base reading of the RNA sequence is not suφrising considering that the interaction occurs primarily via the minor groove. The interaction agrees with the prediction that relatively few highly conserved CTD residues would make specific sidechain contacts with RNA (Xing et al., 1997). However, the related prediction that RNA binding by the CTD would not involve extensive recognition of the RNA bases is incorrect, as most of the base pairs are recognized by either hydrogen bonding or hydrophobic interactions. However, most of these hydrogen bonds occur via main chain amides or carbonyls, rather than side chains. Finally, it is worth noting that LI 1 does not directly recognize the bulged-out nucleotides, which have previously been proposed as specificity determinants in ribosomal RNA-protein complexes. Biochemical experiments have shown that Ll l stabilizes the tertiary structure of the RNA, and that this is a property of the CTD (Draper and Xing, 1995; Xing and Draper, 1995). Since nearly all of the direct RNA-protein contacts within the complex are to the 1067 stem, the resulting stabilization of the RNA tertiary structure appears to be indirect. The binding of one face of helix 5 with both strands of the 1067 stem is extensive and universally conserved, and this interaction must be particularly important for stabilization of the RNA tertiary structure. Consistent with a crucial role in RNA binding, helix 5 contains most of the mutation sites that have the greatest - 28- HEET JLE26 adverse effect on binding affinity (T131V, G130A, K126A, and S134A) (Xing et al., 1997). As for the RNA-binding loops 6 and 7, both are disordered when not bound to RNA (Markus et al., 1997), but they are highly ordered in the complex, and their conformations match the groove surface perfectly. The loops contain conserved structural features, which are important in the complex and which may predispose them for RNA-binding. Although it makes many interactions with RNA and contains the other two sites most sensitive to mutation (G88P and P92G), the longer RNA-binding loop 6 is relatively poorly conserved between kingdoms, with the bacterial and archaeal loops differing significantly from the eukaryotic loops (Figure 4A). This variability in the protein sequence correlates with variability between phylogenetic kingdoms in the base-pairing of the upper portion of the 1067 stem. The NTD as a molecular switch Prior to these structural studies, the molecular basis for cooperative binding within the RNA- Ll l-thiostrepton ternary complex was unknown. The crystal structure now provides a very straightforward explanation that also rationalizes the particular importance of the LI 1 NTD. The model also provides insights into how the GAR might function as a molecular switch. The putative thiostrepton/micrococcin binding site is centered on a small gap between helix 1 of the NTD and the 1067/1095 region of the RNA (Figure 6). The antibiotics are proposed to bind within this gap, possibly enlarging it somewhat, making specific interactions with the RNA on one side and further interactions with the NTD on the other side. In the absence of the NTD, the antibiotic's binding affinity would be greatly compromised, thus explaining the importance of the NTD for antibiotic binding (Xing and Draper, 1996). An alternative proposal, that thiostrepton binds directly only to the RNA and that this RNA conformation requires the presence of the NTD, is unlikely because the NTD does not appear to stabilize the RNA tertiary structure significantly, and because the NTD sites of resistance mutations are not in contact with the RNA. In a model that better accounts for previously known data and agrees with the crystal structure reported herein, the mechanism for the resistance to thiostrepton in Pro22 mutants would be a disruption of direct - 29- SUBSTTTUTE SHEET (RUUΞ26) thiostrepton-Pro22 interaction. A similar mechanism must hold true for the micrococcin sites given the more recent data (Porse et al., 1999). Regarding the details of the interaction of thiostrepton and micrococcin with RNA, we note that these antibiotics contain an array of thiazole rings that resembles the array of prolines in the conserved proline-rich NTD helix. The data disclosed herein suggests a potential mechanism of thiostrepton inhibition of factor-dependent GTPase activity involves restriction or "trapping" of one of the many conformational states that must occur during elongation (Cundliffe, 1986) by the antibiotic. In their analysis of the effects of the Pro22Ser and Pro22Thr mutations, Porse et al. (1998) suggest that thiostrepton binding may affect the ability of the LI 1 NTD to undergo a conformational change, an idea which merits closer examination in light of the crystal structure. In the structure, the CTD is rather firmly anchored to one of the two RNA subdomains, while the NTD is somewhat tenuously bound across the RNA subdomain-subdomain interface. Even in the absence of other data, this overall architecture suggests that the NTD may function as a molecular switch that reversibly associates with the GAR RNA during the elongation cycle. In light of the other data — in particular the cooperative binding of thiostrepton and full-length LI 1 to RNA, and the clustering of antibiotic resistance mutations to the cleft defined by A1067/A1095 and the proline-rich NTD helix — it appears even more likely that the NTD functions as a molecular switch, and that the thiazole antibiotics work by binding to the NTD-RNA interface, thereby preventing the NTD from switching between RNA-bound and RNA-free states. It is possible that the switch is coupled to, or triggered by, the binding of elongation factors. It is important to note that the NTD itself cannot provide the actual GTPase enhancing activity since LI 1 is not required for viability in E. coli (Stoffler et al., 1980). Therefore, the switch appears likely to function by controlling either the accessibility or the conformation of the GAR RNA. This switch hypothesis could also explain why EF-Tu and IF2 do not footprint the 1067/1095 region of RNA, while EF-G does, even though all these factors interact with the sarcin/ricin loop (Moazed et al., 1988). The sarcin/ricin loop is known to bind to a nearby (Wilson and Noller, 1998) but distinct (Munishkin and Wool, 1997) site on EF-G. The EF-Tu-tRNA complex is similar in structure to EF-G, and the similarity is thought to be a case of molecular mimicry, with the factors binding to the same general region of the ribosome (Nissen et al., 1995). Thus the footprinting differences could be explained if EF-Tu and IF2 recognize a different conformation of the switch than EF-G does. This reasoning suggests that the two conformations of the GAR molecular switch correspond to different functional states of the ribosome. The structure features a complex and very compact RNA fold stabilized by many bound metal ions, by a dense network of RNA tertiary interactions, and by extensive interactions with the protein. The overall architecture of the complex suggests that the N-terminal domain functions as a molecular switch, either by facilitating changes in the tertiary structure of the GAR RNA, or by controlling access to the RNA. Thiostrepton and micrococcin are proposed to bind to the NTD-RNA interface, thus locking the switch and disrupting GAR function. Uses of the Crystal Structure Coordinates of the Lll/GAR Complex One approach enabled by the X-ray crystal structure disclosed herein is the use of the crystal coordinates for the rational design of GAR activity modulators, either de novo or by modification of known compounds. The modulators identified through use of the crystal structure coordinates will be useful for altering the rate of bacterial protein synthesis, and thereby the rate of bacterial cell growth. It is expected that, for example, an inhibitor of GAR function will inhibit bacterial cell proliferation, and will thus potentially have immediate medical usefulness. One of skill in the art may use the structure data disclosed herein and the computer-modeling techniques described herein to develop models of target domains also selected through analysis of the crystal structure data (see below). These models can be used to provide a detailed analysis of the binding surfaces, including factors such as van der Waals contacts, electrostatic interactions and hydrogen-bonding opportunities. This information is then used with computer simulation techniques - 31- SUBSTITUTE SHEEr(RU_f26) to map the favorable interaction positions for functional groups such as protons, hydroxyl groups, amine groups, divalent cations, aromatic and aliphatic functional groups, acetamide, methanol, etc. These groups may then be designed into a synthetic ligand. The LI 1/GAR structure coordinates may be used to screen computationally small molecule data bases for chemical entities or compounds that may bind in whole, or in part, to the LI 1/GAR, to GAR, or to Lll. In addition, because the Ll l/GAR RNA complex may be crystallized in more than one crystal form (e.g, as a co-crystal with another factor, such as EF-G), the structure coordinates of the LI 1/GAR RNA, or portions thereof, as provided by this invention are useful to solve the structure of those other crystal forms of the LI 1/GAR RNA complex. One method that may be employed for this puφose is molecular replacement. In this method, the unknown crystal structure (i.e., that of the co-complex) may be determined using the Ll l/GAR complex structure coordinates of this invention as provided in Fig. 7. This method will provide an accurate structural form for the unknown crystal more quickly and efficiently than attempting to determine such information from first principles. In addition, in accordance with this invention, the LI 1/GAR complex may be crystallized in co-complex with known GAR inhibitors (e.g., thiostrepton, micrococcin). The crystal structures of such complexes may then be solved by molecular replacement and compared with that of inhibitor-free LI 1/GAR complex. Critical sites for interaction of the known inhibitor with the LI 1/GAR may thus be identified at high resoultion. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between LI 1/GAR and a chemical entity or compound. All of the complexes referred to above may be studied using well-known X-ray diffraction techniques and may be refined versus 2-3 / resolution X-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, ©1992, distributed by Molecular Simulations, Inc.). See, e.g., Blundel & Johnson, supra; Methods in Enzymology, 1985, vol. 114 - 32- SUBSTm j TESHEET(RULE26) & 115, H. W. Wyckoff et al., eds., Academic Press. The crystallographic information disclosed herein may thus be used to optimize known classes of LI 1/GAR inhibitors or activators. Importantly, the X-ray crystal data disclosed herein also allows the design and synthesis of novel classes of LI 1/GAR inhibitors or activators (i.e., modulators). The design of compounds that bind to or modulate LI 1/GAR function according to this invention generally involves consideration of several factors. In particular, the compound must be capable of physically and structurally associating with Ll l/GAR. Non-covalent molecular interactions important in the functional association of Ll l/GAR with its accessory factors include hydrogen bonding, van der Waals, electrostatic and hydrophobic interactions. It is recognized that although certain portions of the compound will not directly participate in this association with the LI 1/GAR, those portions may still influence the overall conformation of the molecule. This, in turn, may have a significant impact on potency. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical entity or compound in relation to all or a portion of the binding site, or the spacing between functional groups of a compound comprising several chemical entities that directly interact with LI 1/GAR. The potential modulating or binding effect of a chemical compound on the LI 1/GAR may be analyzed prior to its actual synthesis and testing by the use of computer modelling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and the Ll l/GAR, synthesis and testing of the compound is obviated. However, if computer modelling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to the LI 1/GAR domain and to inhibit using the assays described herein. In this manner, synthesis of inoperative compounds may be avoided. A modulating or binding compound of the LI 1/GAR may be computationally evaluated and designed by means of a series of steps in which chemical entities or fragments are screened and selected for their ability to associate with the individual binding targets on the LI 1/GAR. One skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to associate with Ll l/GAR and more particularly with the individual binding domains comprising the LI 1/GAR active sites. This process may begin by visual inspection of, for example, the active site on the computer screen based on the LI 1/GAR RNA coordinates in Fig.7. Selected fragments or chemical entities may then be positioned in a variety of orientations, or "docked", within an individual binding target site of the LI 1/GAR as defined herein from analysis of the crystal structure data. Docking may be accomplished using software such as Quanta (Molecular Simulations, Inc., San Diego, CA) and Sybyl (Tripos, Inc., St. Louis, MO) followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM (Molecular Simulations, Inc., San Diego, CA) and AMBER (University of California at San Francisco). Specialized computer programs may also assist in the process of selecting fragments or chemical entities. These include: 1. GRID (Goodford, P. J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules", J. Med. Chem., 28, pp. 849-857 (1985)). GRID is available from Oxford University, Oxford, UK. 2. MCSS (Miranker, A. and M. Kaφlus, "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method." Proteins: Structure. Function and Genetics, 11, pp. 29-34 (1991)). MCSS is available from Molecular Simulations, San Diego, CA. 3. AUTODOCK (Goodsell, D. S. and A. J. Olsen, "Automated Docking of Substrates to Proteins by Simulated Annealing", Proteins: Structure. Function, and Genetics, 8, pp. 195-202 (1990)). AUTODOCK is available from Scripps Research Institute, La Jolla, CA. 4. DOCK (Kuntz, I. D. et al., "A Geometric Approach to Macromolecule-Ligand Interactions", J. Mol. Biol., 161, pp. 269-288 (1982)). DOCK is available from University of California, San Francisco, CA. 5. CERIUS II (available from Molecular Simulations, Inc., San Diego, CA). 6. Flexx (Rarey et al., 1996, J. Mol. Biol. 261: 470-489). Once suitable chemical entities or fragments have been selected, they can be assembled into a single compound or modulator. Assembly may proceed by visual inspection of the relationship of the fragments to each other on the three-dimensional image displayed on a computer screen in relation to the structure coordinates of the LI 1/GAR. This would be followed by manual model building using software such as Quanta or Sybyl. Useful programs to aid one of skill in the art in connecting the individual chemical entities or fragments include: 1. CAVEAT (Bartlett, P. A. et al, "CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules". In "Molecular Recognition in Chemical and Biological Problems", Special Pub., Royal Chem. Soc, 78, pp. 182-196 (1989)). CAVEAT is available from the University of California, Berkeley, CA. 2. 3D Database systems such as MACCS-3D (MDL Information Systems, San Leandro, CA). This area is reviewed in Martin, Y. C, "3D Database Searching in Drug Design", J. Med. Chem., 35, pp. 2145-2154 (1992)). 3. HOOK (available from Molecular Simulations Inc., San Diego, CA.). Instead of proceeding to build an LI 1/GAR modulator in a step-wise fashion one fragment or chemical entity at a time as described above, modulatory LI 1/GAR binding compounds may be designed as a whole or "de novo" using either an empty active site or optionally including some portion(s) of a known inhibitor(s). These methods include: 1. LUDI (Bohm, H.-J., "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors", J. Comp. Aid. Molec. Design, 6, pp. 61-78 (1992)). LUDI is available from Molecular Simulations, Inc., San Diego, CA. 2. LEGEND (Nishibata, Y. and A. Itai, Tetrahedron, 47, p. 8985 (1991)). LEGEND is available from Molecular Simulations, San Diego, CA. 3. LeapFrog (available from Tripos Associates, St. Louis, Mo.). Other molecular modelling techniques may also be employed in accordance with this invention. See, e.g., Cohen, N. C. et al., "Molecular Modeling Software and Methods for Medicinal Chemistry", J. Med. Chem., 33, pp. 883-894 (1990). See also, Navia, M. A. and M. A. Murcko, "The Use of Structural Information in Drug Design", Current Opinions in Structural Biology, 2, pp. 202-210 (1992); Hubbard, "Can Drugs Be Designed?", Curr. Opin. Biotechnol., 8, pp. 696-700 (1997); and Afshar et al., "Structure-Based and Combinatorial Search for New RNA-Binding Drugs", Curr. Opin. Biotechnol., 10, pp.59-63 (1999). Once a compound has been designed or selected by the above methods, the efficiency with which that compound may bind to Ll l/GAR may be tested and optimized by computational evaluation. For example, a compound may be optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target site. Such non-complementary (e.g., electrostatic) interactions include repulsive charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the modulator and the enzyme when the modulator is bound to Ll l/GAR preferably make a neutral or favorable contribution to the enthalpy of binding. Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses include: Gaussian 92, revision C [M. J. Frisch, Gaussian, Inc., Pittsburgh, Pa. ©1992]; AMBER, version 4.0 [P. A. Kollman, University of California at San Francisco,© 1994]; QUANTA/CHARMM [Molecular Simulations, Inc., San Diego, CA.©.1994]; and Insight II/Discover (Biosysm Technologies Inc., San Diego, CA. ©1994). These programs may be implemented, for instance, using a Silicon Graphics workstation, 02-R10000 or IBM RISC/6000 - 36- SUBSTITUTE SHEET 0ΪULE26) workstation model 550. Other hardware systems and software packages will be known to those skilled in the art. Once an LI 1/GAR-binding compound has been optimally selected or designed, as described above, substitutions may then be made in some of its atoms or side groups in order to improve or modify its binding properties. Generally, initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. It should, of course, be understood that components known in the art to alter conformation should be avoided. Such substituted chemical compounds may then be analyzed for efficiency of fit to LI 1/GAR by the same computer methods described in detail, above. Targets for Modification of Lll/GAR Function The X-ray crystal structure co-ordinates disclosed herein may be used to define structural features of the LI 1/GAR which represent targets for inhibition or activation of the GTPase activity of the ribosome. The following regions of the LI 1/GAR, defined by the X-ray co-ordinate data, represent particularly useful targets for the development of inhibitory or activating compounds. 1. LI 1 N terminus:GAR RNA interface. The putative site for binding of the antibiotics thiostrepton and micrococcin to the GAR is between the N terminus of LI 1 and the interface between the 1067 and 1095 stem loops of the GAR RNA. The structural data as disclosed in Table II and described herein above suggest that the N terminal lobe of Ll l behaves as a rigid body that flexes about the so-called "tether sequence" between the C terminal and N terminal lobes of the protein. Therefore, the binding pocket is not limited to those residues at the interface of the LI 1 N terminus and the GAR RNA that are in direct contact. The binding pocket can include all of the following: A) all exposed residues from the LI 1 N terminus; B) all exposed residues from the GAR RNA that are on its LI 1 binding surface, including A1070, U1061, A1095, A1096, C1097, and A1098; C) LI 1 amino acid residues that are in direct contact with the GAR RNA, including K10, - 37- SUBSiπUTESHEET(RULE26) Q12, Q30 and K71; D) LI 1 amino acid residues from the helical region between P20 and H31; and E) the LI 1 J sheet between Q8 and PI 4, and neighboring 153. Computer simulation techniques may be used to determine which parameters of the binding pocket may be exploited in designing or screening compounds that interact with the binding pocket. Such techniques allow for the construction of structural models that can then be used in designing inhibitory/activating compounds targeted to the LI 1/GAR binding pocket. These techniques may involve any of the software packages described above or known in the art, and include: A) Interactive movement of the LI 1 N terminus as a rigid body with concurrent geometry optimization, using, for example, Quanta. B) Molecular dynamics simulation of the GAR RNA-L11 complex using. For example, CHARMM and/or AMBER. C) Normal mode dynamics simulation of the GAR RNA-L11 complex using, for example, CHARMM. D) Molecular docking of thiostrepton and/or micrococcin to the models of the binding pocket. 2. The Lll flexible tether or the flexible tether.GAR RNA interface. The flexible tether domain of Ll l and the GAR RNA surfaces that the tether domain interacts with are defined by the crystal structure coordinates disclosed in Table II and discussed herein above. The X-ray crystal data suggest that the LI 1 N terminus may act as a molecular switch that triggers the GTPase activity. It is thought that thiostrepton and micrococcin act by modifying the interaction between the LI 1 N terminus and the GAR RNA. Therefore, the region tethering the N terminal and C terminal lobes of LI 1, (i.e., amino acids K71 through A75) represent a target for the development of compounds that inhibit or activate GAR function, as does the domain comprising the interface of the tether region with GAR RNA residues. The GAR RNA domain interacting with the tether includes U1061, the backbone of U1060, and G1059. Any molecule that could modify the relative positioning of the Lll NTD and CTD may disrupt the funtion of the molecular switch and thereby modulate the function of the GAR. For example, this could be performed by a molecule interacting with the Lll tether domain and/or the GAR in close contact with the tether. Any molecule that could interact with both the C terminal and N terminal lobes of LI 1 and stabilize one orientation of the lobes relative to the alternate orientation may disrupt the function of the molecular switch and thereby disrupt the function of the GAR. Computer simulation techniques similar to those described above for modeling the LI 1 N terminus: GAR RNA interface may be used to determine which parameters of the 4 way junction and Cd" coordination site may be exploited in designing or screening compounds that interact with or disrupt the junction/Cd" coordination site and or modify the activity of the GTPase. 3. The GAR RNA.EF-G interface. The interaction of translational elongation factor EF-G with the ribosome has been mapped by directed hydroxyl radical probing (Wilson & Noller, 1998, Cell 92: 131-139). This approach indicated that GAR RNA residues in the region of A 1070 and in the region of CI 100 are involved in the binding of EF-G. A1070 is included in the GAR RNA:L11 N terminal interface discussed as a target above, but is nonetheless of interest in approaches aimed at disrupting or modifying EF-G binding. The crystal structure coordinates disclosed in Table II and discussed herein above define the structure of the GAR RNA at CI 100, and the RNA bases and LI 1 amino acid residues around it. This structure defines a novel target for the design and/or selection of molecules that can disrupt the GAR RNA:EF-G interaction. Computer simulation techniques similar to those described above for modeling the Ll l NTD: GAR RNA interface may be used to determine which parameters of the binding pocket may be exploited in designing or screening compounds that modify the relative positioning of Lll NTD and CTD and modify the activity of the GTPase. 4. RNA Folding/Stability. The X-ray crystal structure coordinates disclosed in Table II and discussed herein above define the structure of a novel "4 way junction" fold in the ribosomal RNA in the LI 1/GARcomplex. The data further reveal the importance of a Cd" ion that occupies the center of the four way junction between bases 1056-1057 and 1086-1087. Because a ligand that can modify the folding of the RNA would be predicted to disrupt or otherwise modify the GTPase activity, this folded RNA structure represents a strong target for development of inhibitors or activators of the GTPase. Because the Cd" ion likely stabilizes the unusual RNA fold, the region defined by those amino acid and RNA residues interacting with the Cd" ion is particularly attractive as a target. 5. The Lll C terminus.GAR RNA interface. The domain comprising the interaction surface of the C terminal lobe of LI 1 and the GAR RNA is defined by the crystal structure data disclosed in Table II (X-ray co-ord's) and is described herein above. The crystal data indicate that the C terminus of LI 1 interacts very tightly with the GAR RNA. As such, the interaction may be difficult to disrupt. Computer simulation techniques similar to those described above for modeling the LI 1 N terminus: GAR RNA interface may be used to determine which parameters of the binding pocket may be exploited in designing or screening compounds that interact with the C terminal Ll l: GAR RNA interface domain and/or modify the activity of the GTPase. The analysis of the various targets made possible by the crystal structure coordinate data disclosed herein, including the GAR RNA:L11 interface, the GAR RNA:L11: Micrococcin interface, the Ll l N terminus:Ll l C terminus interface (with or without GAR RNA), the GAR RNA:EF-G interface, and the GAR RNA:L11 :EF-G interface, may be used to define specific features (e.g., a pattern of hydrogen bond donors and acceptors, a hydrophobic patch, etc.) of these targets. These features in turn define a three dimensional "pharmacophore" pattern. This pattern can then be used to screen virtual libraries of existing compounds, such as the Available Chemical - 40- SUBST..UTE SHEET (RULE26) Directory (MDL, Inc.) for compounds exhibiting the desired combination of chemical entities. In this screening, the quality of fit of such entities or compounds to the target site may be judged by a scoring fuction. The scoring function can account for shape complementarity (Katchalski-Katzir et al., 1992, Proc. Natl. Acad. Sci. USA, 89, pp.2195-2199.), estimated interaction energy (Meng et al., 1992, J.Comp. Chem., 13, pp. 505-524), surface accessibility, or a combination of these (see for example, Bohm, 1994, J. Comp. Aided Mol. Design, pp.243-256). A program such as Catalyst (MSI) can perform this task. Libraries of compounds can also be screened virtually using the coordinates of the targets and molecular docking programs such as DOCK (UCSF) or FLEXX. Once one or more compounds have been identified as potential ligands using any of the methods described above, they may be screened for biological activity. A variety of assays can be used to evaluate the activity of compounds designed to inhbit the activity of the LI 1/GAR. These include, but are not limited to: inhibition of bacterial growth, inhibition of in vitro protein synthesis using messenger RNA as a template, inhibition of the elongation phase of in vitro protein synthesis using polyU as a template, inhibition of GTP hydrolysis mediated by EF-G as described by Pestka (1970) and Rodnina et al. (1997); activation of GTP hydrolysis mediated by EF-G as described by Cundliffe and Thompson (1981). Binding of EF-G to both the LI 1/GAR complex and to the sarcin/ricin domain can be measured as described by Munishkin and Wool (1997, Proc. Natl. Acad. Sci. USA 94, 12280-12284; "The ribosome in pieces: Binding of elongation factor EF-G to oligoribonucleotides that mimic the sarcin ricin and thiostrepton domains of 23 S ribosomal RNA"). In addition, compound interaction with the LI 1/GAR complex can be evaluated by direct binding assays. Filter binding assays that measure the ability of thiostrepton to cause retention of radiolabelled GAR RNA to nitrocellulose filters have been described by GuhaThakurta and Draper (1999; Biochemistry, 38, 3633-3640 "Protein-RNA sequence covariation in a ribosomal protein- rRNA complex"). As revealed herein, these assays can be modified to evaluate small molecules that competitively inhibit the binding of thiostrepton and/or micrococcin to the LI 1/GAR complex or - 41- SUBSTITUTESHEET(RULK6) to GAR. For molecules that do not themselves cause filter retention, the RNA may be labelled. For molecules that do cause filter retention, the RNA and or RNA- protein complex can be immobilised on a solid support and the binding of radiolabelled thiostrepton or other known LI 1/GAR binding compound can be measured. Thiostrepton or micrococcin can be labelled metabolically by incoφoration of 35 S, 3H or 14C labelled precursors, or post- synthetically by modifcation of the molecule with radiolablled precursors. In addition thiostrepton or micrococcin can be labelled with another detectable group, including, but not limited to, fluorescent and luminescent groups. Displacement assays can also be performed by using as reporter molecules any labelled molecule that binds to the LI 1/GAR complex or GAR RNA with an affinity of 50 uM or less. Suitable reporters include, but are not limited to, oligonucleotides, peptides and oligonucleotide- peptide conjugates. Libraries for Screening According to the Invention. Inhibitors and/or activators identified according to the methods of the invention may be provided from libraries of compounds available from a number of sources or may be derived by combinatorial chemistry approaches known in the art. Such libraries include but are not limited to the available Chemical Directory, Maybridge, and natural product collections. Compounds identified as ligands using the methods described herein may be further optimized to improve binding activity. Using the docked models of the known ligands thiostrepton and micrococcin, it is possible to identify structures of the ligand that may be altered to improve binding affinity. Similarly, features of a ligand that are identified as unimportant for binding may be excluded to reduce the molecular weight of the ligand. EXAMPLES In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative puφoses only - 42- SUBSTπUTESHEET RU and are not to be construed as limiting this invention in any manner. EXAMPLE 1: Preparation and Analysis of Lll/GAR RNA Crystal. A. Sample Preparation The gene for T. maritima ribosomal protein Ll l was cloned and overexpressed in E. coli using the T7-based expression system (Studier et al., 1990). The protein was purified by a combination of cation-exchange, hydroxylapatite and size-exclusion chromatography as reported for the purification of ribosomal protein S7 (Wimberly et al., 1997). For cocrystallization with RNA, the protein was dialysed into a buffer A containing 0.1 M KC1, 5 mM Na-cacodylate pH 6.0, 0.1 mM Na2EDTA, 1 mM DTT. A fragment of RNA corresponding to nucleotides 1111-1168 of T maritima 23 S rRNA was synthesized by in vitro run-off transcription from a linearized plasmid using T7 RNA polymerase. The plasmid contained the following elements: a T7 promoter, a self-cleaving hammerhead ribozyme to generate a homogeneous RNA 5' end (Price et al., 1995), a template for the target RNA sequence, and a Pst I site used for plasmid linearization. RNA was purified on denaturing polyacrylamide slab gels, eluted, concentrated by ethanol precipitation, and dialyzed into buffer A. The RNA was rearmealed by heating to 90 0C and slow cooling. Ll l protein was added to yield a 1: 1 RNA:protein mixture, which was concentrated to 0.15 mM in each component for crystallization experiments. B. Crystallization and Structure Determination Crystals of the complex were obtained at 40C using the hanging drop technique. The equimolar mixture of LI 1 and RNA in dialysis buffer A was mixed with an equal volume of well solution (25% glycerol, 15% PEG 4000, 0.2 M KC1, 50 mM MgC12, 20 mM CdC12, 1 mM DTT, 50 mM Tris pH 7.5 at 220C). The crystals were in the space group P212121, with cell dimensions of a = 63.9 A, b = 84.3 A and c - 155.5 A, and diffracted to better than 2.6 A resolution using a synchrotron source. Diffraction data were collected under cryogenic conditions, and the crystals were flash- frozen by plunging into liquid nitrogen. For mercury derivatization, crystals were soaked for 24 hours in the well solution containing 1 mM CH3HgNO3 but lacking DTT. Efforts to obtain cocrystals of RNA with selenomethione-substituted LI 1 were unsuccessful, apparently because the preparation of selenomethionyl Ll l used was at least partly misfolded. The structure was solved using a multiwavelength anomalous diffraction (MAD) experiment (Hendrickson, 1991) on the methylmercury derivative. Straightforward isomoφhous replacement was not possible because the derivative is not isomoφhous with native crystals. Because the mercury LIII edge does not have a significant white line, data were collected at just two wavelengths, the inflection point of the mercury edge at 1.01 A and a remote wavelength at 0.98 A. This remote wavelength is near the maximum f" for accurate measurement of anomalous differences, and is also sufficiently remote from the inflection point to give useful isomoφhous differences. Data were collected from a single flash-cooled crystal at beamline X12-C of the NSLS. To optimize measurement of anomalous differences, we used the inverse beam method in which pairs of sweeps separated by 180 degrees in were collected every 30 degrees. The data were integrated and scaled using the HKL suite of programs (Otwinowski and Minor, 1997). Phasing was done by treating MAD as a special case of MIR (Ramakrishnan and Biou, 1997; Ramakrishnan et al., 1993). Local scaling of the data, determination of initial heavy atom sites, and initial phasing was done using the program SOLVE (Terwilliger and Berendzen, 1999). Subsequent phasing was done using the program SHARP (de la Fortelle and Bricogne, 1997). A significant improvement in phasing was obtained by including several well-ordered cadmium sites in a final round of SHARP heavy atom refinement. Each round of phasing was followed by density modification with Solomon (Abrahams and Leslie, 1996). The unaveraged, solvent-flattened map revealed virtually unbroken main-chain density for the RNA and the LI 1 C-terminal domains of both complexes in the asymmetric unit, which were easily built using the program O (Jones and Kjeldgaard, 1997). Twofold non-crystallographic symmetry (NCS) averaging followed by solvent flattening was then carried out using NCS and solvent masks based on the RNA and C-terminal domain coordinates. The resulting map was of high quality and revealed a few minor building errors, but the Ll l N-terminal domain density was still of insufficient quality to permit unambiguous fitting. Inteφretation of the density for the entire LI 1 N-terminal domain was possible only from iterative rounds of refinement and 2E 0 -E_ maps. The final model was refined to an Rfree of 27 % using the program X-PLOR (Briinger, 1988) using standard parameters for protein (Εngh and Huber, 1991) and nucleic acid (Parkinson et al., 1996) structure refinement. Magnesium and cadmium ions were distinguished by inspection of an anomalous difference Fourier map. Magnesium ions were distinguished from ordered waters by inspection of 2F 0 -F C maps, in which an octahedral coordination of magnesium by water and RNA ligands was often visible. A Ramachandran plot of the protein revealed only three outliers, Lys93 in the C-terminal domain, which clearly has a positive phi angle in the original experimental map, and Ala21 and Val24 in the N-terminal domain, for which the side chains are very poorly defined. Details of the data collection, phasing and refinement are shown in Table I. EXAMPLE 2. Use of the Ribosomal Protein Lll/GAR Crystal Structure Coordinates to Design a Modulator of GAR Activity. Example 1 illustrates the methods involved in generating a structure of the LI 1/GAR RNA complex at atomic resolution. The crystal structure data make clear, for example, that the N terminus of LI 1 can move within the context of the LI 1/GAR. Because the crystal structure data, in conjunction with available biochemical data, point to a molecular switch mechanism whereby the relative position of the LI 1 N terminal lobe determines the activity of the GAR, it is of interest to select or design compounds that can effect restriction of modification of this movement. 1. Modeling the movement and interactions of the LI 1 N terminal lobe. One of skill in the art may use the crystal structure coordinates, along with the software package Quanta to interactively model the movement of the LI 1 N terminus as a rigid body relative to the other GAR surfaces. This model will provide information on the many possible interactions between the LI 1 N terminus and the other amino acid and nucleotide residues comprising the GAR, as well as solvent interactions. To develop a more detailed picture of the molecular interactions involving the Ll l N terminal lobe in the GAR, the software packages CHARMM and AMBER may be applied by one of skill in the art to the crystal structure coordinates. These will provide a molecular dynamics simulation of the N terminal lobe of LI 1 within the LI 1/ GAR RNA complex. Similarly, CHARMM may be used by one of skill in the art to provide a normal mode dynamics simulation of the LI 1 N terminal lobe within the LI 1/GAR context. Finally, the crystal structure coordinates allow the use of software packages such as DOCK or to simulate docking of the known GAR modulators thiostrepton and micrococcin with the GAR, thereby providing a finely detailed description of those interactions within the GAR critical to its function. Used in combination, the software approaches described above can manipulate the crystal structure coordinate data to provide a very high resolution three dimensional model of the LI 1 N terminal lobe and its interactions with other portions of the GAR including van der Waals contacts, electrostatic interactions and hydrogen bonding opportunities. 2. Design of a candidate modulator compound. Once a detailed three dimensional model of the LI 1/GAR has been created as described above, one of skill in the art may use the grid-based software approaches GRID or CERIUS II, and MCSS techniques (see, for example, Castro et al., 1999, Medicinal Chem. Res. 9: 98-107) to map favorable interaction positions for functional groups such as protons, hydroxyl groups, anime groups, divalent cations, aromatic and aliphatic functional groups, acetamide, methanol, etc. Once a set of favorable groups for each position are predicted, one of skill in the art may take one of two different approaches to designing a modulator. First, one may assemble the moieties predicted to interact with the various critical parts of the LI 1/GAR surfaces into a single molecule. This may be accomplished by one of skill in the art using the software packages CAVEAT, MACCS-3D or HOOK. One of skill in the art may then synthesize the selected compounds for in vitro and in vivo testing for effects on GAR activity. Alternatively, one may screen a database, such as the MDL Available Chemical Directory to potentially find existing compounds that combine the required moieties in a favorable conformation for GAR binding. The software packages Catalyst, DOCK and FLEXX may be used to advantage for this puφose by one of skill in the art. EXAMPLE 3. Assaying the Activity of a Candidate Modulator by Displacement of Thiostrepton from the GAR Thiostrepton binding to GTPase centre RNA can be monitored by a filter binding assays (Uchiumi et al., 1995, Biol. Chem., 270(50):29889-93; Draper et al., 1988, Methods Enzymol., 164:203-20). The filter binding assay can be transformed to a 96-well format using Millipore MHAB (mixed cellulose ester) 96-well plates. The dissociation constant for the thiostrepton/GTPase centre-59mer complex of luM is in good accordance with the literature. Additionally, filter binding can show the cooperativity in binding of thiostrepton and Ll l. Thermotoga maritima ribosomes are known to be sensitive to thiostrepton (Londei et al., 1988, J. Bacteriol., 170(9):4353-60), although 100-fold less than B. stearothermophilus ribosomes. The affinity of thiostrepton for Thermotoga GTPase center RNA in vitro has not yet been determined. 35 S- or 32 P-labelled RNA is prepared by transcription in the presence of radiolabelled nucleotides. The labelled RNAs are purified by gel electrophoresis or chromatography by reverse- phase. For filter binding assays the RNA are renatured and 3,000 to 10,000 cpm of RNA are used per assay. Association constants between RNA and thiostrepton in the presence or absence of inhbitor are determined in 100 ul reactions containing 10 mM Tris-HCl (pH 7.4), 3 mM MgC12, 175 mM NH4C1 and 5% v/v DMSO. The reaction mixtures also contain between 2 and 10 uM thiostrepton and a range of inhibitor concentrations up to 50 uM. The RNA-thiostrepton-inhibitor mixtures are incubated for 15 min at room temperature (approximately 22°C) prior to filtration through the nitrocellulose filter membranes. For high-throughput screening, the assay can be performed in 96-well filter plates (Multiscreen HA filtration plates, Millipore) with nitrocellulose membranes incoφorated into the bottom of each well and filtered using Multiscreen vacuum Manifold ( Millipore). The filters are washed once with 100 ul buffer before determining their radioactivities using Microbeta Liquid Scintillation Counter (Wallac). The relative amounts of RNA retained in the presence and absence of inhibitor can be determined by quantitation of the radioactivity on each filter. Compounds that reduce the amount of RNA retained on the filter in a concentration dependent manner are competitive inhibitors of thiostrepton binding to the RNA. EXAMPLE 4. Binding assays with radioactive thiostrepton Binding of [ 35 S]-labelled thiostrepton to 23 S RNA and ribosomes has been shown by gel filtration of RNA and RNA/L11 complexes together with thiostrepton as well as by charcoal (Norit) absoφtion of unbound [ 35 S]thiostrepton (Thompson et al., 1979. Eur. J. Biochem., 98(l):261-5). Using equilibrium dialysis, the dissociation constant of thiostrepton/23S RNA has been determined as 0.23uM (Thompson & Cundliffe, 1991, Biochimie 1991, 73(7-8): 1131-5). The affinity to intact ribosomes is 100-lOOOfold higher (Pestka et al., 1976, Anal. Biochem., 71(1): 137-42). The ability of biotinylated GTPase centre-59mer to bind thiostrepton (as shown by filter binding) gives a route for a displacement assay employing displacement of [ 3 H]-labelled thiostrepton (Amersham) from an immobilised GTPase centre RNA/Ll l complex or from ribosomes. EXAMPLE 5. Luciferase translation assay Using an E. coli S30 lysate and luciferase mRNA (Promega E. coli S30 extract system for linear templates; Cat No: L1030) the active luciferase protein can be synthesised in vitro and the relative amount of luciferase generated is monitored in a bioluminescence assay. The mRNA is either provided by coupled transcription/translation using the linearized plasmid pBESTLucTM as - 48- SUBSTΪTUTESHEET(RULE26) a template or by adding purified luciferase mRNA. The addition of ribosome-inactivating compounds or antibiotics directed to protein biosynthesis (thiostrepton, kanamycin, chloramphenicol and others) leads to a decrease in yield of active luciferase compared to the control. Compound and antibiotic titrations can be used to determine IC50 values (see Langer et al., 1996, Anal. Biochem., 243(l):150-3). EXAMPLE 6. Additional translation assays An S30 transcription/translation system (Promega) can be used to incoφorate [ 35 S]methionine into protein translated from MS2 phage RNA. Translation yield is quantified after alkaline hydrolysis by acid precipitation of the synthesised peptides and scintillation counting. Whole-cell protein synthesis can be measured adding [ 14 C]leucine to exponentially growing E. coli cells and measuring the incoφoration into protein by alkaline hydrolysis and TCA precipitation (see Shinabarger et al., 1997, Antimicrob. Agents Chemother., 41(10):2132-6). EXAMPLE 7. Assay of Translation Elongation Translation elongation is measured using isolated polysomes from E. coli MRE600 (Girbes et al., 1979, Methods Enzymol., 59:353-62), S100 extract from E. coli and poly(U) (Sigma) as a template (e.g. Grise-Miron et al., 1981, Biochim. Biophys. Acta, 656(1):103-10). Incoφoration of [ 3 H]phenylalanine into polyphenylalanine is quantified by acid precipitation and scintillation counting. EXAMPLE 8. In vitro EF-G-dependent GTP Hydrolysis Thiostrepton acts on the tRNA translocation step of translation elongation and inhibits elongation factor G (EF-G)-dependent GTP hydrolysis (Pestka et al., 1970, Biochem. Biophys. Res. Commun., 40(3):667-74; Rodnina et al, 1997, Nature, 385:37-41). EF-G is known to contact the GTPase centre region of 23S RNA (Skold et al., 1983, Nucleic Acids Res., 11(14):4923-32; Moazed & Noller, 1986, Nature, 334:362-4). 70S ribosomes support GTP hydrolysis by EF-G in the absence of other factors normally necessary for protein synthesis. Uncoupled GTP hydrolysis and the inhibition by thiostrepton or other compounds can be measured in an assay containing purified ribosomes, purified EF-G and gamma-[ 32 P]-GTP (Stark&Cundliffe, 1979, J. Mol. Biol, 134(4):767- 9; Lill et al., 1988, EMBO J., 8(12):3933-8). References Abrahams, J. P., and Leslie, A. G. W. (1996). Methods used in the structure determination of bovine mitochondrial FI ATPase. Acta Cryst. D52, 30-42. Briones, E., Briones, C, Remacha, M., and Ballesta, J. P. (1998). The GTPase center protein L12 is required for correct ribosomal stalk assembly but not for Saccharomyces cerevisiae viability. J Biol Chem 273, 31956-61. Briinger, A. T. (1988). Crystallographic refinement by simulated annealing. Application to a 2.8 A structure of aspartate aminotransferase. J. Mol. Biol. 203, 803-16. Bukhman, Y. V., and Draper, D. E. (1997). Affinities and selectivities of divalent cation binding sites within an RNA tertiary structure. J Mol Biol 273, 1020-31. Carson, M. (1991). Ribbons 2.0. J.Appl.Cryst. 24, 958-961. Cate, J., Gooding, A., Podell, E., Zhou, K., Golden, B., Szewczack, A., Kundrot, C, Cech, T., and Doudna, J. (1996). RNA Tertiary Structure Mediation by Adenosine Platforms. Science 273, 1696- 1699. Cate, J. H., Gooding, A. R., Podell, E., Zhou, K., Golden, B. L., Kundrot, C. E., Cech, T. R., and Doudna, J. A. (1996). Crystal structure of a group I ribozyme domain: principles of RNA packing. - 50- SUBSTITUTE SHEET (RLIIE26) Science 273, 1678-85. Conn, G. L., Gutell, R. R., and Draper, D. E. (1998). A functional ribosomal RNA tertiary structure involves a base triple interaction. Biochemistry 37, 1 1980-8. Cundliffe, E. (1986). Involvement of specific portions of rRNA in defined ribosomal functions: a study utilizing antibiotics. In Structure, Function and Genetics of Ribosomes, B. Hardesty and G. Kramer, eds. (New York: Springer- Verlag), pp. 586-604. Cundliffe, E., and Thompson, J. (1981). Concerning the mode of action of micrococcin upon bacterial protein synthesis. Eur J Biochem 118, 47-52. Cundliffe, E., and Thompson, J. (1979). Ribose methylation and resistance to thiostrepton. Nature 275, 859-61. de la Fortelle, E., and Bricogne, G. (1997). Maximum-likelihood heavy-atom parameter refinement for multiple isomoφhous replacement and multiwavelength anomalous diffraction methods. In Methods in Enzymology, C. W. Carter, Jr. and R. M. Sweet, eds. (New York: Academic Press), pp. 472-93. Dormer, D., Villems, R., Liljas, A., and Kurland, C. G. (1978). Guanosinetriphosphatase activity dependent on elongation factor Tu and ribosomal protein L7/L12. Proc Natl Acad Sci U S A 75, 3192-5. Draper, D. E., and Xing, Y. (1995). Protein recognition of a ribosomal RNA tertiary structure. Nucleic Acids Symp Ser 33, 5-7. Engh, R. A., and Huber, R. (1991). Accurate bond and angle parameters for x-ray protein structure refinement. Acta Cryst. A47, 392-400. Ferre-D'Amare, A. R., Zhou, K., and Doudna, J. A. (1998). Crystal structure of a hepatitis delta virus ribozyme. Nature 395, 567-74. Fountain, M. A., Serra, M. J., Krugh, T. R., and Turner, D. H. (1996). Structural features of a six- nucleotide RNA haiφin loop found in ribosomal RNA. Biochemistry 35, 6539-48. Glotz, C, Zwieb, C, Brimacombe, R., Edwards, K., and Kόssel, H. (1981). Secondary structure of the large subunit ribosomal RNA from Escherichia coli, Zea mays chloroplast, and human and mouse mitochondrial ribosomes. Nucleic Acids Res 9, 3287-306. Gruenwedel, D. W., and Davidson, N. (1966). Complexing and denaturation of DNA by methylmercuric hydroxide. I. Spectrophotometric studies. J Mol Biol 21, 129-44. Gruenwedel, D. W., and Davidson, N. (1967). Complexing and denaturation of DNA by methylmercuric hydroxide. II. Ultracentrifugation studies. Biopolymers 5, 847-61. Hendrickson, W. A. (1991). Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254, 51-58. Hinck, A. P., Markus, M. A., Huang, S., Grzesiek, S., Kustonovich, I., Draper, D. E., and Torchia, D. A. (1997). The RNA binding domain of ribosomal protein Ll l: three-dimensional structure of the RNA-bound form of the protein and its interaction with 23 S rRNA. J Mol Biol 274, 101-13. - 52- SUBSTITUTE SHET(RULE26) Jones, T. A., and Kjeldgaard, M. (1997). Electron-density map inteφretation. Meth. Enzymol. 277B, 173-207. Kosturko, L. D., Folzer, C, and Stewart, R. F. (1974). The crystal and molecular structure of a 2:1 complex of 1-methylthymine- mercury (II). Biochemistry 13, 3949-52. Kraulis, P. (1991). MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-50. Lu, M., and Draper, D. E. (1994). Bases defining an ammonium and magnesium ion-dependent tertiary structure within the large subunit ribosomal RNA. J Mol Biol 244, 572-85. Lu, M., and Draper, D. E. (1995). On the role of rRNA tertiary structure in recognition of ribosomal protein LI 1 and thiostrepton. Nucleic Acids Res 23, 3426-33. Markus, M. A., Hinck, A. P., Huang, S., Draper, D. E., and Torchia, D. A. (1997). High resolution solution structure of ribosomal protein LI 1-C76, a helical protein with a flexible loop that becomes structured upon binding to RNA. Nat Struct Biol 4, 70-7. Moazed, D., Robertson, J. M., and Noller, H. F. (1988). Interaction of elongation factors EF-G and EF-Tu with a conserved loop in 23S RNA. Nature 334, 362-4. Munishkin, A., and Wool, I. G. (1997). The ribosome- in-pieces: binding of elongation factor EF-G to oligoribonucleotides that mimic the sarcin/ricin and thiostrepton domains of 23 S ribosomal RNA. Proc Natl Acad Sci U S A 94, 12280-4. Nicholls, A., Shaφ, K. A., and Honig, B. (1991). Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 281-96. Nissen, P., Kjeldgaard, M., Thirup, S., Polekhina, G., Reshetnikova, L., Clark, B. F., and Nyborg, J. (1995). Crystal structure of the ternary complex of Phe-tRNAPhe, EF-Tu, and a GTP analog. Science 270, 1464-72. Noller, H. F., Kop, J., Wheaton, V., Brosius, J., Gutell, R. R., Kopylov, A. M., Dohme, F., Herr, W., Stahl, D. A., Gupta, R., and Waese, C. R. (1981). Secondary structure model for 23S ribosomal RNA. Nucleic Acids Res 9, 6167-89. Otwinowski, Z., and Minor, W. (1997). Processing of x-ray diffraction data collected in oscillation mode. In Methods in Enzymology, C. W. J. Carter and R. M. Sweet, eds. (New York: Academic Press), pp. 307-25. Parkinson, G., Vojtechovsky, J., Clowney, L., Briinger, A. T., and Berman, H. M. (1996). New parameters for the refinement of nucleic acid containing structures. Acta Cryst. D52, 57-64. Pestka, S. (1970). Thiostrepton: a ribosomal inhibitor of translocation. Biochem Biophys Res Commun 40, 667-74. Porse, B. T., Cundliffe, E., and Garrett, R. A. (1999). The antibiotic micrococcin acts on protein LI 1 at the ribosomal GTPase centre. J. Mol. Biol. 257, 33-45. Porse, B. T., Leviev, I., Mankin, A. S., and Garrett, R. A. (1998). The antibiotic thiostrepton inhibits a functional transition within protein LI 1 at the ribosomal GTPase centre. J Mol Biol 276, 391-404. Price, .S. R., Ito, N., Oubridge, C, Avis, J. M., and Nagai, K. (1995). Crystallisation of RNA-protein complexes. I. Methods for the large-scale preparation of RNA suitable for crystallographic studies. J. Mol. Biol. 249, 398-408. Quigley, G. J., and Rich, A. (1976). Structural domains of transfer RNA molecules. Science 194, 796-806. Ramakrishnan, V., and Biou, V. (1997). Treatment of multiwavelength anomalous diffraction data as a special case of multiple isomoφhous replacement. In Meth. Enzymol., C. W. Carter, Jr. and R. M. Sweet, eds. (New York: Academic Press), pp. 538-57. Ramakrishnan, V., Finch, J. T., Graziano, V., Lee, P. L., and Sweet, R. M. (1993). Crystal structure of globular domain of histone H5 and its implications for nucleosome binding. Nature 362, 219-23. Ramakrishnan, V., and White, S. W. (1998). Ribosomal protein structures: insights into the architecture, machinery and evolution of the ribosome. Trends Biochem Sci 23, 208-12. Rodnina, M. V., Savelsbergh, A., Katunin, V. I., and Wintermeyer, W. (1997). Hydrolysis of GTP by elongation factor G drives tRNA movement on the ribosome. Nature 355, 37-41. Rosendahl, G., and Douthwaite, S. (1994). The antibiotics micrococcin and thiostrepton interact directly with 23S rRNA nucleotides 1067A and 1095A. Nucleic Acids Res 22, 357-63. Rosendahl, G., and Douthwaite, S. (1993). Ribosomal proteins Ll l and L10.(L12)4 and the antibiotic thiostrepton interact with overlapping regions of the 23 S rRNA backbone in the ribosomal GTPase centre. J Mol Biol 234, 1013-20. - 55- SUBSTITUTE SHEET (RULE26| Schmidt, F. J., Thompson, J., Lee, K., Dijk, J., and Cundliffe, E. (1981). The binding site for ribosomal protein LI 1 within 23 S ribosomal RNA of Escherichia coli. J Biol Chem 256, 12301-5. Sopori, M. L., and Lengyel, P. (1972). Components of the 50S ribosomal subunit involved in GTP cleavage. Biochem Biophys Res Commun 46, 238-44. Spahn, C. M., and Nierhaus, K. H. (1998). Models of the elongation cycle: an evaluation. Biol Chem 379, 753-72. Stoffler, G., Cundliffe, E., Stoffler-Meilicke, M., and Dabbs, E. R. (1980). Mutants of Escherichia coli lacking ribosomal protein LI 1. J Biol Chem 255, 10517-22. Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990). Use of T7 RNA polymerase to direct expression of cloned genes. Meth. Enzymol. 755, 61-89. Szewczak, A. A., Moore, P. B., Chang, Y. L., and Wool, I. G. (1993). The conformation of the sarcin ricin loop from 28S ribosomal RNA. Proc Natl Acad Sci U S A 90, 9581-5. Terwilliger, T., and Berendzen, J. (1999). Automated MAD and MIR structure determination. Acta Cry st D (in press). Thompson, J., Cundliffe, E., and Stark, M. (1979). Binding of thiostrepton to a complex of 23-S rRNA with ribosomal protein LI 1. Eur J Biochem 98, 261-5. Thompson, J., Schmidt, F., and Cundliffe, E. (1982). Site of action of a ribosomal RNA methylase conferring resistance to thiostrepton. J Biol Chem 257, 7915-7. Wang, Y. X., Lu, M., and Draper, D. E. (1993). Specific ammonium ion requirement for functional ribosomal RNA tertiary structure. Biochemistry 32, 12279-82. Wilson, K. S., and Noller, H. F. (1998). Mapping the position of translational elongation factor EF- G in the ribosome by directed hydroxyl radical probing. Cell 92, 131-9. Wilson, K. S., and Noller, H. F. (1998). Molecular movement inside the translational engine. Cell 92, 337-49. Wimberly, B. (1994). A common RNA loop motif as a docking module and its function in the hammerhead ribozyme. Nat Struct Biol 1, 820-7. Wimberly, B., Varani, G., and Tinoco, I., Jr. (1993). The conformation of loop E of eukaryotic 5S ribosomal RNA. Biochemistry 32, 1078-87. Wimberly, B. T., White, S. W., and Ramakrishnan, V. (1997). The structure of ribosomal protein S7 at 1.9 A resolution reveals a beta-haiφin motif that binds double-stranded nucleic acids. Structure 5, 1187-98. Xing, Y., and Draper, D. E. (1996). Cooperative interactions of RNA and thiostrepton antibiotic with two domains of ribosomal protein Ll l. Biochemistry 35, 1581-8. Xing, Y., and Draper, D. E. (1995). Stabilization of a ribosomal RNA tertiary structure by ribosomal protein L 11. J Mol Biol 249, 319-31. - 57- TITUTE SHEET (RULE2SS Xing, Y., Guha Thakurta, D., and Draper, D. E. (1997). The RNA binding domain of ribosomal protein LI 1 is structurally similar to homeodomains. Nat Struct Biol 4, 24-7. Table I Crystallographic statistics Data collection SI (1.008 A S2 (0.980 A) Reflections 104,096 107,907 Independent reflections 25,927 25,894 Completeness 99% (98%)* 98% (97%)* Mean (II sigma (T)) 20 (4.2)* 20 (4.5)* ■ ^sym 4.1% (17%)* 4.2% (17%)* "min (A) 2.6 2.6 /' (Hg) (electrons)** -12.0 -9.0 f" (Hg) (electrons)** 6.4 8.0 /' (Cd) (electrons)** -0.42 -0.46 f" (Cd) (electrons)** 2.3 2.2 *Values in parentheses refer to the highest resolution shell. ** Values after SHARP refinement. Phasing S1-S2 isomoφhous SI anomalous S2 anomalous ^ C uiii s (centrics) 0.50 — — Λ Krau t (acentrics) 0.09 0.025 0.023 Phasing power (acentrics) 1.25 1.54 1.52 Mean figure of merit (acentrics) 0.39 Mean figure of merit (centrics) 0.23 Refinement Number of atoms 4196 (2474 RNA, 1524 protein, 198 water & ions) Rcryst / Λ free ( 5% of data ) °- 228 f °- 253 RMS deviation from ideal geometry bond lengths 0.005 A bond angles 1.2 degrees TABLE II HEADER RNA-PROTEIN COMPLEX 14-APR-99 ONHOLD ONE- YEAR HOLD; EXPERIMENTAL DATA, ONE- YEAR HOLD TITLE CRYSTAL STRUCTURE OF THE RIBOSOMAL PROTEIN L 11 -RNA COMPLEX COMPND MOLJD: 1; COMPND 2 MOLECULE: 23 S RIBOSOMAL RNA; COMPND 3 CHAIN: C, D; COMPND 4 FRAGMENT: FRAGMENT 1051-1108; COMPND 5 MUTATION: U1108C; COMPND 6 OTHER DETAILS: COVALENT MERCURY LIGAND AT U 1061; COMPND 7 MOLJD: 2; COMPND 8 MOLECULE: RIBOSOMAL PROTEIN Ll l; COMPND 9 CHAIN: A, B; COMPND 10 ENGINEERED: YES; COMPND 11 OTHER_DETAILS: COVALENT MERCURY LIGAND AT CYS39 SOURCE MOLJD: 1; SOURCE 2 ORGANISM_SCIENTIFIC: THERMOTOGA MARITIMA; SOURCE 3 OTHER JDETAILS: IN VITRO TRANSCRIBED RNA; SOURCE 4 MOLJD: 2; SOURCE 5 ORGANISM_SCIENTIFIC: THERMOTOGA MARITIMA; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSIONS YSTEM_PLASMID: PET 13 A; SOURCE 9 OTHER JDETAILS: RECOMBINANT PROTEIN KEYWDS RNA-PROTEIN COMPLEX, RNA, RIBOSOME, TRANSLOCATION, KEYWDS 2 THIOSTREPTON EXPDTA X-RAY DIFFRACTION AUTHOR B.T.WIMBERLY,R.GUYMON,J.P.MCCUTCHEON,S.W.WHITE, AUTHOR 2 V.RAMAKRISHNAN REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH Y.XING,D.DRAPER REMARK 1 TITL COOPERATIVE INTERACTIONS OF RNA AND THIOSTREPTON REMARK 1 TITL 2 ANTIBIOTIC WITH TWO DOMAINS OF RIBOSOMAL PROTEIN REMARK 1 TITL 3 Ll l REMARK 1 REF BIOCHEMISTRY V. 35 1581 1996 REMARK 1 REFN ASTM BICHAW US ISSN 0006-2960 0033 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.THOMPSON,F.SCHMIDT,E.CUNDLIFFE REMARK 1 TITL SITE OF ACTION OF A RIBOSOMAL RNA METHYLASE REMARK 1 TITL 2 CONFERRING RESISTANCE TO THIOSTREPTON REMARK 1 REF J.BIOL.CHEM. V. 257 7915 1982 REMARK 1 REFN ASTM JBCHA3 US ISSN 0021-9258 0071 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.THOMPSON,E.CUNDLIFFE,M.STARK REMARK 1 TITL BINDING OF THIOSTREPTON TO A COMPLEX OF 23 S RNA REMARK 1 TITL 2 WITH RIBOSOMAL PROTEIN Ll l REMARK 1 REF EUR.J.BIOCHEM. V. 98 261 1979 REMARK 1 REFN ASTM EJBCAI IX ISSN 0014-2956 0262 - 59- SUBSTITUTE SHEET (RUIE26) REMARK REMARK 2 RESOLUTION. 2.57 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK PROGRAM : X-PLOR 3.851 REMARK AUTHORS BRUNGER REMARK REMARK DATA USED IN REFINEMENT. REMARK RESOLUTION RANGE HIGH (ANGSTROMS) : 2.57 REMARK RESOLUTION RANGE LOW (ANGSTROMS) : 20.0 REMARK DATA CUTOFF (SIGMA(F)) : 0.0 REMARK DATA CUTOFF HIGH (ABS(F)) : 1000000.0 REMARK DATA CUTOFF LOW (ABS(F)) : 0.001 REMARK COMPLETENESS (WORKING+TEST) (%) : 95.5 REMARK NUMBER OF REFLECTIONS : 49313 REMARK REMARK FIT TO DATA USED IN REFINEMENT. REMARK CROSS-VALIDATION METHOD : THROUGHOUT REMARK FREE R VALUE TEST SET SELECTION : RANDOM REMARK R VALUE (WORKING SET) : 0.219 REMARK FREE R VALUE : 0.254 REMARK FREE R VALUE TEST SET SIZE (%) : 4.9 REMARK FREE R VALUE TEST SET COUNT : 2398 REMARK ESTIMATED ERROR OF FREE R VALUE : 0.005 REMARK REMARK FIT IN THE HIGHEST RESOLUTION BIN. REMARK TOTAL NUMBER OF BINS USED : 6 REMARK BIN RESOLUTION RANGE HIGH (A) : 2.57 REMARK BIN RESOLUTION RANGE LOW (A) : 2.73 REMARK BIN COMPLETENESS (WORKING+TEST) (%) : 86.2 REMARK REFLECTIONS IN BIN (WORKING SET) : 7101 REMARK BIN R VALUE (WORKING SET) : 0.386 REMARK BIN FREE R VALUE : 0.432 REMARK BIN FREE R VALUE TEST SET SIZE (%) : 4.5 REMARK BIN FREE R VALUE TEST SET COUNT : 331 REMARK ESTIMATED ERROR OF BIN FREE R VALUE : 0.024 REMARK REMARK NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT REMARK PROTEIN ATOMS : 1524 REMARK NUCLEIC ACID ATOMS : 2474 REMARK HETEROGEN ATOMS : 35 REMARK SOLVENT ATOMS : 142 REMARK REMARK B VALUES. REMARK FROM WILSON PLOT (A**2) : 58.8 REMARK MEAN B VALUE (OVERALL, A**2) : 42.8 REMARK OVERALL ANISOTROPIC B VALUE. REMARK B11 (A**2) : NULL REMARK B22 (A**2) : NULL REMARK B33 (A**2) : NULL REMARK B12 (A**2) : NULL - 60- ET R LE26 REMARK B13 (A**2) NULL REMARK B23 (A**2) NULL REMARK REMARK ESTIMATED COORDINATE ERROR. REMARK ESD FROM LUZZATI PLOT (A) : 0.32 REMARK ESD FROM SIGMAA (A) : 0.45 REMARK LOW RESOLUTION CUTOFF (A) : 5.00 REMARK REMARK CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK ESD FROM C-V LUZZATI PLOT (A) : 0.39 REMARK ESD FROM C-V SIGMAA (A) : 0.50 REMARK REMARK RMS DEVIATIONS FROM IDEAL VALUES. REMARK BOND LENGTHS (A) : 0.005 REMARK BOND ANGLES (DEGREES) : 1.0 REMARK DIHEDRAL ANGLES (DEGREES) : 28.8 REMARK IMPROPER ANGLES (DEGREES) : 1.40 REMARK REMARK ISOTROPIC THERMAL MODEL : RESTRAINED REMARK REMARK ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK MAIN-CHAIN BOND (A**2) : 3.59 ; 1.50 REMARK MAIN-CHAIN ANGLE (A**2) : 5.28 ; 2.00 REMARK SIDE-CHAIN BOND (A**2) : 6.59 ; 2.00 REMARK SIDE-CHAIN ANGLE (A**2) : 9.24 ; 2.50 REMARK REMARK NCS MODEL : RESTRAINTS REMARK REMARK NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK GROUP 1 POSITIONAL (A) : 0.07 ; 50 REMARK GROUP 1 B-FACTOR (A**2) : 5.51 ; 2 REMARK GROUP 2 POSITIONAL (A) : 0.07 ; 50 REMARK GROUP 2 B-FACTOR (A**2) : 5.51 ; 2 REMARK REMARK PARAMETER FILE 1 : DNA-RNA-MULTI-ENDO.PARAM REMARK PARAMETER FILE 2 : PROTEIN REP.PARAM REMARK TOPOLOGY FILE 1 DNA-RNA-MULTI-ENDO.TOP REMARK TOPOLOGY FILE 2 TOPHCSDX.PRO REMARK TOPOLOGY FILE 3 TOPH19.SOL REMARK REMARK OTHER REFINEMENT REMARKS: NCS RESTRAINTS APPLIED TO RNA REMARK THROUGHOUT, NOT TO PROTEIN REMARK REMARK WARNING REMARK THIS IS LAYER 1 RELEASE. REMARK REMARK PLEASE NOTE THAT THIS ENTRY WAS RELEASED AFTER DEPOSITOR REMARK CHECKING AND APPROVAL BUT WITHOUT PDB STAFF INTERVENTION. REMARK AN AUXILIARY FILE, AUX .RPT, IS AVAILABLE FROM THE REMARK PDB FTP SERVER AND IS ACCESSIBLE THROUGH THE 3DB BROWSER. REMARK THE FILE CONTAINS THE OUTPUT OF THE PROGRAM WHAT CHECK AND REMARK 5 OTHER DIAGNOSTICS. REMARK 5 REMARK 5 NOMENCLATURE IN THIS ENTRY, INCLUDING HET RESIDUE NAMES REMARK 5 AND HET ATOM NAMES, HAS NOT BEEN STANDARDIZED BY THE PDB REMARK 5 PROCESSING STAFF. A LAYER 2 ENTRY WILL BE RELEASED SHORTLY REMARK 5 AFTER THIS STANDARDIZATION IS COMPLETED AND APPROVED BY REMARK 5 DEPOSITOR. THE LAYER 2 ENTRY WILL BE TREATED AS A REMARK 5 CORRECTION TO THIS ONE, WITH THE APPROPRIATE REVDAT RECORD. REMARK 5 REMARK 5 FURTHER INFORMATION INCLUDING VALIDATION CRITERIA USED IN REMARK 5 CHECKING THIS ENTRY AND A LIST OF MANDATORY DATA FIELDS REMARK 5 ARE AVAILABLE FROM THE PDB WEB SITE AT REMARK 5 HTTP://WWW.PDB.BNL.GOV/. REMARK 6 REMARK 6 THE ASYMMETRIC UNIT CONTAINS- TWO LI 1-RNA COMPLEXES. REMARK 6 1 CONSISTS OF CHAINS A AND C, AND COMPLEX 2 CONSISTS OF REMARK 6 CHAINS B AAND D. RESIDUES 1-7 AND 141 OF CHAIN A ARE REMARK 6 DISORDERED. THE DENSITY FOR RESIDUES 8-70 OF CHAIN A WAS OF REMARK 6 SIGNIFICANTLY LOWER QUALITY THAN THE DENSITY FOR THE REMARK 6 REMAINDER OF THE ASYMMETRIC UNIT, AND THE QUALITY OF THE REMARK 6 MODEL FOR THIS N-TERMINAL DOMAIN IS LOWER THAN THAT OF THE REMARK 6 C-TERMINAL DOMAIN (RESIDUES 71-140). RESIDUES 1-70 AND 141 REMARK 6 OF CHAIN B ARE DISORDERED. THE RNA IS NUMBERED WITH THE E. REMARK 6 COLI NUMBERING TO FACILITATE COMPARISON WITH THE EXTENSIVE REMARK 6 BIOCHEMICAL DATA ON THE E. COLI RNA-L11 SYSTEM. THE E. COLI REMARK 6 RNA NUMBERING IS ALSO USED IN THE PRIMARY REFERENCE REMARK 6 DESCRIBING THIS STRUCTURE. REMARK 7 REMARK 7 TER REMARK 7 ASP: TERMINAL RESIDUE NOT SEEN IN MAPS REMARK 7 ASP: TERMINAL RESIDUE NOT SEEN IN MAPS REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 24-SEP-1998 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.3 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X12C REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98, 1.01 REMARK 200 MONOCHROMATOR : SI CRYSTAL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : BRANDEIS IK X 1 K CCD REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK PARAMETER FILE 2 : PROTEIN JIEP.PARAM REMARK TOPOLOGY FILE 1 DNA-RNA-MULTI-ENDO.TOP REMARK TOPOLOGY FILE 2 TOPHCSDX.PRO REMARK TOPOLOGY FILE 3 TOPHI 9.SOL REMARK REMARK OTHER REFINEMENT REMARKS: NCS RESTRAINTS APPLIED TO RNA REMARK THROUGHOUT, NOT TO PROTEIN REMARK REMARK WARNING REMARK THIS IS LAYER 1 RELEASE. REMARK REMARK PLEASE NOTE THAT THIS ENTRY WAS RELEASED AFTER DEPOSITOR REMARK CHECKING AND APPROVAL BUT WITHOUT PDB STAFF INTERVENTION. REMARK AN AUXILIARY FILE, AUX .RPT, IS AVAILABLE FROM THE REMARK PDB FTP SERVER AND IS ACCESSIBLE THROUGH THE 3DB BROWSER. REMARK THE FILE CONTAINS THE OUTPUT OF THE PROGRAM WHAT CHECK AND REMARK OTHER DIAGNOSTICS. REMARK REMARK NOMENCLATURE IN THIS ENTRY, INCLUDING HET RESIDUE NAMES REMARK AND HET ATOM NAMES, HAS NOT BEEN STANDARDIZED BY THE PDB REMARK PROCESSING STAFF. A LAYER 2 ENTRY WILL BE RELEASED SHORTLY REMARK AFTER THIS STANDARDIZATION IS COMPLETED AND APPROVED BY REMARK DEPOSITOR. THE LAYER 2 ENTRY WILL BE TREATED AS A REMARK CORRECTION TO THIS ONE, WITH THE APPROPRIATE REVDAT RECORD. REMARK REMARK FURTHER INFORMATION INCLUDING VALIDATION CRITERIA USED IN REMARK CHECKING THIS ENTRY AND A LIST OF MANDATORY DATA FIELDS REMARK ARE AVAILABLE FROM THE PDB WEB SITE AT REMARK HTTP /WWW.PDB.BNL.GOV/. REMARK REMARK THE ASYMMETRIC UNIT CONTAINS TWO LI 1-RNA COMPLEXES. REMARK 1 CONSISTS OF CHAINS A AND C, AND COMPLEX 2 CONSISTS OF REMARK CHAINS B AAND D. RESIDUES 1-7 AND 141 OF CHAIN A ARE REMARK DISORDERED. THE DENSITY FOR RESIDUES 8-70 OF CHAIN A WAS OF REMARK SIGNIFICANTLY LOWER QUALITY THAN THE DENSITY FOR THE REMARK REMAINDER OF THE ASYMMETRIC UNIT, AND THE QUALITY OF THE REMARK MODEL FOR THIS N-TERMINAL DOMAIN IS LOWER THAN THAT OF THE REMARK C-TERMINAL DOMAIN (RESIDUES 71-140). RESIDUES 1-70 AND 141 REMARK OF CHAIN B ARE DISORDERED. THE RNA IS NUMBERED WITH THE E. REMARK 6 COLI NUMBERING TO FACILITATE COMPARISON WITH THE EXTENSIVE REMARK 6 BIOCHEMICAL DATA ON THE E. COLI RNA-L11 SYSTEM. THE E. COLI REMARK 6 RNA NUMBERING IS ALSO USED IN THE PRIMARY REFERENCE REMARK 6 DESCRIBING THIS STRUCTURE. REMARK 7 REMARK 7 TER REMARK 7 ASP: TERMINAL RESIDUE NOT SEEN IN MAPS REMARK 7 ASP: TERMINAL RESIDUE NOT SEEN IN MAPS REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 24-SEP- 1998 - 62 /1 - SUBSTITUTE SHEET (RUL£2^ REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.3 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : XI 2C REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98,1.01 REMARK 200 MONOCHROMATOR : SI CRYSTAL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : BRANDEIS IK X 1 K CCD REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK RK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 49313 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.57 REMARK 200 RESOLUTION RANGE LOW (A) : 20.0 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.5 REMARK 200 DATA REDUNDANCY : 4.0 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.041 REMARK 200 &LT;I/SIGMA(I)&GT; FOR THE DATA SET : 20 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.57 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.73 REMARK 200 COMPLETENESS FOR SHELL (%) : 86.2 REMARK 200 DATA REDUNDANCY IN SHELL : 3.4 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.17 REMARK 200 &LT;I/SIGMA(I)&GT; FOR SHELL : 4.3 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: MAD REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MAD REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTTNG MODEL: NULL REMARK 200 REMARK 200 REMARK: TWO WAVELENGTH HG MAD REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.1 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: - 63- REMARK 280 25% GLYCEROL, 15% PEG 4000, 50 MM TRIS PH 7.5, REMARK 280 50 MM MGCL2, 20 MM CDCL2, 0.2 M KCL, REMARK 280 1 MM DITHIOTHREITOL, 4 DEGREES C REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 1/2-X--Y.1/2+Z REMARK 290 3555 -X,l/2+Y,l/2-Z REMARK 290 4555 1/2+X.1/2-Y.-Z REMARK 290 REMARK 290 WHERE NNN -&GT; OPERATOR NUMBER REMARK 290 MMM -&GT; TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 0.000000 1.0000000.000000 0.00000 REMARK 290 SMTRY3 1 0.0000000.000000 1.000000 0.00000 REMARK 290 SMTRY1 ■ 1.0000000.0000000.000000 31.94480 REMARK 290 SMTRY2 0.000000 -1.0000000.000000 0.00000 REMARK 290 SMTRY3 0.0000000.000000 1.000000 77.76050 REMARK 290 SMTRY1 •1.0000000.0000000.000000 0.00000 REMARK 290 SMTRY2 0.000000 1.0000000.000000 42.13010 REMARK 290 SMTRY3 0.0000000.000000 -1.000000 77.76050 REMARK 290 SMTRY1 1.0000000.0000000.000000 31.94480 REMARK 290 SMTRY2 0.000000 -1.0000000.000000 42.13010 REMARK 290 SMTRY3 0.0000000.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 295 REMARK 295 NON-CRYSTALLOGRAPHIC SYMMETRY REMARK 295 THE TRANSFORMATIONS PRESENTED ON THE MTRIX RECORDS BELOW REMARK 295 DESCRIBE NON-CRYSTALLOGRAPHIC RELATIONSHIPS AMONG ATOMS REMARK 295 IN THIS ENTRY. APPLYING THE APPROPRIATE MTRIX REMARK 295 TRANSFORMATION TO THE RESIDUES LISTED FIRST WILL YIELD REMARK 295 APPROXIMATE COORDINATES FOR THE RESIDUES LISTED SECOND. REMARK 295 CHAIN IDENTIFIERS GIVEN AS "?" REFER TO CHAINS FOR WHICH REMARK 295 ATOMS ARE NOT FOUND IN THIS ENTRY. REMARK 295 REMARK 295 APPLIED TO TRANSFORMED TO REMARK 295 TRANSFORM CHAIN RESIDUES CHAIN RESIDUES RMSD REMARK 295 SSS REMARK 295 M l C 1051..1108 D 1051..1108 0.07 REMARK 295 M 2 A 71..140 B 71..140 0.99 -64- UB3T1TUTE SHEET (RULE26 REMARK 295 REMARK 295 WHERE SSS -&GT; COLUMNS 8-10 OF MTRIX RECORDS REMARK 295 REMARK 295 REMARK: REMARK 295 NCS RESTRAINTS NOT APPLIED TO PROTEIN REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 2 REMARK 465 LYS A 3 REMARK 465 LYS A 4 REMARK 465 VAL A 5 REMARK 465 ALA A 6 REMARK 465 ALA A 7 REMARK 465 ASP A 141 REMARK 465 AALLAA BB 22 TTOO IILLEE BB 70 REMARK 465 ASP B 141 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 G C1051 P O1P O2P REMARK 470 G D1051 P O1P O2P REMARK 550 REMARK 550 SEGID REMARK 550 RNA1. RNA2 REMARK 550 LI 11, LI 12 REMARK 600 REMARK 600 HETEROGEN REMARK 600 THERE ARE A TOTAL OF 8 CADMIUM IONS IN THE STRUCTURE REMARK 600 REMARK 600 THERE ARE A TOTAL OF 19 MAGNESIUM IONS IN THE STRUCTURE REMARK 600 REMARK 600 THERE ARE A TOTAL OF 8 METHYLMERCURY REMARK 600 IONS IN THE STRUCTURE. REMARK 600 THE METHYL GROUP HAS NOT BEEN MODELLED REMARK 600 FOR ANY OF THESE IONS. REMARK 600 TWO OF THE IONS ARE COVALENTLY BOUND REMARK 600 TO CYS A 39. REMARK 600 ONE IS COVALENTLY BOUND TO U C 1061. REMARK 600 ONE IS COVALENTLY BOUND TO U D 1061. REMARK 600 REMARK 800 REMARK 800 SITE - 65- SUBSϊmπESHEEr REMARK 800 SITEJDENTIFIER: TSR REMARK 800 SITE DESCRIPTION: REMARK 800 PUTATIVE THIOSTREPTON/MICROCOCCIN BINDING SITE REMARK 800 REMARK 800 SITEJDENTIFIER: TSR REMARK 800 SITE J)ESCRIPTION: REMARK 800 PUTATIVE THIOSTREPTON/MICROCOCCIN BINDING SITE REMARK 800 REMARK 800 SITEJDENTIFIER: TSR REMARK 800 SITE_DESCRIPTION: REMARK 800 PUTATIVE THIOSTREPTON/MICROCOCCIN BINDING SITE REMARK 800 DBREF A 8 140 SWS P29395 RL11 THEMA 1 141 DBREF B 71 140 SWS P29395 RL11 THEMA 1 141 DBREF C1051 1108 PDB 1051 1108 DBREF D1051 1108 PDB 1051 1108 SEQADV RES C 1108 Gl M67498 1168 ENGINEERED MUTATION SEQADV RES D 1108 Gl M67498 1168 ENGINEERED MUTATION SEQRES 1 A 140 ALA LYS LYS VAL ALA ALA GLN ILE LYS LEU GLN LEU PRO SEQRES 2 A 140 ALA GLY LYS ALA THR PRO ALA PRO PRO VAL GLY PRO ALA SEQRES 3 A 140 LEU GLY GLN HIS GLY VAL ASN ILE MET GLU PHE CYS LYS SEQRES 4 A 140 ARG PHE ASN ALA GLU THR ALA ASP LYS ALA GLY MET ILE SEQRES 5 A 140 LEU PRO VAL VAL ILE THR VAL TYR GLU ASP LYS SER PHE SEQRES 6 A 140 THR PHE ILE ILE LYS THR PRO PRO ALA SER PHE LEU LEU SEQRES 7 A 140 LYS LYS ALA ALA GLY ILE GLU LYS GLY SER SER GLU PRO SEQRES 8 A 140 LYS ARG LYS ILE VAL GLY LYS VAL THR ARG LYS GLN ILE SEQRES 9 A 140 GLU GLU ILE ALA LYS THR LYS MET PRO ASP LEU ASN ALA SEQRES 10 A 140 ASN SER LEU GLU ALA ALA MET LYS ILE ILE GLU GLY THR SEQRES 11 A 140 ALA LYS SER MET GLY ILE GLU VAL VAL ASP SEQRES 1 B 140 ALA LYS LYS VAL ALA ALA GLN ILE LYS LEU GLN LEU PRO SEQRES 2 B 140 ALA GLY LYS ALA THR PRO ALA PRO PRO VAL GLY PRO ALA SEQRES 3 B 140 LEU GLY GLN HIS GLY VAL ASN ILE MET GLU PHE CYS LYS SEQRES 4B 140 ARG PHE ASN ALA GLU THR ALA ASP LYS ALA GLY MET ILE SEQRES 5 B 140 LEU PRO VAL VAL ILE THR VAL TYR GLU ASP LYS SER PHE SEQRES 6B 140 THR PHE ILE ILE LYS THR PRO PRO ALA SER PHE LEU LEU SEQRES 7 B 140 LYS LYS ALA ALA GLY ILE GLU LYS GLY SER SER GLU PRO SEQRES 8B 140 LYS ARG LYS ILE VAL GLY LYS VAL THR ARG LYS GLN ILE SEQRES 9B 140 GLU GLU ILE ALA LYS THR LYS MET PRO ASP LEU ASN ALA SEQRES 10 B 140 ASN SER LEU GLU ALA ALA MET LYS ILE ILE GLU GLY THR SEQRES 11 B 140 ALA LYS SER MET GLY ILE GLU VAL VAL ASP SEQRES 1C 58 G C U G G G A U G U U G G SEQRES 2C 58 C U U A G A A G C A G C C SEQRES 3C 58 A U C A U U U A A A G A G SEQRES 4C 58 U G C G U A A C A G C U C SEQRES 5C 58 A C C A G C SEQRES ID 58 G C U G G G A U G U U G G SEQRES 2D 58 C U U A G A A G C A G C C SEQRES 3D 58 A U C A U U U A A A G A G SEQRES 4D 58 U G C G U A A C A G C U C SEQRES 5D 58 A C C A G C HET CD 201 0 -66- HET CD 202 0 HET CD 211 0 HET CD 302 0 HET CD 311 0 HET CD 390 0 HET CD 413 0 HET CD 414 0 SEE REMARK 600 HET MG 210 0 HET MG 214 0 HET MG 215 0 HET MG 223 0 HET MG 225 0 HET MG 226 0 HET MG 228 0 HET MG 25.7 0 HET MG 273 0 HET MG 318 0 HET MG 326 0 HET MG 354 0 HET MG 360 0 HET MG 365 0 HET MG 375 0 HET MG 380 0 HET MG 385 0 HET MG 397 0 HET MG 437 0 SEE REMARK 600 HET HG 227 0 HET HG 230 0 HET HG 332 0 HET HG 347 0 HET HG 415 0 HET HG 416 0 HET HG 448 0 HET HG 451 0 SEE REMARK 600 HETNAM CD CD HETNAM MG MG HETNAM HG MMC HETSYN CD CADMIUM (II) HETSYN MG MAGNESIUM (II) HETSYN HG METHYLMERCURY ION FORMUL 5 CD 8(CD1 2+) FORMUL 6 MG 19(MG1 2+) FORMUL 7 HG 8(C1 H3 HG1 1+) FORMUL 8 HOH *142(H2 Ol) HELIX 1 1 PRO A 26 GLN A 30 1 5 HELIX 2 2 ILE A 35 ALA A 47 1 13 HELIX 3 3 ALA A 75 ALA A 83 1 9 HELIX 4 4 ARG A 102 ASP A 115 1 14 HELIX : 5 5 LEU A 121 SER A 134 1 14 HELIX : 6 6 ALA B 75 ALA B 83 1 9 HELIX 7 7 ARG B 102 ASP B 115 1 14 67- SUBSTITUTE SHEET WLE2 HELIX 8 8LEUB 121 MET B 135 1 15 SHEET 1 A 3 ILE A 9 PRO A 140 SHEET 2 A 3 ILE A 53 VAL A 60-1 [ N ILE A 58 O ILE A 9 SHEET 3 A 3 PHE A 66 ILE A 70-1 N ILE A 69 O VAL A 57 SHEET 1 B 2 GLY A 98 THR A 101 0 SHEET 2 B 2 ILE A 137 VAL A 140 1 N GLU A 138 O GLY A 98 SHEET 1 C 2 GLYB 98 VAL B 100 0 SHEET 2 C 2 ILEB 137 VAL B 139 1 N GLUB 138 O GLYB 98 SITE 1 TSR 2 AC1067 AC1095 SITE 2 TSR 2 AD1067 AD1095 SITE 3 TSR 3 PRO A 22 PRO A 23 PROA 26 CRYST1 63.890 84.260 155.51090.0090.0090.00 P 212121 8 ORIGX1 1.0000000.00000 ι0000..000000000000 0.00000 ORIGX2 0.000000 1.00000 ι0000..000000000000 0.00000 ORIGX3 0.0000000.00000 ι00 11..000000000000 0.00000 SCALE 1 0.0156520.00000 ι0000..000000000000 0.00000 SCALE2 0.0000000.01186 18800..000000000000 0.00000 SCALE3 0.0000000.00000 ι0000..000066443300 0.00000 MTRIX1 0.9745050.10145 588--00..220000111177 -4.54330 1 MTRIX2 1 0.097433 -0.99479 933 --00..002299888855 -3.74880 1 MTRIX3 1-0.2021070.00962 266--00..997799331166 -50.69290 1 MTRIX 1 20.9734770.09878 800--00..220066336644 -4.89630 1 MTRIX2 20.098758 -0.99505 577 --00..001100443322 -2.89050 1 MTRIX3 2 -0.206374 -0.01022 255 --00..997788442200 -50.97240 1 ATOM N GLNA -7.803-11.096 -9.783 1.0071.77 L111N ATOM CA GLN A 8 -8.476 -9.887 -9.223 1.0079.42 Llll C ATOM C GLN A 8 -8.010 -8.599 -9.897 1.0080.19 Line ATOM O GLN A 8 -6.857 -8.190 -9.748 1.0077.92 L111O ATOM CB GLN A 8 -8.212 -9.788 -7.722 1.0079.86 Line ATOM CG GLN A 8 -9.065 -8.752 -7.016 1.0080.16 Line ATOM CD GLNA 8 -9.072 -8.948 -5.518 1.0080.58 Line ATOM OE1GLNA 8 -8.020 -8.963 -4.881 1.0082.16 L111O ATOM NE2 GLN A 8 -10.261 -9.104 -4.946 1.0079.20 L111N ATOM 10 N ILE A 9 -8.916 -7.963-10.634 1.0081.13 L111N ATOM 11 CA ILE A 9 -8.604 -6.723-11.337 1.0080.39 LlllC ATOM 12 C ILE A 9 -9.312 -5.530-10.699 1.0079.13 Line ATOM 13 O ILE A 9 ■10.338 -5.680-10.036 1.0078.96 Lino ATOM 14 CB ILE A 9 -9.013 -6.804-12.834 1.0077.02 Llll C ATOM 15 CGI ILE A 9 -10.534 -6.778-12.970 1.0077.57 Llll C ATOM 16 CG2ILEA 9 -8.482 -8.080-13.452 1.0074.06 Llll C ATOM 17 CD1ILEA 9 -11.066 -5.495-13.552 1.0083.48 LlllC ATOM 18 N LYSA 10 -8.752 -4.343-10.900 1.0080.87 L111N ATOM 19 CA LYSA 10 -9.330 -3.121-10.360 1.0077.55 LlllC ATOM 20 C LYSA 10 -9.252 -2.011-11.400 1.0074.90 LlllC ATOM 21 O LYSA 10 -8.308 -1.945-12.191 1.0069.61 L111O ATOM 22 CB LYSA 10 -8.590 -2.696 -9.089 1.0078.72 Llll C ATOM 23 CG LYSA 10 -7.080 -2.607 -9.243 1.0076.53 Llll C ATOM 24 CD LYSA 10 -6.482 -1.615 -8.256 1.0076.55 Llll C ATOM 25 CE LYS A 10 -6.047 -2.300 -6.968 1.0078.93 Llll C ATOM 26 NZ LYS A 10 -4.923 -1.584 -6.296 1.0081.54 L111N ATOM 27 N LEU A 11 -10.261 -1.149-11.403 1.0072.26 L111N -68- ATOM 28 CA LEU A 11 -10.311 -0.037-12.342 1.0077.13 LlllC ATOM 29 C LEU A 11 -11.286 1.024-11.852 1.0078.99 LlllC ATOM 30 O LEU A 11 -12.052 0.790-10.915 1.0078.52 L111O ATOM 31 CB LEU A 11 -10.744 -0.525-13.728 1.0077.54 Llll C ATOM 32 CG LEU A 11 -11.051 -2.014-13.906 1.0072.58 LlllC ATOM 33 CD1 LEU A 11 -12.511 -2.199-14.290 1.0068.73 LlllC ATOM 34 CD2LEUA 11 -10.128 -2.590-14.969 1.0073.75 Llll C ATOM 35 N GLN A 12 -11.255 2.189-12.489 1.0080.79 L111N ATOM 36 CA GLN A 12 -12.144 3.284-12.120 1.0082.10 LlllC ATOM 37 C GLN A 12 -13.115 3.582-13.261 1.0080.51 Llll C ATOM 38 O GLN A 12 -12.791 4.320-14.190 1.0081.39 L111O ATOM 39 CB GLN A 12 -11.329 4.536-11.789 1.0081.65 Llll C ATOM 40 CG GLN A 12 -10.068 4.267-10.979 1.0081.34 Llll C ATOM 41 CD GLN A 12 -9.364 5.545-10.556 1.0088.15 Llll C ATOM 42 OE1GLNA 12 -9.445 6.568-11.239 1.0089.05 L111O ATOM 43 NE2GLNA 12 -8.668 5.493 -9.425 1.0090.09 L111N ATOM 44 N LEU A 13 -14.308 3.003-13.184 1.0080.02 L111N ATOM 45 CA LEU A 13 -15.320 3.197-14.214 1.0079.90 LlllC ATOM 46 C LEU A 13 -16.345 4.256-13.818 1.0081.60 LlllC ATOM 47 O LEU A 13 -16.761 4.331-12.659 1.0082.22 L111O ATOM 48 CB LEU A 13 -16.033 1.873-14.502 1.0073.75 Llll C ATOM 49 CG LEU A 13 -15.191 0.615-14.276 1.0073.16 Llll C ATOM 50 CD1LEUA 13 -16.100 -0.586-14.059 1.0074.99 Llll C ATOM 51 CD2LEUA 13 -14.277 0.397-15.470 1.0068.58 Llll C ATOM 52 N PROA 14 -16.759 5.097-14.783 1.0080.42 L111N ATOM 53 CA PRO A 14 -17.745 6.151-14.511 1.0076.54 LlllC ATOM 54 C PROA 14 -19.065 5.553-14.041 1.0074.17 LlllC ATOM 55 O PROA 14 -19.364 4.396-14.328 1.0073.53 L111O ATOM 56 CB PROA 14 -17.877 6.880-15.846 1.0074.99 LlllC ATOM 57 CG PROA 14 -17.358 5.919-16.870 1.0077.83 LlllC ATOM 58 CD PROA 14 -16.315 5.101-16.188 1.0076.88 LlllC ATOM 59 N ALA A 15 -19.844 6.349-13.317 1.0075.75 L111N ATOM 60 CA ALA A 15 -21.128 5.917-12.774 1.0082.83 LlllC ATOM 61 C ALA A 15 -21.947 5.008-13.691 1.0089.65 LlllC ATOM 62 O ALA A 15 -21.711 3.800-13.753 1.0093.73 Llll O ATOM 63 CB ALA A 15 -21.947 7.132-12.387 1.0088.09 LlllC ATOM 64 N GLY A 16 -22.921 5.590-14.387 1.0094.26 L111N ATOM 65 CA GLY A 16 -23.761 4.810-15.282 1.0098.24 LlllC ATOM 66 C GLY A 16 -23.218 4.696-16.697 1.00100.00 LlllC ATOM 67 O GLY A 16 -23.672 5.395 -17.607 1.00100.00 L111O ATOM 68 N LYSA 17 -22.239 3.813-16.881 1.0099.48 L111N ATOM 69 CA LYS A 17 -21.621 3.594-18.187 1.0098.41 Llll C ATOM 70 C LYSA 17 -20.588 2.467-18.117 1.0099.13 LlllC ATOM 71 O LYSA 17 -19.851 2.351 -17.134 1.00100.00 L111O ATOM 72 CB LYSA 17 -20.951 4.883-18.685 1.0094.26 LlllC ATOM 73 CG LYS A 17 -20.492 5.822-17.580 1.0096.55 LlllC ATOM 74 CD LYS A 17 -21.088 7.220-17.728 1.0097.02 Llll C ATOM 75 CE LYSA 17 -21.564 7.773-16.385 1.0096.31 LlllC ATOM 76 NZ LYS A 17 -20.459 8.345-15.556 1.0090.28 L111N ATOM 77 N ALA A 18 -20.545 1.642-19.163 1.0098.71 L111N ATOM 78 CA ALA A 18 -19.615 0.517-19.243 1.0096.77 LlllC - -69- ATOM 79 C ALA A 18 -19.707 -0.148-20.614 1.0096.63 LlllC ATOM 80 O ALA A 18 -20.502 0.271-21.453 1.0098.42 L111O ATOM 81 CB ALA A 18 -19.932 -0.500-18.152 1.0095.01 LlllC ATOM 82 N THR A 19 -18.872 -1.165-20.837 1.0096.19 L111N ATOM 83 CA THR A 19 -18.843 -1.936-22.089 1.0098.62 LlllC ATOM 84 C THR A 19 -17.834 -1.538-23.177 1.0098.30 LlllC ATOM 85 O THR A 19 -17.439 -2.379-23.987 1.0094.28 L111O ATOM 86 CB THR A 19 -20.250 -2.000-22.756 1.00100.00 LlllC ATOM 87 OG1THRA 19 -21.255 -2.212-21.753 1.00100.00 L111O ATOM 88 CG2THRA 19 -20.311 -3.135-23.772 1.0099.76 LlllC ATOM 89 N PROA 20 -17.392 -0.267-23.212 1.00100.00 L111N ATOM 90 CA PRO A 20 -16.433 0.087-24.268 1.00100.00 LlllC ATOM 91 C PROA 20 -15.174 -0.778-24.289 1.00100.00 LlllC ATOM 92 O PROA 20 -14.692 -1.220-23.246 1.00100.00 L111O ATOM 93 CB PROA 20 -16.117 1.561-23.995 1.00100.00 LlllC ATOM 94 CG PROA 20 -16.510 1.782-22.568 1.00100.00 LlllC ATOM 95 CD PROA 20 -17.690 0.887-22.347 1.00100.00 LlllC ATOM 96 N ALA A 21 -14.650 -1.015-25.487 1.00100.00 L111N ATOM 97 CA ALA A 21 -13.450 -1.823-25.640 1.00100.00 LlllC ATOM 98 C ALA A 21 -12.238 -1.115-25.030 1.00100.00 LlllC ATOM 99 O ALA A 21 -11.622 -1.626-24.097 1.00100.00 L111O ATOM 100 CB ALA A 21 -13.204 -2.130-27.121 1.00100.00 LlllC ATOM 101 N PROA 22 -11.886 0.079-25.542 1.00100.00 L111N ATOM 102 CA PROA 22 -10.725 0.773-24.969 1.00100.00 LlllC ATOM 103 C PROA 22 -10.740 0.904-23.434 1.00100.00 LlllC ATOM 104 O PROA 22 -9.793 0.478-22.768 1.00100.00 L111O ATOM 105 CB PROA 22 -10.726 2.127-25.683 1.00100.00 LlllC ATOM 106 CG PROA 22 -11.439 1.862-26.979 1.00100.00 LlllC ATOM 107 CD PROA 22 -12.496 0.845-26.645 1.00100.00 LlllC ATOM 108 N PROA 23 -11.807 1.495-22.853 1.00100.00 L111N ATOM 109 CA PROA 23 -11.880 1.650-21.390 1.00100.00 LlllC ATOM 110 C PROA 23 -11.941 0.338-20.592 1.00100.00 LlllC ATOM 111 O PROA 23 -11.025 0.026-19.829 1.00100.00 L111O ATOM 112 CB PROA 23 -13.135 2.507-21.173 1.0099.53 LlllC ATOM 113 CG PROA 23 -13.446 3.100-22.519 1.00100.00 LlllC ATOM 114 CD PROA 23 -12.988 2.077-23.513 1.00100.00 LlllC ATOM 115 N VAL A 24 -13.020 -0.423-20.767 1.00100.00 L111N ATOM 116 CA VAL A 24 -13.199 -1.689-20.051 1.0095.98 LlllC ATOM 117 C VAL A 24 -12.711 -2.903-20.844 1.0094.54 , LlllC ATOM 118 O VAL A 24 -11.538 -3.272-20.773 1.0088.41 L111O ATOM 119 CB VAL A 24 -14.688 -1.923-19.689 1.0092.89 LlllC ATOM 120 CGI VAL A 24 -14.809 -2.320-18.232 1.0090.90 LlllC ATOM 121 CG2VALA 24 -15.504 -0.668-19.969 1.0091.81 LlllC ATOM 122 N GLY A 25 -13.636 -3.515-21.584 1.0095.43 L111N ATOM 123 CA GLY A 25 -13.343 -4.683-22.401 1.0094.07 LlllC ATOM 124 C GLY A 25 -11.973 -5.312-22.224 1.0094.21 LlllC ATOM 125 O GLY A 25 -11.738 -6.020-21.243 1.0093.12 L111O ATOM 126 N PRO A 26 -11.051 -5.081-23.176 1.0093.73 LI UN ATOM 127 CA PROA 26 -9.684 -5.606-23.165 1.0093.06 LlllC ATOM 128 C PROA 26 -9.110 -5.852-21.774 1.0094.47 LlllC ATOM 129 O PRO A 26 -8.633 -6.947-21.480 1.0096.39 L111O -70- S ATOM 130 CB PROA 26 -8.893 -4.546-23.929 1.0091.97 L111C ATOM 131 CG PROA 26 -9.909 -3.882-24.840 1.0086.86 Llll C ATOM 132 CD PROA 26 -11.299 -4.278-24.385 1.0089.82 LlllC ATOM 133 N ALA A 27 -9.167 -4.829-20.927 1.0095.87 L111N ATOM 134 CA ALA A 27 -8.647 -4.902-19.561 1.0096.04 LlllC ATOM 135 C ALA A 27 -8.916 -6.234-18.858 1.0093.76 LlllC ATOM 136 O ALA A 27 -8.098 -7.152-18.912 1.0089.80 L111O ATOM 137 CB ALA A 27 -9.218 -3.755-18.730 1.0098.77 LlllC ATOM 138 N LEU A 28 -10.057 -6.326-18.185 1.0092.88 L111N ATOM 139 CA LEU A 28 -10.424 -7.543-17.473 1.0092.03 Llll C ATOM 140 C LEU A 28 -10.935 -8.593-18.454 1.0091.54 LlllC ATOM 141 O LEU A 28 -10.992 -9.782-18.137 1.0091.91 Llll O ATOM 142 CB LEU A 28 -11.495 -7.237-16.422 1.0092.11 LlllC ATOM 143 CG LEU A 28 -12.912 -6.897-16.898 1.0091.83 Llll C ATOM 144 CD1 LEU A 28 -13.728 -6.405-15.711 1.0087.53 LlllC ATOM 145 CD2 LEU A 28 -12.870 -5.837-17.996 1.0089.79 LlllC ATOM 146 N GLY A 29 -11.304 -8.143-19.650 1.0090.13 L111N ATOM 147 CA GLY A 29 -11.794 -9.060-20.661 1.0088.78 Llll C ATOM 148 C GLY A 29 -10.732-10.074-21.044 1.0088.80 Llll C ATOM 149 O GLY A 29 -11.022-11.064-21.716 1.0086.10 L111O ATOM 150 N GLN A 30 -9.497 -9.826-20.616 1.0089.64 L111N ATOM 151 CA GLN A 30 -8.389-10.726-20.919 1.0091.11 LlllC ATOM 152 C GLN A 30 -7.986-11.569-19.712 1.0091.31 LlllC ATOM 153 O GLN A 30 -6.980-12.277-19.747 1.0089.05 L111O ATOM 154 CB GLN A 30 -7.177 -9.932-21.439 1.0092.85 LlllC ATOM 155 CG GLN A 30 -6.545 -8.965-20.440 1.0090.47 LlllC ATOM 156 CD GLN A 30 -5.431 -8.119-21.055 1.0092.62 LlllC ATOM 157 OE1GLNA 30 -4.260 -8.511-21.057 1.0093.46 L111O ATOM 158 NE2GLNA 30 -5.796 -6.955-21.584 1.0092.21 L111N ATOM 159 N HIS A 31 -8.776-11.489-18.646 1.0094.67 L111N ATOM 160 CA HIS A 31 -8.505-12.256-17.432 1.0094.53 LlllC ATOM 161 C HIS A 31 -9.521 -13.393 -17.329 1.0093.97 Llll C ATOM 162 O HIS A 31 -9.323 -14.351 -16.582 1.0094.95 L111O ATOM 163 CB HIS A 31 -8.594-11.350-16.193 1.0092.77 LlllC ATOM 164 CG HIS A 31 -7.423 -10.425 -16.028 1.0090.32 LlllC ATOM 165 ND1HISA 31 -7.531 -9.056-16.160 1.0088.08 L111N ATOM 166 CD2HISA 31 -6.126 -10.671 -15.729 1.0086.03 LlllC ATOM 167 CE1HISA 31 -6.351 -8.500-15.950 1.0081.34 LlllC ATOM 168 NE2HISA 31 -5.480 -9.457-15.686 1.0084.77 L111N ATOM 169 N GLY A 32 -10.604-13.278-18.094 1.0093.26 L111N ATOM 170 CA GLY A 32 -11.637-14.299-18.091 1.0090.69 Llll C ATOM 171 C GLY A 32 -13.032-13.721-17.950 1.0090.58 LlllC ATOM 172 O GLY A 32 -14.022-14.353-18.323 1.0091.06 L111O ATOM 173 N VAL A 33 -13.107-12.509-17.415 1.0089.92 L111N ATOM 174 CA VAL A 33 -14.376-11.822-17.196 1.0090.50 LlllC ATOM 175 C VAL A 33 -15.254-11.711-18.443 1.0088.55 LlllC ATOM 176 O VAL A 33 -14.753-11.581-19.560 1.0088.34 L111O ATOM 177 CB VAL A 33 -14.135-10.398-16.652 1.0092.08 LlllC ATOM 178 CGI VAL A 33 -15.292 -9.976-15.770 1.0090.59 Llll C ATOM 179 CG2VALA 33 -12.830-10.351-15.873 1.0093.31 LlllC ATOM 180 N ASN A 34 -16.568-11.766-18.237 1.0089.80 L111N -71- ATOM 181 CA ASN A 34 -17.533-11.650-19.327 1.0094.89 L111C ATOM 182 C ASN A 34 -18.128-10.245-19.290 1.0096.48 LlllC ATOM 183 O ASN A 34 -19.141-10.008-18.630 1.0097.04 Llll O ATOM 184 CB ASN A 34 -18.661-12.681-19.182 1.0097.83 LlllC ATOM 185 CG ASN A 34 -18.405-13.683-18.072 1.00100.00 LlllC ATOM 186 OD1 ASN A 34 -19.205-13.813-17.141 1.00100.00 L111O ATOM 187 ND2ASNA 34 -17.291 -14.405 -18.167 1.00100.00 L111N ATOM 188 N ILE A 35 17.486 -9.325-20.006 1.0098.20 L111N ATOM 189 CA ILE A 35 -17.898 -7.922-20.071 1.0097.32 Llll C ATOM 190 C ILE A 35 19.392 -7.651-19.844 1.0099.75 Llll C ATOM 191 O ILE A 35 19.776 -7.148-18.788 1.00100.00 L111O ATOM 192 CB ILE A 35 -17.478 -7.282-21.426 1.0095.15 Llll C ATOM 193 CGI ILE A 35 -16.341 -8.094-22.064 1.0093.73 Llll C ATOM 194 CG2ILEA 35 -17.066 -5.823-21.213 1.0087.68 Llll C ATOM 195 CD1ILEA 35 -14.960 -7.824-21.485 1.0091.66 LlllC ATOM 196 N MET A 36 -20.220 -7.980-20.835 1.00100.00 L111N ATOM 197 CA MET A 36 -21.672 -7.767-20.773 1.0099.82 LlllC ATOM 198 C MET A 36 -22.294 -7.868-19.376 1.0097.54 Llll C ATOM 199 O MET A 36 -23.032 -6.975-18.950 1.0095.12 L111O ATOM 200 CB MET A 36 -22.384 -8.752-21.713 1.00100.00 LlllC ATOM 201 CG MET A 36 -23.911 -8.645-21.709 1.00100.00 LlllC ATOM 202 SD MET A 36 -24.759-10.248-21.810 1.00100.00 Llll S ATOM 203 CE MET A 36 -25.601-10.300-20.213 1.0097.00 LlllC ATOM 204 N GLU A 37 -22.001 -8.960-18.674 1.0095.35 L111N ATOM 205 CA GLU A 37 -22.535 -9.190-17.335 1.0092.68 LlllC ATOM 206 C GLU A 37 -22.124 -8.100-16.349 1.0093.66 LlllC ATOM 207 O GLU A 37 -22.925 -7.672-15.515 1.0091.34 L111O ATOM 208 CB GLU A 37 -22.071 -10.552 -16.819 1.0090.67 LlllC ATOM 209 CG GLU A 37 -23.205-11.512-16.511 1.0093.38 LlllC ATOM 210 CD GLU A 37 -22.929-12.372-15.290 1.0096.55 LlllC ATOM 211 OE1GLUA 37 -22.044-13.254-15.365 1.0091.81 L111O ATOM 212 OE2 GLU A 37 -23.600-12.163-14.256 1.0099.15 L111O ATOM 213 N PHE A 38 -20.872 -7.657-16.449 1.0094.99 L111N ATOM 214 CA PHE A 38 -20.335 -6.614-15.575 1.0095.14 LlllC ATOM 215 C PHE A 38 -20.928 -5.243-15.907 1.0093.32 LlllC ATOM 216 O PHE A 38 -21.382 -4.527-15.017 1.0092.65 Llll O ATOM 217 CB PHE A 38 -18.802 -6.565-15.693 1.0093.51 Llll C ATOM 218 CG PHE A 38 -18.139 -5.586-14.748 1.0096.97 Llll C ATOM 219 CD1PHEA 38 -18.716 -5.269-13.518 1.0098.99 LlllC ATOM 220 CD2PHEA 38 -16.935 -4.978-15.094 1.0096.40 Llll C ATOM 221 CE1PHEA 38 -18.106 -4.355-12.651 1.0095.25 LlllC ATOM 222 CE2 PHE A 38 -16.318 -4.064-14.233 1.0096.95 Llll C ATOM 223 CZ PHE A 38 -16.905 -3.754-13.010 1.0092.93 LlllC ATOM 224 N CYS A 39 -20.925 -4.884-17.187 1.0094.43 L111N ATOM 225 CA CYS A 39 -21.461 -3.597-17.632 1.0095.64 Llll C ATOM 226 C CYS A 39 -22.840 -3.321-17.044 1.0096.32 Llll C ATOM 227 O CYS A 39 -23.051 -2.295-16.392 1.0095.48 L111O ATOM 228 CB CYS A 39 -21.540 -3.563-19.159 1.0093.89 LlllC ATOM 229 SG CYS A 39 -19.986 -3.992-19.971 1.00100.00 Llll S ATOM 230 N LYS A 40 -23.774 -4.239-17.279 1.0096.81 L111N ATOM 231 CA LYSA 40 -25.133 -4.101-16.768 1.0096.22 LlllC -72- SUBSTITUTE SHETRULE2@ ATOM 232 C LYSA 40 -25.135 - 4.168-15.240 1.0095.74 LlllC ATOM 233 O LYS A 40 -25.823 - 3.389-14.576 1.0096.26 L111O ATOM 234 CB LYS A 40 -26.029 -5.205-17.339 1.0095.66 LlllC ATOM 235 CG LYS A 40 -25.956 -5.344-18.855 1.0097.68 LlllC ATOM 236 CD LYS A 40 -27.132 -6.148-19.401 1.0095.99 LlllC ATOM 237 CE LYS A 40 -26.947 -6.475-20.880 1.0094.18 LlllC ATOM 238 NZ LYS A 40 -28.171 -6.189-21.684 1.0088.70 L111N ATOM 239 N ARG A 41 -24.356 -5.097-14.688 1.0092.53 L111N ATOM 240 CA ARG A 41 -24.262 -5.260-13.239 1.0089.97 LlllC ATOM 241 C ARG A 41 -23.694 ■ -4.003-12.582 1.0090.13 LlllC ATOM 242 O ARG A 41 -24.306 -3.433-11.679 1.0091.63 L111O ATOM 243 CB ARG A 41 -23.375 -6.459-12.900 1.0085.72 LlllC ATOM 244 CG ARG A 41 -24.143 -7.710-12.526 1.0085.51 LlllC ATOM 245 CD ARG A 41 -23.330 -8.594-11.595 1.0090.22 LlllC ATOM 246 NE ARG A 41 -22.610 -9.641-12.318 1.0088.90 L111N ATOM 247 CZ ARG A 41 -21.670 -10.412-11.778 1.0087.28 LlllC ATOM 248 NH1 ARG A 41 -21.332 1-10.257-10.501 1.0084.21 L111N ATOM 249 NH2ARGA 41 -21.07C 1-11.340-12.511 1.0080.87 ' L111N ATOM 250 N PHE A 42 -22.517 - 3.583-13.037 1.0087.95 L111N ATOM 251 CA PHE A 42 -21.865 -2.393-12.509 1.0082.17 LlllC ATOM 252 C PHE A 42 -22.838 - 1.228-12.587 1.0083.84 LlllC ATOM 253 O PHE A 42 -23.215 - 0.648-11.566 1.0084.64 Llll O ATOM 254 CB PHE A 42 -20.608 -2.074-13.325 1.0078.71 LlllC ATOM 255 CG PHE A 42 -19.934 -0.792-12.925 1.0083.84 LlllC ATOM 256 CD1 PHE A 42 -19.109 -0.745-11.802 1.0084.59 LlllC ATOM 257 CD2 PHE A 42 -20.132 0.373-13.662 1.0083.65 LlllC ATOM 258 CE1 PHE A 42 -18.490 0.444-11.417 1.0079.21 Llll C ATOM 259 CE2 PHE A 42 -19.518 1.567-13.289 1.0077.97 Llll C ATOM 260 CZ PHE A 42 -18.695 1.602-12.162 1.0081.55 LlllC ATOM 261 N ASN A 43 -23.253 - ■0.906-13.808 1.0085.30 L111N ATOM 262 CA ASN A 43 -24.181 0.191-14.053 1.0086.52 LlllC ATOM 263 C ASN A 43 -25.488 0.062-13.284 1.0085.43 Llll C ATOM 264 O ASN A 43 -26.281 1.000-13.240 1.0085.51 L111O ATOM 265 CB ASN A 43 -24.476 0.296-15.548 1.0086.27 LlllC ATOM 266 CG ASN A 43 -23.265 0.716-16.344 1.0092.38 LlllC ATOM 267 OD1 ASN A 43 -22.347 1.340-15.811 1.0096.74 L111O ATOM 268 ND2 ASN A 43 -23.249 0.374-17.627 1.0099.06 L111N ATOM 269 N ALA A 44 -25.712 ■ -1.098-12.679 1.0085.49 L111N ATOM 270 CA ALA A 44 -26.930 -1.319-11.912 1.0084.79 LlllC ATOM 271 C ALA A 44 -26.900 - 0.515 -10.618 1.0085.21 Llll C ATOM 272 O ALA A 44 -27.668 0.433-10.452 1.0084.84 Llll O ATOM 273 CB ALA A 44 -27.092 -2.797-11.603 1.0086.85 LlllC ATOM 274 N GLU A 45 -26.005 ■ -0.893 -9.708 1.0085.98 L111N ATOM 275 CA GLU A 45 -25.885 -0.211 -8.420 1.0090.10 LlllC ATOM 276 C GLU A 45 -25.222 1.158 -8.536 1.0089.46 LlllC ATOM 277 O GLU A 45 -25.388 2.010 -7.661 1.0088.02 L111O ATOM 278 CB GLU A 45 -25.103 -1.076 -7.427 1.0089.91 LlllC ATOM 279 CG GLU A 45 -23.812 -1.641 -7.983 1.0093.26 Llll C ATOM 280 CD GLU A 45 -23.917 -3.118 -8.293 1.0095.55 LlllC ATOM 281 OE1GLUA 45 -24.558 -3.844 -7.503 1.0094.41 L111O ATOM 282 OE2 GLU A 45 -23.360 -3.551 -9.326 1.0098.04 Llll O -73- ATOM 283 N THR A 46 -24.463 1.369 -9.608 1.0089.00 L111N ATOM 284 CA THR A 46 -23.806 2.655 -9.810 1.0091.97 LlllC ATOM 285 C THR A 46 -24.849 3.680-10.261 1.0095.20 LlllC ATOM 286 O THR A 46 -24.516 4.737-10.806 1.0095.92 L111O ATOM 287 CB THR A 46 -22.681 2.560-10.865 1.0090.40 LlllC ATOM 288 OG1THRA 46 -23.232 2.170-12.129 1.0088.41 L111O ATOM 289 CG2 THR A 46 -21.634 1.545-10.429 1.0087.67 LlllC ATOM 290 N ALA A 47 -26.116 3.343-10.031 1.0095.70 L111N ATOM 291 CA ALA A 47 -27.237 4.208-10.374 1.0093.30 LlllC ATOM 292 C ALA A 47 -27.464 5.142 -9.191 1.0095.59 LlllC ATOM 293 O ALA A 47 -27.681 6.341 -9.367 1.0097.14 L111O ATOM 294 CB ALA A 47 -28.488 3.373-10.634 1.0085.02 Llll C ATOM 295 N ASP A 48 -27.409 4.580 -7.985 1.0098.95 L111N ATOM 296 CA ASP A 48 -27.589 5.360 -6.764 1.00100.00 LlllC ATOM 297 C ASP A 48 -26.667 6.582 -6.823 1.00100.00 LlllC ATOM 298 O ASP A 48 -27.065 7.697 -6.477 1.00100.00 L111O ATOM 299 CB ASP A 48 -27.248 4.515 -5.526 1.00100.00 Llll C ATOM 300 CG ASP A 48 -27.577 3.038 -5.706 1.00100.00 Llll C ATOM 301 OD1 ASP A 48 -28.633 2.721 -6.297 1.00100.00 Llll O ATOM 302 OD2 ASP A 48 -26.777 2.191 -5.249 1.00100.00 Llll O ATOM 303 N LYS A 49 -25.434 6.356 -7.270 1.00100.00 L111N ATOM 304 CA LYS A 49 -24.440 7.419 -7.394 1.0099.10 LlllC ATOM 305 C LYS A 49 -24.009 7.547 -8.859 1.0098.06 LlllC ATOM 306 O LYS A 49 -23.106 6.842 -9.318 1.0095.26 L111O ATOM 307 CB LYS A 49 -23.226 7.105 -6.512 1.0094.97 LlllC ATOM 308 CG LYS A 49 -23.561 6.908 -5.037 1.0092.57 LlllC ATOM 309 CD LYS A 49 -22.956 5.619 -4.498 1.0093.51 Llll C ATOM 310 CE LYSA 49 -21.611 5.873 -3.827 1.0094.40 Llll C ATOM 311 NZ LYSA 49 -20.528 4.998 -4.365 1.0088.97 L111N ATOM 312 N ALA A 50 -24.661 8.450 -9.587 1.0095.33 L111N ATOM 313 CA ALA A 50 -24.360 8.653-10.999 1.0093.02 Llll C ATOM 314 C ALA A 50 -23.680 9.985-11.305 1.0091.25 Llll C ATOM 315 O ALA A 50 -23.898 10.986-10.619 1.0090.14 L111O ATOM 316 CB ALA A 50 -25.636 8.522-11.819 1.0096.51 LlllC ATOM 317 N GLY A 51 -22.861 9.984-12.353 1.0089.39 L111N ATOM 318 CA GLY A 51 -22.153 11.186-12.752 1.0090.09 Llll C ATOM 319 C GLY A 51 -20.709 11.173-12.289 1.0091.40 Llll C ATOM 320 O GLY A 51 -19.828 11.733-12.943 1.0091.06 Llll O ATOM 321 N MET A 52 -20.465 10.520-11.158 1.0091.81 L111N ATOM 322 CA MET A 52 -19.125 10.440-10.591 1.0088.05 LlllC ATOM 323 C MET A 52 -18.347 9.218-11.062 1.0084.95 Llll C ATOM 324 O MET A 52 -18.927 8.206-11.455 1.0085.89 L111O ATOM 325 CB MET A 52 -19.207 10.425 -9.065 1.0085.66 LlllC ATOM 326 CG MET A 52 -20.358 11.236 -8.503 1.0086.98 LlllC ATOM 327 SD MET A 52 -20.028 11.840 -6.840 1.0094.43 Llll S ATOM 328 CE MET A 52 -18.414 12.577 -7.060 1.0092.32 Llll C ATOM 329 N ILE A 53 ■ -17.025 9.330-11.021 1.0080.70 L111N ATOM 330 CA ILE A 53 -16.145 8.242-11.415 1.0076.40 LlllC ATOM 331 C ILE A 53 - ■15.856 7.437-10.157 1.0076.01 Llll C ATOM 332 O ILE A 53 -15.214 7.937 -9.238 1.0080.34 L111O ATOM 333 CB ILE A 53 -14.815 8.781-11.987 1.0072.67 Llll C -74- EET JLE26 ATOM 334 CGI ILE A 53 -15.035 9.279-13.421 1.0073.66 L Π C ATOM 335 CG2ILEA 53 -13.735 7.706-11.897 1.0069.87 Line ATOM 336 CD1ILEA 53 -14.073 8.712-14.461 1.0067.81 Llll C ATOM 337 N LEU A 54 -16.337 6.199-10.110 1.0077.62 L111N ATOM 338 CA LEU A 54 -16.123 5.355 -8.940 1.0075.31 LlllC ATOM 339 C LEU A 54 -15.263 4.129 -9.242 1.0073.26 LlllC ATOM 340 O LEU A 54 -15.468 3.448-10.248 1.0069.71 Llll O ATOM 341 CB LEU A 54 -17.471 4.913 -8.354 1.0074.18 LlllC ATOM 342 CG LEU A 54 -18.446 4.186 -9.283 1.0076.71 LlllC ATOM 343 CD1LEUA 54 -19.398 3.339 -8.456 1.0078.50 LlllC ATOM 344 CD2 LEU A 54 -19.221 5.196-10.112 1.0077.50 Llll C ATOM 345 N PROA 55 -14.277 3.841 -8.368 1.0073.50 L111N ATOM 346 CA PROA 55 -13.379 2.694 -8.531 1.0073.63 LlllC ATOM 347 C PROA 55 -13.998 1.397 -8.010 1.0072.99 LlllC ATOM 348 O PROA 55 -14.516 1.349 -6.895 1.0076.87 L111O ATOM 349 CB PROA 55 -12.139 3.096 -7.736 1.0069.02 LlllC ATOM 350 CG PROA 55 -12.654 4.000 -6.669 1.0066.68 LlllC ATOM 351 CD PROA 55 -13.950 4.617 -7.157 1.0072.43 LlllC ATOM 352 N VAL A 56 -13.945 0.349 -8.825 1.0070.25 L111N ATOM 353 CA VAL A 56 -14.496 -0.942 -8.440 1.0070.19 LlllC ATOM 354 C VAL A 56 -13.399 -1.999 -8.486 1.0070.07 LlllC ATOM 355 O VAL A 56 -12.502 -1.937 -9.329 1.0067.23 Llll O ATOM 356 CB VAL A 56 -15.654 -1.361 -9.384 1.0067.10 LlllC ATOM 357 CGI VAL A 56 -15.246 -1.161-10.828 1.0067.75 LlllC ATOM 358 CG2 VAL A 56 -16.034 -2.808 -9.143 1.0062.26 LlllC ATOM 359 N VAL A 57 -13.459 -2.956 -7.565 1.0072.09 L111N ATOM 360 CA VAL A 57 -12.472 -4.027 -7.527 1.0073.93 LlllC ATOM 361 C VAL A 57 -13.121 -5.341 -7.934 1.0076.94 Llll C ATOM 362 O VAL A 57 -13.788 -6.001 -7.131 1.0078.31 L111O ATOM 363 CB VAL A 57 -11.849 -4.189 -6.127 1.0068.90 LlllC ATOM 364 CGI VAL A 57 -10.940 -5.410 -6.104 1.0066.82 Llll C ATOM 365 CG2VALA 57 -11.058 -2.948 -5.767 1.0067.57 LlllC ATOM 366 N ILE A 58 ■ -12.923 -5.702 -9.197 1.0079.04 L111N ATOM 367 CA ILE A 58 -13.467 -6.930 -9.756 1.0077.59 LlllC ATOM 368 C ILE A 58 - ■ 12.611 -8.115 -9.319 1.0077.59 LlllC ATOM 369 O ILE A 58 - -11.383 -8.023 -9.262 1.0073.20 Llll O ATOM 370 CB ILE A 58 -13.490 -6.863-11.307 1.0076.77 LlllC ATOM 371 CGI ILE A 58 -14.689 -6.033-11.773 1.0079.34 LlllC ATOM 372 CG2 ILE A 58 -13.526 -8.267-11.904 1.0073.40 LlllC ATOM 373 CD1 ILE A 58 -15.970 -6.832-11.963 1.0082.47 LlllC ATOM 374 N THR A 59 -13.270 -9.224 -8.999 1.0082.32 L111N ATOM 375 CA THR A 59 -12.581-10.444 -8.589 1.0082.77 LlllC ATOM 376 C THR A 59 -13.114-11.602 -9.430 1.0083.16 LlllC ATOM 377 O THR A 59 -14.312-11.888 -9.417 1.0078.62 L111O ATOM 378 CB THR A 59 -12.815-10.761 -7.091 1.0081.80 Line ATOM 379 OG1THRA 59 -12.872 -9.539 -6.341 1.0079.00 Lino ATOM 380 CG2THRA 59 -11.682-11.629 -6.552 1.0074.95 Llll C ATOM 381 N VAL A 60 -12.221-12.256-10.168 1.0084.63 L111N ATOM 382 CA VAL A 60 -12.603-13.377-11.022 1.0085.45 LlllC ATOM 383 C VAL A 60 -12.140-14.723-10.466 1.0085.80 LlllC ATOM 384 O VAL A 60 -10.947-14.934-10.228 1.0083.46 L111O 75- ATOM 385 CB VAL A 60 -12.030-13.211-12.445 1.0085.69 LlllC ATOM 386 CG1VALA 60 -12.984-12.383-13.295 1.0080.95 LlllC ATOM 387 CG2 VAL A 60 -10.653-12.563-12.380 1.0084.62 LlllC ATOM 388 N TYR A 61 -13.098-15.629-10.272 1.0086.41 L111N ATOM 389 CA TYR A 61 -12.827-16.965 -9.747 1.0088.03 LlllC ATOM 390 C TYR A 61 -12.459 -17.915 -10.877 LOO 89.54 LlllC ATOM 391 O TYR A 61 -12.885-17.721-12.015 1.0093.25 L111O ATOM 392 CB TYR A 61 -14.056-17.486 -8.998 1.0087.73 LlllC ATOM 393 CG TYRA 61 -14.589-16.487 -7.999 1.0091.62 LlllC ATOM 394 CD1 TYRA 61 -13.873-16.187 -6.837 1.0089.76 LlllC ATOM 395 CD2TYRA 61 -15.772-15.788 -8.244 1.0089.94 LlllC ATOM 396 CE1 TYRA 61 -14.316-15.214 -5.947 1.0089.76 LlllC ATOM 397 CE2 TYR A 61 -16.225-14.810 -7.358 1.0092.12 LlllC ATOM 398 CZ TYRA 61 -15.489-14.526 -6.214 1.0092.07 LlllC ATOM 399 OH TYRA 61 -15.910-13.543 -5.347 1.0094.51 L111O ATOM 400 N GLUA 62 -11.666-18.936-10.557 1.0089.59 L111N ATOM 401 CA GLU A 62 -11.218-19.921-11.541 1.0086.30 LlllC ATOM 402 C GLU A 62 -12.248-20.245-12.626 1.0084.38 LlllC ATOM 403 O GLU A 62 -11.886-20.480-13.779 1.0083.12 L111O ATOM 404 CB GLU A 62 -10.798-21.217-10.835 1.0086.59 LlllC ATOM 405 CG GLUA 62 -11.842-21.781 -9.872 1.0098.78 LlllC ATOM 406 CD GLUA 62 -12.709-22.865-10.502 1.00100.00 LlllC ATOM 407 OE1 GLUA 62 -12.149-23.866-11.007 1.00100.00 L111O ATOM 408 OE2 GLUA 62 -13.952-22.711-10.490 1.00100.00 L111O ATOM 409 N ASP A 63 -13.527-20.246-12.261 1.0083.04 L111N ATOM 410 CA ASP A 63 -14.593-20.554-13.210 1.0083.65 LlllC ATOM 411 C ASP A 63 -15.045-19.360-14.066 1.0089.63 LlllC ATOM 412 O ASP A 63 -16.153-19.364-14.609 1.0090.46 L111O ATOM 413 CB ASP A 63 -15.795-21.132-12.461 1.0080.07 LlllC ATOM 414 CG ASP A 63 -16.738-20.061-11.968 1.0079.27 LlllC ATOM 415 OD1ASPA 63 -16.275-19.146-11.254 1.0085.70 L111O ATOM 416 OD2 ASP A 63 -17.941-20.130-12.298 1.0076.37 L111O ATOM 417 N LYS A 64 -14.188-18.347-14.185 1.0091.01 L111N ATOM 418 CA LYSA 64 -14.481-17.150-14.976 1.0089.76 LlllC ATOM 419 C LYSA 64 -15.585-16.261-14.398 1.0089.42 LlllC ATOM 420 O LYSA 64 -15.809-15.149-14.882 1.0091.74 L111O ATOM 421 CB LYSA 64 -14.833-17.540-16.418 1.0092.48 LlllC ATOM 422 CG LYS A 64 -13.737-17.237-17.436 1.0092.64 LlllC ATOM 423 CD LYSA 64 -12.362-17.682-16.936 1.0089.88 LlllC ATOM 424 CE LYS A 64 -11.520-18.269-18.060 1.0087.02 LlllC ATOM 425 NZ LYSA 64 -12.331-18.548-19.280 1.0089.34 L111N ATOM 426 N SERA 65 -16.280-16.748-13.373 1.0088.30 L111N ATOM 427 CA SERA 65 -17.336-15.966-12.738 1.0087.60 LlllC ATOM 428 C SERA 65 -16.668-14.827-11.979 1.0090.25 LlllC ATOM 4290 SERA 65 -15.443-14.800-11.857 1.0094.42 L111O ATOM 430 CB SERA 65 -18.138-16.830-11.766 1.0083.90 LlllC ATOM 431 OG SERA 65 -19.255-16.115-11.265 1.0086.12 L111O ATOM 432 N PHE A 66 -17.459-13.895-11.456 1.0089.68 L111N ATOM 433 CA PHE A 66 -16.872-12.769-10.737 1.0086.65 LlllC ATOM 434 C PHE A 66 -17.824-11.963 -9.852 1.0084.85 LlllC ATOM 435 O PHEA 66 -19.049-12.065 -9.956 1.0084.96 Llll O -76- UBST WE SHEET fULE2β ATOM 436 CB PHE A 66 -16.207-11.819-11.740 1.0083.79 LlllC ATOM 437 CG PHE A 66 -17.166-11.224-12.736 1.0084.15 LlllC ATOM 438 CD1PHEA 66 -17.849-10.044-12.446 1.0084.23 LlllC ATOM 439 CD2PHEA 66 -17.402-11.851-13.955 1.0085.47 ' LlllC ATOM 440 CE1PHEA 66 -18.756 -9.496-13.358 1.0083.49 LlllC ATOM 441 CE2PHEA 66 -18.307-11.312-14.875 1.0085.83 LlllC ATOM 442 CZ PHE A 66 -18.985-10.132-14.574 1.0081.40 LlllC ATOM 443 N THR A 67 -17.223-11.166 -8.975 1.0083.77 L111N ATOM 444 CA THR A 67 -17.937-10.279 -8.065 1.0079.66 Llll C ATOM 445 C THR A 67 -17.102 -9.009 -8.062 1.0079.21 Llll C ATOM 446 O THR A 67 -16.005 -8.985 -8.623 1.0078.86 Llll O ATOM 447 CB THR A 67 -17.990-10.835 -6.630 1.0077.12 LlllC ATOM 448 OG1THRA 67 -16.660-11.101 -6.169 1.0071.17 L111O ATOM 449 CG2THRA 67 -18.807-12.112 -6.585 1.0076.03 LlllC ATOM 450 N PHE A 68 -17.603 -7.954 -7.439 1.0077.92 L111N ATOM 451 CA PHE A 68 -16.850 -6.711 -7.409 1.0076.33 LlllC ATOM 452 C PHE A 68 -17.396 -5.750 -6.379 1.0074.52 LlllC ATOM 453 O PHE A 68 -18.609 -5.594 -6.241 1.0074.74 L111O ATOM 454 CB PHE A 68 -16.871 -6.046 -8.789 1.0079.76 LlllC ATOM 455 CG PHE A 68 -18.255 -5.772 -9.311 1.0078.43 LlllC ATOM 456 CD1PHEA 68 -18.994 -6.781 -9.922 1.0077.56 LlllC ATOM 457 CD2PHEA 68 -18.821 -4.506 -9.193 1.0077.06 Llll C ATOM 458 CE1PHEA 68 -20.276 -6.532-10.409 1.0079.65 LlllC ATOM 459 CE2 PHE A 68 -20.103 -4.247 -9.677 1.0076.90 LlllC ATOM 460 CZ PHE A 68 -20.831 -5.263-10.285 1.0077.56 Llll C ATOM 461 N ILE A 69 -16.491 -5.105 -5.656 1.0073.94 L111N ATOM 462 CA ILE A 69 -16.885 -4.142 -4.644 1.0070.90 LlllC ATOM 463 C ILE A 69 ■ -16.752 -2.736 -5.218 1.0071.09 LlllC ATOM 464 O ILE A 69 -15.773 -2.420 -5.901 1.0068.28 L111O ATOM 465 CB ILE A 69 -16.010 -4.273 -3.377 1.0065.36 LlllC ATOM 466 CGI ILE A 69 -14.550 -3.966 -3.709 1.0063.63 LlllC ATOM 467 CG2 ILE A 69 -16.119 -5.682 -2.820 1.0061.98 Llll C ATOM 468 CD1 ILE A 69 -13.850 -3.146 -2.650 1.0054.75 Llll C ATOM 469 N ILE A 70 -17.753 -1.903 -4.962 1.0068.20 L111N ATOM 470 CA ILE A 70 -17.740 -0.530 -5.443 1.0065.88 Llll C ATOM 471 C ILE A 70 ■ -17.350 0.388 -4.283 1.0061.84 LlllC ATOM 472 O ILE A 70 -17.975 0.367 -3.222 1.0060.58 L111O ATOM 473 CB ILE A 70 -19.126 -0.135 -6.022 1.0066.46 LlllC ATOM 474 CGI ILE A 70 -19.030 -0.026 -7.545 1.0067.64 LlllC ATOM 475 CG2 ILE A 70 -19.608 1.187 -5.432 1.0069.87 LlllC ATOM 476 CD1 ILE A 70 -19.695 -1.163 -8.283 1.0063.00 LlllC ATOM 477 N LYSA 71 -16.301 1.179 -4.489 1.0055.49 L111N ATOM 478 CA LYS A 71 -15.820 2.092 -3.463 1.0049.56 Llll C ATOM 479 C LYSA 71 -16.181 3.531 -3.773 1.0051.89 LlllC ATOM 480 O LYSA 71 -16.814 3.826 -4.787 1.0058.09 L111O ATOM 481 CB LYSA 71 -14.301 1.996 -3.325 1.0041.23 LlllC ATOM 482 CG LYS A 71 -13.736 0.617 -3.549 1.0045.62 LlllC ATOM 483 CD LYSA 71 -12.280 0.573 -3.134 1.0047.82 LlllC ATOM 484 CE LYSA 71 -12.066 -0.371 -1.962 1.0053.59 LlllC ATOM 485 NZ LYSA 71 -10.785 -1.130 -2.085 1.0054.56 L111N ATOM 486 N THR A 72 -15.763 4.424 -2.883 1.0051.64 L111N -77- SUBSmUT ATOM 487 CA THR A 72 -16.005 5.851 -3.034 1.0048.54 LlllC ATOM 488 C THR A 72 -15.040 6.390 - ■ 4.088 1.0047.19 LlllC ATOM 489 O THR A 72 -13.919 5.896 ■ -4.227 1.0051.43 L111O ATOM 490 CB THR A 72 -15.758 6.584 -1.711 1.0049.44 LlllC ATOM 491 OG1THRA 72 -14.374 6.469 -1.356 1.0056.76 L111O ATOM 492 CG2THRA 72 -16.598 5.975 -0.602 1.0049.50 Llll C ATOM 493 N PROA 73 -15.463 7.409 - ■ 4.850 1.0043.35 L111N ATOM 494 CA PROA 73 -14.603 7.989 -5.890 1.0039.98 LlllC ATOM 495 C PROA 73 -13.260 8.487 - 5.357 1.0038.40 LlllC ATOM 496 O PROA 73 -13.153 8.908 - ■4.206 1.0041.41 L111O ATOM 497 CB PROA 73 -15.449 9.117 -6.483 1.0040.56 LlllC ATOM 498 CG PROA 73 -16.536 9.360 -5.490 1.0044.56 LlllC ATOM 499 CD PROA 73 -16.775 8.071 -4.781 1.0042.40 LlllC ATOM 500 N PRO A 74 -12.217 8.453 - 6.198 1.0036.48 L111N ATOM 501 CA PROA 74 -10.882 8.904 -5.788 1.0035.21 Llll C ATOM 502 C PROA 74 -10.881 10.296 -5.162 1.0032.68 LlllC ATOM 503 O PROA 74 -11.778 11.102 -5.406 1.0030.40 L111O ATOM 504 CB PROA 74 -10.066 8.856 -7.082 1.0037.87 LlllC ATOM 505 CG PRO A 74 -10.787 7.880 -7.956 1.0031.11 Llll C ATOM 506 CD PROA 74 -12.244 8.000 -7.601 1.0035.28 LlllC ATOM 507 N ALA A 75 -9.868 10.570 ■ -4.348 1.0031.58 L111N ATOM 508 CA ALA A 75 -9.763 11.862 -3.698 1.0029.59 LlllC ATOM 509 C ALA A 75 -9.517 12.901 - ■ 4.774 1.0034.00 LlllC ATOM 510 O ALA A 75 -10.210 13.915 -4.837 1.0037.52 L111O ATOM 511 CB ALA A 75 -8.618 11.856 -2.694 1.0034.28 Llll C ATOM 512 N SERA 76 -8.532 12.638 - 5.627 1.0030.09 L111N ATOM 513 CA SERA 76 -8.211 13.561 -6.702 1.0031.31 Llll C ATOM 514 C SERA 76 -9.467 13.929 - 7.483 1.0031.25 LlllC ATOM 515 O SERA 76 -9.661 15.091 - 7.825 1.0036.66 L111O ATOM 516 CB SERA 76 -7.169 12.951 -7.643 1.0032.45 LlllC ATOM 517 OG SERA 76 -7.473 11.608 -7.957 1.0036.38 L111O ATOM 518 N PHE A 77 -10.323 12.946 -7.752 1.0031.85 L111N ATOM 519 CA PHE A 77 -11.564 13.194 -8.489 1.0034.16 Llll C ATOM 520 C PHE A 77 -12.502 14.125 • -7.734 1.0038.37 LlllC ATOM 521 O PHE A 77 -12.919 15.160 -8.251 1.0041.67 L111O ATOM 522 CB PHE A 77 -12.307 11.894 -8.769 1.0033.17 LlllC ATOM 523 CG PHE A 77 -13.623 12.095 -9.468 1.0040.76 LlllC ATOM 524 CD1PHEA 77 -13.667 12.357 -10.837 1.0047.11 LlllC ATOM 525 CD2PHEA 77 -14.818 12.034 -8.761 1.0042.42 Llll C ATOM 526 CE1 PHE A 77 -14.880 12.554 -11.492 1.0038.82 Llll C ATOM 527 CE2PHEA 77 -16.041 12.230 -9.409 1.0042.68 LlllC ATOM 528 CZ PHE A 77 -16.069 12.491 -10.777 1.0038.85 LlllC ATOM 529 N LEU A 78 -12.852 13.743 -6.514 1.0039.27 L111N ATOM 530 CA LEU A 78 -13.732 14.568 -5.703 1.0042.01 LlllC ATOM 531 C LEU A 78 -13.162 15.986 -5.625 1.0044.64 LlllC ATOM 532 O LEU A 78 -13.892 16.967 -5.777 1.0045.86 L111O ATOM 533 CB LEU A 78 -13.861 13.966 -4.303 1.0042.80 LlllC ATOM 534 CG LEU A 78 -14.640 12.646 -4.258 1.0047.12 LlllC ATOM 535 CD1LEUA 78 -14.485 11.973 i -2.899 1.0038.14 Line ATOM 536 CD2LEUA 78 -16.108 12.925 : -4.548 1.0050.88 LlllC ATOM 537 N LEU A 79 -11.851 16.081 -5.406 1.0043.07 L111N -78- ATOM 538 CA LEU A 79 -11.164 17.367 -5.309 1.0034.91 LlllC ATOM 539 C LEU A 79 -11.352 18.182 -6.580 1.0035.68 LlllC ATOM 540 O LEU A 79 -11.701 19.355 -6.522 1.0036.29 L111O ATOM 541 CB LEU A 79 -9.676 17.150 -5.056 1.0032.85 Llll C ATOM 542 CG LEU A 79 -9.326 16.833 -3.603 1.0029.72 LlllC ATOM 543 CD 1 LEU A 79 -7.848 16.529 -3.480 1.0033.33 LlllC ATOM 544 CD2 LEU A 79 -9.703 18.013 -2.730 1.0029.46 LlllC ATOM 545 N LYS A 80 -11.113 17.558 -7.727 1.0039.06 L111N ATOM 546 CA LYS A 80 -11.292 18.235 -9.006 1.0038.30 LlllC ATOM 547 C LYSA 80 -12.692 18.832 -8.990 1.0039.56 Llll C ATOM 548 O LYSA 80 -12.87220.036 -9.144 1.0044.34 L111O ATOM 549 CB LYSA 80 -11.191 17.239 -10.163 1.0032.02 LlllC ATOM 550 CG LYS A 80 -9.805 17.066 -10.750 1.0032.26 LlllC ATOM 551 CD LYSA 80 -9.758 15.821- -11.628 1.0037.75 Llll C ATOM 552 CE LYSA 80 -8.410 15.660- 12.313 1.0049.50 Llll C ATOM 553 NZ LYS A 80 -8.046 14.224- ■12.490 1.0054.98 L111N ATOM 554 N LYSA 81 -13.681 17.969 -8.789 1.0039.53 L111N ATOM 555 CA LYSA 81 -15.070 18.386 -8.754 1.0038.23 LlllC ATOM 556 C LYSA 81 -15.268 19.576 ■ -7.832 1.0041.10 LlllC ATOM 557 O LYSA 81 -15.79720.603 -8.242 1.0050.63 L111O ATOM 558 CB LYSA 81 -15.949 17.230 -8.290 1.0040.15 LlllC ATOM 559 CG LYSA 81 -17.433 17.521 -8.367 1.0056.64 Llll C ATOM 560 CD LYSA 81 -18.209 16.317 -8.878 1.0068.16 LlllC ATOM 561 CE LYSA 81 -19.133 15.761 -7.799 1.0076.64 Llll C ATOM 562 NZ LYSA 81 -18.420 15.535 -6.502 1.0078.09 L111N ATOM 563 N ALA A 82 -14.836 19.435 -6.585 1.0045.28 L111N ATOM 564 CA ALA A 82 -14.97620.500 -5.598 1.0043.40 LlllC ATOM 565 C ALA A 82 -14.38421.832 -6.056 1.0049.00 LlllC ATOM 566 O ALA A 82 -15.00322.884 -5.892 1.0053.59 L111O ATOM 567 CB ALA A 82 -14.33020.076 -4.290 1.0042.16 LlllC ATOM 568 N ALA A 83 -13.18321.790 -6.621 1.0048.31 L111N ATOM 569 CA ALA A 83 -12.52723.004 -7.089 1.0044.61 LlllC ATOM 570 C ALA A 83 -13.11523.458 -8.416 1.0044.02 LlllC ATOM 571 O ALA A 83 -12.69324.467 -8.978 1.0050.26 L111O ATOM 572 CB ALA A 83 -11.04222.764 -7.236 1.0040.08 Llll C ATOM 573 N GLY A 84 -14.08622.699 -8.912 1.0042.49 L111N ATOM 574 CA GLY A 84 -14.72723.029 -10.169 1.0037.87 LlllC ATOM 575 C GLY A 84 -13.80422.971 - ■11.370 1.0039.67 Llll C ATOM 576 O GLY A 84 -14.12723.511 - -12.424 1.0050.03 L111O ATOM 577 N ILE A 85 -12.65422.323-11.226 1.0037.41 L111N ATOM 578 CA ILE A 85 -11.71522.219- 12.334 1.0037.65 LlllC ATOM 579 C ILE A 85 ■ -11.82620.868-13.037 1.0041.62 LlllC ATOM 580 O ILE A 85 -12.532 19.974-12.571 1.0045.50 Llll O ATOM 581 CB ILE A 85 -10.261 22.429- 11.863 1.0037.93 Llll C ATOM 582 CGI ILE A 85 -9.90521.408- ■10.784 1.0032.73 LlllC ATOM 583 CG2ILEA 85 -10.08823.845 -11.336 1.0042.04 LlllC ATOM 584 CD1ILEA 85 -8.43521.395 - ■10.442 1.0022.67 LlllC ATOM 585 N GLUA 86 -11.12620.728- -14.159 1.0045.67 L111N ATOM 586 CA GLUA 86 -11.156 19.499 -14.948 1.0047.13 LlllC ATOM 587 C GLUA 86 -9.874 18.675- 14.831 1.0047.71 LlllC ATOM 588 O GLUA 86 -9.882 17.460- 15.044 1.0048.51 L111O 79- SUB ATOM 589 CB GLU A 86 -11.408 19.839-16.421 1.0057.79 LlllC ATOM 590 CG GLUA 86 -12.374 18.896-17.128 1.0077.13 LlllC ATOM 591 CD GLUA 86 -13.815 19.383-17.078 1.0086.58 LlllC ATOM 592 OE1GLUA 86 -14.02520.594-16.849 1.0090.24 L111O ATOM 593 OE2 GLU A 86 -14.734 18.553-17.268 1.0089.81 L111O ATOM 594 N LYS A 87 -8.771 19.335-14.499 1.0039.94 L111N ATOM 595 CA LYSA 87 -7.499 18.645-14.366 1.0038.76 LlllC ATOM 596 C LYS A 87 -6.699 19.204-13.204 1.0034.61 LlllC ATOM 597 O LYS A 87 -6.981 20.291-12.715 1.0046.69 L111O ATOM 598 CB LYSA 87 -6.686 18.784-15.656 1.0041.37 Llll C ATOM 599 CG LYSA 87 -7.279 18.057-16.847 1.0047.04 Llll C ATOM 600 CD LYS A 87 -6.550 18.426-18.128 1.0053.23 Llll C ATOM 601 CE LYSA 87 -5.833 17.224-18.724 1.0060.76 LlllC ATOM 602 NZ LYS A 87 -6.109 15.961-17.979 1.0061.63 L111N ATOM 603 N GLY A 88 -5.703 18.452-12.759 1.0034.29 L111N ATOM 604 CA GLY A 88 -4.871 18.914-11.669 1.0033.53 LlllC ATOM 605 C GLY A 88 -3.718 19.688-12.261 1.0035.94 LlllC ATOM 606 O GLY A 88 -3.422 19.547-13.445 1.0037.03 L111O ATOM 607 N SERA 89 -3.06520.511-11.453 1.0035.86 L111N ATOM 608 CA SERA 89 -1.941 21.285-11.951 1.0031.79 LlllC ATOM 609 C SERA 89 -0.96820.358-12.658 1.0033.45 LlllC ATOM 610 O SERA 89 -0.868 19.185-12.317 1.0036.12 L111O ATOM 611 CB SERA 89 -1.22721.987-10.801 1.0030.17 LlllC ATOM 612 OG SERA 89 0.141 22.195-11.114 1.0029.65 L111O ATOM 613 N SERA 90 -0.26020.881-13.651 1.0036.82 L111N ATOM 614 CA SERA 90 0.71620.083-14.372 1.0035.62 LlllC ATOM 615 C SERA 90 1.981 20.112-13.530 1.0035.74 LlllC ATOM 616 O SERA 90 2.879 19.287-13.692 1.0037.58 L111O ATOM 617 CB SERA 90 0.97620.682-15.758 1.0037.33 LlllC ATOM 618 OG SERA 90 1.95521.708-15.701 1.0051.94 L111O ATOM 619 N GLUA 91 2.03421.083-12.625 1.0033.32 L111N ATOM 620 CA GLUA 91 3.16621.246-11.726 1.0038.55 LlllC ATOM 621 C GLUA 91 2.61921.648-10.362 1.0037.86 LlllC ATOM 622 O GLUA 91 2.55322.832-10.026 1.0036.53 L111O ATOM 623 CB GLUA 91 4.11522.317-12.262 1.0042.92 LlllC ATOM 624 CG GLUA 91 4.92721.857-13.457 1.0056.44 LlllC ATOM 625 CD GLUA 91 6.02522.832-13.841 1.0069.04 Llll C ATOM 626 OE1GLUA 91 6.22323.832-13.113 1.0067.53 Llll O ATOM 627 OE2GLUA 91 6.69222.593-14.876 1.0073.04 Llll O ATOM 628 N PRO A 92 2.19920.652 -9.561 1.0039.75 L111N ATOM 629 CA PROA 92 1.64320.871 -8.222 1.0037.71 LlllC ATOM 630 C PROA 92 2.53621.749 -7.365 1.0033.98 LlllC ATOM 631 O PROA 92 3.76021.633 -7.418 1.0031.75 L111O ATOM 632 CB PROA 92 1.505 19.459 -7.655 1.0034.90 LlllC ATOM 633 CG PROA 92 1.371 18.596 -8.852 1.0030.25 LlllC ATOM 634 CD PROA 92 2.246 19.219 -9.898 1.0039.42 Llll C ATOM 635 N LYS A 93 1.91022.625 -6.584 1.0030.90 L111N ATOM 636 CA LYS A 93 2.62023.544 -5.703 1.0036.65 LlllC ATOM 637 C LYSA 93 3.25024.695 -6.477 1.0036.64 LlllC ATOM 638 O LYSA 93 3.181 25.841 -6.044 1.0045.57 L111O ATOM 639 CB LYSA 93 3.69922.800 -4.907 1.0042.76 LlllC -80- ATOM 640 CG LYS A 93 4.53223.681 -3.993 1.0047.27 LlllC ATOM 641 CD LYSA 93 4.991 22.907 -2.768 1.0053.52 LlllC ATOM 642 CE LYS A 93 5.91523.744 -1.894 1.0054.40 LlllC ATOM 643 NZ LYSA 93 7.23523.085 -1.673 1.0061.73 L111N ATOM 644 N ARG A 94 3.86424.394 -7.616 1.0035.63 L111N ATOM 645 CA ARG A 94 4.48625.432 -8.430 1.0029.80 LlllC ATOM 646 C ARG A 94 3.40826.252 -9.125 1.0032.19 LlllC ATOM 647 O ARG A 94 3.59327.443 -9.371 1.0036.21 L111O ATOM 648 CB ARG A 94 5.41824.817 -9.475 1.0021.41 LlllC ATOM 649 CG ARG A 94 6.81824.559 -8.966 1.0026.71 LlllC ATOM 650 CD ARG A 94 7.77924.180-10.088 1.0028.16 LlllC ATOM 651 NE ARG A 94 9.00223.582 -9.551 1.0040.63 L111N ATOM 652 CZ ARG A 94 10.01623.133-10.289 1.0042.98 Llll C ATOM 653 NH1 ARG A 94 9.96523.212-11.610 1.0045.19 L111N ATOM 654 NH2 ARG A 94 11.08522.606 -9.704 1.0048.46 L111N ATOM 655 N LYS A 95 2.28425.612 -9.440 1.0028.46 L111N ATOM 656 CA LYS A 95 1.17726.298-10.104 1.0030.94 Llll C ATOM 657 C LYSA 95 -0.14525.834 -9.542 1.0028.39 LlllC ATOM 658 O LYSA 95 -0.511 24.679 -9.700 1.0040.28 L111O ATOM 659 CB LYS A 95 1.16926.024-11.614 1.0036.77 LlllC ATOM 660 CG LYS A 95 2.531 25.791-12.244 1.0049.47 Llll C ATOM 661 CD LYS A 95 2.42625.746-13.765 1.0048.94 LlllC ATOM 662 CE LYSA 95 3.78225.970-14.420 1.0050.63 LlllC ATOM 663 NZ LYS A 95 3.73025.733-15.886 1.0046.96 L111N ATOM 664 N ILE A 96 -0.87226.728 -8.892 1.0030.02 L111N ATOM 665 CA ILE A 96 -2.16226.357 -8.337 1.0031.34 LlllC ATOM 666 C ILE A 96 -3.20926.537 -9.425 1.0035.19 LlllC ATOM 667 O ILE A 96 -3.28627.593-10.048 1.0042.96 L111O ATOM 668 CB ILE A 96 -2.50227.231 -7.115 1.0033.87 LlllC ATOM 669 CGI ILE A 96 -1.37927.115 -6.079 1.0033.04 LlllC ATOM 670 CG2 ILE A 96 -3.84026.812 -6.518 1.0028.64 LlllC ATOM 671 CD1ILEA 96 -0.89225.695 -5.843 1.0035.36 LlllC ATOM 672 N VAL A 97 -4.00825.504 -9.664 1.0032.56 L111N ATOM 673 CA VAL A 97 -5.02225.570-10.704 1.0029.74 LlllC ATOM 674 C VAL A 97 -6.42725.650-10.148 1.0036.58 LlllC ATOM 675 O VAL A 97 -7.39925.737-10.905 1.0038.60 L111O ATOM 676 CB VAL A 97 -4.93024.351-11.648 1.0038.47 LlllC ATOM 677 CGI VAL A 97 -3.50224.185-12.123 1.0037.01 LlllC ATOM 678 CG2VALA 97 -5.40323.086-10.940 1.0037.97 LlllC ATOM 679 N GLY A 98 -6.531 25.623 -8.823 1.0035.02 L111N ATOM 680 CA GLY A 98 -7.83625.690 -8.192 1.0035.16 Llll C ATOM 681 C GLY A 98 -7.74425.779 -6.683 1.0038.01 LlllC ATOM 682 O GLY A 98 -6.64825.832 -6.117 1.0038.34 L111O ATOM 683 N LYSA 99 -8.89625.801 -6.023 1.0035.14 L111N ATOM 684 CA LYS A 99 -8.911 25.883 -4.575 1.0040.57 LlllC ATOM 685 C LYSA 99 -10.23025.403 -3.991 1.0042.95 LlllC ATOM 686 O LYSA 99 -11.26425.396 -4.663 1.0042.23 L111O ATOM 687 CB LYSA 99 -8.63427.320 -4.130 1.0050.99 LlllC ATOM 688 CG LYS A 99 -9.85028.231 -4.172 1.0060.57 LlllC ATOM 689 CD LYSA 99 -9.46929.678 -3.885 1.0065.97 LlllC ATOM 690 CE LYSA 99 -10.64630.614 -4.127 1.0063.49 Llll C -81- SUBSTπUTE SHEET RULE26 ATOM 691 NZ LYS A 99 -10.21631.886 -4.768 1.0065.04 L111N ATOM 692 N VAL A 100 -10.18024.992 -2.731 1.0040.70 L111N ATOM 693 CA VAL A 100 -11.361 24.511 -2.036 1.0041.33 LlllC ATOM 694 C VAL A 100 -11.33024.980 -0.592 1.0041.84 LlllC ATOM 695 O VAL A 100 -10.26325.188 -0.012 1.0040.91 L111O ATOM 696 CB VAL A 100 -11.44022.973 -2.057 1.0042.37 LlllC ATOM 697 CGI VAL A 100 -11.84022.498 -3.442 1.0043.81 LlllC ATOM 698 CG2VALA100 -10.10222.377 -1.651 1.0037.38 LlllC ATOM 699 N THR A 101 -12.511 25.145 -0.016 1.0043.68 L111N ATOM 700 CA THR A 101 -12.62925.595 1.355 1.0042.43 LlllC ATOM 701 C THR A 101 -12.36224.454 2.321 1.0045.89 LlllC ATOM 702 O THR A 101 -12.49523.284 1.963 1.0046.60 Llll O ATOM 703 CB THR A 101 -14.02626.153 1.610 1.0045.72 LlllC ATOM 704 OG1THRA101 -15.00525.154 1.293 1.0040.56 L111O ATOM 705 CG2THRA101 -14.26027.380 0.738 1.0042.52 LlllC ATOM 706 N ARG A 102 -11.981 24.799 3.545 1.0049.33 L111N ATOM 707 CA ARG A 102 -11.701 23.797 4.565 1.0049.44 LlllC ATOM 708 C ARG A 102 -12.92522.925 4.792 1.0049.34 LlllC ATOM 709 O ARG A 102 -12.80721.744 5.115 1.0053.45 L111O ATOM 710 CB ARG A 102 -11.301 24.469 5.879 1.0051.60 LlllC ATOM 711 CG ARG A 102 -10.12623.806 6.574 1.0064.32 LlllC ATOM 712 CD ARG A 102 -10.57923.003 7.777 1.0072.71 LlllC ATOM 713 NE ARG A 102 -10.49523.786 9.006 1.0086.85 L111N ATOM 714 CZ ARG A 102 -10.08023.304 10.174 1.0096.04 LlllC ATOM 715 NH1 ARGA102 -9.71022.033 10.275 1.0095.91 L111N ATOM 716 NH2ARGA102 -10.03324.095 11.242 1.0096.71 L111N ATOM 717 N LYS A 103 -14.10323.514 4.626 1.0050.48 L111N ATOM 718 CA LYS A 103 -15.341 22.774 4.811 1.0051.76 LlllC ATOM 719 C LYS A 103 -15.441 21.718 3.719 1.0051.34 LlllC ATOM 720 O LYS A 103 -15.88420.600 3.966 1.0059.36 L111O ATOM 721 CB LYS A 103 -16.54523.721 4.751 1.0053.67 LlllC ATOM 722 CG LYS A 103 -17.83923.135 5.319 1.0062.90 LlllC ATOM 723 CD LYS A 103 -17.717.22.781 6.806 1.0065.48 LlllC ATOM 724 CE LYS A 103 -18.84021.841 7.257 1.0063.76 LlllC ATOM 725 NZ LYS A 103 -19.07721.884 8.732 1.0058.26 L111N ATOM 726 N GLN A 104 -15.01322.073 2.512 1.0051.89 L111N ATOM 727 CA GLN A 104 -15.05221.145 1.388 1.0044.08 LlllC ATOM 728 C GLN A 104 -14.161 19.939 1.664 1.0042.43 LlllC ATOM 729 O GLN A 104 -14.519 18.804 1.347 1.0040.53 Llll O ATOM 730 CB GLN A 104 -14.60221.850 0.110 1.0042.64 LlllC ATOM 731 CG GLN A 104 -15.66322.751 -0.484 1.0035.82 LlllC ATOM 732 CD GLN A 104 -15.24223.354 -1.804 1.0044.67 LlllC ATOM 733 OE1GLNA104 -14.30324.154 -1.867 1.0037.53 L111O ATOM 734 NE2GLNA104 -15.93622.975 -2.873 1.0035.39 L111N ATOM 735 N ILE A 105 - 12.99820.186 2.254 1.0039.32 L111N ATOM 736 CA ILE A 105 -12.088 19.103 2.584 1.0035.57 LlllC ATOM 737 C ILE A 105 - 12.846 18.187 3.525 1.0041.32 LlllC ATOM 738 O ILE A 105 - 12.770 16.965 3.411 1.0046.00 L111O ATOM 739 CB ILE A 105 -10.832 19.624 3.298 1.0033.68 LlllC ATOM 740 CGI ILE A 105 -9.87320.242 2.277 1.0032.96 LlllC ATOM 741 CG2 ILE A 105 -10.154 18.495 4.061 1.0034.33 LlllC -82- ATOM 742 CD1ILEA105 -9.501 19.321 1.131 1.0034.42 LlllC ATOM 743 N GLU A 106 -13.584 18.800 4.448 1.0047.08 L111N ATOM 744 CA GLUA 106 -14.382 18.068 5.428 1.0053.52 LlllC ATOM 745 C GLUA 106 -15.411 17.186 4.719 1.0055.13 LlllC ATOM 746 O GLUA 106 -15.606 16.027 5.087 1.0059.36 L111O ATOM 747 CB GLU A 106 -15.094 19.051 6.381 1.0050.72 LlllC ATOM 748 CG GLU A 106 -15.480 18.464 7.748 1.0055.56 LlllC ATOM 749 CD GLU A 106 -16.029 19.504 8.734 1.0062.03 LlllC ATOM 750 OE1GLUA106 -15.30820.476 9.054 1.0063.26 L111O ATOM 751 OE2GLUA106 -17.182 19.345 9.199 1.0053.90 L111O ATOM 752 N GLUA 107 -16.061 17.731 3.695 1.0051.75 L111N ATOM 753 CA GLU A 107 -17.071 16.982 2.954 1.0052.07 Llll C ATOM 754 C GLUA 107 -16.476 15.755 2.282 1.0050.13 Llll C ATOM 755 O GLU A 107 -16.990 14.642 2.417 1.0049.53 L111O ATOM 756 CB GLU A 107 -17.720 17.871 1.891 1.0056.84 Llll C ATOM 757 CG GLU A 107 -17.859 19.328 2.293 1.0073.20 LlllC ATOM 758 CD GLU A 107 -18.84320.088 1.422 1.0081.27 LlllC ATOM 759 OE1 GLUA 107 -19.271 19.540 0.382 1.0084.05 L111O ATOM 760 OE2GLUA 107 -19.18721.237 1.779 1.0086.15 L111O ATOM 761 N ILE A 108 ■ -15.391 15.973 1.549 1.0046.89 L111N ATOM 762 CA ILE A 108 -14.719 14.900 0.844 1.0039.41 LlllC ATOM 763 C ILE A 108 - ■14.222 13.854 1.829 1.0040.77 Llll C ATOM 764 O ILE A 108 ■ -14.441 12.658 1.637 1.0043.65 L111O ATOM 765 CB ILE A 108 -13.542 15.447 0.019 1.0038.05 LlllC ATOM 766 CGI ILE A 108 -14.072 16.428 -1.032 1.0036.44 LlllC ATOM 767 CG2ILEA108 -12.796 14.305 -0.649 1.0041.19 Llll C ATOM 768 CD1 ILE A 108 -13.004 17.084 -1.882 1.0031.78 Llll C ATOM 769 N ALA A 109 -13.561 14.303 2.891 1.0040.57 L111N ATOM 770 CA ALA A 109 -13.053 13.380 3.895 1.0042.41 LlllC ATOM 771 C ALA A 109 -14.205 12.546 4.429 1.0044.77 LlllC ATOM 772 O ALA A 109 -14.051 11.356 4.685 1.0048.40 L111O ATOM 773 CB ALA A 109 -12.393 14.140 5.032 1.0038.72 LlllC ATOM 774 N LYS A 110 -15.365 13.174 4.589 1.0047.97 L111N ATOM 775 CA LYS A 110 -16.537 12.474 5.099 1.0044.59 LlllC ATOM 776 C LYSA 110 -17.027 11.474 4.066 1.0045.30 LlllC ATOM 777 O LYS A no -17.377 10.342 4.401 1.0044.67 Llll O ATOM 778 CB LYS A no -17.651 13.469 5.422 1.0045.45 LlllC ATOM 779 CG LYSA no -17.991 13.562 6.902 1.0047.29 LlllC ATOM 780 CD LYSA no -17.733 14.963 7.448 1.0051.84 LlllC ATOM 781 CE LYS A no -18.991 15.558 8.070 1.0053.58 Line ATOM 782 NZ LYS A 110 -18.712 16.257 9.356 1.0055.16 L111N ATOM 783 N THRA111 -17.043 11.902 2.807 1.0044.49 L111N ATOM 784 CA THR A 111 -17.492 11.060 1.705 1.0042.63 LlllC ATOM 785 C THR A 111 -16.635 9.810 1.548 1.0044.42 LlllC ATOM 786 O THR A 111 -17.149 8.707 1.375 1.0044.77 L111O ATOM 787 CB THR A 111 -17.452 11.830 0.376 1.0040.13 LlllC ATOM 788 OG1 THR A 111 -18.545 12.754 0.325 1.0046.15 Llll O ATOM 789 CG2 THR A 111 -17.552 10.871 -0.799 1.0043.65 LlllC ATOM 790 N LYSA 112 -15.323 9.995 1.609 1.0042.25 L111N ATOM 791 CA LYS A 112 -14.382 8.898 1.448 1.0042.77 LlllC ATOM 792 C LYS A 112 -14.081 8.127 2.732 1.0043.93 LlllC -83- ATOM 793 O LYS A 112 -13.321 7.157 2.713 1.0047.28 L111O ATOM 794 CB LYS A 112 -13.072 9.442 0.873 1.0044.33 Llll C ATOM 795 CG LYS A 112 -13.129 9.772 -0.607 1.0040.93 Llll C ATOM 796 CD LYS A 112 -11.806 9.474 -1.281 1.0035.66 LlllC ATOM 797 CE LYSA 112 -11.377 8.032 -1.062 1.0031.03 LlllC ATOM 798 NZ LYS A 112 -11.960 7.113 -2.076 1.0028.57 L111N ATOM 799 N MET A 113 -14.673 8.554 3.842 1.0042.32 L111N ATOM 800 CA MET A 113 -14.436 7.911 5.132 1.0041.26 Llll C ATOM 801 C MET A 113 -14.492 6.379 5.116 1.0039.35 Llll C ATOM 802 O MET A 113 -13.619 5.717 5.688 1.0039.20 Llll O ATOM 803 CB MET A 113 -15.410 8.457 6.177 1.0039.84 Llll C ATOM 804 CG MET A 113 -14.931 8.283 7.609 1.0045.81 Llll C ATOM 805 SD MET A 113 -13.481 9.269 8.040 1.0047.31 Llll S ATOM 806 CE MET A 113 -14.261 10.78" ' 8.610 1.0049.60 LlllC ATOM 807 N PRO A 114 -15.524 5.793 4.484 1.0032.93 L111N ATOM 808 CA PRO A 114 -15.582 4.328 4.458 1.0029.51 LlllC ATOM 809 C PRO A 114 -14.301 3.703 3.912 1.0035.05 LlllC ATOM 810 O PROA 114 -13.918 2.609 4.314 1.0041.74 Llll O ATOM 811 CB PRO A 114 -16.791 4.013 3.575 1.0027.80 Llll C ATOM 812 CG PRO A 114 -17.214 5.307 2.967 1.0023.57 Llll C ATOM 813 CD PRO A 114 -16.678 6.411 3.811 1.0031.92 Llll C ATOM 814 N ASP A 115 -13.629 4.408 3.008 1.0038.82 L111N ATOM 815 CA ASP A 115 -12.399 3.898 2.419 1.0036.41 LlllC ATOM 816 C ASP A 115 -11.138 4.462 3.069 1.0036.55 LlllC ATOM 817 O ASP A 115 -10.025 4.080 2.713 1.0040.35 Llll O ATOM 818 CB ASP A 115 -12.385 4.193 0.919 1.0048.68 Llll C ATOM 819 CG ASP A 115 -13.453 3.418 0.162 1.0057.41 LlllC ATOM 820 OD1 ASP A 115 -13.653 2.221 0.464 1.0051.55 L111O ATOM 821 OD2ASPA115 -14.090 4.009 -0.737 1.0058.21 Llll O ATOM 822 N LEU A 116 -11.311 5.368 4.024 1.0038.89 L111N ATOM 823 CA LEU A 116 -10.178 5.969 4.720 1.0033.57 LlllC ATOM 824 C LEU A 116 -9.916 : 5.199 i 5.007 1.0032.97 LlllC ATOM 825 O LEU A 116 -10.817 4.567 6.547 1.0040.69 L111O ATOM 826 CB LEU A 116 -10.482 7.427 5.055 1.0038.53 Llll C ATOM 827 CG LEU A 116 -9.930 8.533 4.156 1.0037.13 LlllC ATOM 828 CD1LEUA116 -9.839 8.062 2.720 1.0034.98 LlllC ATOM 829 CD2LEUA116 -10.837 9.742 4.261 1.0033.33 LlllC ATOM 830 N ASN A 117 -8.686 5.256 6.501 1.0032.67 L111N ATOM 831 CA ASN A 117 -8.336 4.549 7.725 1.0033.28 LlllC ATOM 832 C ASN A 117 -8.052 : 5.502 I 8.889 1.0039.76 LlllC ATOM 833 O ASN A 117 -7.373 5.140 9.851 1.0036.63 L111O ATOM 834 CB ASN A 117 -7.117 3.666 7.475 1.0023.35 LlllC ATOM 835 CG ASN A 117 -5.872 4.470 7.208 1.0024.02 Llll C ATOM 836 OD1 ASNA117 -5.949 5.659 6.916 1.0031.18 L111O ATOM 837 ND2ASNA117 -4.714 3.828 7.306 1.0018.87 L111N ATOM 838 N ALA A 118 -8.572 6.720 8.799 1.0041.20 L111N ATOM 839 CA ALA A 118 -8.363 7.710 9.846 1.0041.18 L1T1C ATOM 840 C ALA A 118 -9.297 7.443 11.018 1.0043.82 LlllC ATOM 841 O ALA A 118 -10.455 7.069 10.827 1.0045.81 L111O ATOM 842 CB ALA A 118 -8.604 9.103 9.296 1.0041.30 LlllC ATOM 843 N ASN A 119 -8.793 7.644 12.230 1.0042.07 L111N 84- SUBSTITUTE SHEET PULE26) ATOM 844 CA ASN A 119 -9.589 7.419 13.429 1.0042.41 LlllC ATOM 845 C ASN A 119 -10.370 8.660 13.847 1.0048.14 LlllC ATOM 846 O ASN A 119 -11.141 8.625 14.807 1.0053.14 L111O ATOM 847 CB ASN A 119 -8.684 6.981 14.575 1.0037.27 LlllC ATOM 848 CG ASN A 119 -8.180 5.575 14.400 1.0033.45 Llll C ATOM 849 OD1 ASNA119 -8.886 4.714 13.876 1.0031.47 Llll O ATOM 850 ND2ASNA119 -6.951 5.328 14.837 1.0038.73 L111N ATOM 851 N SERA 120 -10.168 9.756 13.125 1.0048.44 L111N ATOM 852 CA SERA 120 -10.851 11.005 13.430 1.0043.86 LlllC ATOM 853 C SERA 120 -11.091 11.809 12.163 1.0045.90 LlllC ATOM 854 O SERA 120 -10.321 11.715 11.208 1.0053.71 L111O ATOM 855 CB SERA 120 -10.010 11.834 14.401 1.0038.80 LlllC ATOM 856 OG SERA 120 -8.642 11.834 14.030 1.0032.06 L111O ATOM 857 N LEU A 121 -12.157 12.601 12.156 1.0046.97 L111N ATOM 858 CA LEU A 121 -12.476 13.429 11.000 1.0044.83 LlllC ATOM 859 C LEU A 121 -11.297 14.333 10.678 1.0045.31 LlllC ATOM 860 O LEU A 121 -11.078 14.693 9.526 1.0052.25 L111O ATOM 861 CB LEU A 121 -13.705 14.291 11.277 1.0039.77 LlllC ATOM 862 CG LEU A 121 -13.904 15.469 10.325 1.0041.18 LlllC ATOM 863 CD1LEUA121 -14.063 14.958 8.900 1.0041.06 LlllC ATOM 864 CD2LEUA121 -15.128 16.260 10.751 1.0041.00 LlllC ATOM 865 N GLU A 122 -10.542 14.701 11.705 1.0046.54 L111N ATOM 866 CA GLU A 122 -9.383 15.562 11.522 1.0047.46 LlllC ATOM 867 C GLUA 122 -8.327 14.834 10.702 1.0045.12 LlllC ATOM 868 O GLUA 122 -7.781 15.383 9.747 1.0051.65 Llll O ATOM 869 CB GLUA 122 -8.807 15.962 12.881 1.0045.32 LlllC ATOM 870 CG GLU A 122 -9.646 16.987 13.629 1.0057.78 Llll C ATOM 871 CD GLU A 122 -10.643 16.353 14.588 1.0063.03 LlllC ATOM 872 OE1GLUA122 -10.380 15.234 15.075 1.0064.43 L111O ATOM 873 OE2 GLU A 122 -11.690 16.979 14.857 1.0069.35 L111O ATOM 874 N ALA A 123 -8.045 13.593 11.083 1.0041.17 L111N ATOM 875 CA ALA A 123 -7.062 12.786 10.381 1.0038.97 LlllC ATOM 876 C ALA A 123 -7.516 12.566 8.944 1.0041.17 LlllC ATOM 877 O ALA A 123 -6.701 12.562 8.022 1.0041.16 L111O ATOM 878 CB ALA A 123 -6.891 11.452 11.081 1.0036.50 LlllC ATOM 879 N ALA A 124 -8.822 12.389 8.760 1.0036.64 L111N ATOM 880 CA ALA A 124 -9.390 12.168 7.432 1.0036.26 LlllC ATOM 881 C ALA A 124 -9.133 13.362 6.533 1.0035.14 Llll C ATOM 882 O ALA A 124 -8.742 13.207 5.379 1.0041.09 Llll O ATOM 883 CB ALA A 124 -10.886 11.914 7.533 1.0032.82 LlllC ATOM 884 N MET A 125 -9.358 14.555 7.072 1.0038.73 L111N ATOM 885 CA MET A 125 -9.158 15.785 6.322 1.0034.84 LlllC ATOM 886 C MET A 125 -7.686 15.968 6.003 1.0031.87 LlllC ATOM 887 O MET A 125 -7.330 16.458 4.938 1.0042.09 L111O ATOM 888 CB MET A 125 -9.671 16.977 7.126 1.0035.51 LlllC ATOM 889 CG MET A 125 -11.072 16.769 7.695 1.0040.88 Llll C ATOM 890 SD MET A 125 -12.008 18.287 7.948 1.0045.99 Llll S ATOM 891 CE MET A 125 -10.675 19.462 8.286 1.0044.96 LlllC ATOM 892 N LYS A 126 -6.831 15.567 6.930 1.0028.09 L111N ATOM 893 CA LYS A 126 -5.397 15.684 6.730 1.0028.15 LlllC ATOM 894 C LYS A 126 -5.007 14.801 5.551 1.0030.29 LlllC 85- SUBSTITUTE SHET(RULE26) ATOM 895 O LYS A 126 -4.107 15.129 4.781 1.0032.85 L111O ATOM 896 CB LYS A 126 -4.652 15.229 7.989 1.0034.95 LlllC ATOM 897 CG LYS A 126 -4.010 16.351 8.781 1.0028.05 LlllC ATOM 898 CD LYS A 126 -4.465 16.328 10.229 1.0031.31 LlllC ATOM 899 CE LYS A 126 -3.431 15.676 11.140 1.0039.80 Llll C ATOM 900 NZ LYS A 126 -2.064 16.271 11.016 1.0045.29 L111N ATOM 901 N ILE A 127 -5.691 13.669 5.417 1.0032.92 L111N ATOM 902 CA ILE A 127 -5.414 12.748 4.325 1.0029.89 LlllC ATOM 903 C ILE A 127 -5.820 13.405 3.014 1.0030.60 LlllC ATOM 904 O ILE A 127 -5.024 13.492 2.086 1.0036.08 L111O ATOM 905 CB ILE A 127 -6.179 11.423 4.501 1.0023.98 Llll C ATOM 906 CGI ILE A 127 -5.591 10.649 5.689 1.0033.32 LlllC ATOM 907 CG2ILEA127 -6.074 10.590 3.234 1.0026.83 Llll C ATOM 908 CD1ILEA127 -6.427 9.465 6.152 1.0025.44 LlllC ATOM 909 N ILE A 128 -7.060 13.875 2.947 1.0030.31 L111N ATOM 910 CA ILE A 128 -7.559 14.543 1.756 1.0027.70 LlllC ATOM 911 C ILE A 128 -6.681 15.730 1.359 1.0030.19 LlllC ATOM 912 O ILE A 128 -6.406 15.939 0.181 1.0037.83 Llll O ATOM 913 CB ILE A 128 -8.980 15.065 1.974 1.0029.26 LlllC ATOM 914 CGI ILE A 128 -9.911 13.906 2.325 1.0027.20 LlllC ATOM 915 CG2ILEA128 -9.454 15.802 0.731 1.0029.10 LlllC ATOM 916 CD1ILEA128 -9.915 12.793 1.304 1.0021.41 LlllC ATOM 917 N GLU A 129 -6.245 16.507 2.342 1.0027.35 L111N ATOM 918 CA GLUA 129 -5.412 17.669 2.065 1.0028.43 LlllC ATOM 919 C GLU A 129 -4.116 17.249 1.418 1.0025.38 LlllC ATOM 920 O GLUA 129 -3.554 17.983 0.613 1.0033.17 Llll O ATOM 921 CB GLU A 129 -5.092 18.429 3.348 1.0039.34 Llll C ATOM 922 CG GLU A 129 -6.223 19.289 3.870 1.0049.18 Llll C ATOM 923 CD GLUA 129 -6.093 19.546 5.355 1.0057.36 LlllC ATOM 924 OE1 GLUA 129 -4.942 19.571 5.849 1.0062.27 Llll O ATOM 925 OE2GLUA129 -7.136 19.716 6.024 1.0061.09 L111O ATOM 926 N GLY A 130 -3.634 16.071 1.785 1.0024.18 L111N ATOM 927 CA GLY A 130 -2.394 15.591 1.210 1.0021.91 LlllC ATOM 928 C GLY A 130 -2.536 15.392 -0.285 1.0023.19 LlllC ATOM 929 O GLY A 130 -1.597 15.625 -1.042 1.0021.99 L111O ATOM 930 N THR A 131 -3.720 14.962 -0.705 1.0022.49 L111N ATOM 931 CA THR A 131 -4.005 14.723 -2.111 1.0025.94 LlllC ATOM 932 C THR A 131 -4.160 16.049 -2.849 1.0028.86 LlllC ATOM 933 O THR A 131 -3.629 16.229 -3.946 1.0031.66 L111O ATOM 934 CB THR A 131 -5.292 13.896 -2.270 1.0027.10 LlllC ATOM 935 OG1THRA131 -5.078 12.577 -1.747 1.0026.23 L111O ATOM 936 CG2THRA131 -5.694 13.808 -3.734 1.0027.07 LlllC ATOM 937 N ALA A 132 -4.887 16.979 -2.241 1.0027.56 L111N ATOM 938 CA ALA A 132 -5.096 18.292 -2.835 1.0026.64 LlllC ATOM 939 C ALA A 132 -3.753 18.974 -3.058 1.0028.30 LlllC ATOM 940 O ALA A 132 -3.524 19.602 -4.084 1.0030.29 Llll O ATOM 941 CB ALA A 132 -5.954 19.134 -1.922 1.0032.54 Llll C ATOM 942 N LYS A 133 -2.866 18.843 -2.082 1.0029.52 L111N ATOM 943 CA LYS A 133 -1.545 19.443 -2.158 1.0027.21 LlllC ATOM 944 C LYS A 133 -0.754 18.848 -3.311 1.0030.72 Llll C ATOM 945 O LYS A 133 0.190 19.458 -3.813 1.0034.77 Llll O -86- 1.7 - gliii J7ES. ATOM 946 CB LYS A 133 -0.784 19.205 -0.846 1.0030.61 LlllC ATOM 947 CG LYS A 133 -0.84320.371 0.138 1.0038.23 Llll C ATOM 948 CD LYS A 133 -0.782 19.897 1.581 1.0035.27 LlllC ATOM 949 CE LYS A 133 0.653 19.826 2.079 1.0045.39 Llll C ATOM 950 NZ LYS A 133 0.737 19.680 3.568 1.0050.50 L111N ATOM 951 N SERA 134 -1.141 17.650 - 3.729 1.0031.51 L111N ATOM 952 CA SERA 134 -0.441 16.966 -4.807 1.0033.04 LlllC ATOM 953 C SERA 134 -0.969 17.300 - 6.202 1.0030.13 LlllC ATOM 954 O SERA 134 -0.345 16.952 - 7.198 1.0027.50 L111O ATOM 955 CB SERA 134 -0.510 15.452 -4.588 1.0031.88 LlllC ATOM 956 OG SERA 134 -1.741 14.927 -5.055 1.0023.70 Llll O ATOM 957 N MET A 135 -2.107 17.977 -6.276 1.0026.88 L111N ATOM 958 CA MET A 135 -2.691 18.308 -7.563 1.0025.82 Llll C ATOM 959 C MET A 135 -2.887 19.801 -7.783 1.0031.45 LlllC ATOM 960 O MET A 135 -3.73720.209 -8.581 1.0030.19 L111O ATOM 961 CB MET A 135 -4.029 17.597 -7.711 1.0027.23 Llll C ATOM 962 CG MET A 135 -4.974 17.857 -6.574 1.0022.80 Llll C ATOM 963 SD MET A 135 -6.230 16.597 -6.491 1.0037.09 Llll S ATOM 964 CE MET A 135 -7.008 16.793 -8.089 1.0041.07 Llll C ATOM 965 N GLY A 136 -2.10520.613 -7.078 1.0027.82 L111N ATOM 966 CA GLY A 136 -2.21522.050 -7.228 1.0022.84 LlllC ATOM 967 C GLY A 136 -3.56922.630 ■ -6.854 1.0027.99 Llll C ATOM 968 O GLY A 136 -4.06823.538 -7.515 1.0033.90 L111O ATOM 969 N ILE A 137 -4.181 22.099 -5.806 1.0027.75 L111N ATOM 970 CA ILE A 137 -5.45822.621 ■ -5.345 1.0029.45 LlllC ATOM 971 C ILE A 137 -5.20723.141 -3.934 1.0037.77 Llll C ATOM 972 O ILE A 137 -4.72222.409 -3.066 1.0042.44 L111O ATOM 973 CB ILE A 137 -6.55321.535 - ■ 5.334 1.0029.74 LlllC ATOM 974 CGI ILE A 137 -6.75520.994 -6.751 1.0030.99 LlllC ATOM 975 CG2ILEA137 -7.86422.117 -4.842 1.0021.17 LlllC ATOM 976 CD1ILEA137 -7.883 19.989 -6.877 1.0023.63 Llll C ATOM 977 N GLUA 138 -5.50824.419 -3.723 1.0040.79 L111N ATOM 978 CA GLU A 138 -5.29925.058 -2.435 1.0039.24 LlllC ATOM 979 C GLU A 138 -6.52825.003 ■ -1.549 1.0043.73 LlllC ATOM 980 O GLUA 138 -7.64024.799 -2.031 1.0048.97 L111O ATOM 981 CB GLUA 138 -4.90326.506 -2.644 1.0041.53 LlllC ATOM 982 CG GLUA 138 -3.46626.787 -2.294 1.0059.35 LlllC ATOM 983 CD GLUA 138 -3.09428.228 -2.556 1.0067.14 Llll C ATOM 984 OE1 GLUA 138 -3.95028.970 -3.098 1.0059.01 L111O ATOM 985 OE2GLUA138 -1.95028.613 -2.220 1.0067.00 L111O ATOM 986 N VAL A 139 -6.31625.193 -0.251 1.0048.03 L111N ATOM 987 CA VAL A 139 -7.40425.171 0.725 1.0052.55 LlllC ATOM 988 C VAL A 139 -7.561 26.549 1.370 1.0053.32 Llll C ATOM 989 O VAL A 139 -6.57827.164 1.782 1.0054.50 L111O ATOM 990 CB VAL A 139 -7.14424.122 1.838 1.0047.09 LlllC ATOM 991 CGI VAL A 139 -7.48622.741 1.332 1.0046.28 LlllC ATOM 992 CG2VALA139 -5.68924.171 2.281 1.0054.07 LlllC ATOM 993 N VAL A 140 -8.79927.028 1.454 1.0057.53 L111N ATOM 994 CA VAL A 140 -9.07628.334 2.045 1.0058.40 Llll C ATOM 995 C VAL A 140 -10.29528.298 2.970 1.0064.90 LlllC ATOM 996 O VAL A 140 -11.24327.540 2.674 1.0063.16 L111O -87- ATOM 997 CB VAL A 140 -9.321 29.394 0.950 1.0056.76 LlllC ATOM 998 CGI VAL A 140 -8.20729.343 -0.082 1.0048.47 LlllC ATOM 999 CG2 VAL A 140 -10.66729.156 0.288 1.0056.93 LlllC ATOM 1000 OXT VAL A 140 -10.29029.036 3.980 1.0072.53 L111O TER 1001 VAL A 140 ATOM 1002 N LYSB 71 21.043 -5.854-42.905 1.0063.31 L112N ATOM 1003 CA LYS B 71 -20.335 -6.681-43.925 1.0062.12 L112C ATOM 1004 C LYSB 71 - -20.331 -8.162-43.563 1.0064.08 L112C ATOM 1005 O LYSB 71 -20.688 -8.546-42.446 1.0064.38 LI 120 ATOM 1006 CB LYSB 71 -18.892 -6.202-44.080 1.0058.09 L112C ATOM 1007 CG LYSB 71 -18.753 -4.928-44.883 1.0057.55 L112C ATOM 1008 CD LYSB 71 -17.414.4.877-45.584 1.0059.51 L112C ATOM 1009 CE LYSB 71 -17.502 -4.091-46.883 1.0073.52 L112C ATOM 1010 NZ LYSB 71 -16.276 -3.277-47.136 1.0074.38 L112N ATOM 1011 N THRB 72 -19.922 -8.992-44.517 1.0060.82 L112N ATOM 1012 CA THRB 72 -19.866-10.432-44.305 1.0053.90 L112C ATOM 1013 C THRB 72 -18.602-10.793-43.534 1.0045.75 L112C ATOM 1014 O THRB 72 -17.573-10.123-43.661 1.0042.26 LI 120 ATOM 1015 CB THRB 72 -19.881-11.190-45.647 1.0054.39 L112C ATOM 1016 OG1THRB 72 -20.261-10.291-46.695 1.0053.11 LI 120 ATOM 1017 CG2THRB 72 -20.877-12.340-45.603 1.0054.95 L112C ATOM 1018 N PROB 73 -18.664-11.860-42.721 1.0037.48 L112N ATOM 1019 CA PROB 73 17.507-12.290-41.935 1.0034.20 L112C ATOM 1020 C PROB 73 - ■16.302-12.518-42.828 1.0036.67 L112C ATOM 1021 O PROB 73 -16.441-12.715-44.034 1.0042.32 LI 120 ATOM 1022 CB PROB 73 -17.977-13.578-41.271 1.0035.95 L112C ATOM 1023 CG PROB 73 -19.465-13.478-41.261 1.0038.50 L112C ATOM 1024 CD PROB 73 -19.831-12.733-42.504 1.0038.65 L112C ATOM 1025 N PROB 74 - ■15.097-12.500-42.247 1.0030.98 L112N ATOM 1026 CA PROB 74 -13.896-12.712-43.056 1.0029.22 L112C ATOM 1027 C PROB 74 - -13.949-14.071-43.737 1.0030.46 L112C ATOM 1028 O PROB 74 . -14.664-14.971-43.292 1.0034.58 LI 120 ATOM 1029 CB PROB 74 -12.755-12.620-42.042 1.0026.89 L112C ATOM 1030 CG PROB 74 -13.334-11.909-40.876 1.0016.14 L112C ATOM 1031 CD PROB 74 -14.773-12.302-40.828 1.0024.82 L112C ATOM 1032 N ALAB 75 -13.196-14.217-44.819 1.0026.98 L112N ATOM 1033 CA ALAB 75 -13.162-15.472-45.540 1.0021.93 L112C ATOM 1034 C ALAB 75 -12.623-16.534-44.597 1.0029.69 L112C ATOM 1035 O ALAB 75 -13.190-17.619-44.481 1.0033.14 L112O ATOM 1036 CB ALAB 75 -12.264-15.346-46.760 1.0029.99 L112C ATOM 1037 N SERB 76 - -11.530-16.210-43.912 1.0029.96 L112N ATOM 1038 CA SERB 76 -10.911-17.143-42.978 1.0031.14 L112C ATOM 1039 C SERB 76 - ■11.908-17.595-41.918 1.0036.21 L112C ATOM 1040 O SERB 76 - -11.922-18.760-41.517 1.0038.58 L112O ATOM 1041 CB SERB 76 -9.700-16.496-42.305 1.0028.76 L112C ATOM 1042 OG SERB 76 -10.103-15.622-41.266 1.0033.61 LI 120 ATOM 1043 N PHEB 77 - -12.748-16.674-41.465 1.0035.12 L112N ATOM 1044 CA PHEB 77 -13.731-17.018-40.457 1.0036.06 L112C ATOM 1045 C PHEB 77 - -14.684-18.047-41.025 1.0038.63 L112C ATOM 1046 O PHEB 77 - -14.874-19.116-40.448 1.0043.61 LI 120 ATOM 1047 CB PHEB 77 -14.518-15.787-40.025 1.0044.62 L112C -88- ATOM 1048 CG PHEB 77 -15.644-16.097-39.080 1.0047.58 L112C ATOM 1049 CD 1 PHEB 77 -15.388-16.347-37.733 1.0044.42 L112C ATOM 1050 CD2PHEB 77 -16.959-16.151-39.536 1.0044.81 L112C ATOM 1051 CE1PHEB 77 -16.424-16.646-36.855 1.0040.74 L112C ATOM 1052 CE2PHEB 77 -18.003 -16.449 -38.667 1.0042.72 L112C ATOM 1053 CZ PHEB 77 -17.736-16.697-37.322 1.0044.82 L112C ATOM 1054 N LEUB 78 -15.288-17.719-42.161 1.0037.81 L112N ATOM 1055 CA LEUB 78 -16.228 -18.625 -42.810 1.0036.34 L112C ATOM 1056 C LEUB 78 -15.574-19.970-43.100 1.0031.89 L112C ATOM 1057 O LEUB 78 -16.204-21.017-42.980 1.0035.90 L112O ATOM 1058 CB LEUB 78 -16.743-17.998-44.105 1.0034.71 L112C ATOM 1059 CG LEUB 78 -17.603-16.750-43.895 1.0033.80 L112C ATOM 1060 CD 1 LEUB 78 -18.030-16.182-45.238 1.0029.39 L112C ATOM 1061 CD2LEUB 78 -18.817-17.113-43.052 1.0029.74 L112C ATOM 1062 N LEUB 79 -14.302-19.936-43.474 1.0026.28 L112N ATOM 1063 CA LEUB 79 -13.566-21.153-43.765 1.0031.61 L112C ATOM 1064 C LEUB 79 -13.420-22.002-42.498 1.0039.25 L112C ATOM 1065 O LEUB 79 -13.727-23.194-42.508 1.0040.69 L112O ATOM 1066 CB LEUB 79 -12.192-20.799-44.344 1.0031.36 L112C ATOM 1067 CG LEUB 79 -12.229-20.369-45.816 1.0025.54 L112C ATOM 1068 CD 1 LEUB 79 -10.852-19.971-46.314 1.0021.73 L112C ATOM 1069 CD2LEUB 79 -12.763-21.520-46.635 1.0023.94 L112C ATOM 1070 N LYS B 80 -12.960-21.384-41.411 1.0044.27 L112N ATOM 1071 CA LYS B 80 -12.794-22.078-40.131 1.0039.57 L112C ATOM 1072 C LYSB 80 -14.075-22.822-39.785 1.0035.79 L112C ATOM 1073 O LYSB 80 -14.049 -23.993 -39.418 1.0037.45 L112O ATOM 1074 CB LYSB 80 -12.500-21.077-39.008 1.0044.26 L112C ATOM 1075 CG LYS B * 80 -11.028-20.840-38.710 1.0046.47 L112C ATOM 1076 CD LYS B 80 -10.839-19.591-37.850 1.0045.33 L112C ATOM 1077 CE LYS B 80 -9.377-19.388-37.474 1.0050.24 L112C ATOM 1078 NZ LYS B 80 -9.071-17.963-37.174 1.0050.61 L112N ATOM 1079 N LYSB 81 -15.197-22.122-39.907 1.0034.23 L112N ATOM 1080 CA LYSB 81 -16.508-22.682-39.609 1.0039.48 L112C ATOM 1081 C LYSB 81 -16.845 -23.880 -40.485 1.0042.52 L112C ATOM 1082 O LYSB 81 -17.253 -24.929 -39.991 1.0049.15 L112O ATOM 1083 CB LYSB 81 -17.580-21.607-39.787 1.0041.03 L112C ATOM 1084 CG LYSB 81 -18.306-21.234-38.510 1.0052.41 L112C ATOM 1085 CD LYSB 81 -19.812-21.200-38.730 1.0068.51 L112C ATOM 1086 CE LYSB 81 -20.234 -19.983 -39.549 1.0073.66 L112C ATOM 1087 NZ LYSB 81 -20.152-20.217-41.023 1.0071.12 L112N ATOM 1088 N ALAB 82 -16.678-23.722-41.792 1.0045.81 L112N ATOM 1089 CA ALAB 82 -16.979-24.800-42.725 1.0044.23 L112C ATOM 1090 C ALAB 82 -16.154-26.049-42.431 1.0040.55 L112C ATOM 1091 O ALAB 82 -16.662-27.165-42.503 1.0039.77 L112O ATOM 1092 CB ALAB 82 -16.729-24.336-44.149 1.0042.43 L112C ATOM 1093 N ALAB 83 -14.882-25.855-42.101 1.0035.34 L112N ATOM 1094 CA ALAB 83 -13.990-26.967-41.807 1.0033.10 L112C ATOM 1095 C ALAB 83 -14.259-27.559-40.431 1.0040.90 L112C ATOM 1096 O ALAB 83 -13.797-28.659-40.123 1.0042.00 L112O ATOM 1097 CB ALAB 83 -12.544-26.514-41.898 1.0030.83 L112C ATOM 1098 N GLYB 84 -15.000 -26.823 -39.605 1.0043.37 L112N -89- SUBSTI ATOM 1099 CA GLYB 84 -15.320-27.292-38.267 1.0040.61 L112C ATOM 1100 C GLYB 84 -14.164-27.194-37.287 1.0041.90 L112C ATOM 1101 O GLYB 84 -14.061-27.997-36.361 1.0045.63 L112O ATOM 1102 N ILEB 85 -13.283-26.222-37.495 1.0040.72 L112N ATOM 1103 CA ILEB 85 -12.141-26.025-36.612 1.0039.23 L112C ATOM 1104 C ILEB 85 -12.283-24.664-35.944 1.0044.21 L112C ATOM 1105 O ILEB 85 -13.168-23.884-36.304 1.0048.06 LI 12 O ATOM 1106 CB ILEB 85 -10.801-26.081-37.388 1.0034.91 L112C ATOM 1107 CGI ILEB 85 -10.738-24.959-38.423 1.0034.57 L112C ATOM 1108 CG2 ILEB 85 -10.657-27.425-38.076 1.0033.20 L112C ATOM 1109 CD1 ILEB 85 -9.477-24.973-39.258 1.0032.16 L112C ATOM 1110 N GLU B 86 -11.422-24.380-34.972 1.0045.20 L112N ATOM llll CA GLUB 86 -11.484-23.108-34.266 1.0043.68 L112C ATOM 1112 C GLUB 86 -10.261-22.245-34.544 1.0041.68 L112C ATOM 1113 O GLUB 86 -10.258-21.049-34.257 1.0047.94 LI 12O ATOM 1114 CB GLUB 86 -11.632-23.347-32.760 1.0046.15 L112C ATOM 1115 CG GLUB 86 -10.322-23.581-32.020 1.0065.68 L112C ATOM 1116 CD GLUB 86 -10.394-23.163-30.561 1.0076.24 L112C ATOM 1117 OE1GLUB 86 -11.440-23.417-29.922 1.0079.61 L112O ATOM 1118 OE2GLUB 86 -9.409-22.580-30.054 1.0077.24 LI 12O ATOM 1119 N LYSB 87 -9.222-22.850-35.103 1.0033.13 L112N ATOM 1120 CA LYSB 87 -8.011-22.109-35.416 1.0040.07 L112C ATOM 1121 C LYSB 87 -7.423-22.570-36.741 1.0040.26 L112C ATOM 11220 LYSB 87 -7.610-23.712-37.150 1.0046.66 L112O ATOM 1123 CB LYSB 87 -6.973-22.293-34.306 1.0043.57 L112C ATOM 1124 CG LYSB 87 -7.240-21.468-33.057 1.0057.30 L112C ATOM 1125 CD LYSB 87 -6.210-21.759-31.970 1.0060.56 L112C ATOM 1126 CE LYSB 87 -5.750-20.483-31.279 1.0059.04 L112C ATOM 1127 NZ LYSB 87 -6.112-19.261-32.054 1.0064.31 L112N ATOM 1128 N GLY B 88 -6.725-21.671-37.418 1.0034.46 L112N ATOM 1129 CA GLYB 88 -6.110-22.038-38.672 1.0033.11 L112C ATOM 1130 C GLYB 88 -4.818-22.742-38.333 1.0031.13 L112C ATOM 1131 O GLYB 88 -4.402-22.747-37.180 1.0034.45 LI 12O ATOM 1132 N SERB 89 -4.183-23.345-39.325 1.0031.44 L112N ATOM 1133 CA SERB 89 -2.935-24.043-39.093 1.0029.45 L112C ATOM 1134 C SERB 89 -1.871-23.027-38.709 1.0037.64 L112C ATOM 1135 O SERB 89 -1.904-21.889-39.167 1.0039.44 L112O ATOM 1136 CB SERB 89 -2.519-24.789-40.357 1.0030.04 L112C ATOM 1137 OG SERB 89 -1.138-25.097-40.339 1.0030.69 L112O ATOM 1138 N SERB 90 -0.932-23.437-37.863 1.0034.79 L112N ATOM 1139 CA SERB 90 0.145-22.556-37.434 1.0036.73 L112C ATOM 1140 C SERB 90 1.250-22.593-38.480 1.0037.59 L112C ATOM 1141 O SERB 90 2.173-21.778-38.474 1.0038.46 LI 12O ATOM 1142 CB SERB 90 0.698-23.023-36.092 1.0042.80 L112C ATOM 1143 OG SERB 90 1.368-24.265-36.234 1.0057.39 LI 12O ATOM 1144 N GLUB 91 1.153-23.565-39.373 1.0040.27 L112N ATOM 1145 CA GLUB 91 2.122-23.726-40.445 1.0044.62 L112C ATOM 1146 C GLUB 91 1.352-24.125-41.697 1.0042.72 L112C ATOM 11470 GLUB 91 1.316-25.295-42.067 1.0049.13 L112O ATOM 1148 CB GLUB 91 3.135-24.812-40.085 1.0047.12 L112C ATOM 1149 CG GLUB 91 4.520-24.289-39.768 1.0058.48 L112C -90- UBSTITUTE SHEET ATOM 1150 CD GLUB 91 5.431-25.364-39.208 1.0065.15 L112C ATOM 1151 OE1GLUB 91 5.935-26.197-39.997 1.0068.92 L112O ATOM 1152 OE2GLUB 91 5.643-25.374-37.976 1.0074.00 LI 12 O ATOM 1153 N PROB 92 0.699-23.154-42.352 1.0040.19 L112N ATOM 1154 CA PROB 92 -0.071-23.435-43.566 1.0040.89 L112C ATOM 1155 C PROB 92 0.736-24.213-44.603 1.0042.71 L112C ATOM 1156 O PROB 92 1.955-24.035-44.720 1.0032.77 L112O ATOM 1157 CB PROB 92 -0.467-22.049-44.062 1.0043.77 L112C ATOM 1158 CG PROB 92 -0.489-21.217-42.818 1.0042.90 L112C ATOM 1159 CD PROB 92 0.642-21.729-41.987 1.0035.83 L112C ATOM 1160 N LYSB 93 0.043-25.074-45.346 1.0045.71 L112N ATOM 1161 CA LYSB 93 0.656-25.905-46.380 1.0042.76 L112C ATOM 1162 C LYSB 93 1.431-27.073-45.773 1.0042.07 L112C ATOM 1163 O LYSB 93 1.296-28.210-46.223 1.0047.50 LI 12O ATOM 1164 CB LYSB 93 1.588-25.068-47.267 1.0046.12 L112C ATOM 1165 CG LYSB 93 1.163-24.984-48.735 1.0052.73 L112C ATOM 1166 CD LYSB 93 -0.145-24.214-48.924 1.0053.15 L112C ATOM 1167 CE LYSB 93 0.025-23.038-49.883 1.0056.74 L112C ATOM 1168 NZ LYSB 93 0.637-23.435-51.187 1.0065.38 L112N ATOM 1169 N ARGB 94 2.232-26.790-44.748 1.0039.69 L112N ATOM 1170 CA ARGB 94 3.028-27.815-44.077 1.0028.33 L112C ATOM 1171 C ARGB 94 2.200-28.678-43.134 1.0027.71 L112C ATOM 1172 O ARGB 94 2.515-29.841-42.919 1.0039.31 LI 12O ATOM 1173 CB ARGB 94 4.159-27.172-43.282 1.0022.60 L112C ATOM 1174 CG ARGB 94 5.305-26.668-44.121 1.0029.42 L112C ATOM 1175 CD ARGB 94 6.358-26.019-43.246 1.0031.23 L112C ATOM 1176 NE ARGB 94 7.463-25.486-44.033 1.0042.70 L112N ATOM 1177 CZ ARGB 94 8.628-25.108-43.516 1.0056.07 L112C ATOM 1178 NH1 ARGB 94 8.833-25.207-42.207 1.0058.35 L112N ATOM 1179 NH2ARGB 94 9.584-24.628-44.304 1.0057.97 L112N ATOM 1180 N LYSB 95 1.146-28.110-42.568 1.0027.38 L112N ATOM 1181 CA LYSB 95 0.301-28.850-41.645 1.0029.34 L112C ATOM 1182 C LYSB 95 -1.150-28.482-41.891 1.0030.96 L112C ATOM 1183 O LYSB 95 -1.551-27.342-41.680 1.0036.81 LI 12O ATOM 1184 CB LYSB 95 0.688-28.513-40.200 1.0039.33 L112C ATOM 1185 CG LYSB 95 0.177-29.500-39.158 1.0054.73 L112C ATOM 1186 CD LYSB 95 -0.879-28.870-38.249 1.0067.65 L112C ATOM 1187 CE LYSB 95 -0.393-28.746-36.801 1.0074.12 L112C ATOM 1188 NZ LYSB 95 -0.959-27.548-36.096 1.0063.57 L112N ATOM 1189 N ILEB 96 -1.937-29.446-42.345 1.0032.10 L112N ATOM 1190 CA ILEB 96 -3.347-29.195-42.614 1.0032.15 L112C ATOM 1191 C ILEB 96 -4.165-29.436-41.353 1.0033.56 L112C ATOM 1192 O ILEB 96 -4.075-30.496-40.739 1.0042.84 L112O ATOM 1193 CB ILEB 96 -3.863-30.103-43.759 1.0028.05 L112C ATOM 1194 CGI ILEB 96 -3.017-29.876-45.014 1.0011.50 L112C ATOM 1195 CG2ILEB 96 -5.330-29.814-44.048 1.0019.38 L112C ATOM 1196 CD1ILEB 96 -2.904-28.429-45.429 1.0019.93 L112C ATOM 1197 N VALB 97 -4.964-28.448-40.973 1.0032.84 L112N ATOM 1198 CA VALB 97 -5.776-28.552-39.770 1.0029.62 L112C ATOM 1199 C VALB 97 -7.232-28.853-40.066 1.0029.20 L112C ATOM 1200 O VALB 97 -8.015-29.112-39.156 1.0036.19 L112O -91- ATOM 1201 CB VALB 97 -5.717-27.246-38.949 1.0028.85 L112C ATOM 1202 CGI VALB 97 -4.288-26.945-38.556 1.0028.11 L112C ATOM 1203 CG2VALB 97 -6.291 -26.094 -39.760 1.0028.49 LI 12 C ATOM 1204 N GLYB 98 -7.605-28.811-41.337 1.0034.31 L112N ATOM 1205 CA GLYB 98 -8.988-29.072-41.685 1.0028.21 L112C ATOM 1206 C GLYB 98 -9.152-29.147-43.181 1.0030.18 L112C ATOM 1207 O GLYB 98 -8.192-28.965-43.923 1.0030.67 L112O ATOM 1208 N LYS B 99 -10.373-29.402-43.627 1.0029.50 L112N ATOM 1209 CA LYS B 99 -10.634-29.516-45.046 1.0032.51 L112C ATOM 1210 C LYSB 99 -12.080-29.187-45.374 1.0036.44 L112C ATOM 1211 O LYSB 99 -12.976-29.448-44.575 1.0035.95 LI 12O ATOM 1212 CB LYSB 99 -10.315-30.937-45.507 1.0039.97 L112C ATOM 1213 CG LYSB 99 -10.933-32.025-44.639 1.0041.83 L112C ATOM 1214 CD LYSB 99 -11.335-33.237-45.469 1.0051.41 L112C ATOM 1215 CE LYSB 99 -10.486-34.453-45.134 1.0053.02 L112C ATOM 1216 NZ LYSB 99 -11.298-35.553-44.538 1.0066.17 L112N ATOM 1217 N VALB 100 -12.298-28.609-46.555 1.0040.79 L112N ATOM 1218 CA VALB 100 -13.642-28.263-47.010 1.0040.95 L112C ATOM 1219 C VALB 100 -13.871-28.788-48.419 1.0041.23 L112C ATOM 1220 O VAL B 100 -12.927-28.948-49.199 1.0037.76 LI 120 ATOM 1221 CB VALB 100 -13.877-26.742-47.033 1.0042.14 L112C ATOM 1222 CGI VALB 100 -14.062-26.228-45.623 1.0047.48 L112C ATOM 1223 CG2 VALB 100 -12.714-26.049-47.719 1.0046.52 L112C ATOM 1224 N THRB 101 -15.134-29.054-48.737 1.0043.68 L112N ATOM 1225 CA THRB 101 -15.505-29.556-50.052 1.0044.90 L112C ATOM 1226 C THRB 101 -15.572-28.401-51.030 1.0046.97 L112C ATOM 1227 O THRB 101 -15.847-27.266-50.641 1.0049.23 LI 120 ATOM 1228 CB THRB 101 -16.882-30.228-50.037 1.0044.59 L112C ATOM 1229 OG1THRB 101 -17.875-29.262-49.670 1.0047.42 LI 12O ATOM 1230 CG2THRB 101 -16.904-31.382-49.050 1.0037.18 L112C ATOM 1231 N ARGB 102 -15.319-28.692-52.301 1.0047.23 L112N ATOM 1232 CA ARGB 102 -15.376-27.664-53.324 1.0042.99 L112C ATOM 1233 C ARG B 102 -16.760-27.046-53.255 1.0039.27 L112C ATOM 1234 O ARGB 102 -16.947-25.888-53.609 1.0051.83 LI 12O ATOM 1235 CB ARGB 102 -15.140-28.272-54.708 1.0050.12 L112C ATOM 1236 CG ARGB 102 -14.295-27.405-55.639 1.0058.67 L112C ATOM 1237 CD ARGB 102 -12.884-27.964-55.821 1.0061.68 L112C ATOM 1238 NE ARG B 102 -12.827-29.413-55.632 1.0063.94 L112N ATOM 1239 CZ ARGB 102 -11.703-30.124-55.623 1.0067.71 L112C ATOM 1240 NH1 ARGB 102 -10.534-29.517-55.793 1.0066.40 L112N ATOM 1241 NH2ARGB 102 -11.747-31.442-55.443 1.0060.88 L112N ATOM 1242 N LYS B 103 -17.730-27.823-52.786 1.0037.67 L112N ATOM 1243 CA LYS B 103 -19.096-27.333-52.664 1.0041.92 L112C ATOM 1244 C LYS B 103 -19.160-26.308-51.547 1.0044.83 L112C ATOM 1245 O LYS B 103 -19.856-25.298-51.649 1.0049.24 LI 12O ATOM 1246 CB LYS B 103 -20.056-28.483-52.354 1.0049.35 L112C ATOM 1247 CG LYS B 103 -21.265-28.079-51.510 1.0057.47 L112C ATOM 1248 CD LYS B 103 -22.244 -27.221 -52.298 1.0066.45 LI 12 C ATOM 1249 CE LYSB 103 -23.683-27.670-52.075 1.0076.17 L112C ATOM 1250 NZ LYS B 103 -24.099-27.557-50.645 1.0075.72 L112N ATOM 1251 N GLNB 104 -18.434-26.578-50.471 1.0044.97 L112N -92- UBSTITUTE SHEET (fM£2β) ATOM 1252 CA GLN B 104 -18.412-25.662-49.347 1.0043.50 L112C ATOM 1253 C GLN B 104 -17.766-24.359-49.796 1.0037.68 L112C ATOM 1254 O GLNB 104 -18.268-23.277-49.500 1.0038.95 L112O ATOM 1255 CB GLNB 104 -17.640-26.279-48.181 1.0047.34 L112C ATOM 1256 CG GLNB 104 -18.442-27.328-47.425 1.0042.38 L112C ATOM 1257 CD GLNB 104 -17.693-27.890-46.237 1.0042.53 L112C ATOM 1258 OE1 GLNB 104 -16.603-28.446-46.380 1.0035.56 LI 12O ATOM 1259 NE2 GLN B 104 -18.275-27.745-45.050 1.0036.61 L112N ATOM 1260 N ILEB 105 -16.660-24.471-50.525 1.0030.76 L112N ATOM 1261 CA ILEB 105 -15.962-23.296-51.026 1.0035.17 L112C ATOM 1262 C ILEB 105 -16.931-22.427-51.811 1.0039.38 L112C ATOM 1263 O ILEB 105 -16.880-21.202-51.736 1.0044.28 LI 12O ATOM 1264 CB ILEB 105 -14.808-23.678-51.962 1.0026.23 L112C ATOM 1265 CGI ILEB 105 -13.674-24.314-51.159 1.0035.32 L112C ATOM 1266 CG2 ILE B 105 -14.320-22.442-52.714 1.0030.76 L112C ATOM 1267 CD 1 ILEB 105 -12.778-23.317-50.444 1.0030.65 L112C ATOM 1268 N GLUB 106 -17.815-23.074-52.563 1.0044.23 L112N ATOM 1269 CA GLUB 106 -18.800-22.367-53.366 1.0048.57 L112C ATOM 1270 C GLUB 106 -19.776-21.590-52.488 1.0050.45 L112C ATOM 1271 O GLUB 106 -20.083-20.430-52.769 1.0052.09 LI 12O ATOM 1272 CB GLUB 106 -19.563-23.358-54.249 1.0056.57 L112C ATOM 1273 CG GLUB 106 -20.814-22.786-54.920 1.0065.87 L112C ATOM 1274 CD GLU B 106 -21.335-23.664-56.053 1.0068.27 L112C ATOM 1275 OE1 GLUB 106 -20.505-24.254-56.781 1.0062.09 L112O ATOM 1276 OE2 GLU B 106 -22.573-23.762-56.214 1.0066.69 L112O ATOM 1277 N GLUB 107 -20.258-22.222-51.422 1.0048.38 L112N ATOM 1278 CA GLUB 107 -21.204-21.567-50.523 1.0050.26 L112C ATOM 1279 C GLUB 107 -20.610-20.317-49.890 1.0050.25 L112C ATOM 1280 O GLUB 107 -21.311-19.332-49.661 1.0052.98 L112O ATOM 1281 CB GLUB 107 -21.648-22.527-49.425 1.0052.51 L112C ATOM 1282 CG GLUB 107 -22.481-23.685-49.921 1.0072.08 L112C ATOM 1283 CD GLUB 107 -22.371-24.896-49.016 1.0086.41 L112C ATOM 1284 OE1 GLUB 107 -21.249-25.188-48.545 1.0091.57 LI 12O ATOM 1285 OE2 GLUB 107 -23.405-25.554-48.772 1.0092.70 LI 12O ATOM 1286 N ILEB 108 -19.315-20.355-49.602 1.0046.38 L112N ATOM 1287 CA ILEB 108 -18.667-19.206-48.999 1.0043.09 L112C ATOM 1288 C ILEB 108 -18.525-18.099-50.030 1.0042.47 L112C ATOM 1289 O ILEB 108 -18.815-16.937-49.748 1.0047.10 LI 12O ATOM 1290 CB ILEB 108 -17.272-19.565-48.449 1.0042.76 L112C ATOM 1291 CGI ILEB 108 -17.407-20.613-47.345 1.0035.09 L112C ATOM 1292 CG2 ILEB 108 -16.592-18.317-47.891 1.0031.13 L112C ATOM 1293 CD 1 ILEB 108 -16.084-21.041-46.747 1.0041.11 L112C ATOM 1294 N ALAB 109 -18.081-18.464-51.229 1.0038.62 L112N ATOM 1295 CA ALA B 109 -17.900-17.486-52.293 1.0038.24 L112C ATOM 1296 C ALAB 109 -19.208-16.761-52.539 1.0037.79 L112C ATOM 1297 O ALAB 109 -19.222-15.562-52.807 1.0037.18 LI 12O ATOM 1298 CB ALAB 109 -17.436-18.172-53.562 1.0038.10 L112C ATOM 1299 N LYSB 110 -20.309-17.497-52.437 1.0038.29 L112N ATOM 1300 CA LYSB 110 -21.626-16.917-52.647 1.0042.58 L112C ATOM 1301 C LYSB 110 -21.945-15.951-51.518 1.0045.99 L112C ATOM 1302 O LYSB 110 -22.468-14.858-51.747 1.0055.26 LI 12O -93- ATOM 1303 CB LYSB 110 -22.689 -18.016-52.702 1.0039.40 L112C ATOM 1304 CG LYSB 110 -22.558 -18.947-53.898 1.0051.26 L112C ATOM 1305 CD LYSB 110 -23.911 -19.512-54.329 1.0060.46 L112C ATOM 1306 CE LYSB 110 -23.897 -19.968-55.790 1.0063.75 L112C ATOM 1307 NZ LYSB 110 -24.464 -21.340-55.985 1.0064.25 L112N ATOM 1308 N THRB 111 -21.620- 16.357-50.297 1.0040.79 L112N ATOM 1309 CA THRB 111 -21.876 -15.527-49.134 1.0038.24 L112C ATOM 1310 C THRB 111 -21.088- 14.231-49.196 1.0042.37 L112C ATOM 1311 O THRB 111 -21.644- 13.152-48.998 1.0048.64 L112O ATOM 1312 CB THRB 111 -21.490 -16.256-47.845 1.0042.62 L112C ATOM 1313 OG1 THRB 111 -22.14C ) -17.531 -47.812 1.0049.22 L112O ATOM 1314 CG2THRB 111 -21.899 .-15.441-46.630 1.0041.08 L112C ATOM 1315 N LYSB 112 -19.794- 14.346-49.479 1.0041.09 L112N ATOM 1316 CA LYSB 112 -18.900 -13.194-49.544 1.0038.50 L112C ATOM 1317 C LYSB 112 -18.910- 12.449-50.879 1.0043.09 L112C ATOM 1318 O LYSB 112 -18.246- 11.424-51.018 1.0040.13 L112O ATOM 1319 CB LYSB 112 -17.467 -13.640-49.240 1.0035.11 L112C ATOM 1320 CG LYSB 112 -17.124 -13.715-47.764 1.0033.43 L112C ATOM 1321 CD LYSB 112 -16.011 -12.742-47.409 1.0029.28 L112C ATOM 1322 CE LYSB 112 -16.567 -11.530-46.680 1.0035.42 L112C ATOM 1323 NZ LYSB 112 -15.524 -10.509-46.385 1.0031.34 L112N ATOM 1324 N METB 113 -19.654- -12.957-51.857 1.0050.88 L112N ATOM 1325 CA METB 113 -19.709 -12.331-53.180 1.0051.11 L112C ATOM 1326 C METB 113 -19.879- 10.807 -53.156 1.0049.15 L112C ATOM 1327 O METB 113 -19.130- -10.081 -53.813 1.0050.15 L112O ATOM 1328 CB METB 113 -20.824 -12.962-54.022 1.0051.18 L112C ATOM 1329 CG METB 113 -20.717 -12.654-55.515 1.0047.98 L112C ATOM 1330 SD METB 113 -19.263 -13.400-56.298 1.0049.73 L112S ATOM 1331 CE METB 113 -18.549 -11.969-57.088 1.0052.43 L112C ATOM 1332 N PROB 114 -20.870 - 10.301-52.409 1.0042.31 L112N ATOM 1333 CA PROB 114 -21.051 -8.849-52.369 1.0041.88 L112C ATOM 1334 C PROB 114 -19.781 - ■8.079-51.997 1.0044.88 L112C ATOM 1335 O PROB 114 -19.589 ■ -6.945-52.439 1.0051.97 L112O ATOM 1336 CB PROB 114 -22.171 -8.646-51.345 1.0038.22 L112C ATOM 1337 CG PROB 114 -22.290 -9.946-50.621 1.0043.79 L112C ATOM 1338 CD PROB 114 -21.870 -11.000-51.588 1.0046.66 L112C ATOM 1339 N ASP B 115 -18.912 - ■ 8.690-51.197 1.0046.07 L112N ATOM 1340 CA ASP B 115 -17.673 -8.030-50.785 1.0045.61 L112C ATOM 1341 C ASP B 115 -16.506 - 8.353 -51.709 1.0042.88 L112C ATOM 1342 O ASP B 115 -15.435 - •7.758 -51.598 1.0047.89 L112O ATOM 1343 CB ASP B 115 -17.292 -8.429-49.355 1.0051.51 L112C ATOM 1344 CG ASPB 115 -18.431 -8.252-48.368 1.0050.88 L112C ATOM 1345 OD1 ASPB 115 -19.514 -7.787-48.779 1.0057.98 L112O ATOM 1346 OD2ASPB 115 -18.240 -8.582-47.178 1.0059.37 L112O ATOM 1347 N LEUB 116 -16.713 ■ -9.298-52.618 1.0040.70 L112N ATOM 1348 CA LEUB 116 -15.669 -9.698-53.553 1.0037.46 L112C ATOM 1349 C LEUB 116 -15.698 - ■8.849-54.819 1.0037.00 L112C ATOM 1350 O LEUB 116 -16.757 ■ -8.385-55.242 1.0038.81 L112O ATOM 1351 CB LEUB 116 -15.851 -11.169-53.939 1.0040.60 L112C ATOM 1352 CG LEUB 116 -15.289 -12.293-53.065 1.0035.62 L112C ATOM 1353 CD1LEUB 116 -14.872 -11.765-51.707 1.0042.51 L112C -94- SUBSTITUTE SHffTpULE26) ATOM 1354 CD2 LEUB 116 -16.347-13.368-52.923 1.0033.28 L112C ATOM 1355 N ASNB 117 -14.535 -8.653-55.429 1.0032.39 L112N ATOM 1356 CA ASNB 117 -14.467 -7.886-56.662 1.0032.20 L112C ATOM 1357 C ASNB 117 -14.427 -8.835-57.867 1.0037.64 L112C ATOM 1358 O ASNB 117 -14.193 -8.415-59.001 1.0035.01 L112O ATOM 1359 CB ASNB 117 -13.235 -6.984-56.655 1.0024.31 L112C ATOM 1360 CG ASNB 117 -11.952 -7.762-56.709 1.0029.72 L112C ATOM 1361 OD1 ASNB 117 -11.914 -8.941-56.354 1.0032.78 LI 12O ATOM 1362 ND2 ASN B 117 -10.883 -7.110-57.154 1.0025.55 L112N ATOM 1363 N ALAB 118 -14.662-10.117-57.608 1.0039.75 L112N ATOM 1364 CA ALAB 118 -14.665-11.130-58.656 1.0041.80 L112C ATOM 1365 C ALAB 118 -15.862-10.910-59.567 1.0045.30 L112C ATOM 1366 O ALAB 118 -16.863-10.330-59.156 1.0053.58 L112O ATOM 1367 CB ALAB 118 -14.734-12.512-58.043 1.0030.65 L112C ATOM 1368 N ASNB 119 -15.760-11.381-60.804 1.0046.03 L112N ATOM 1369 CA ASNB 119 -16.840-11.216-61.766 1.0048.46 L112C ATOM 1370 C ASNB 119 -17.574-12.516-62.081 1.0050.16 L112C ATOM 1371 O ASNB 119 -18.557-12.512-62.817 1.0055.94 LI 12O ATOM 1372 CB ASNB 119 -16.287-10.625-63.061 1.0049.26 L112C ATOM 1373 CG ASNB 119 -16.023 -9.137-62.958 1.0050.05 L112C ATOM 1374 OD1 ASNB 119 -16.747 -8.407-62.269 1.0048.95 LI 12O ATOM 1375 ND2 ASNB 119 -14.981 -8.674-63.646 1.0048.05 L112N ATOM 1376 N SERB 120 -17.096-13.624-61.527 1.0051.92 L112N ATOM 1377 CA SERB 120 -17.711-14.924-61.771 1.0047.70 L112C ATOM 1378 C SERB 120 -17.599-15.828-60.555 1.0050.21 L112C ATOM 1379 O SERB 120 -16.614-15.770-59.823 1.0058.54 LI 12O ATOM 1380 CB SERB 120 -17.034-15.609-62.964 1.0046.48 L112C ATOM 1381 OG SERB 120 -15.617-15.558-62.866 1.0029.64 LI 12O ATOM 1382 N LEUB 121 -18.607-16.670-60.346 1.0049.76 L112N ATOM 1383 CA LEUB 121 -18.591-17.600-59.225 1.0044.29 L112C ATOM 1384 C LEUB 121 -17.276-18.369-59.261 1.0042.13 L112C ATOM 1385 O LEUB 121 -16.669-18.628-58.229 1.0045.70 LI 12O ATOM 1386 CB LEUB 121 -19.760-18.578-59.327 1.0041.45 L112C ATOM 1387 CG LEUB 121 -19.784-19.676-58.262 1.0041.89 L112C ATOM 1388 CD1 LEUB 121 -19.585-19.051-56.890 1.0040.55 L112C ATOM 1389 CD2 LEUB 121 -21.102 -20.431 -58.320 1.0032.73 LI 12 C ATOM 1390 N GLUB 122 -16.842-18.722-60.465 1.0039.88 L112N ATOM 1391 CA GLUB 122 -15.593-19.447-60.666 1.0040.08 L112C ATOM 1392 C GLUB 122 -14.444-18.620-60.091 1.0038.04 L112C ATOM 1393 O GLUB 122 -13.606-19.135-59.355 1.0043.79 L112O ATOM 1394 CB GLUB 122 -15.377-19.699-62.170 1.0047.41 L112C ATOM 1395 CG GLUB 122 -14.120-20.496-62.548 1.0066.40 L112C ATOM 1396 CD GLUB 122 -14.105-20.935-64.023 1.0079.56 L112C ATOM 1397 OE1 GLUB 122 -15.061-21.614-64.461 1.0083.56 L112O ATOM 1398 OE2 GLUB 122 -13.137-20.604-64.747 1.0080.21 LI 12O ATOM 1399 N ALAB 123 -14.416-17.332-60.422 1.0037.15 L112N ATOM 1400 CA ALA B 123 -13.369-16.432-59.946 1.0031.33 L112C ATOM 1401 C ALAB 123 -13.466-16.220-58.440 1.0032.49 L112C ATOM 1402 O ALAB 123 -12.458-16.207-57.736 1.0032.50 LI 12O ATOM 1403 CB ALA B 123 -13.472-15.096-60.655 1.0028.73 L112C ATOM 1404 N ALA B 124 -14.689-16.042-57.958 1.0026.80 L112N -95- SUBSΪITUTESHEE ATOM 1405 CA ALA B 124 -14.937-15.835-56.545 1.0022.39 L112C ATOM 1406 C ALAB 124 -14.365-16.994-55.736 1.0030.24 L112C ATOM 1407 O ALAB 124 -13.632-16.790-54.773 1.0032.38 L112O ATOM 1408 CB ALAB 124 -16.434-15.714-56.304 1.0019.73 L112C ATOM 1409 N METB 125 -14.695-18.214-56.147 1.0038.83 L112N ATOM 1410 CA METB 125 -14.232-19.422-55.468 1.0034.24 L112C ATOM 1411 C METB 125 -12.718-19.546-55.464 1.0030.68 L112C ATOM 1412 O METB 125 -12.142-20.147-54.562 1.0039.64 L112O ATOM 1413 CB METB 125 -14.839-20.659-56.125 1.0037.17 L112C ATOM 1414 CG METB 125 -16.346-20.783-55.948 1.0034.83 L112C ATOM 1415 SD METB 125 -16.993 -22.386 -56.480 1.0044.61 L112S ATOM 1416 CE METB 125 -15.586-23.063-57.397 1.0033.28 L112C ATOM 1417 N LYSB 126 -12.074-18.991-56.480 1.0026.30 L112N ATOM 1418 CA LYSB 126 -10.622-19.038-56.558 1.0027.93 L112C ATOM .1419 C LYS B 126 -10.072-18.083-55.503 1.0030.79 L112C ATOM 1420 O LYS B 126 -8.932-18.220-55.056 1.0035.96 L112O ATOM 1421 CB LYSB 126 -10.146-18.601-57.946 1.0032.20 L112C ATOM 1422 CG LYS B 126 -10.107-19.703-58.994 1.0027.48 L112C ATOM 1423 CD LYS B 126 -8.844-19.598-59.850 1.0040.52 L112C ATOM 1424 CE LYS B 126 -9.159-19.142-61.268 1.0032.95 L112C ATOM 1425 NZ LYS B 126 -9.919-20.188-62.011 1.0051.40 L112N ATOM 1426 N ILEB 127 -10.895-17.110-55.114 1.0031.30 L112N ATOM 1427 CA ILE B 127 -10.511-16.117-54.111 1.0030.96 L112C ATOM 1428 C ILE B 127 ■ 10.523 -16.741 -52.718 1.0028.53 L112C ATOM 1429 O ILE B 127 -9.570-16.587-51.952 1.0027.30 L112O ATOM 1430 CB ILE B 127 -11.469-14.899-54.139 1.0027.50 L112C ATOM 1431 CGI ILEB 127 -11.203-14.064-55.391 1.0029.44 L112C ATOM 1432 CG2 ILE B 127 -11.268-14.038-52.902 1.0028.00 L112C ATOM 1433 CD1 ILE B 127 -12.047-12.810-55.482 1.0031.68 L112C ATOM 1434 N ILE B 128 ■11.608-17.439-52.396 1.0020.75 L112N ATOM 1435 CA ILE B 128 -11.731 -18.104-51.111 1.0018.60 L112C ATOM 1436 C ILE B 128 • 10.637-19.152 -50.969 1.0023.21 L112C ATOM 1437 O ILEB 128 -9.936-19.202-49.960 1.0034.11 L112O ATOM 1438 CB ILEB 128 -13.084 -18.796 -50.975 1.0017.63 L112C ATOM 1439 CGI ILEB 128 -14.208 -17.807 -51.280 1.0017.94 L112C ATOM 1440 CG2 ILEB 128 -13.236-19.348-49.581 1.0023.67 L112C ATOM 1441 CD1ILEB 128 -14.138-16.529-50.469 1.0020.35 L112C ATOM 1442 N GLU B 129 -10.488-19.985-51.989 1.0023.93 L112N ATOM 1443 CA GLUB 129 -9.473-21.025-51.982 1.0027.79 L112C ATOM 1444 C GLUB 129 -8.116-20.447-51.612 1.0028.96 L112C ATOM 1445 O GLUB 129 -7.332-21.079-50.907 1.0034.08 L112O ATOM 1446 CB GLU B 129 -9.379-21.666-53.359 1.0043.68 L112C ATOM 1447 CG GLU B 129 -9.007-23.129-53.344 1.0054.25 L112C ATOM 1448 CD GLU B 129 -9.708-23.894-54.445 1.0067.26 L112C ATOM 1449 OE1 GLU B 129 -10.697-23.356-54.998 1.0058.57 L112O ATOM 1450 OE2 GLUB 129 -9.272-25.027-54.754 1.0076.46 L112O ATOM 1451 N GLYB 130 -7.836-19.248-52.108 1.0029.13 L112N ATOM 1452 CA GLYB 130 -6.571-18.609-51.809 1.0023.84 L112C ATOM 1453 C GLYB 130 -6.440-18.423-50.315 1.0027.27 L112C ATOM 1454 O GLYB 130 -5.372-18.629-49.735 1.0029.16 L112O ATOM 1455 N THRB 131 -7.536-18.031-49.680 1.0019.93 L112N -96- SUBSΪΪTWESHEET01ULE26) ATOM 1456 CA THRB 131 -7.521-17.839-48.242 1.0027.52 L112C ATOM 1457 C THRB 131 -7.337-19.204-47.579 1.0028.05 L112C ATOM 1458 O THRB 131 -6.453-19.383-46.741 1.0033.97 L112O ATOM 1459 CB THRB 131 -8.832-17.187-47.758 1.0025.95 L112C ATOM 1460 OG1THRB131 -8.954-15.883-48.335 1.0019.66 L112O ATOM 1461 CG2THRB131 -8.836-17.050-46.255 1.0029.87 L112C ATOM 1462 N ALAB 132 -8.164-20.167-47.977 1.0023.92 L112N ATOM 1463 CA ALAB132 -8.101-21.523-47.436 1.0021.36 L112C ATOM 1464 C ALAB 132 -6.704-22.108-47.505 1.0021.61 L112C ATOM 1465 O ALAB 132 -6.253-22.768-46.575 1.0034.50 LI 12O ATOM 1466 CB ALAB 132 -9.060-22.428-48.182 1.0019.47 L112C ATOM 1467 N LYSB 133 -6.015-21.870-48.610 1.0025.84 L112N ATOM 1468 CA LYSB 133 -4.674-22.405-48.779 1.0029.20 L112C ATOM 1469 C LYSB 133 -3.693-21.721-47.851 1.0027.88 L112C ATOM 1470 O LYSB 133 -2.642-22.270-47.530 1.0037.04 L112O ATOM 1471 CB LYSB133 -4.213-22.232-50.230 1.0033.18 L112C ATOM 1472 CG LYSB133 -5.011-23.052-51.235 1.0037.46 L112C ATOM 1473 CD LYS B 133 -4.884 -22.487 -52.640 1.0050.67 LI 12 C ATOM 1474 CE LYSB 133 -3.636-23.010-53.343 1.0051.75 L112C ATOM 1475 NZ LYSB 133 -3.389-22.329-54.654 1.0054.53 L112N ATOM 1476 N SERB 134 -4.042-20.518-47.416 1.0036.66 L112N ATOM 1477 CA SERB 134 -3.168-19.747-46.539 1.0036.64 L112C ATOM 1478 C SERB 134 -3.344-20.080-45.066 1.0033.11 L112C ATOM 1479 O SERB 134 -2.635-19.541-44.223 1.0037.50 L112O ATOM 1480 CB SERB 134 -3.414-18.252-46.741 1.0034.18 L112C ATOM 1481 OG SERB 134 -4.603-17.857-46.080 1.0023.48 LI 12O ATOM 1482 N METB 135 -4.281-20.964-44.748 1.0029.84 L112N ATOM 1483 CA METB135 -4.509-21.312-43.357 1.0023.70 L112C ATOM 1484 C METB 135 -4.602-22.808-43.089 1.0029.55 L112C ATOM 1485 O METB 135 -5.283-23.242-42.161 1.0023.32 LI 12O ATOM 1486 CB METB 135 -5.768-20.618-42.857 1.0022.94 L112C ATOM 1487 CG METB 135 -7.034-21.139-43.448 1.0017.81 L112C ATOM 1488 SD METB 135 -8.303-19.898-43.327 1.0034.08 L112S ATOM 1489 CE METB 135 -9.264-20.525-41.959 1.0035.79 L112C ATOM 1490 N GLYB 136 -3.914-23.592-43.910 1.0035.43 L112N ATOM 1491 CA GLYB 136 -3.911-25.030-43.728 1.0027.07 L112C ATOM 1492 C GLYB 136 -5.245-25.737-43.854 1.0028.44 L112C ATOM 1493 O GLYB 136 -5.524-26.683-43.120 1.0030.60 L112O ATOM 1494 N ILEB 137 -6.088-25.289-44.770 1.0027.95 L112N ATOM 1495 CA ILEB 137 -7.357-25.966-44.963 1.0031.48 L112C ATOM 1496 C ILEB 137 -7.358-26.505-46.389 1.0036.97 L112C ATOM 1497 O ILEB 137 -7.192-25.752-47.350 1.0043.45 L112O ATOM 1498 CB ILEB 137 -8.547-25.019-44.736 1.0031.35 L112C ATOM 1499 CGI ILEB 137 -8.702-24.756-43.233 1.0030.66 L112C ATOM 1500 CG2ILEB137 -9.826-25.634-45.302 1.0023.26 L112C ATOM 1501 CD1 ILEB 137 -9.853-23.843-42.859 1.0019.47 L112C ATOM 1502 N GLUB 138 -7.516-27.820-46.508 1.0034.70 L112N ATOM 1503 CA GLUB 138 -7.523-28.504-47.793 1.0024.78 L112C ATOM 1504 C GLUB 138 -8.909-28.509-48.402 1.0030.83 L112C ATOM 1505 O GLUB 138 -9.911-28.509-47.685 1.0025.06 LI 12O ATOM 1506 CB GLUB 138 -7.065-29.949-47.617 1.0033.57 L112C -97- ATOM 1507 CG GLUB 138 -5.717-30.270-48.240 1.0053.60 L112C ATOM 1508 CD GLUB 138 -5.435-31.769-48.293 1.0061.48 L112C ATOM 1509 OE1GLUB 138 -6.286-32.555-47.810 1.0052.54 L112O ATOM 1510 OE2GLUB 138 -4.359-32.152-48.818 1.0061.92 L112O ATOM 1511 N VALB 139 -8.962 -28.518 -49.733 1.0036.08 L112N ATOM 1512 CA VALB 139 -10.234-28.552-50.450 1.0032.76 L112C ATOM 1513 C VALB 139 -10.392-29.933-51.077 1.0035.50 L112C ATOM 1514 O VALB 139 -9.434-30.484-51.624 1.0035.56 L112O ATOM 1515 CB VALB 139 -10.293 -27.477 -51.557 1.0024.66 L112C ATOM 1516 CGI VALB 139 -11.653 -27.507 -52.234 1.0022.0S • L112C ATOM 1517 CG2 VALB 139 -10.044-26.102-50.959 1.0019.96 i L112C ATOM 1518 N VALB 140 -11.593-30.499-50.978 1.0039.97 L112N ATOM 1519 CA VAL B 140 -11.862-31.825-51.534 1.0047.65 L112C ATOM 1520 C VAL B 140 -13.287-31.934-52.091 1.0051.84 L112C ATOM 1521 O VAL B 140. -13.610-32.955-52.740 1.0048.50 L112O ATOM 1522 CB VAL B 140 -11.651-32.933-50.467 1.0046.88 L112C ATOM 1523 CGI VAL B 140 -11.479-34.280-51.152 1.0053.45 I L112C ATOM 1524 CG2 VAL B 140 -10.421 -32.628 -49.615 1.0037.90 I L112C ATOM 1525 OXT VAL B 140 -14.071-30.988-51.877 1.0056.26 L112 O TER 1526 VAL B 140 ATOM 1527 O5* GC1051 24.335-12.173 6.313 1.0073.26 RNA1O ATOM 1528 C5* GC1051 22.929-12.367 6.147 1.0060.23 RNA1 C ATOM 1529 C4* GC1051 22.454-13.612 6.854 1.0060.92 RNA1C ATOM 1530 O4* GC1051 22.709-13.474 8.275 1.0063.63 RNA1O ATOM 1531 C3* GC1051 20.961-13.878 6.747 1.0062.37 RNA1C ATOM 1532 O3* GC1051 20.640-14.594 5.557 1.0056.24 RNA1 O ATOM 1533 C2* GC1051 20.665-14.668 8.018 1.0060.79 RNA1C ATOM 1534 O2* GC1051 20.939-16.050 7.900 1.0063.11 RNA1O ATOM 1535 CI* GC1051 21.637-14.032 9.016 1.0057.61 RNA1C ATOM 1536 N9 GC1051 21.014-12.959 9.786 1.0054.68 RNA1N ATOM 1537 C8 GC1051 21.204-11.607 9.624 1.0057.52 RNA1 C ATOM 1538 N7 GC1051 20.474-10.887 10.430 1.0063.57 RNA1N ATOM 1539 C5 GC1051 19.766-11.817 11.176 1.0060.31 RNA1 C ATOM 1540 C6 GC1051 18.808-11.631 12.205 1.0065.69 RNA1C ATOM 1541 O6 GC1051 18.372-10.568 12.669 1.0071.42 RNA1O ATOM 1542 NI GC1051 18.347-12.847 12.698 1.0061.97 RNA1N ATOM 1543 C2 GC1051 18.751-14.081 12.257 1.0058.15 RNA1C ATOM 1544 N2 GC1051 18.193-15.135 12.861 1.0061.86 RNA1N ATOM 1545 N3 GC1051 19.636-14.269 11.294 1.0058.41 RNA1N ATOM 1546 C4 GC1051 20.099-13.101 10.802 1.0056.62 RNA1 C ATOM 1547 P CC1052 19.126-14.611 5.015 1.0050.79 RNA1 P ATOM 1548 O1P CC1052 18.620-13.217 4.973 1.0058.55 RNA1 O ATOM 1549 O2P CC1052 19.094-15.438 3.784 1.0067.52 RNA1O ATOM 1550 O5* CC1052 18.323-15.374 6.155 1.0048.31 RNA1O ATOM 1551 C5* CC1052 18.502-16.781 6.372 1.0035.63 RNA1C ATOM 1552 C4* CC1052 17.510-17.267 7.392 1.0038.42 RNA1 C ATOM 1553 O4* CC1052 17.824-16.686 8.682 1.0047.16 RNA1O ATOM 1554 C3* CC1052 16.087-16.825 7.117 1.0044.09 RNA1 C ATOM 1555 O3* CC1052 15.438-17.673 6.200 1.0049.32 RNA1 O ATOM 1556 C2* CC1052 15.449-16.814 8.499 1.0046.87 RNA1 C ATOM 1557 O2* CC1052 14.978-18.071 8.935 1.0046.62 RNA1 O -98- ATOM 1558 CI* CC1052 16.623 -16.360 9.368 1.0048.30 RNAIC ATOM 1559 NI CC1052 16.588 -14.902 9.601 1.0047.59 RNA1N ATOM 1560 C2 CC1052 15.778 -14.405 10.629 1.0047.88 RNA1C ATOM 1561 O2 CC1052 15.145 -15.205 11.338 1.0045.47 RNAl O ATOM 1562 N3 CC1052 15.706 -13.069 10.824 1.0051.51 RNA1N ATOM 1563 C4 CC1052 16.406 • -12.242 10.045 1.0047.87 RNA1C ATOM 1564 N4 CC1052 16.289 -10.929 10.263 1.0045.35 RNA1N ATOM 1565 C5 CC1052 17.252 ■ -12.720 9.006 1.0042.28 RNAIC ATOM 1566 C6 CC1052 17.314 -14.043 8.821 1.0043.16 RNAIC ATOM 1567 P UC1053 14.314- 17.067 5.236 1.0053.77 RNA1P ATOM 1568 O1P UC1053 14.776 -15.724 4.784 1.0061.48 RNA1O ATOM 1569 O2P UC1053 13.984 -18.106 4.231 1.0067.30 RNA1O ATOM 1570 O5* UC1053 13.059 -16.888 6.196 1.0051.10 RNA1O ATOM 1571 C5* UC1053 12.448 -18.032 6.809 1.0047.98 RNAIC ATOM 1572 C4* UC1053 11.467 -17.603 7.868 1.0047.08 RNAl C ATOM 1573 O4* UC1053 12.170 -16.895 8.917 1.0048.31 RNAl O ATOM 1574 C3* UC1053 10.382 -16.641 7.423 1.0049.60 RNAl C ATOM 1575 O3* UC1053 9.295 -17.321 6.812 1.0061.44 RNA1O ATOM 1576 C2* UC1053 9.993 -15.961 8.730 1.0050.47 RNAIC ATOM 1577 O2* UC1053 9.119 -16.731 9.531 1.0043.66 RNAl O ATOM 1578 CI* UC1053 11.339 -15.875 9.443 1.0044.87 RNAl C ATOM 1579 NI UC1053 12.003 -14.575 9.247 1.0055.73 RNA1N ATOM 1580 C2 UC1053 11.564 ■ -13.505 10.018 1.0053.37 RNAl C ATOM 1581 O2 UC1053 10.644 -13.591 10.824 1.0047.71 RNAl O ATOM 1582 N3 UC1053 12.240 -12.328 9.807 1.0043.32 RNA1N ATOM 1583 C4 UC1053 13.281 -12.110 8.928 1.0042.60 RNAIC ATOM 1584 O4 UC1053 13.827 -11.008 8.906 1.0044.05 RNAl O ATOM 1585 C5 UC1053 13.666 -13.253 8.157 1.0039.63 RNAIC ATOM 1586 C6 UC1053 13.032 -14.415 8.336 1.0051.41 RNAIC ATOM 1587 P GC1054 8.426-16.576 5.682 1.0062.77 RNA1P ATOM 1588 O1P GC1054 9.391 -15.966 4.732 1.0048.23 RNAl O ATOM 1589 O2P GC1054 7.391 -17.524 5.177 1.0063.46 RNAl O ATOM 1590 O5* GC1054 7.673 -15.417 6.482 1.0057.93 RNA1O ATOM 1591 C5* GC1054 6.589 ■ -15.737 7.376 1.0058.01 RNAl C ATOM 1592 C4* GC1054 6.160- -14.521 8.162 1.0054.61 RNAl C ATOM 1593 04* GC1054 7.279 -14.019 8.937 1.0057.89 RNAl O ATOM 1594 C3* GC1054 5.693 ■ -13.296 7.392 1.0056.27 RNAl C ATOM 1595 O3* GC1054 4.352 -13.378 6.946 1.0061.66 RNA1O ATOM 1596 C2* GC1054 5.851 ■ -12.189 8.425 1.0052.95 RNAIC ATOM 1597 O2* GC1054 4.779 -12.130 9.346 1.0049.43 RNA1O ATOM 1598 CI* GC1054 7.119- -12.626 9.148 1.0047.41 RNAIC ATOM 1599 N9 GC1054 8.274 - 11.911 8.616 1.0041.21 RNA1N ATOM 1600 C8 GC1054 9.205 - 12.347 7.703 1.0035.70 RNAl C ATOM 1601 N7 GC1054 10.100 ■ -11.440 7.414 1.0039.32 RNA1N ATOM 1602 C5 GC1054 9.741 - 10.342 8.190 1.0034.83 RNAl C ATOM 1603 C6 GC1054 10.333 -9.051 8.304 1.0030.48 RNAIC ATOM 1604 O6 GC1054 11.333 -8.604 7.728 1.0027.46 RNA1O ATOM 1605 NI GC1054 9.635 -8.245 ! 9.199 1.0030.56 RNA1N ATOM 1606 C2 GC1054 8.511 ■ -8.623 ! 898 1.0043.91 RNAIC ATOM 1607 N2 GC1054 7.967 • -7.703 10.717 1.0037.62 RNA1N ATOM 1608 N3 GC1054 7.957 ■ -9.818 ! 9.803 1.0043.41 RNA1N -99- SUBSTITUTE SHEET (RULE26 ATOM 1609 C4 GC1054 8.619- ■ 10.620 8.938 1.0041.38 RNAl C ATOM 1610 P GC1055 3.878-1 12.469 5.704 1.0066.88 RNA1P ATOM 1611 O1P GC1055 4.889 -12.575 i 4.612 1.0048.03 RNA1O ATOM 1612 O2P GC1055 2.452 -12.820 i 5.440 1.0064.70 RNA1O ATOM 161305* GC1055 3.943 -10.971 6.248 1.0063.61 RNA1O ATOM 1614 C5* GC1055 3.012 -10.512 7.237 1.0053.95 RNAIC ATOM 1615 C4* GC1055 3.371 -9.125 7.706 1.0046.33 RNAIC ATOM 1616 O4* GC1055 4.737 -9.107 8.201 1.0045.69 RNA1O ATOM 1617 C3* GC1055 3.363 -8.001 6.687 1.0040.52 RNAIC ATOM 1618 O3* GC1055 2.066 -7.500 6.421 1.0047.06 RNAl O ATOM 1619 C2* GC1055 4.212 -6.943 7.377 1.0042.04 RNAIC ATOM 1620 O2* GC1055 3.475 -6.224 8.348 1.0043.70 RNA1O ATOM 1621 CI* GC1055 5.264 -7.798 8.076 1.0031.41 RNAIC ATOM 1622 N9 GC1055 6.501 -7.839 7.307 1.0024.39 RNA1N ATOM 1623 C8 GC1055 7.026 -8.888 6.592 1.0029.37 RNAIC ATOM 1624 N7 GC1055 8.158 -8.591 6.005 1.0032.88 RNA1N ATOM 1625 C5 GC1055 8.388 -7.266 6.352 1.0023.47 RNAIC ATOM 1626 C6 GC1055 9.458 -6.393 6.013 1.0028.67 RNAIC ATOM 162706 GC1055 10.450 -6.622 5.314 1.0027.35 RNA1O ATOM 1628 NI GC1055 9.292 -5.136 6.584 1.0024.95 RNA1N ATOM 1629 C2 GC1055 8.235 -4.763 7.377 1.0026.92 RNAIC ATOM 1630 N2 GC1055 8.255 -3.513 7.838 1.0028.71 RNA1N ATOM 1631 N3 GC1055 7.234 -5.561 7.696 1.0022.90 ■ RNA1N ATOM 1632 C4 GC1055 7.375 -6.789 7.155 1.0029.13 RNAl C ATOM 1633 P GC1056 1.758 - 6.834 ' 4.989 1.0049.25 RNA1P ATOM 1634 O1P GC1056 1.991 -7.883 3.963 1.0042.81 RNA1O ATOM 1635 O2P GC1056 0.428 -6.158 5.065 1.0037.09 RNA1O ATOM 163605* GC1056 2.899 -5.734 4.819 1.0032.92 RNA1O ATOM 1637 C5* GC1056 2.796 -4.457 5.476 1.0035.07 RNAIC ATOM 1638 C4* GC1056 3.939 -3.563 5.065 1.0031.58 RNAIC ATOM 163904* GC1056 5.187 -4.183 5.457 1.0035.44 RNA1O ATOM 1640 C3* GC1056 4.089 -3.329 3.575 1.0034.14 RNAIC ATOM 1641 03* GC1056 3.270 -2.275 3.113 1.0039.89 RNAl O ATOM 1642 C2* GC1056 5.567 -3.005 3.429 1.0033.87 RNAl C ATOM 164302* GC1056 5.865 -1.651 3.704 1.0036.26 RNAl O ATOM 1644 CI* GC1056 6.184 -3.915 4.489 1.0031.52 RNAl C ATOM 1645 N9 GC1056 6.611 -5.191 3.922 1.0035.38 RNA1N ATOM 1646 C8 GC1056 5.874 -6.350 3.845 1.0033.57 RNAIC ATOM 1647 N7 GC1056 6.516 -7.326 3.265 1.0040.73 RNA1N ATOM 1648 C5 GC1056 7.752 -6.782 2.941 1.0037.74 RNAIC ATOM 1649 C6 GC1056 8.875 -7.367 2.290 1.0041.95 RNAIC ATOM 165006 GC1056 8.999 -8.519 1.852 1.0052.67 RNA1O ATOM 1651 NI GC1056 9.925 -6.460 2.169 1.0034.10 RNA1N ATOM 1652 C2 GC1056 9.899 -5.160 2.611 1.0028.22 RNAIC ATOM 1653 N2 GC1056 11.011 -4.444 2.407 1.0029.23 RNA1N ATOM 1654 N3 GC1056 8.860 -4.603 3.211 1.0030.05 RNA1N ATOM 1655 C4 GC1056 7.829 -5.466 3.344 1.0033.38 RNAIC ATOM 1656 P AC1057 2.647 - 2.350 1.636 1.0036.51 RNA1P ATOM 1657 O1P AC1057 2.944 -1.053 0.973 1.0050.45 RNA1O ATOM 1658 O2P AC1057 3.064 -3.614 0.988 1.0031.54 RNA1O ATOM 165905* AC1057 1.085 -2.420 1.900 1.0024.51 RNA1O -100 ATOM 1660 C5* AC1057 0.516 -3.490 2.659 1.0023.76 RNAIC ATOM 1661 C4* AC1057 -0.421 -2.936 3.703 1.0025.17 RNAIC ATOM 1662 O4* AC1057 0.346 -2.384 4.802 1.0026.26 RNA1O ATOM 1663 C3* AC1057 -1.282 -1.776 3.240 1.0026.38 RNAl C ATOM 166403* AC1057 -2.429 -2.174 2.517 1.0039.01 RNA1O ATOM 1665 C2* AC1057 -1.612 -1.068 4.542 1.0023.04 RNAIC ATOM 166602* AC1057 -2.658 -1.705 5.241 1.0026.68 RNA1O ATOM 1667 CI* AC1057 -0.304 -1.230 5.310 1.0020.72 RNAIC ATOM 1668 N9 AC1057 0.587 -0.081 5.125 1.0025.31 RNA1N ATOM 1669 C8 AC1057 1.840 -0.055 4.550 1.0024.58 RNAl C ATOM 1670 N7 AC1057 2.393 1.135 4.537 1.0016.48 RNA1N ATOM 1671 C5 AC1057 1.445 1.949 5.143 1.0018.96 RNAl C ATOM 1672 C6 AC1057 1.428 3.322 5.438 1.0021.91 RNAl C ATOM 1673 N6 AC1057 2.445 4.150 5.174 1.0018.97 RNA1N ATOM 1674 NI AC1057 0.322 3.824 6.029 1.0028.79 RNA1N ATOM 1675 C2 AC1057 -0.688 2.991 6.317 1.0026.99 RNAIC ATOM 1676 N3 AC1057 -0.786 1.681 6.104 1.0027.54 RNA1N ATOM 1677 C4 AC1057 0.326 1.215 5.505 1.0019.03 RNAIC ATOM 1678 P UC1058 -2.943 - 1.256 1.300 1.0033.80 RNA1P ATOM 1679 O1P UC1058 -1.733 -0.731 0.608 1.0032.34 RNA1O ATOM 1680 O2P UC1058 -3.967 -1.996 0.524 1.0030.00 RNAl O ATOM 1681 O5* UC1058 -3.665 -0.043 2.030 1.0029.35 RNAIO ATOM 1682 C5* UC1058 -4.955 -0.218 2.627 1.0031.01 RNAIC ATOM 1683 C4* UC1058 -5.530 1.120 3.008 1.0033.02 RNAl C ATOM 168404* UC1058 -4.686 1.734 4.018 1.0032.59 RNAIO ATOM 1685 C3* UC1058 -5.554 2.156 1.902 1.0034.36 RNAIC ATOM 168603* UC1058 -6.626 2.018 0.993 1.0036.65 RNAl O ATOM 1687 C2* UC1058 -5.596 3.459 2.680 1.0027.20 RNAIC ATOM 168802* UC1058 -6.886 3.727 3.188 1.0026.74 RNAIO ATOM 1689 CI* UC1058 -4.652 3.139 3.831 1.0024.15 RNAIC ATOM 1690 NI UC1058 -3.267 3.546 3.532 1.0018.02 RNA1N ATOM 1691 C2 UC1058 -2.971 4.898 3.590 1.0019.91 RNAIC ATOM 169202 UC1058 -3.802 5.750 3.879 1.0030.16 RNAIO ATOM 1693 N3 UC1058 -1.671 5.219 3.300 1.0013.57 RNA1N ATOM 1694 C4 UC1058 -0.655 4.353 2.965 1.0020.26 RNAl C ATOM 169504 UC1058 0.470 4.801 2.729 1.0030.19 RNAl O ATOM 1696 C5 UC1058 -1.035 2.981 2.926 1.0012.30 RNAIC ATOM 1697 C6 UC1058 -2.296 2.631 3.205 1.0013.08 RNAIC ATOM 1698 P i GC1059 -6.470 : 2.631 -i 0.484 1.0030.00 RNA1P ATOM 1699 O1P GC1059 -5.071 2.397 -0.938 1.0016.05 RNAIO ATOM 1700 O2P GC1059 -7.607 2.157 -1.311 1.0033.73 RNAIO ATOM 1701 05* GC1059 -6.635 4.196 -0.256 1.0030.83 RNAIO ATOM 1702 C5* GC1059 -7.854 4.731 0.279 1.0022.74 RNAIC ATOM 1703 C4* GC1059 -7.798 6.231 0.278 1.0024.79 RNAl C ATOM 170404* GC1059 -6.727 6.667 1.149 1.0028.49 RNAl O ATOM 1705 C3* GC1059 -7.475 6.869 -1.060 1.0026.72 RNAIC ATOM 170603* GC1059 -8.642 7.007 -1.857 1.0034.13 RNAIO ATOM 1707 C2* GC1059 -6.884 8.214 -0.657 1.0028.17 RNAIC ATOM 170802* GC1059 -7.880 9.178 -0.371 1.0038.10 RNAIO ATOM 1709 CI* GC1059 -6.157 7.860 0.640 1.0023.13 RNAIC ATOM 1710 N9 GC1059 -4.721 7.665 0.480 1.0015.04 RNA1N 101- SUBSTITUTE SHEET LE26 ATOM 1711 C8 GC1059 -4.064 6.490 0.206 1.0017.72 RNAIC ATOM 1712 N7 GC1059 -2.766 6.634 0.130 1.0021.45 RNA1N ATOM 1713 C5 GC1059 -2.552 7.989 0.360 1.009.82 RNAIC ATOM 1714 C6 GC1059 -1.344 8.740 0.392 1.0023.72 RNAl C ATOM 1715 O6 GC1059 -0.177 8.344 0.216 1.0019.54 RNAIO ATOM 1716 NI GC1059 -1.585 10.082 0.661 1.0019.14 RNA1N ATOM 1717 C2 GC1059 -2.822 10.638 0.874 1.0019.08 RNAl C ATOM 1718 N2 GC1059 -2.837 11.957 1.125 1.0016.35 RNA1N ATOM 1719 N3 GC1059 -3.955 9.953 0.844 1.0020.08 RNA1N ATOM 1720 C4 GC1059 -3.746 8.641 0.582 1.0020.00 RNAIC ATOM 1721 P UC1060 -8.509 7.045 - 3.456 1.0031.42 RNA1P ATOM 1722 O1P UC1060 -9.692 6.330 -3.996 1.0031.37 RNAl O ATOM 1723 O2P UC1060 -8.243 8.446 -3.872 1.0036.54 RNAIO ATOM 1724 O5* UC1060 -7.195 6.198 -3.754 1.0022.64 RNAIO ATOM 1725 C5* UC1060 -7.016 5.523 -5.009 1.0022.76 RNAIC ATOM 1726 C4* UC1060 -5.589 5.064 -5.145 1.0018.28 RNAIC ATOM 1727 04* UC1060 -4.739 6.232 -5.160 1.0020.83 RNAl O ATOM 1728 C3* UC1060 -5.079 4.166 -4.022 1.0028.38 RNAl C ATOM 1729 O3* UC1060 -4.142 3.234 -4.559 1.0034.99 RNAIO ATOM 1730 C2* UC1060 -4.336 5.141 -3.110 1.0028.41 RNAl C ATOM 1731 O2* UC1060 -3.277 4.523 -2.401 1.0041.53 RNAIO ATOM 1732 CI* UC1060 -3.794 6.157 -4.115 1.0023.82 RNAIC ATOM 1733 NI UC1060 -3.613 7.518 -3.587 1.0015.63 RNA1N ATOM 1734 C2 UC1060 -2.336 7.922 -3.245 1.0018.51 RNAl C ATOM 1735 02 UC1060 -1.353 7.193 -3.325 1.0021.06 RNAIO ATOM 1736 N3 UC1060 -2.245 9.216 -2.800 1.0013.56 RNA1N ATOM 1737 C4 UC1060 -3.271 10.129 -2.661 1.0021.90 RNAIC ATOM 1738 04 UC1060 -3.015 11.281 -2.293 1.0025.73 RNAl O ATOM 1739 C5 UC1060 -4.559 9.632 -3.018 1.007.65 RNAIC ATOM 1740 C6 UC1060 -4.686 8.377 -3.455 1.0023.41 RNAl C ATOM 1741 P UC1061 -4.622 : 2.136 - 5.633 1.0028.90 RNA1P ATOM 1742 O1P UC1061 -3.994 0.840 -5.253 1.0034.87 RNAl O ATOM 1743 O2P UC1061 -6.093 2.222 -5.792 1.0016.57 RNAl O ATOM 1744 O5* UC1061 -3.946 2.631 -6.983 1.0024.02 RNAIO ATOM 1745 C5* UC1061 -2.514 2.667 -7.117 1.0025.58 RNAIC ATOM 1746 C4* UC1061 -2.122 3.503 -8.311 1.0031.26 RNAIC ATOM 1747 04* UC1061 -2.694 2.914 -9.507 1.0036.66 RNAIO ATOM 1748 C3* UC1061 -2.584 4.961 -8.290 1.0033.14 RNAIC ATOM 1749 03* UC1061 -1.601 5.740 -8.967 1.0023.50 RNAIO ATOM 1750 C2* UC1061 -3.831 4.934 -9.167 1.0032.29 RNAIC ATOM 1751 02* UC1061 -4.100 6.183 -9.775 1.0033.30 RNAl O ATOM 1752 CI* UC1061 -3.414 3.896 -10.205 1.0040.61 RNAl C ATOM 1753 NI UC1061 -4.461 3.257 - 11.015 1.0050.51 RNA1N ATOM 1754 C2 UC1061 -4.299 3.335- 12.387 1.0062.28 RNAIC ATOM 1755 02 UC1061 -3.330 3.880- 12.914 1.0062.30 RNAl O ATOM 1756 N3 UC1061 -5.303 2.754 - •13.123 1.0073.69 RNA1N ATOM 1757 C4 UC1061 -6.427 2.110- 12.641 1.0067.10 RNAl C ATOM 1758 04 UC1061 -7.260 1.668- 13.440 1.0068.66 RNAl O ATOM 1759 C5 UC1061 -6.515 2.056 - 11.210 1.0054.52 RNAIC ATOM 1760 C6 UC1061 -5.552 2.617- 10.463 1.0045.73 RNAIC ATOM 1761 P GC1062 -0.570 i 6.637 - 8.138 1.0027.54 RNA1P -102 - SUBSTπ ATOM 1762 O1P GC1062 -0.356 5.986 -6.813 1.0024.54 RNAl O ATOM 1763 O2P GC1062 0.600 6.908 -9.017 1.0015.00 RNAIO ATOM 176405* GC1062 -1.358 8.001 -7.930 1.0014.13 RNAIO ATOM 1765 C5* GC1062 -2.396 8.125 -6.939 1.0022.88 RNAIC ATOM 1766 C4* GC1062 -2.448 9.547 -6.435 1.0015.45 RNAIC ATOM 176704* GC1062 -1.246 9.824 -5.677 1.0024.75 RNAIO ATOM 1768 C3* GC1062 -2.438 10.568 -7.550 1.0012.59 RNAIC ATOM 176903* GC1062 -3.742 10.823 -8.006 1.0033.25 RNAIO ATOM 1770 C2* GC1062 -1.783 11.777 -6.911 1.0019.71 RNAIC ATOM 1771 02* GC1062 -2.709 12.520 -6.141 1.0023.78 RNAl O ATOM 1772 CI* GC1062 -0.751 11.111 -5.999 1.0016.39 RNAl C ATOM 1773 N9 GC1062 0.564 10.927 -6.611 1.0014.13 RNA1N ATOM 1774 C8 GC1062 1.229 9.734 - ■6.776 1.0024.14 RNAl C ATOM 1775 N7 GC1062 2.388 9.866 - ■7.361 1.0025.47 RNA1N ATOM 1776 C5 GC1062 2.495 11.229 -7.605 1.0026.26 RNAIC ATOM 1777 C6 GC1062 3.527 11.966 -8.235 1.0031.66 RNAIC ATOM 177806 GC1062 4.572 11.542 -8.758 1.0028.31 RNAIO ATOM 1779 NI GC1062 3.246 13.328 -8.243 1.0023.22 RNA1N ATOM 1780 C2 GC1062 2.108 13.904 -7.739 1.0023.93 RNAIC ATOM 1781 N2 GC1062 2.025 15.238 -7.844 1.0018.71 RNA1N ATOM 1782 N3 GC1062 1.125 13.226 -7.174 1.0019.22 RNA1N ATOM 1783 C4 GC1062 1.384 11.902 -7.137 1.0021.18 RNAl C ATOM 1784 P i GC1063 -3.983 11.091 - 9.564 1.0032.90 RNA1P ATOM 1785 O1P GC1063 -3.162 10.105 -10.324 1.0029.07 RNAIO ATOM 1786 O2P GC1063 -5.446 11.159 -9.776 1.0028.95 RNAIO ATOM 1787 O5* GC1063 -3.361 12.534 -9.798 1.0032.11 RNAIO ATOM 1788 C5* GC1063 -4.042 13.712 -9.342 1.0023.86 RNAIC ATOM 1789 C4* GC1063 -3.302 14.944 -9.798 1.0022.38 RNAIC ATOM 179004* GC1063 -1.983 14.950 -9.201 1.0024.88 RNAl O ATOM 1791 C3* GC1063 -3.019 15.022 -11.287 1.0026.89 RNAIC ATOM 179203* GC1063 -4.110 15.506 -12.042 1.0033.17 RNAl O ATOM 1793 C2* GC1063 -1.806 15.936 -11.343 1.0025.82 RNAIC ATOM 179402* GC1063 -2.149 17.294 -11.168 1.0034.75 RNAl O ATOM 1795 CI* GC1063 -1.035 15.472 -10.118 1.0014.96 RNAl C ATOM 1796 N9 GC1063 -0.093 14.412- -10.461 1.0016.28 RNA1N ATOM 1797 C8 GC1063 -0.201 13.070- ■10.178 1.0017.00 RNAIC ATOM 1798 N7 GC1063 0.820 12.373- 10.602 1.0023.95 RNA1N ATOM 1799 C5 GC1063 1.644 13.309- 11.212 1.0013.66 RNAIC ATOM 1800 C6 GC1063 2.898 13.151 - 11.857 1.0019.46 RNAIC ATOM 1801 O6 GC1063 3.555 12.117 - 12.032 1.0027.29 RNAl O ATOM 1802 NI GC1063 3.385 14.363- 12.326 1.0019.82 RNA1N ATOM 1803 C2 GC1063 2.749 15.571 - 12.201 1.0024.09 RNAIC ATOM 1804 N2 GC1063 3.385 16.631 - ■ 12.718 1.0033.27 RNA1N ATOM 1805 N3 G.C1063 1.579 15.731 - 11.609 1.0025.48 RNA1N ATOM 1806 C4 GC1063 1.091 14.569- 11.137 1.0016.05 RNAIC ATOM 1807 P ( CC1064 -4.385 14.882-1 .3.495 1.0032.63 RNA1P ATOM 1808 O1P CC1064 -4.311 13.399 -13.376 1.0034.14 RNAIO ATOM 1809 O2P CC1064 -5.610 15.520 -14.047 1.0034.53 RNAIO ATOM 1810 O5* CC1064 -3.124 15.351 -14.340 1.0025.39 RNAIO ATOM 1811 C5* C C1064 -2.841 16.743 -14.483 1.0020.47 RNAl C ATOM 1812 C4* CC1064 -1.510 16.945 -15.158 1.0022.15 RNAl C -103- SUBSTITUTE SHEET RULE2B ATOM 1813 04* C C1064 -0.455 16.348-14.362 1.0025.83 RNAIO ATOM 1814 C3* C C1064 -1.320 16.321-16.528 1.0029.48 RNAIC ATOM 181503* CC1064 -1.921 17.088-17.565 1.0035.84 RNAIO ATOM 1816 C2* C C1064 0.199 16.267-16.648 1.0029.04 RNAl C ATOM 181702* CC1064 0.774 17.500-17.036 1.0028.73 RNAIO ATOM 1818 CI* CC1064 0.611 15.958-15.212 1.0021.28 RNAl C ATOM 1819 NI CC1064 0.899 14.525-15.020 1.0019.09 RNA1N ATOM 1820 C2 CC1064 2.155 14.044-15.409 1.0027.83 RNAIC ATOM 1821 02 C C1064 2.977 14.836-15.897 1.0032.73 RNAl O ATOM 1822 N3 CC1064 2.442 12.734-15.247 1.0023.67 RNA1N ATOM 1823 C4 CC1064 1.535 11.915-14.716 1.0022.40 RNAl C ATOM 1824 N4 CC1064 1.871 10.635-14.564 1.0029.03 RNA1N ATOM 1825 C5 CC1064 0.246 12.374-14.314 1.009.70 RNAl C ATOM 1826 C6 C C1064 -0.027 13.674-14.482 1.0020.34 RNAl C ATOM 1827 P UC1065 -2.537 ] 16.339-18.853 1.0031.56 RNA1P ATOM 1828 O1P UC1065 -3.488 15.293-18.407 1.0029.35 RNAl O ATOM 1829 O2P UC1065 -3.011 17.398-19.774 1.0046.70 RNAIO ATOM 183005* UC1065 -1.266 15.617-19.495 1.0022.04 RNAIO ATOM 1831 C5* UC1065 -0.138 16.392-19.935 1.0025.90 RNAIC ATOM 1832 C4* UC1065 1.022 15.492-20.286 1.0032.86 RNAIC ATOM 1833 04* UC1065 1.493 14.818-19.094 1.0035.71 RNAIO ATOM 1834 C3* UC1065 0.721 14.374-21.270 1.0035.55 RNAl C ATOM 183503* UC1065 0.799 14.834-22.609 1.0037.39 RNAl O ATOM 1836 C2* UC1065 1.793 13.340-20.939 1.0036.11 RNAl C ATOM 183702* UC1065 3.047 13.612-21.536 1.0027.98 RNAl O ATOM 1838 CI* UC1065 1.917 13.505-19.423 1.0033.40 RNAl C ATOM 1839 NI UC1065 1.088 12.543-18.676 1.0017.15 RNA1N ATOM 1840 C2 UC1065 1.653 11.323-18.364 1.0021.75 RNAIC ATOM 1841 02 UC1065 2.789 11.015-18.700 1.0024.53 RNAl O ATOM 1842 N3 UC1065 0.841 10.472-17.652 1.0012.86 RNA1N ATOM 1843 C4 UC1065 -0.454 10.708-17.245 1.0022.54 RNAIC ATOM 184404 UC1065 -1.068 9.829-16.631 1.0033.30 RNAl O ATOM 1845 C5 UC1065 -0.972 11.988-17.617 1.0018.28 RNAl C ATOM 1846 C6 UC1065 -0.202 12.840-18.300 1.0012.72 RNAl C ATOM 1847 P C1066 -0.290 1 [4.345-23.688 1.0038.85 RNA1P ATOM 1848 O1P UC1066 -1.664 14.499-23.126 1.0018.29 RNAIO ATOM 1849 O2P UC1066 0.064 15.034-24.964 1.0040.95 RNAl O ATOM 185005* UC1066 0.014 12.790-23.851 1.0036.40 RNAIO ATOM 1851 C5* UC1066 1.288 12.346-24.350 1.0035.84 RNAIC ATOM 1852 C4* UC1066 1.461 10.870-24.107 1.0038.35 RNAIC ATOM 185304* UC1066 1.463 10.613-22.679 1.0039.66 RNAl O ATOM 1854 C3* UC1066 0.359 9.974-24.652 1.0044.84 RNAl C ATOM 185503* UC1066 0.570 9.660-26.021 1.0045.33 RNAl O ATOM 1856 C2* UC1066 0.473 8.739-23.769 1.0044.55 RNAl C ATOM 185702* UC1066 1.511 7.884-24.213 1.0033.40 RNAl O ATOM 1858 CI* UC1066 0.859 9.357-22.421 1.0039.47 RNAl C ATOM 1859 NI UC1066 -0.301 9.556-21.535 1.0027.32 RNA1N ATOM 1860 C2 UC1066 -0.598 8.548-20.630 1.0027.94 RNAIC ATOM 1861 02 UC1066 0.086 7.545-20.506 1.0031.42 RNAIO ATOM 1862 N3 UC1066 -1.722 8.759-19.869 1.0019.18 RNA1N ATOM 1863 C4 UC1066 -2.556 9.854-19.905 1.0025.49 RNAIC -104- s ATOM 1864 O4 UC1066 -3.565 9.870-19.194 1.0036.42 RNAl O ATOM 1865 C5 UC1066 -2.168 10.867-20.840 1.0019.93 RNAl C ATOM 1866 C6 UC1066 -1.082 10.689-21.604 1.0023.45 RNAIC ATOM 1867 P AC1067 -0.690 9.514-27.002 1.0046.85 RNA1P ATOM 1868 O1P AC1067 -1.666 10.598-26.712 1.0036.17 RNAIO ATOM 1869 O2P AC1067 -0.149 9.350-28.374 1.0052.36 RNAIO ATOM 1870 O5* AC1067 -1.379 8.151-26.562 1.0045.01 RNAIO ATOM 1871 C5* AC1067 -2.763 7.888-26.874 1.0042.12 RNAl C ATOM 1872 C4* AC1067 -3.108 6.464-26.511 1.0037.93 RNAIC ATOM 1873 04* AC1067 -2.272 5.567-27.279 1.0037.30 RNAIO ATOM 1874 C3* AC1067 -2.805 6.123-25.068 1.0039.89 RNAIC ATOM 1875 O3* AC1067 -3.905 6.462-24.244 1.0044.47 RNAl O ATOM 1876 C2* AC1067 -2.505 4.632-25.107 1.0027.28 RNAIC ATOM 1877 O2* AC1067 -3.664 3.829-25.084 1.0044.22 RNAIO ATOM 1878 CI* AC1067 -1.845 4.494-26.472 1.0020.11 RNAIC ATOM 1879 N9 AC1067 -0.389 4.519-26.443 1.0016.55 RNA1N ATOM 1880 C8 AC1067 0.450 5.516-26.872 1.0013.35 RNAIC ATOM 1881 N7 AC1067 1.722 5.206-26.785 1.0021.36 RNA1N ATOM 1882 C5 AC1067 1.715 3.927-26.244 1.006.97 RNAIC ATOM 1883 C6 AC1067 2.746 3.037-25.917 1.0018.48 RNAIC ATOM 1884 N6 AC1067 4.046 3.301-26.105 1.0025.96 RNA1N ATOM 1885 NI AC1067 2.400 1.845-25.391 1.0013.59 RNA1N ATOM 1886 C2 AC1067 1.102 1.575-25.214 1.0028.55 RNAl C ATOM 1887 N3 AC1067 0.041 2.326-25.488 1.0023.97 RNA1N ATOM 1888 C4 AC1067 0.423 3.503-26.009 1.0016.34 RNAl C ATOM 1889 P GC1068 -3.632 7.060-22.783 1.0039.02 RNA1P ATOM 1890 O1P GC1068 -2.666 8.189-22.930 1.0031.97 RNAIO ATOM 1891 O2P GC1068 -4.955 7.282-22.122 1.0023.85 RNAIO ATOM 1892 O5* GC1068 -2.872 5.872-22.052 1.0029.64 RNAIO ATOM 1893 C5* GC1068 -3.560 4.650-21.753 1.0026.14 RNAl C ATOM 1894 C4* GC1068 -2.611 3.675-21.128 1.0030.68 RNAl C ATOM 1895 O4* GC1068 -1.612 3.299-22.105 1.0033.92 RNAIO ATOM 1896 C3* GC1068 -1.821 4.231-19.956 1.0037.79 RNAIC ATOM 1897 O3* GC1068 -2.586 4.140-18.752 1.0040.54 RNAl O ATOM 1898 C2* GC1068 -0.564 3.368-19.963 1.0031.49 RNAIC ATOM 1899 O2* GC1068 -0.774 2.123-19.322 1.0038.55 RNAIO ATOM 1900 CI* GC1068 -0.364 3.120-21.463 1.0028.77 RNAl C ATOM 1901 N9 GC1068 0.605 3.989-22.123 1.0018.63 RNA1N ATOM 1902 C8 GC1068 0.381 5.255-22.612 1.0021.10 RNAIC ATOM 1903 N7 GC1068 1.437 5.779-23.177 1.0018.47 RNA1N ATOM 1904 C5 GC1068 2.419 4.808-23.047 1.0012.57 RNAIC ATOM 1905 C6 GC1068 3.776 4.807-23.476 1.0023.53 RNAIC ATOM 1906 O6 GC1068 4.402 5.696-24.076 1.0026.90 RNAl O ATOM 1907 NI GC1068 4.417 3.616-23.140 1.0026.41 RNA1N ATOM 1908 C2 GC1068 3.831 2.561-22.479 1.0023.88 RNAl C ATOM 1909 N2 GC1068 4.625 1.500-22.232 1.0022.10 RNA1N ATOM 1910 N3 GC1068 2.564 2.546-22.085 1.0017.30 RNA1N ATOM 1911 C4 GC1068 1.924 3.695-22.396 1.0015.61 RNAl C ATOM 1912 P C1069 -2.674 ; 5.408-17.758 1.0035.85 RNA1P ATOM 1913 O1P AC1069 -2.982 6.639-18.536 1.0034.22 RNAIO ATOM 1914 O2P AC1069 -3.551 5.029-16.625 1.0034.69 RNAIO - 105- ATOM 1915 05* AC1069 -1.186 5.532 -17.220 1.0022.83 RNAIO ATOM 1916 C5* AC1069 -0.570 4.437 -16.545 1.0016.26 RNAIC ATOM 1917 C4* AC1069 0.859 4.768 -16.237 1.0021.94 RNAIC ATOM 1918 04* AC1069 1.694 4.585 -17.417 1.0035.64 RNAIO ATOM 1919 C3* AC1069 1.093 6.209 -15.768 1.0037.69 RNAIC ATOM 1920 O3* AC1069 2.058 6.196 -14.714 1.0040.68 RNAIO ATOM 1921 C2* AC1069 1.737 6.855 -16.996 1.0039.67 RNAIC ATOM 1922 02* AC1069 2.583 7.960 -16.731 1.0043.60 RNAIO ATOM 1923 CI* AC1069 2.567 5.680 -17.491 1.0037.65 RNAl C ATOM 1924 N9 AC1069 3.223 5.772 - ■ 18.793 1.0033.82 RNA1N ATOM 1925 C8 AC1069 2.972 6.600 - 19.858 1.0028.66 RNAl C ATOM 1926 N7 AC1069 3.878 6.527 - ■ 20.805 1.0037.91 RNA1N ATOM 1927 C5 AC1069 4.758 5.554- ■ 20.349 1.0034.14 RNAl C TOM 1928 C6 AC 1069 5.949 5.022-20.886 1.0038.86 RNAl C ATOM 1929 N6 AC1069 6.490 5.420 - ■22.038 1.0044.62 RNA1N ATOM 1930 NI AC1069 6.577 4.054 - ■20.180 1.0040.40 RNA1N ATOM 1931 C2 AC1069 6.041 3.661 - 19.017 1.0035.55 RNAIC ATOM 1932 N3 AC1069 4.939 4.093 - ■ 18.408 1.0028.51 RNA1N ATOM 1933 C4 AC1069 4.342 5.053 - 19.133 1.0031.82 RNAl C ATOM 1934 P . AC1070 1.715 I 5.875 -1 13.302 1.0033.11 RNA1P ATOM 1935 O1P AC1070 3.039 7.134 -12.680 1.0018.08 RNAl O ATOM 1936 O2P AC1070 0.734 7.989 -13.469 1.0018.52 RNAl O ATOM 193705* AC1070 0.968 5.723 -12.497 1.0030.46 RNAIO ATOM 1938 C5* AC1070 1.690 4.589 -11.998 1.0021.05 RNAl C ATOM 1939 C4* AC1070 0.844 3.851 -11.000 1.0030.01 RNAIC ATOM 194004* AC1070 -0.391 3.424 -11.634 1.0025.30 RNAIO ATOM 1941 C3* AC1070 1.479 2.612 -10.390 1.0036.56 RNAIC ATOM 1942 03* AC1070 1.078 2.564 -9.026 1.0037.18 RNAIO ATOM 1943 C2* AC1070 0.847 1.469 -11.185 1.0037.06 RNAIC ATOM 194402* AC1070 0.739 0.256 -10.463 1.0048.87 RNAIO ATOM 1945 CI* AC1070 -0.539 2.028 -11.495 1.0032.98 RNAIC ATOM 1946 N9 AC1070 -1.107 1.501- -12.735 1.0042.72 RNA1N ATOM 1947 C8 AC1070 -0.659 1.702- ■ 14.019 1.0049.93 RNAl C ATOM 1948 N7 AC1070 -1.380 1.098- -14.929 1.0050.90 RNA1N ATOM 1949 C5 AC1070 -2.366 0.452 - ■ 14.198 1.0055.33 RNAIC ATOM 1950 C6 AC1070 -3.435 -0.367 ■ -14.582 1.0059.78 RNAl C ATOM 1951 N6 AC1070 -3.697 -0.683 -15.850 1.0068.95 RNA1N ATOM 1952 NI AC1070 -4.235 -0.857 -13.608 1.0056.29 RNA1N ATOM 1953 C2 AC1070 -3.965 -0.536 ■ -12.340 1.0041.79 RNAl C ATOM 1954 N3 AC1070 -2.987 0.222 ■ -11.854 1.0044.24 RNA1N ATOM 1955 C4 AC1070 -2.212 0.692 - ■ 12.847 1.0046.56 RNAIC ATOM 1956 P i GC1071 2.022 : 1.866 - 7.940 1.0029.75 RNA1P ATOM 1957 O1P GC1071 1.299 1.985 -6.653 1.0039.09 RNAl O ATOM 1958 O2P GC1071 2.436 0.526 -8.435 1.0039.01 RNAl O ATOM 195905* GC1071 3.325 2.769 -7.901 1.0019.92 RNAIO ATOM 1960 C5* GC1071 3.295 4.113 -7.406 1.0016.74 RNAIC ATOM 1961 C4* GC1071 4.704 4.562 -7.133 1.0023.89 RNAIC ATOM 196204* GC1071 5.222 3.769 -6.044 1.0022.65 RNAIO ATOM 1963 C3* GC1071 5.633 4.285 -8.302 1.0025.19 RNAIC ATOM 196403* GC1071 5.646 5.390 -9.187 1.0038.67 RNAIO ATOM 1965 C2* GC1071 6.974 4.006 -7.639 1.0021.49 RNAl C -106 ATOM 1966 O2* GC1071 7.729 5.164 -7.347 1.0030.27 RNAIO ATOM 1967 CI* GC1071 6.533 3.335 -6.340 1.0018.58 RNAIC ATOM 1968 N9 GC1071 6.500 1.878 -6.393 1.0022.64 RNA1N ATOM 1969 C8 GC1071 5.389 1.076 -6.272 1.0020.39 RNAl C ATOM 1970 N7 GC1071 5.672 -0.196 -6.315 1.0031.29 RNA1N ATOM 1971 C5 GC1071 7.048 -0.236 -6.482 1.0014.55 RNAIC ATOM 1972 C6 GC1071 7.922 -1.342 -6.582 1.0028.22 RNAIC ATOM 1973 O6 GC1071 7.647 -2.549 -6.512 1.0031.85 RNAIO ATOM 1974 NI GC1071 9.239 -0.934 -6.762 1.0015.53 RNA1N ATOM 1975 C2 GC1071 9.660 0.371 -6.818 1.0020.27 RNAl C ATOM 1976 N2 GC1071 10.977 0.567 -6.997 1.0025.10 RNA1N ATOM 1977 N3 GC1071 8.853 1.411 -6.707 1.0019.36 RNA1N ATOM 1978 C4 GC1071 7.570 1.035 -6.546 1.0011.18 RNAIC ATOM 1979 P CC1072 5.597 . 5.137-10.767 1.0027.21 RNA1P ATOM 1980 O1P CC1072 4.563 4.110 -11.043 1.0030.50 RNAIO ATOM 1981 O2P CC1072 5.512 6.459 -11.426 1.0025.77 RNAIO ATOM 1982 O5* CC1072 7.022 4.506 -11.073 1.0015.96 RNAIO ATOM 1983 C5* CC1072 8.198 5.315 -11.019 1.0023.11 RNAIC ATOM 1984 C4* CC1072 9.419 4.471 • -11.280 1.0032.01 RNAl C ATOM 1985 04* CC1072 9.601 3.533 -10.192 1.0036.03 RNAIO ATOM 1986 C3* CC1072 9.365 3.597- -12522 1.0030.99 RNAIC ATOM 1987 O3* CC1072 9.711 4.326 -13.688 1.0033.23 RNAIO ATOM 1988 C2* CC1072 10.362 2.496 -12.188 1.0029.75 RNAl C ATOM 1989 O2* CC1072 11.703 2.904 -12.371 1.0034.64 RNAIO ATOM 1990 CI* CC1072 10.121 2.314 -10.692 1.0029.06 RNAIC ATOM 1991 NI CC1072 9.151 1.242- 10.401 1.0021.88 RNA1N ATOM 1992 C2 CC1072 9.623 ■ -0.062 - 10.229 1.0022.42 RNAIC ATOM 1993 O2 CC1072 10.852 -0.281 -10.328 1.0027.87 RNAIO ATOM 1994 N3 CC1072 8.735 -1.053 -9.964 1.009.91 RNA1N ATOM 1995 C4 CC1072 7.430 ■ -0.780 -9.883 1.0019.29 RNAl C ATOM 1996 N4 CC1072 6.591 -1.789 -9.644 1.0023.91 RNA1N ATOM 1997 C5 CC1072 6.925 0.538- 10.048 1.0013.70 RNAIC ATOM 1998 C6 CC1072 7.812 1.510- 10.304 1.0024.95 RNAIC ATOM 1999 P AC1073 8.702 4.336-14.936 1.0033.99 RNAl P ATOM 2000 O1P AC1073 8.504 2.919 -15.333 1.0035.83 RNAIO ATOM 2001 O2P AC1073 7.512 5.181 -14.614 1.0022.96 RNAIO ATOM 2002 O5* AC1073 9.551 5.050 -16.074 1.0031.36 RNAIO ATOM 2003 C5* AC1073 10.772 4.462 -16.571 1.0035.37 RNAIC ATOM 2004 C4* AC1073 11.245 5.227 -17.781 1.0039.45 RNAIC ATOM 2005 O4* AC1073 10.229 5.143 -18.815 1.0039.78 RNAIO ATOM 2006 C3* AC1073 11.400 6.713 -17.522 1.0040.87 RNAIC ATOM 2007 O3* AC1073 12.673 7.017 -16.987 1.0044.46 RNAIO ATOM 2008 C2* AC1073 11.147 7.327 -18.890 1.0038.57 RNAIC ATOM 2009 O2* AC1073 12.279 7.252 -19.738 1.0041.89 RNAIO ATOM 2010 CI* AC1073 10.054 6.409 -19.426 1.0027.18 RNAIC ATOM 2011 N9 AC1073 8.713 6.872 - 19.081 1.0023.78 RNA1N ATOM 2012 C8 AC1073 7.835 6.282 - 18.209 1.0031.10 RNAIC ATOM 2013 N7 AC1073 6.685 6.903 - 18.112 1.0030.54 RNA1N ATOM 2014 C5 AC1073 6.819 7.979 - 18.974 1.0022.89 RNAIC ATOM 2015 C6 AC1073 5.948 9.015 - 19.319 1.0024.05 RNAIC ATOM 2016 N6 AC1073 4.711 9.130- 18.836 1.0024.67 RNA1N -107 T* ,r_ ATOM 2017 NI AC1073 6.391 9.940-20.193 1.0027.06 RNA1N ATOM 2018 C2 AC1073 7.627 9.815-20.684 1.0028.92 RNAl C ATOM 2019 N3 AC1073 8.539 8.879-20.442 1.0033.22 RNA1N ATOM 2020 C4 AC1073 8.066 7.979-19.568 1.0024.70 RNAIC ATOM 2021 P GC1074 12.790 8.131-15.846 1.0037.49 RNA1P ATOM 2022 O1P GC1074 11.994 7.638-14.698 1.0042.76 RNAIO ATOM 2023 O2P GC1074 14.226 8.458-15.661 1.0037.27 RNAl O ATOM 2024 O5* G C1074 12.052 9.389-16.488 1.0032.12 RNAl O ATOM 2025 C5* GC1074 12.636 10.074-17.611 1.0030.38 RNAl C ATOM 2026 C4* GC1074 11.776 11.239-18.042 1.0029.26 RNAl C ATOM 2027 O4* GC1074 10.505 10.762-18.552 1.0028.39 RNAl O ATOM 2028 C3* GC1074 11.393 12.245-16.972 1.0030.49 RNAIC ATOM 2029 O3* GC1074 12.431 13.170-16.697 1.0040.29 RNAIO ATOM 2030 C2* GC1074 10.152 12.899-17.566 1.0032.10 RNAIC ATOM 2031 O2* GC1074 10.452 13.891-18.528 1.0036.08 RNAIO ATOM 2032 CI* GC1074 9.491 11.714-18.268 1.0026.45 RNAIC ATOM 2033 N9 GC1074 8.479 11.075-17.435 1.0022.10 RNA1N ATOM 2034 C8 G C1074 8.576 9.862-16.794 1.0021.18 RNAl C ATOM 2035 N7 GC1074 7.490 9.539-16.145 1.0028.77 RNA1N ATOM 2036 C5 GC1074 6.628 10.604-16.362 1.0015.54 RNAIC ATOM 2037 C6 GC1074 5.300 10.815-15.917 1.0022.89 RNAIC ATOM 2038 O6 GC1074 4.589 10.071-15.240 1.0028.81 RNAIO ATOM 2039 NI GC1074 4.802 12.038-16.351 1.0026.73 RNA1N ATOM 2040 C2 GC1074 5.487 12.937-17.126 1.0024.75 RNAIC ATOM 2041 N2 GC1074 4.828 14.058-17.440 1.0020.91 RNA1N ATOM 2042 N3 GC1074 6.724 12.748-17.560 1.0019.40 RNA1N ATOM 2043 C4 GC1074 7.228 11.568-17.144 1.0019.49 RNAIC ATOM 2044 P i CC1075 12.535 13.826-15.232 1.0035.74 RNA1P ATOM 2045 O1P CC1075 12.251 12.757-14.239 1.0037.48 RNAIO ATOM 2046 O2P CC1075 13.814 14.574-15.147 1.0035.45 RNAIO ATOM 2047 O5* CC1075 11.326 14.864-15.223 1.0029.10 RNAIO ATOM 2048 C5* CC1075 11.373 16.035-16.052 1.0020.72 RNAl C ATOM 2049 C4* CC1075 10.144 16.884-15.848 1.0027.73 RNAl C ATOM 2050 O4* CC1075 8.980 16.162-16.316 1.0025.49 RNAl O ATOM 2051 C3* CC1075 9.804 17.254-14.413 1.0029.84 RNAIC ATOM 2052 O3* CC1075 10.548 18.355-13.924 1.0032.76 RNAIO ATOM 2053 C2* CC1075 8.311 17.537-14.490 1.0032.29 RNAl C ATOM 2054 O2* CC1075 8.018 18.838-14.963 1.0033.04 RNAIO ATOM 2055 CI* CC1075 7.860 16.488-15.508 1.0030.74 RNAl C ATOM 2056 NI CC1075 7.407 15.259-14.836 1.0023.00 RNA1N ATOM 2057 C2 CC1075 6.083 15.178-14.407 1.0025.39 RNAIC ATOM 2058 O2 CC1075 5.320 16.133-14.627 1.0027.71 RNAl O ATOM 2059 N3 CC1075 5.666 14.063-13.764 1.0020.56 RNA1N ATOM 2060 C4 CC1075 6.518 13.054-13.553 1.0024.69 RNAIC ATOM 2061 N4 CC1075 6.067 11.975-12.911 1.0022.56 RNA1N ATOM 2062 C5 CC1075 7.870 13.108-13.991 1.0016.20 RNAIC ATOM 2063 C6 CC1075 8.269 14.217-14.622 1.0023.77 RNAIC ATOM 2064 P < CC1076 10.912 18.423-12.358 1.0042.91 RNA1P ATOM 2065 O1P CC1076 11.372 17.085-11.911 1.0024.52 RNAIO ATOM 2066 O2P C C1076 11.781 19.612-12.113 1.0041.73 RNAIO ATOM 2067 O5* CC1076 9.491 18.679-11.696 1.0032.86 RNAIO -108- SUM flE SHEET ( RULE ATOM 2068 C5* CC1076 8.768 19.870 -11.997 1.0027.46 RNAIC ATOM 2069 C4* CC1076 7.458 19.893 -11.255 1.0030.86 RNAIC ATOM 2070 O4* CC1076 6.570 18.885 -11.798 : 1.0034.77 RNAIO ATOM 2071 C3* CC1076 7.500 19.581 -9.769 1.0026.66 RNAIC ATOM 2072 O3* CC1076 7.913 20.668 -8.961 1.0036.57 RNAIO ATOM 2073 C2* CC1076 6.062 19.172 -9.499 1.0032.47 RNAIC ATOM 2074 O2* CC1076 5.198 20.290 -9.410 1.0032.97 RNAIO ATOM 2075 CI* CC1076 5.735 18.385 -10.765 1.0034.29 RNAIC ATOM 2076 NI CC1076 6.012 16.945 - 10.577 1.0022.34 RNA1N ATOM 2077 C2 CC1076 5.036 16.150 -9.959 1.0024.18 RNAIC ATOM 2078 O2 CC1076 3.977 16.680 -9.577 1.0025.15 RNAIO ATOM 2079 N3 CC1076 5.271 14.825 -9.784 1.0020.85 RNA1N ATOM 2080 C4 CC1076 6.428 14.295 - 10.185 1.0021.45 RNAIC ATOM 2081 N4 CC1076 6.611 12.987 -9.994 1.0019.48 RNA1N ATOM 2082 C5 CC1076 7.446 15.083 - 10.805 1.0018.25 RNAIC ATOM 2083 C6 CC1076 7.196 16.389- 10.984 1.0025.90 RNAl C ATOM 2084 P . AC1077 8.72520.374 - 7.602 1.0034.53 RNAl P ATOM 2085 O1P AC1077 9.776 19.366 -7.891 1.0032.29 RNAIO ATOM 2086 O2P AC1077 9.115 21.689 -7.025 1.0055.02 RNAIO ATOM 2087 O5* AC1077 7.641 19.691 -6.652 1.0022.72 RNAIO ATOM 2088 C5* AC1077 6.447 20.399 -6.283 1.0017.11 RNAIC ATOM 2089 C4* AC1077 5.461 19.477 -5.601 1.0026.56 RNAl C ATOM 2090 O4* AC1077 5.058 18.423 -6.514 1.0034.54 RNAIO ATOM 2091 C3* AC1077 5.916 18.724 -4.357 1.0032.85 RNAIC ATOM 2092 O3* AC1077 5.872 19.511 -3.175 1.0037.36 RNAl O ATOM 2093 C2* AC1077 4.913 17.576 -4.297 1.0036.94 RNAIC ATOM 2094 O2* AC1077 3.661 17.943 -3.748 1.0032.73 RNAl O ATOM 2095 CI* AC1077 4.723 17.255 -5.778 1.0032.51 RNAIC ATOM 2096 N9 AC1077 5.612 16.160 -6.172 1.0027.14 RNA1N ATOM 2097 C8 AC1077 6.830 16.224 -6.802 1.0022.59 RNAIC ATOM 2098 N7 AC1077 7.406 15.054 -6.959 1.0028.95 RNA1N ATOM 2099 C5 AC1077 6.500 14.158 -6.405 1.0023.18 RNAIC ATOM 2100 C6 AC1077 6.524 12.758 -6.252 1.0029.03 RNAIC ATOM 2101 N6 AC1077 7.543 11.984 -6.643 1.0032.89 RNA1N ATOM 2102 NI AC1077 5.454 12.174 -5.669 1.0023.42 RNA1N ATOM 2103 C2 AC1077 4.443 12.948 -5.259 1.0010.65 RNAl C ATOM 2104 N3 AC1077 4.309 14.266 -5.338 1.0026.74 RNA1N ATOM 2105 C4 AC1077 5.385 14.821 -5.930 1.0026.08 RNAl C ATOM 2106 P UC1078 6.978 1 .9.284 - 2.026 1.0029.17 RNAl P ATOM 2107 O1P UC1078 8.330 19.420 -2.616 1.0022.94 RNAIO ATOM 2108 O2P UC1078 6.586 20.141 -0.877 1.0041.57 RNAIO ATOM 2109 O5* UC1078 6.828 17.754 -1.608 1.0029.90 RNAIO ATOM 2110 C5* UC1078 5.706 17.287 -0.830 1.0021.78 RNAIC ATOM 2111 C4* UC1078 5.789 15.785 -0.649 1.0021.19 RNAIC ATOM 2112 O4* UC1078 5.732 15.157 -1.957 1.0029.99 RNAIO ATOM 2113 C3* UC1078 7.075 15.241 -0.031 1.0027.77 RNAIC ATOM 2114 O3* UC1078 7.057 15.184 1.390 1.0036.77 RNAIO ATOM 2115 C2* UC1078 7.094 13.812 -0.554 1.0034.85 RNAIC ATOM 2116 O2* UC1078 6.229 12.972 0.191 1.0032.65 RNAIO ATOM 2117 CI* UC1078 6.532 13.986 -1.963 1.0028.35 RNAIC ATOM 2118 NI UC1078 7.611 14.137 -2.955 1.0021.70 RNA1N - 109 ATOM 2119 C2 UC1078 8.275 12.987 -3.352 1.0027.00 RNAl C ATOM 212002 UC1078 7.975 11.872 -2.946 1.0029.58 RNAIO ATOM 2121 N3 UC1078 9.305 13.189 -4.238 1.0024.66 RNA1N ATOM 2122 C4 UC1078 9.728 14.393 -4.760 1.0026.71 RNAIC ATOM 212304 UC1078 10.714 14.417 -5.504 1.0044.05 RNAIO ATOM 2124 C5 UC1078 8.978 15.530 -4.320 1.0018.54 RNAIC ATOM 2125 C6 UC1078 7.970 15.368 -3.459 1.0019.12 RNAIC ATOM 2126 P CC1079 7.168 16.527 : 2.260 1.0028.61 RNA1P ATOM 2127 O1P CC1079 7.780 16.107 3.544 1.0034.30 RNAl O ATOM 2128 O2P CC1079 7.770 17.644 1.487 1.0031.33 RNAIO ATOM 212905* CC1079 5.641 16.867 2.520 1.0013.04 RNAl O ATOM 2130 C5* CC1079 4.851 15.965 3.271 1.0017.43 RNAl C ATOM 2131 C4* CC1079 3.398 16.246 3.064 1.0019.74 RNAl C ATOM 213204* CC1079 2.954 15.688 1.803 1.0026.36 RNAl O ATOM 2133 C3* CC1079 2.556 15.540 4.098 1.0025.66 RNAl C ATOM 213403* CC1079 2.525 16.312 5.278 1.0037.56 RNAIO ATOM 2135 C2* CC1079 1.217 15.382 3.394 1.0027.27 RNAl C ATOM 213602* CC1079 0.452 16.573 3.416 1.0025.00 RNAIO ATOM 2137 CI* CC1079 1.672 15.091 1.963 1.0017.88 RNAIC ATOM 2138 NI CC1079 1.795 13.641 1.677 1.0017.52 RNA1N ATOM 2139 C2 CC1079 0.629 12.878 1.441 1.0019.34 RNAIC ATOM 214002 CC1079 -0.488 13.427 1.500 1.0024.52 RNAIO ATOM 2141 N3 CC1079 0.748 11.561 1.159 1.0015.18 RNA1N ATOM 2142 C4 CC1079 1.955 10.994 1.111 1.0020.12 RNAIC ATOM 2143 N4 CC1079 2.018 9.691 0.814 1.0014.62 RNA1N ATOM 2144 C5 CC1079 3.150 11.734 1.359 1.0016.35 RNAIC ATOM 2145 C6 CC1079 3.025 13.040 1.635 1.0014.99 RNAIC ATOM 2146 P AC1080 2.747 15.593 ι 6.692 1.0032.18 RNA1P ATOM 2147 O1P AC1080 3.901 14.668 6.598 1.0027.65 RNAIO ATOM 2148 O2P AC1080 2.748 16.674 7.711 1.0042.21 RNAIO ATOM 214905* AC1080 1.413 14.745 6.853 1.0024.30 RNAIO ATOM 2150 C5* AC1080 0.157 15.421 6.836 1.0025.92 RNAIC ATOM 2151 C4* AC1080 -0.967 14.459 6.593 1.0027.37 RNAl C ATOM 215204* AC1080 -0.902 13.924 5.248 1.0035.15 RNAIO ATOM 2153 C3* AC1080 -1.028 13.223 7.462 1.0026.09 RNAl C ATOM 215403* AC1080 -1.528 13.489 8.759 1.0036.10 RNAIO ATOM 2155 C2* AC1080 -1.956 12.331 6.651 1.0033.11 RNAIC ATOM 215602* AC1080 -3.309 12.717 6.787 1.0032.80 RNAIO ATOM 2157 CI* AC1080 -1.510 12.643 5.223 1.0026.83 RNAIC ATOM 2158 N9 AC1080 -0.538 11.650 4.767 1.0016.76 RNA1N ATOM 2159 C8 AC1080 0.838 11.722 4.719 1.0020.21 RNAIC ATOM 2160 N7 AC1080 1.411 10.609 4.319 1.008.53 RNA1N ATOM 2161 C5 AC1080 0.340 9.754 4.073 1.007.38 RNAl C ATOM 2162 C6 AC1080 0.273 8.414 3.649 1.0015.76 RNAIC ATOM 2163 N6 AC1080 1.348 7.660 3.376 1.0025.46 RNA1N ATOM 2164 NI AC1080 -0.952 7.859 3.514 1.0017.62 RNA1N ATOM 2165 C2 AC1080 -2.029 8.606 3.785 1.0016.21 RNAl C ATOM 2166 N3 AC1080 -2.095 9.868 4.192 1.0017.28 RNA1N ATOM 2167 C4 AC1080 -0.861 10.389 4.323 1.007.47 RNAIC ATOM 2168 P UC1081 -1.136 1 12.505 9.973 1.0029.01 RNA1P ATOM 2169 O1P UC1081 0.273 12.088 9.807 1.0019.32 RNAIO no- ATOM 2170 O2P UC1081 -1.558 13.151 11.237 1.0036.17 RNAIO ATOM 2171 O5* UC1081 -2.072 11.248 : 9.708 1.0027.53 RNAl O ATOM 2172 C5* UC1081 -3.469 11.439 9.421 1.0034.97 RNAl C ATOM 2173 C4* UC1081 -4.093 10.146 8.967 1.0039.34 RNAIC ATOM 2174 O4* UC1081 -3.488 9.719 7.725 1.0036.64 RNAIO ATOM 2175 C3* UC1081 -3.908 8.982 9.922 1.0036.77 RNAIC ATOM 2176 O3* UC1081 -4.954 9.001 10.888 1.0049.64 RNAIO ATOM 2177 C2* UC1081 -4.001 7.774 9.001 1.0031.27 RNAl C ATOM 2178 O2* UC1081 -5.344 7.418 8.739 1.0035.76 RNAl O ATOM 2179 CI* UC1081 -3.375 8.311 7.713 1.0027.99 RNAl C ATOM 2180 NI UC1081 -1.959 7.966 7.513 1.0016.45 RNA1N ATOM 2181 C2 UC1081 -1.659 6.684 7.082 1.0015.53 RNAl C ATOM 2182 O2 UC1081 -2.511 5.822 6.912 1.0024.70 RNAIO ATOM 2183 N3 UC1081 -0.328 6.446 6.856 1.006.42 RNA1N ATOM 2184 C4 UC1081 0.717 7.335 7.015 1.0017.75 RNAIC ATOM 2185 O4 UC1081 1.850 7.005 6.656 1.0012.74 RNAIO ATOM 2186 C5 UC1081 0.332 8.627 7.495 1.0015.50 RNAIC ATOM 2187 C6 UC1081 -0.961 8.890 7.724 1.0017.69 RNAl C ATOM 2188 P UC1082 -4.709 ! 8.375 12.348 1.0043.16 RNA1P ATOM 2189 O1P UC1082 -3.513 9.034 12.942 1.0033.87 RNAIO ATOM 2190 O2P UC1082 -6.019 8.423 13.060 1.0035.46 RNAl O ATOM 2191 O5* UC1082 -4.357 6.855 12.050 1.0039.66 RNAIO ATOM 2192 C5* UC1082 -5.388 5.949 11.643 1.0036.85 RNAl C ATOM 2193 C4* UC1082 -4.834 4.563 11.500 1.0035.35 RNAl C ATOM 2194 O4* UC1082 -4.024 4.471 10.301 1.0027.83 RNAIO ATOM 2195 C3* UC1082 -3.895 4.106 12.600 1.0042.67 RNAIC ATOM 2196 O3* UC1082 -4.544 3.677 13.786 1.0048.43 RNAIO ATOM 2197 C2* UC1082 -3.130 2.979 11.925 1.0041.00 RNAIC ATOM 2198 O2* UC1082 -3.847 1.757 11.941 1.0043.11 RNAIO ATOM 2199 CI* UC1082 -3.000 3.510 10.496 1.0029.73 RNAl C ATOM 2200 NI UC1082 -1.691 4.146 10.281 1.0021.48 RNA1N ATOM 2201 C2 UC1082 -0.650 3.342 9.826 1.0024.74 RNAIC ATOM 2202 O2 UC1082 -0.781 2.155 9.573 1.0035.44 RNAl O ATOM 2203 N3 UC1082 0.552 3.980 9.678 1.0016.73 RNA1N ATOM 2204 C4 UC1082 0.825 5.303 9.921 1.0020.16 RNAIC ATOM 2205 O4 UC1082 1.963 5.730 9.715 1.0029.48 RNAIO ATOM 2206 C5 UC1082 -0.293 6.069 10.378 1.0015.77 RNAl C ATOM 2207 C6 UC1082 -1.485 5.479 10.536 1.0020.32 RNAIC ATOM 2208 P i UC1083 -3.685 : 3.548 15.138 1.0044.11 RNA1P ATOM 2209 O1P UC1083 -3.013 4.855 15.416 1.0033.72 RNATO ATOM 2210 O2P UC1083 -4.550 2.923 16.170 1.0044.56 RNAIO ATOM 2211 O5* UC1083 -2.554 2.515 14.732 1.0026.53 RNAl O ATOM 2212 C5* UC1083 -1.204 2.710 15.133 1.0027.01 RNAIC ATOM 2213 C4* UC1083 -0.310 1.810 14.328 1.0035.50 RNAl C ATOM 2214 O4* UC1083 0.049 2.450 13.077 1.0037.83 RNAIO ATOM 2215 C3* UC1083 1.014 1.490 14.985 1.0042.54 RNAIC ATOM 2216 O3* UC1083 0.829 0.394 15.868 1.0053.77 RNAIO ATOM 2217 C2* UC1083 1.899 1.142 13.797 1.0040.40 RNAIC ATOM 2218 O2* UC1083 1.676 -0.184 13.354 1.0050.14 RNAIO ATOM 2219 CI* UC1083 1.383 2.112 12.733 1.0031.81 RNAl C ATOM 2220 NI UC1083 2.176 3.350 12.641 1.0027.07 RNA1N -111- ATOM 2221 C2 UC1083 3.403 3.291 11.995 1.0027.98 RNAl C ATOM 222202 UC1083 3.842 2.278 11.491 1.0038.26 RNAl O ATOM 2223 N3 UC1083 4.101 4.471 11.959 1.0027.06 RNA1N ATOM 2224 C4 UC1083 3.711 5.686 12.480 1.0029.89 RNAIC ATOM 222504 UC1083 4.463 6.660 12.376 1.0035.97 RNAl O ATOM 2226 C5 UC1083 2.432 5.676 13.120 1.0028.35 RNAl C ATOM 2227 C6 UC1083 1.726 4.538 13.180 1.0034.18 RNAl C ATOM 2228 P AC1084 1.531 ' 0.409 1 17.308 1 1.0046.22 RNA1P ATOM 2229 O1P AC1084 1.502 1.811 17.819 1.0047.82 RNAl O ATOM 2230 O2P AC1084 0.915 -0.683 18.102 1.0045.99 RNAl O ATOM 2231 O5* AC1084 3.037 0.024 16.984 1.0032.44 RNAl O ATOM 2232 C5* AC1084 4.103 0.403 17.854 1.0026.01 RNAl C ATOM 2233 C4* AC1084 5.395 -0.104 17.293 1.0030.31 RNAIC ATOM 223404* AC1084 5.314 -1.544 17.185 1.0039.98 RNAl O ATOM 2235 C3* AC1084 5.631 0.378 15.881 1.0031.04 RNAIC ATOM 223603* AC1084 6.308 1.611 15.926 1.0035.76 RNAl O ATOM 2237 C2* AC1084 6.448 -0.741 15.252 1.0034.39 RNAl C ATOM 223802* AC1084 7.825 -0.635 15.548 1.0029.53 RNAl O ATOM 2239 CI* AC1084 5.872 -1.970 15.956 1.0036.40 RNAl C ATOM 2240 N9 AC1084 4.827 -2.698 15.230 1.0038.88 RNA1N ATOM 2241 C8 AC1084 3.464 -2.577 15.388 1.0038.21 RNAIC ATOM 2242 N7 AC1084 2.770 -3.432 14.677 1.0033.92 RNA1N ATOM 2243 C5 AC1084 3.737 -4.151 13.984 1.0035.92 RNAIC ATOM 2244 C6 AC1084 3.648 -5.222 13.069 1.0034.35 RNAIC ATOM 2245 N6 AC1084 2.493 -5.781 12.695 1.0038.02 RNA1N ATOM 2246 NI AC1084 4.802 -5.704 12.551 1.0036.24 RNA1N ATOM 2247 C2 AC1084 5.960 -5.145 12.935 1.0038.72 RNAIC ATOM 2248 N3 AC1084 6.173 -4.143 13.790 1.0034.15 RNA1N ATOM 2249 C4 AC1084 5.007 -3.689 14.291 1.0036.93 RNAl C ATOM 2250 P AC1085 5.839 : 2.793 14.965 1.0032.91 RNAl P ATOM 2251 O1P AC1085 4.351 2.768 14.939 1.0023.95 RNAl O ATOM 2252 O2P AC1085 6.554 4.030 15.366 1.0036.15 RNAIO ATOM 225305* AC1085 6.414 2.342 13.557 1.0034.02 RNAIO ATOM 2254 C5* AC1085 7.826 2.172 13.384 1.0035.68 RNAIC ATOM 2255 C4* AC1085 8.100 1.383 12.136 1.0040.49 RNAIC ATOM 225604* AC1085 7.592 0.035 12.283 1.0046.64 RNAIO ATOM 2257 C3* AC1085 7.426 1.921 10.889 1.0037.28 RNAIC ATOM 225803* AC1085 8.249 2.933 10.322 1.0038.08 RNAIO ATOM 2259 C2* AC1085 7.311 0.685 10.002 1.0036.45 RNAl C ATOM 226002* AC1085 8.496 0.425 9.278 1.0044.66 RNAl O ATOM 2261 CI* AC1085 7.122 -0.432 11.032 1.0036.77 RNAIC ATOM 2262 N9 AC1085 5.743 -0.875 11.198 1.0024.80 RNA1N ATOM 2263 C8 AC1085 4.754 -0.265 11.923 1.0028.92 RNAIC ATOM 2264 N7 AC1085 3.606 -0.896 11.888 1.0028.93 RNA1N ATOM 2265 C5 AC1085 3.857 -2.000 11.087 1.0022.34 RNAIC ATOM 2266 C6 AC1085 3.040 -3.060 10.664 1.0026.52 RNAl C ATOM 2267 N6 AC1085 1.749 -3.175 11.000 1.0026.24 RNA1N ATOM 2268 NI AC1085 3.596 -4.006 9.874 1.0025.01 RNA1N ATOM 2269 C2 AC1085 4.889 -3.875 9.532 1.0027.90 RNAIC ATOM 2270 N3 AC1085 5.758 -2.920 9.864 1.0023.94 RNA1N ATOM 2271 C4 AC1085 5.171 -2.002 10.654 1.0023.81 RNAl C -n ATOM 2272 P AC1086 7.578 ■ 4.220 ! 9.636 1.0038.44 RNA1P ATOM 2273 O1P AC1086 6.238 4.440 10.244 1.0021.00 RNAIO ATOM 2274 O2P AC1086 8.578 5.315 9.641 1.0032.04 RNAIO ATOM 227505* AC1086 7.359 3.750 8.133 1.0044.64 RNAIO ATOM 2276 C5* AC1086 8.465 3.286 7.337 1.0027.97 RNAIC ATOM 2277 C4* AC1086 7.965 2.407 6.217 1.0034.03 RNAIC ATOM 227804* AC1086 7.509 1.138 6.753 1.0034.69 RNAIO ATOM 2279 C3* AC1086 6.759 2.929 5.455 1.0038.31 RNAIC ATOM 228003* AC1086 7.095 3.913 4.484 1.0030.65 RNAIO ATOM 2281 C2* AC1086 6.166 1.659 4.850 1.0040.89 RNAIC ATOM 228202* AC1086 6.734 1.284 3.610 1.0037.38 RNAIO ATOM 2283 CI* AC1086 6.488 0.616 5.925 1.0029.88 RNAIC ATOM 2284 N9 AC1086 5.326 0.253 6.739 1.0026.28 RNA1N ATOM 2285 C8 AC1086 4.885 -1.015 7.018 1.0026.71 RNAIC ATOM 2286 N7 AC1086 3.748 -1.049 7.675 1.0032.50 RNA1N ATOM 2287 C5 AC1086 3.437 0.289 7.869 1.0023.83 RNAl C ATOM 2288 C6 AC1086 2.346 0.926 8.486 1.0032.24 RNAl C ATOM 2289 N6 AC1086 1.320 0.274 9.042 1.0040.46 RNA1N ATOM 2290 NI AC1086 2.340 2.275 8.508 1.0027.06 RNA1N ATOM 2291 C2 AC1086 3.359 2.928 7.943 1.0026.31 RNAl C ATOM 2292 N3 AC1086 4.435 2.444 7.329 1.0027.72 RNA1N ATOM 2293 C4 AC1086 4.413 1.102 7.323 1.0023.09 RNAIC ATOM 2294 P GC1087 6.254 : 5.281 < 1.430 1.0030.97 RNA1P ATOM 2295 O1P GC1087 4.896 4.969 3.921 1.0019.34 RNAl O ATOM 2296 O2P GC1087 6.402 5.980 5.734 1.0046.09 RNAl O ATOM 229705* GC1087 7.006 6.141 3.329 1.0029.62 RNAl O ATOM 2298 C5* GC1087 8.108 6.998 3.667 1.0028.45 RNAl C ATOM 2299 C4* GC1087 8.911 7.283 2.428 1.0031.27 RNAIC ATOM 230004* GC1087 9.604 6.075 2.060 1.0035.33 RNAIO ATOM 2301 C3* GC1087 8.034 7.656 1.244 1.0031.37 RNAIC ATOM 230203* GC1087 7.978 9.077 1.163 1.0019.46 RNAIO ATOM 2303 C2* GC1087 8.776 7.064 0.049 1.0032.80 RNAIC ATOM 2304 O2* GC1087 9.745 7.961 -0.462 1.0029.59 RNAIO ATOM 2305 CI* GC1087 9.484 5.854 0.674 1.0027.32 RNAIC ATOM 2306 N9 GC1087 8.899 4.525 0.520 1.0019.62 RNA1N ATOM 2307 C8 GC1087 7.596 4.129 0.735 1.0023.90 RNAl C ATOM 2308 N7 GC1087 7.429 2.836 0.618 1.009.45 RNA1N ATOM 2309 C5 GC1087 8.685 2.359 0.273 1.0016.55 RNAIC ATOM 2310 C6 GC1087 9.128 1.036 0.007 1.0025.58 RNAl C ATOM 2311 O6 GC1087 8.476 -0.016 0.029 1.0025.76 RNAIO ATOM 2312 NI GC1087 10.483 1.004 -0.307 1.0013.38 RNA1N ATOM 2313 C2 GC1087 11.309 2.103 -0.354 1.0025.58 RNAIC ATOM 2314 N2 GC1087 12.595 1.870 -0.653 1.0021.09 RNA1N ATOM 2315 N3 GC1087 10.906 3.341 -0.116 1.0022.18 RNA1N ATOM 2316 C4 GC1087 9.596 3.394 0.191 1.0016.33 RNAIC ATOM 2317 P . AC1088 6.677 . J.862 : 1.669 1.0023.48 RNA1P ATOM 2318 O1P AC1088 6.035 9.121 2.788 1.0034.67 RNAIO ATOM 2319 O2P AC1088 7.106 11.267 1.858 1.0030.75 RNAl O ATOM 2320 O5* AC1088 5.683 9.810 0.434 1.0034.79 RNAIO ATOM 2321 C5* AC1088 6.166 10.084 -0.886 1.0033.74 RNAIC ATOM -2322 C4* AC1088 5.808 8.952 -1.804 1.0029.37 RNAIC -113 ATOM 2323 04* AC1088 4.376 8.744 -1.752 1.0030.18 RNAIO ATOM 2324 C3* AC1088 6.153 9.200 -3.261 1.0027.75 RNAIC ATOM 2325 03* AC1088 6.465 7.951 -3.847 1.0019.39 RNAl O ATOM 2326 C2* AC1088 4.848 9.717 -3.842 1.0020.69 RNAIC ATOM 232702* AC1088 4.730 9.462 -5.224 1.0039.54 RNAIO ATOM 2328 CI* AC1088 3.821 8.926 -3.035 1.0019.38 RNAl C ATOM 2329 N9 AC1088 2.553 9.623 -2.868 1.0012.67 RNA1N ATOM 2330 C8 AC1088 1.291 9.132 ■ -3.089 1.0019.49 RNAIC ATOM 2331 N7 AC1088 0.338 9.996 -2.842 1.0019.80 RNA1N ATOM 2332 C5 AC1088 1.019 11.134 -2.432 1.0011.03 RNAIC ATOM 2333 C6 AC1088 0.578 12.406 -2.033 1.0014.84 RNAIC ATOM 2334 N6 AC1088 -0.708 12.768 -1.988 1.0013.38 RNA1N ATOM 2335 NI AC1088 1.517 13.309 -1.680 1.0016.35 RNA1N ATOM 2336 C2 AC1088 2.807 12.952 -1.736 1.0016.68 RNAIC ATOM 2337 N3 AC1088 3.343 11.792 -2.099 1.0019.47 RNA1N ATOM 2338 C4 AC1088 2.383 10.917 -2.440 1.0011.60 RNAl C ATOM 2339 P GC1089 7.282 ' 7.896 -: 5.216 1.0026.48 RNAl P ATOM 2340 O1P GC1089 7.768 9.270 -5.525 1.0030.79 RNAIO ATOM 2341 O2P GC1089 6.437 7.171 -6.198 1.0018.45 RNAIO ATOM 234205* GC1089 8.548 7.011 -4.853 1.0014.93 RNAIO ATOM 2343 C5* GC1089 9.568 7.515 -3.971 1.0029.50 RNAIC ATOM 2344 C4* GC1089 10.362 6.367 -3.400 1.0026.25 RNAIC ATOM 2345 04* GC1089 9.469 5.554 -2.600 1.0034.26 RNAIO ATOM 2346 C3* GC1089 10.981 5.439 -4.439 1.0020.63 RNAIC ATOM 2347 03* GC1089 12.197 4.922 -3.925 1.0028.79 RNAIO ATOM 2348 C2* GC1089 9.965 4.305 -4.531 1.0028.82 RNAl C ATOM 234902* GC1089 10.543 3.072 -4.908 1.0040.76 RNAl O ATOM 2350 CI* GC1089 9.439 4.238 -3.099 1.0019.76 RNAIC ATOM 2351 N9 GC1089 8.069 3.749 • -2.988 1.0015.09 RNA1N ATOM 2352 C8 GC1089 6.930 4.499 ■ -2.817 1.0017.24 RNAIC ATOM 2353 N7 GC1089 5.848 3.773 • -2.729 1.0020.25 RNA1N ATOM 2354 C5 GC1089 6.301 2.466 ■ -2.857 1.0014.36 RNAIC ATOM 2355 C6 GC1089 5.590 1.243 ■ -2.839 1.0023.53 RNAIC ATOM 235606 GC1089 4.368 1.060 -2.704 1.0038.04 RNAIO ATOM 2357 NI GC1089 6.442 0.156 ■ -2.998 1.0010.56 RNA1N ATOM 2358 C2 GC1089 7.801 0.235 - ■3.159 1.0016.75 RNAIC ATOM 2359 N2 GC1089 8.456 -0.931 -3.305 1.0018.05 RNA1N ATOM 2360 N3 GC1089 8.475 1.369 ■ -3.178 1.0014.70 RNA1N ATOM 2361 C4 GC1089 7.668 2.437 - ■3.022 1.0010.92 RNAl C ATOM 2362 P UC1090 13.585 5.675 - 4.221 1.0043.14 RNA1P ATOM 2363 O1P UC1090 13.436 6.453 -5.476 1.0042.35 RNAl O ATOM 2364 O2P UC1090 14.010 6.371 -2.971 1.0042.92 RNAIO ATOM 2365 05* UC1090 14.587 4.467 -4.490 1.0039.62 RNAIO ATOM 2366 C5* UC1090 15.989 4.585 -4.207 1.0045.78 RNAIC ATOM 2367 C4* UC1090 16.693 3.275 -4.492 1.0055.27 RNAIC ATOM 2368 04* UC1090 16.237 2.246 -3.570 1.0055.21 RNAIO ATOM 2369 C3* UC1090 16.455 2.661 -5.862 1.0053.66 RNAl C ATOM 237003* UC1090 17.267 3.222 -6.875 1.0051.89 RNAl O ATOM 2371 C2* UC1090 16.781 1.194 -5.637 1.0048.18 RNAIC ATOM 2372 02* UC1090 18.172 0.949 -5.690 1.0054.31 RNAl O ATOM 2373 CI* UC1090 16.271 0.979 -4.213 1.0041.15 RNAIC - 114 ATOM 2374 NI UC1090 14.922 0.387 -4.190 1.0041.07 RNA1N ATOM 2375 C2 UC1090 14.823 -0.998 -4.283 1.0036.51 RNAIC ATOM 237602 UC1090 15.792 -1.730 -4.388 1.0037.99 RNAIO ATOM 2377 N3 UC1090 13.542 -1.493 -4.256 1.0024.06 RNA1N ATOM 2378 C4 UC1090 12.374 -0.772 -4.150 1.0029.36 RNAl C ATOM 237904 UC1090 11.297 -1.373 -4.078 1.0032.44 RNAl O ATOM 2380 C5 UC1090 12.554 0.649 -4.068 1.0027.73 RNAl C ATOM 2381 C6 UC1090 13.788 1.167 -4.087 1.0033.24 RNAl C ATOM 2382 P GC1091 16.725 3.245 - 8.383 1.0058.06 RNA1P ATOM 2383 O1P GC1091 15.277 3.599 -8.351 1.0049.18 RNAIO ATOM 2384 O2P GC1091 17.668 4.074 -9.177 1.0062.85 RNAIO ATOM 2385 O5* GC1091 16.838 1.724 -8.851 1.0059.36 RNAl O ATOM 2386 C5* GC1091 18.123 1.141 -9.135 1.0062.76 RNAl C ATOM 2387 C4* GC1091 18.029 -0.370 -9.212 1.0062.76 RNAIC ATOM 238804* GC1091 17.448 -0.882 -7.980 1.0057.83 RNAl O ATOM 2389 C3* GC1091 17.168 -0.998 -10.302 1.0067.15 RNAIC ATOM 239003* GC1091 17.800 -1.073 -11.581 1.0073.47 RNAIO ATOM 2391 C2* GC1091 16.911 -2.391 -9.736 1.0063.68 RNAl C ATOM 239202* GC1091 17.997 -3.276 -9.939 1.0066.38 RNAl O ATOM 2393 CI* GC1091 16.766 -2.098 -8.243 1.0052.76 RNAIC ATOM 2394 N9 GC1091 15.354 -1.954 -7.902 1.0042.68 RNA1N ATOM 2395 C8 GC1091 14.638 -0.795 -7.717 1.0043.79 RNAIC ATOM 2396 N7 GC1091 13.368 -1.009 -7.490 1.0042.36 RNA1N ATOM 2397 C5 GC1091 13.243 -2.392 -7.512 1.0031.07 RNAl C ATOM 2398 C6 GC1091 12.100 -3.220 -7.342 1.0032.80 RNAl C ATOM 239906 GC1091 10.926 -2.886 -7.133 1.0029.29 RNAIO ATOM 2400 NI GC1091 12.427 -4.567 -7.442 1.0027.53 RNA1N ATOM 2401 C2 GC1091 13.687 -5.057 -7.676 1.0037.58 RNAIC ATOM 2402 N2 GC1091 13.806 -6.387 -7.734 1.0043.37 RNA1N ATOM 2403 N3 GC1091 14.754 -4.300 -7.840 1.0037.83 RNA1N ATOM 2404 C4 GC1091 14.461 -2.989 -7.748 1.0034.74 RNAl C ATOM 2405 P CC1092 16.901 - 1.334-1 .2.902 1.0078.16 RNAl P ATOM 2406 O1P CC1092 15.717 -0.429 -12.869 1.0076.90 RNAl O ATOM 2407 O2P CC1092 17.813 -1.307 -14.079 1.0077.44 RNAIO ATOM 2408 O5* CC1092 16.360 -2.822 -12.721 1.0069.64 RNAIO ATOM 2409 C5* CC1092 17.277 -3.929 -12.693 1.0063.11 RNAIC ATOM 2410 C4* CC1092 16.536 -5.243 -12.604 1.0059.28 RNAl C ATOM 2411 O4* CC1092 15.859 -5.364 -11.322 1.0050.31 RNAIO ATOM 2412 C3* CC1092 15.433 -5.487 -13.621 1.0060.54 RNAIC ATOM 2413 O3* CC1092 15.910 -5.898 -14.893 1.0061.03 RNAl O ATOM 2414 C2* C C1092 14.614 -6.580 -12.949 1.0056.00 RNAIC ATOM 2415 O2* CC1092 15.155 -7.875 -13.128 1.0059.60 RNAIO ATOM 2416 CI* CC1092 14.704 -6.175 -11.477 1.0046.68 RNAIC ATOM 2417 NI CC1092 13.500 -5.411- ■ 11.103 1.0045.69 RNA1N ATOM 2418 C2 CC1092 12.311 ■ -6.125 - 10.845 1.0048.75 RNAIC ATOM 2419 O2 CC1092 12.334 -7.367 - 10.877 1.0035.22 RNAIO ATOM 2420 N3 CC1092 11.175 -5.443 - 10.568 1.0040.06 RNA1N ATOM 2421 C4 CC1092 11.191 -4.109- 10.529 1.0043.65 RNAIC ATOM 2422 N4 CC1092 10.043 -3.483 - 10.269 1.0038.14 RNA1N ATOM 2423 C5 CC1092 12.386 -3.357- 10.759 1.0043.83 RNAl C ATOM 2424 C6 CC1092 13.508 -4.043 - 11.036 1.0048.70 RNAIC - 115- S B T E EET ATOM 2425 P GC1093 15.082 - ■ 5.497-16.210 1.0059.69 RNA1P ATOM 2426 O1P GC1093 14.954 -4.014-16.213 1.0064.26 RNAl O ATOM 2427 O2P GC1093 15.706 -6.182-17.376 1.0068.36 RNAIO ATOM 242805* GC1093 13.629 -6.109-15.961 1.0039.18 RNAl O ATOM 2429 C5* GC1093 13.440 -7.525-15.810 1.0034.94 RNAl C ATOM 2430 C4* GC1093 12.017 -7.828-15.395 1.0040.12 RNAIC ATOM 2431 04* GC1093 11.737 -7.199-14.117 1.0045.67 RNAIO ATOM 2432 C3* GC1093 10.929 -7.304-16.315 1.0043.53 RNAl C ATOM 2433 03* GC1093 10.687 -8.168-17.410 1.0048.03 RNAIO ATOM 2434 C2* GC1093 9.720 -7.183-15.391 1.0041.69 RNAIC ATOM 2435 02* GC1093 8.996 -8.389-15.229 1.0027.92 RNAl O ATOM 2436 CI* GC1093 10.381 -6.769-14.075 1.0038.16 RNAIC ATOM 2437 N9 GC1093 10.350 -5.318-13.870 1.0036.77 RNA1N ATOM 2438 C8 GC1093 11.401 -4.431-13.970 1.0034.83 RNAl C ATOM 2439 N7 GC1093 11.048 -3.190-13.762 1.0032.06 RNA1N ATOM 2440 C5 GC1093 9.685 -3.259-13.505 1.0027.72 RNAl C ATOM 2441 C6 GC1093 8.752 ■ -2.231 -13.223 1.0027.54 RNAl C ATOM 244206 GC1093 8.947 -1.013-13.160 1.0034.45 RNAIO ATOM 2443 NI GC1093 7.475 -2.743 -13.014 1.0019.53 RNA1N ATOM 2444 C2 GC1093 7.136 -4.075-13.075 1.0019.64 RNAIC ATOM 2445 N2 GC1093 5.851 -4.382-12.830 1.0017.24 RNA1N ATOM 2446 N3 G C1093 7.993 -5.040-13.352 1.0021.92 RNA1N ATOM 2447 C4 GC1093 9.241 ■ -4.566-13.554 1.0025.99 RNAIC ATOM 2448 P UC1094 10.214 - ■ 7.545-18.808 1.0048.86 RNA1P ATOM 2449 O1P U C1094 11.019 -6.314-19.033 1.0051.40 RNAIO ATOM 2450 O2P UC1094 10.225 -8.631-19.820 1.0062.99 RNAl O ATOM 2451 05* UC1094 8.700 -7.137-18.549 1.0035.14 RNAl O ATOM 2452 C5* UC1094 7.726 -8.151-18.319 1.0039.65 RNAl C ATOM 2453 C4* UC1094 6.342 -7.561-18.289 1.0045.60 RNAl C ATOM 245404* UC1094 6.086 -6.907-17.022 1.0047.84 RNAIO ATOM 2455 C3* UC1094 6.030 -6.503-19.328 1.0046.03 RNAIC ATOM 245603* UC1094 5.775 -7.078-20.601 1.0056.79 RNAIO ATOM 2457 C2* UC1094 4.829 -5.786-18.713 1.0044.04 RNAIC ATOM 2458 02* U C1094 3.588 -6.431-18.943 1.0037.76 RNAIO ATOM 2459 CI* UC1094 5.168 -5.844-17.219 1.0044.47 RNAIC ATOM 2460 NI UC1094 5.770 -4.589-16.742 1.0026.87 RNA1N ATOM 2461 C2 UC1094 4.909 ■ -3.585-16.329 1.0022.09 RNAIC ATOM 246202 UC1094 3.691 -3.719-16.288 1.0025.93 RNAIO ATOM 2463 N3 UC1094 5.519 -2.419-15.962 1.0013.38 RNA1N ATOM 2464 C4 UC1094 6.869 ■ -2.159-15.947 1.0036.16 RNAIC ATOM 2465 04 UC1094 7.263 ■ -1.036-15.621 1.0036.16 RNAl O ATOM 2466 C5 UC1094 7.696 ■ -3.256-16.357 1.0027.39 RNAl C ATOM 2467 C6 UC1094 7.131 ■ -4.404-16.729 1.0019.00 RNAIC ATOM 2468 P . C1095 6.404 -( 5.394-21.913 1.0056.22 RNA1P ATOM 2469 O1P AC1095 7.761 -5.866-21.571 1.0036.24 RNAIO ATOM 2470 O2P AC1095 6.257 -7.345-23.045 1.0062.45 RNAIO ATOM 2471 05* AC1095 5.420 -5.169-22.156 1.0037.34 RNAl O ATOM 2472 C5* AC1095 5.858 -3.993-22.836 1.0026.88 RNAl C ATOM 2473 C4* AC1095 4.732 -3.002-22.897 1.0025.01 RNAl C ATOM 247404* AC1095 3.576 -3.668-23.451 1.0031.13 RNAIO ATOM 2475 C3* AC1095 4.254 -2.489-21.555 1.0030.12 RNAl C -116- ATOM 247603* AC1095 5.068 -1.403 -21.134 1.0047.22 RNAIO ATOM 2477 C2* AC1095 2.797 -2.116 -21.824 1.0032.85 RNAIC ATOM 247802* AC1095 2.630 -0.839 -22.418 1.0029.79 RNAIO ATOM 2479 CI* AC1095 2.395 -3.179 -22.845 1.0021.93 RNAIC ATOM 2480 N9 AC1095 1.649 -4.328 ■ -22.333 1.0017.01 RNA1N ATOM 2481 C8 AC1095 2.142 -5.568 - ■21.985 1.0021.36 RNAIC ATOM 2482 N7 AC1095 1.211 -6.424 ■ -21.627 1.0021.32 RNA1N ATOM 2483 C5 AC1095 0.031 -5.696 - ■21.729 1.0010.86 RNAIC ATOM 2484 C6 AC1095 -1.315 -6.037 • -21.498 1.0023.82 RNAIC ATOM 2485 N6 AC1095 -1.717 -7.254 -21.118 1.0035.80 RNA1N ATOM 2486 NI AC1095 -2.249 -5.076 -21.679 1.0030.20 RNA1N ATOM 2487 C2 AC1095 -1.844 -3.861 -22.076 1.0023.15 RNAIC ATOM 2488 N3 AC1095 -0.610 -3.423 -22.337 1.0020.47 RNA1N ATOM 2489 C4 AC1095 0.289 -4.399 - ■ 22.143 1.00 9.00 RNAIC ATOM 2490 P AC1096 5.554 - 1.325 -1 19.607 1.0033.71 RNA1P ATOM 2491 O1P AC1096 5.985 -2.689 -19.209 1.0038.06 RNAIO ATOM 2492 O2P AC1096 6.505 -0.198 -19.472 1.0030.42 RNAIO ATOM 2493 O5* AC1096 4.203 -0.950 -18.856 1.0019.71 RNAIO ATOM 2494 C5* AC1096 3.610 0.332 -19.065 1.0017.59 RNAIC ATOM 2495 C4* AC1096 2.176 0.335 -18.609 1.0025.20 RNAIC ATOM 249604* AC1096 1.399 -0.548 -19.452 1.0036.18 RNAIO ATOM 2497 C3* AC1096 1.916 -0.155 -17.197 1.0031.52 RNAl C ATOM 249803* AC1096 2.158 0.858 -16.224 1.0040.13 RNAIO ATOM 2499 C2* AC1096 0.458 -0.589 -17.277 1.0029.94 RNAl C ATOM 250002* AC1096 -0.436 0.497 -17.220 1.0033.53 RNAl O ATOM 2501 CI* AC1096 0.392 -1.181 -18.684 1.0028.76 RNAl C ATOM 2502 N9 AC1096 0.682 -2.615 - -18.662 1.0029.57 RNA1N ATOM 2503 C8 AC1096 1.915 -3.230 - ■ 18.760 1.0020.07 RNAIC ATOM 2504 N7 AC1096 1.862 -4.536 ■ -18.673 1.0016.60 RNA1N ATOM 2505 C5 AC1096 0.506 -4.803 - •18.515 1.0021.73 RNAIC ATOM 2506 C6 AC1096 -0.207 -6.004 ■ -18.372 1.0021.62 RNAl C ATOM 2507 N6 AC1096 0.376 -7.207 ■ -18.386 1.0030.29 RNA1N ATOM 2508 NI AC1096 -1.551 -5.928 -18.222 1.0019.53 RNA1N ATOM 2509 C2 AC1096 -2.130 -4.715 ■ -18.234 1.0019.83 RNAl C ATOM 2510 N3 AC1096 -1.565 -3.512 -18.377 1.0021.31 RNA1N ATOM 2511 C4 AC1096 -0.231 -3.630 ■ -18.511 1.0013.07 RNAIC ATOM 2512 P i CC1097 2.770 0.451 -14.795 1.0034.58 RNA1P ATOM 2513 O1P CC1097 3.901 -0.488 -15.013 1.0024.95 RNAIO ATOM 2514 O2P CC1097 3.010 1.716 -14.062 1.0042.37 RNAIO ATOM 2515 O5* CC1097 1.558 -0.333 -14.115 1.0033.44 RNAl O ATOM 2516 C5* CC1097 1.711 -1.664 -13.564 1.0027.30 RNAIC ATOM 2517 C4* CC1097 0.347 -2.298 -13.386 1.0034.16 RNAIC ATOM 2518 O4* CC1097 -0.067 -2.943 -14.625 1.0037.39 RNAl O ATOM 2519 C3* CC1097 0.219 -3.406 -12.354 1.0033.88 RNAl C ATOM 2520 O3* CC1097 0.093 -2.924 -11.025 1.0036.37 RNAIO ATOM 2521 C2* CC1097 -1.041 -4.120 -12.816 1.0036.19 RNAIC ATOM 2522 O2* CC1097 -2.214 -3.415 -12.457 1.0031.86 RNAIO ATOM 2523 CI* CC1097 -0.865 -4.089 -14.334 1.0035.36 RNAl C ATOM 2524 NI CC1097 -0.146 -5.311- -14.780 1.0029.78 RNA1N ATOM 2525 C2 CC1097 -0.859 -6.537- ■14.895 1.0031.29 RNAIC ATOM 2526 O2 CC1097 -2.097 -6.552 ■ -14.732 1.0030.74 RNAl O -117 ATOM 2527 N3 CC1097 -0.175 -7.667 ■ -15.188 1.0027.52 RNA1N ATOM 2528 C4 CC1097 1.146 -7.616- 15.390 1.0035.55 RNAIC ATOM 2529 N4 CC1097 1.788 -8.764 - ■15.640 1.0038.53 RNA1N ATOM 2530 C5 CC1097 1.874 -6.389 - 15.338 1.0027.77 RNAIC ATOM 2531 C6 CC1097 1.197 -5.275 - 15.036 1.0024.47 RNAIC ATOM 2532 P AC1098 1.072 - 3.493 - 9.886 1.0038.47 RNA1P ATOM 2533 O1P AC1098 2.477 -3.131 -10.212 1.0022.01 RNAIO ATOM 2534 O2P AC1098 0.484 -3.068 -8.588 1.0056.40 RNAIO ATOM 253505* AC1098 0.959 -5.079 -10.023 1.0040.54 RNAIO ATOM 2536 C5* AC1098 -0.328 -5.740 -9.972 1.0047.03 RNAl C ATOM 2537 C4* AC1098 -0.192 -7.201 -10.348 1.0050.05 RNAIC ATOM 253804* AC1098 0.276 -7.310 -11.720 1.0043.04 RNAIO ATOM 2539 C3* AC1098 0.819 -8.007 -9.544 1.0059.35 RNAl C ATOM 2540 O3* AC1098 0.289 -8.467 -8.305 1.0057.94 RNAl O ATOM 2541 C2* AC1098 1.170 -9.146 -10.496 1.0054.42 RNAIC ATOM 254202* AC1098 0.229 -10.203 -10.479 1.0063.88 RNAIO ATOM 2543 CI* AC1098 1.125 -8.440 -11.851 1.0042.41 RNAIC ATOM 2544 N9 AC1098 2.456 -7.982 - ■ 12.247 1.0029.98 RNA1N ATOM 2545 C8 AC1098 2.967 -6.709 - 12.213 1.0032.72 RNAIC ATOM 2546 N7 AC1098 4.222 -6.633 - ■12.588 1.0034.32 RNA1N ATOM 2547 C5 AC1098 4.557 -7.942 - 12.902 1.0034.44 RNAIC ATOM 2548 C6 AC1098 5.751 -8.533 - 13.363 1.0043.55 RNAIC ATOM 2549 N6 AC1098 6.879 -7.852 - ■13.597 1.0039.58 RNA1N ATOM 2550 NI AC1098 5.746 -9.866 - ■13.579 1.0048.91 RNA1N ATOM 2551 C2 AC1098 4.615- 10.549 -13.348 1.0042.95 RNAl C ATOM 2552 N3 AC1098 3.435 - ■ 10.108 -12.916 1.0035.82 RNA1N ATOM 2553 C4 AC1098 3.474 -8.782 - 12.708 1.0035.65 RNAl C ATOM 2554 P GC1099 1.238 - 8.516 - 7.006 1.0052.26 RNA1P ATOM 2555 O1P GC1099 1.696 -7.137 -6.706 1.0052.99 RNAIO ATOM 2556 O2P GC1099 0.511 -9.287 -5.970 1.0054.62 RNAIO ATOM 255705* GC1099 2.513 -9.346 -7.481 1.0043.47 RNAIO ATOM 2558 C5* GC1099 2.413 -10.749 -7.772 1.0041.68 RNAIC ATOM 2559 C4* GC1099 3.735 -11.273 -8.271 1.0042.05 RNAIC ATOM 256004* GC1099 4.033 -10.671 -9.554 1.0043.83 RNAIO ATOM 2561 C3* GC1099 4.938 -10.934 -7.409 1.0048.09 RNAIC ATOM 256203* GC1099 5.100 -11.821 -6.317 1.0058.27 RNAIO ATOM 2563 C2* GC1099 6.089 -10.992 -8.402 1.0050.43 RNAl C ATOM 256402* GC1099 6.588 -12.296 -8.639 1.0057.02 RNAIO ATOM 2565 CI* GC1099 5.426 -10.432 -9.660 1.0044.89 RNAIC ATOM 2566 N9 GC1099 5.639 -8.989 -9.729 1.0045.65 RNA1N ATOM 2567 C8 GC1099 4.714 -7.993 -9.515 1.0038.56 RNAIC ATOM 2568 N7 GC1099 5.228 -6.796 -9.584 1.0041.94 RNA1N ATOM 2569 C5 GC1099 6.569 -7.014 -9.873 1.0034.92 RNAl C ATOM 2570 C6 GC1099 7.631 -6.094 - 10.053 1.0042.48 RNAIC ATOM 2571 06 GC1099 7.601 -4.857 -9.985 1.0044.46 RNAl O ATOM 2572 NI GC1099 8.829 -6.746 - 10.336 1.0041.82 RNA1N ATOM 2573 C2 GC1099 8.982 -8.108 - 10.437 1.0042.77 RNAl C ATOM 2574 N2 GC1099 10.211 -8.548 -10.736 1.0031.50 RNA1N ATOM 2575 N3 GC1099 8.001 -8.974 - 10.262 1.0031.12 RNA1N ATOM 2576 C4 GC1099 6.832 -8.362 -9.984 1.0033.36 RNAl C ATOM 2577 P ' ccnoo 5.772-11.286 - 4.956 1.0062.31 RNA1P -118 . ATOM 2578 O1P ccnoo 5.270 -9.914 -4.687 1.0056.23 RNAIO ATOM 2579 O2P ccnoo 5.583 ■ -12.348 -3.934 1.0065.10 RNAIO ATOM 258005* ccnoo 7.320 ■ -11.188 -5.316 1.0045.54 RNAIO ATOM 2581 C5* ccnoo 8.052 - ■ 12.366 -5.670 1.0043.72 RNAIC ATOM 2582 C4* ccnoo 9.458 - ■ 12.015 -6.069 1.0040.97 RNAIC ATOM 2583 04* ccnoo 9.429 ■ -11.213 -7.276 1.0044.70 RNAIO ATOM 2584 C3* ccnoo 10.249 -11.173 -5.087 1.0043.30 RNAIC ATOM 2585 03* ccnoo 10.817 -11.913 -4.022 1.0057.32 RNAl O ATOM 2586 C2* ccnoo 11.306 -10.543 -5.980 1.0045.40 RNAIC ATOM 258702* ccnoo 12.407 -11.390 -6.236 1.0041.08 RNAl O ATOM 2588 CI* ccnoo 10.508 -10.293 -7.258 1.0040.42 RNAl C ATOM 2589 NI ccnoo 9.968 - -8.923 - 7.239 1.0034.22 RNA1N ATOM 2590 C2 ccnoo 10.851 -7.860 -7.450 1.0034.09 RNAIC ATOM 2591 02 ccnoo 12.043 -8.112 -7.698 1.0030.44 RNAIO ATOM 2592 N3 ccnoo 10.390 -6.595 -7.377 1.0032.20 RNA1N ATOM 2593 C4 ccnoo 9.102 - 6.369 - 7.112 1.0036.06 RNAl C ATOM 2594 N4 ccnoo 8.695 - ■ 5.101 - 7.023 1.0042.37 RNA1N ATOM 2595 C5 ccnoo 8.173 - 7.432 - 6.920 1.0031.00 RNAl C ATOM 2596 C6 ccnoo 8.643 - 8.681 - 6.995 1.0029.98 RNAl C ATOM 2597 P i ucnoi 11.026-1 11.199 ■ -2.592 1.0060.70 RNA1P ATOM 2598 O1P UC1101 9.727 ■ -10.588 -2.196 1.0050.26 RNAIO ATOM 2599 O2P UC1101 11.694 -12.160 ' -1.673 1.0070.90 RNAIO ATOM 2600 O5* ucnoi 12.055 -10.024 -2.904 1.0044.87 RNAIO ATOM 2601 C5* UC1101 13.364 -10.316 -3.411 1.0039.54 RNAIC ATOM 2602 C4* UC1101 14.139 -9.041 -3.619 1.0045.93 RNAIC ATOM 2603 O4* UC1101 13.487 -8.234 -4.635 1.0053.56 RNAl O ATOM 2604 C3* UC1101 14.232 -8.111 -2.424 1.0045.04 RNAIC ATOM 2605 O3* UC1101 15.241 -8.491 -1.503 1.0055.35 RNAl O ATOM 2606 C2* ucnoi 14.519 -6.767 -3.078 1.0045.97 RNAIC ATOM 2607 O2* UC1101 15.875 -6.620 -3.450 1.0043.86 RNAl O ATOM 2608 CI* ucnoi 13.668 -6.856 -4.341 1.0043.43 RNAl C ATOM 2609 NI ucnoi 12.349 -6.220 -4.172 1.0040.87 RNA1N ATOM 2610 C2 ucnoi 12.289 -4.831 -4.234 1.0035.67 RNAIC ATOM 2611 O2 ucnoi 13.277 -4.130 -4.420 1.0034.43 RNAl O ATOM 2612 N3 ucnoi 11.032 -4.294 -4.067 1.0027.89 RNA1N ATOM 2613 C4 ucnoi 9.851 - ■ 4.983 - 3.852 1.0038.34 RNAIC ATOM 2614 O4 ucnoi 8.792 ■ -4.355 - 3.727 1.0030.79 RNAl O ATOM 2615 C5 ucnoi 9.993 - ■6.408 - 3.801 1.0038.67 RNAl C ATOM 2616 C6 ucnoi 11.204 -6.965 -3.959 1.0040.99 RNAl C ATOM 2617 P i CC1102 15.110 - 8.040 0.038 1.0056.93 RNAl P ATOM 2618 O1P CC1102 13.690 -8.220 0.458 1.0045.32 RNAl O ATOM 2619 O2P CC1102 16.195 -8.697 0.810 1.0059.07 RNAIO ATOM 262005* CC1102 15.415 -6.479 0.002 1.0047.10 RNAIO ATOM 2621 C5* CC1102 16.687 -6.002 -0.447 1.0040.92 RNAl C ATOM 2622 C4* CC1102 16.706 -4.495 -0.480 1.0041.54 RNAIC ATOM 2623 04* CC1102 15.809 -4.001 -1.511 1.0045.86 RNAIO ATOM 2624 C3* CC1102 16.235 -3.772 0.769 1.0043.22 RNAl C ATOM 2625 03* CC1102 17.189 -3.732 1.814 1.0049.70 RNAl O ATOM 2626 C2* CC1102 15.910 -2.389 0.227 1.0045.44 RNAIC ATOM 262702* CC1102 17.061 -1.587 0.031 1.0039.52 RNAIO ATOM 2628 CI* CC1102 15.294 -2.733 -1.125 1.0041.32 RNAIC -119- ATOM 2629 NI CC1102 13.822 -2.807 -1.006 1.0035.07 RNA1N ATOM 2630 C2 CC1102 13.091 -1.607 -0.999 1.0035.73 RNAIC ATOM 2631 02 CC1102 13.700 -0.530 -1.134 1.0040.70 RNAIO ATOM 2632 N3 CC1102 11.748 -1.649 -0.843 1.0024.21 RNA1N ATOM 2633 C4 CC1102 11.131 -2.821 -0.703 1.0025.56 RNAIC ATOM 2634 N4 CC1102 9.805 - -2.813 ■ -0.534 1.0027.04 RNA1N ATOM 2635 C5 CC1102 11.844 -4.056 -0.726 1.0025.22 RNAl C ATOM 2636 C6 CC1102 13.175 -4.004 -0.880 1.0029.24 RNAIC ATOM 2637 P AC1103 16.678 - 3.598 3.336 1.0046.37 RNA1P ATOM 2638 O1P AC1103 15.453 -4.431 3.507 1.0034.79 RNAIO ATOM 2639 O2P AC1103 17.841 -3.806 4.238 1.0053.23 RNAIO ATOM 2640 O5* AC1103 16.223 -2.077 3.443 1.0050.88 RNAl O ATOM 2641 C5* AC1103 17.095 -1.012 3.017 1.0045.92 RNAIC ATOM 2642 C4* AC1103 16.368 0.307 3.082 1.0042.03 RNAIC ATOM 2643 O4* AC1103 15.249 0.282 2.164 1.0042.45 RNAl O ATOM 2644 C3* AC1103 15.748 0.629 4.431 1.0046.34 RNAIC ATOM 2645 O3* AC1103 16.697 1.231 5.297 1.0050.61 RNAIO ATOM 2646 C2* AC1103 14.604 1.568 4.068 1.0040.60 RNAIC ATOM 264702* AC1103 15.018 2.911 3.913 1.0043.99 RNAIO ATOM 2648 CI* AC1103 14.163 1.007 2.714 1.0035.23 RNAIC ATOM 2649 N9 AC1103 13.007 0.114 2.815 1.0024.56 RNA1N ATOM 2650 C8 AC1103 12.964 -1.259 2.771 1.0012.09 RNAIC ATOM 2651 N7 AC1103 11.755 -1.754 2.912 1.0021.27 RNA1N ATOM 2652 C5 AC1103 10.949 -0.629 3.052 1.0011.33 RNAIC ATOM 2653 C6 AC1103 9.566 - •0.469 3.247 1.0017.54 RNAl C ATOM 2654 N6 AC1103 8.699 ■ -1.485 3.341 1.0018.44 RNA1N ATOM 2655 NI AC1103 9.091 0.792 3.351 1.0023.77 RNA1N ATOM 2656 C2 AC1103 9.947 1.810 3.270 1.0020.47 RNAIC ATOM 2657 N3 AC1103 11.262 1.789 3.093 1.0025.40 RNA1N ATOM 2658 C4 AC1103 11.706 0.525 2.990 1.0022.14 RNAIC ATOM 2659 P CC1104 16.907 1 0.637 ( 5.771 1.0047.34 RNA1P ATOM 2660 O1P CC1104 17.274 -0.801 6.656 1.0047.39 RNAIO ATOM 2661 O2P CC1104 17.809 1.572 7.493 1.0049.59 RNAIO ATOM 2662 O5* CC1104 15.454 0.717 7.410 1.0032.80 RNAIO ATOM 2663 C5* CC1104 14.847 1.985 7.660 1.0032.89 RNAIC ATOM 2664 C4* CC1104 13.409 1.804 8.055 1.0033.67 RNAIC ATOM 266504* CC1104 12.654 1.301 6.924 1.0036.61 RNAl O ATOM 2666 C3* CC1104 13.151 0.793 9.157 1.0044.60 RNAIC ATOM 266703* CC1104 13.379 1.321 10.455 1.0047.83 RNAIO ATOM 2668 C2* CC1104 11.699 0.409 8.912 1.0041.50 RNAIC ATOM 266902* CC1104 10.802 1.363 9.443 1.0039.51 RNAIO ATOM 2670 CI* CC1104 11.635 0.426 7.382 1.0035.38 RNAIC ATOM 2671 NI CC1104 11.881 -0.915 6.818 1.0026.79 RNA1N ATOM 2672 C2 CC1104 10.807 -1.804 6.699 1.0030.49 RNAIC ATOM 267302 CC1104 9.672 - 1.426 7.039 1.0025.17 RNAIO ATOM 2674 N3 CC1104 11.031 -3.049 6.216 1.0035.06 RNA1N ATOM 2675 C4 CC1104 12.264 -3.412 5.850 1.0035.48 RNAIC ATOM 2676 N4 CC1104 12.440 -4.649 5.381 1.0039.73 RNA1N ATOM 2677 C5 CC1104 13.370 -2.524 5.948 1.0026.28 RNAl C ATOM 2678 C6 CC1104 13.137 -1.298 6.432 1.0026.38 RNAIC ATOM 2679 P i CC1105 13.943 ( 3.357 11.610 1.0045.15 RNA1P 120- ATOM 2680 O1P CC1105 14.937 -0.579 11.008 1.0037.59 RNAIO ATOM 2681 O2P CC1105 14.345 1.217 12.749 1.0050.66 RNAIO ATOM 2682 O5* CC1105 12.669 -0.496 12.036 1.0027.84 RNAIO ATOM 2683 C5* CC1105 11.541 0.141 12.636 1.0026.44 RNAl C ATOM 2684 C4* CC1105 10.431 -0.855 12.852 1.0036.80 RNAIC ATOM 2685 O4* CC1105 9.967 -1.354 11.569 1.0046.02 RNAIO ATOM 2686 C3* CC1105 10.793 -2.111 13.623 1.0039.57 RNAIC ATOM 2687 O3* CC1105 10.794 -1.905 15.026 1.0048.60 RNAIO ATOM 2688 C2* CC1105 9.713 -3.084 13.169 1.0042.79 RNAIC ATOM 2689 O2* CC1105 8.473 -2.848 13.811 1.0036.52 RNAIO ATOM 2690 CI* CC1105 9.576 -2.714 11.693 1.0039.01 RNAIC ATOM 2691 NI CC1105 10.448 -3.539 10.827 1.0031.92 RNA1N ATOM 2692 C2 CC1105 10.029 -4.832 10.461 1.0029.04 RNAIC ATOM 2693 O2 CC1105 8.934 - -5.259 10.875 1.0027.41 RNAl O ATOM 2694 N3 CC1105 10.831 -5.584 9.672 1.0026.50 RNA1N ATOM 2695 C4 CC1105 12.005 -5.100 9.255 1.0026.95 RNAl C ATOM 2696 N4 CC1105 12.768 -5.879 8.473 1.0032.01 RNA1N ATOM 2697 C5 CC1105 12.453 -3.798 9.614 1.0031.44 RNAIC ATOM 2698 C6 CC1105 11.652 -3.059 10.389 1.0027.18 RNAIC ATOM 2699 P AC1106 11.685 - 2.860 1 15.964 1.0049.11 RNA1P ATOM 2700 O1P AC1106 12.987 -3.106 15.282 1.0036.36 RNAIO ATOM 2701 O2P AC1106 11.676 -2.277 17.331 1.0055.01 RNAIO ATOM 2702 O5* AC1106 10.861 -4.222 15.988 1.0033.45 RNAIO ATOM 2703 C5* AC1106 9.507 -4.255 16.482 1.0040.30 RNAl C ATOM 2704 C4* AC1106 8.910 -5.628 16.280 1.0055.66 RNAl C ATOM 2705 O4* AC1106 8.774 -5.892 14.859 1.0057.89 RNAl O ATOM 2706 C3* AC1106 9.747 -6.785 16.804 1.0061.21 RNAl C ATOM 2707 O3* AC1106 9.552 -7.004 18.196 1.0063.93 RNAIO ATOM 2708 C2* AC1106 9.287 -7.945 15.928 1.0060.31 RNAIC ATOM 2709 O2* AC1106 8.040 -8.478 16.344 1.0054.72 RNAIO ATOM 2710 CI* AC1106 9.104 -7.244 14.582 1.0050.43 RNAIC ATOM 2711 N9 AC1106 10.327 -7.245 13.772 1.0040.12 RNA1N ATOM 2712 C8 AC1106 11.297 -6.265 13.730 1.0043.18 RNAIC ATOM 2713 N7 AC1106 12.279 -6.522 12.899 1.0035.92 RNA1N ATOM 2714 C5 AC1106 11.940 -7.754 12.356 1.0035.80 RNAIC ATOM 2715 C6 AC1106 12.574 -8.570 11.401 1.0032.97 RNAIC ATOM 2716 N6 AC1106 13.721 -8.242 10.791 1.0042.58 RNA1N ATOM 2717 NI AC1106 11.984 -9.744 11.088 1.0028.98 RNA1N ATOM 2718 C2 AC1106 10.831 - •10.065 11.694 1.0037.34 RNAIC ATOM 2719 N3 AC1106 10.132 -9.379 12.601 1.0037.05 RNA1N ATOM 2720 C4 AC1106 10.746 -8.218 12.893 1.0037.35 RNAIC ATOM 2721 P i GC1107 10.770 - 7.554 1 19.093 1.0058.93 RNA1P ATOM 2722 O1P GC1107 12.057 -7.023 18.562 1.0036.85 RNAIO ATOM 2723 O2P GC1107 10.406 -7.307 20.512 1.0061.45 RNAIO ATOM 2724 O5* GC1107 10.741 -9.124 18.823 1.0057.72 RNAIO ATOM 2725 C5* GC1107 9.559 -9.898 19.117 1.0058.74 RNAIC ATOM 2726 C4* GC1107 9.678 - ■ 11.278 18.520 1.0065.40 RNAIC ATOM 2727 O4* GC1107 9.633 - ■11.183 17.073 1.0061.43 RNAIO ATOM 2728 C3* GC1107 10.983 -11.999 1 18.818 1.0066.79 RNAIC ATOM 2729 O3* GC1107 10.969 -12.653 i 20.079 1.0066.96 RNAIO ATOM 2730 C2* GC1107 11.110 -12.966 i 17.647 1.0065.40 RNAIC -121 SUBSTITUTE SHEET (RULE2φ ATOM 2731 02* GC1107 10.392 -14.174 17.833 1.0059.25 RNAIO ATOM 2732 CI* GC1107 10.509 -12.142 16.504 1.0056.87 RNAIC ATOM 2733 N9 GC1107 11.541 ■ -11.428 15.759 1.0046.90 RNA1N ATOM 2734 C8 GC1107 11.980- -10.140 15.964 1.0049.14 RNAIC ATOM 2735 N7 GC1107 12.952 -9.797 15.163 1.0045.19 RNA1N ATOM 2736 C5 GC1107 13.159- -10.921 14.374 1.0043.33 RNAIC ATOM 2737 C6 GC1107 14.092 ■ -11.155 13.326 1.0044.94 RNAIC ATOM 2738 06 GC1107 14.953 -10.387 12.869 1.0041.91 RNAl O ATOM 2739 NI GC1107 13.958 -12.437 12.803 1.0044.05 RNA1N ATOM 2740 C2 GC1107 13.048 ■ -13.374 13.227 1.0048.45 RNAIC ATOM 2741 N2 GC1107 13.071 -14.553 12.597 1.0049.02 RNA1N ATOM 2742 N3 GC1107 12.177- -13.169 14.198 1.0048.55 RNA1N ATOM 2743 C4 GC1107 12.289- -11.932 14.725 1.0047.37 RNAIC ATOM 2744 P CC1108 12.345 -1 12.84020.886 1.0071.15 RNA1P ATOM 2745 O1P CC1108 13.100 -11.558 20.849 1.0059.46 RNAl O ATOM 2746 O2P CC1108 12.015 -13.463 22.194 1.0075.00 RNAl O ATOM 2747 O5* CC1108 13.155 -13.893 20.010 1.0072.84 RNAl O ATOM 2748 C5* CC1108 12.697 -15.251 19.876 1.0075.04 RNAl C ATOM 2749 C4* CC1108 13.581 -16.004 18.914 1.0076.03 RNAIC ATOM 275004* CC1108 13.459 -15.420 17.592 1.0073.82 RNAIO ATOM 2751 C3* CC1108 15.073 -15.954 19.208 1.0077.22 RNAIC ATOM 275203* CC1108 15.576 -16.62220.377 1.0076.14 RNAIO ATOM 2753 C2* CC1108 15.696 -16.220 17.844 1.0077.82 RNAIC ATOM 275402* CC1108 15.731 -17.593 17.507 1.0080.53 RNAIO ATOM 2755 CI* CC1108 14.705 -15.511 16.916 1.0074.18 RNAIC ATOM 2756 NI CC1108 15.147- ■ 14.151 16.545 1.0069.37 RNA1N ATOM 2757 C2 CC1108 15.946- ■ 13.987 15.400 1.0064.11 RNAIC ATOM 275802 CC1108 16.232- ■14.979 14.713 1.0063.69 RNAIO ATOM 2759 N3 CC1108 16.383- ■ 12.750 15.074 1.0059.38 RNA1N ATOM 2760 C4 CC1108 16.047 - ■ 11.702 15.829 1.0057.06 RNAIC ATOM 2761 N4 CC1108 16.508 - •10.503 15.472 1.0058.03 RNA1N ATOM 2762 C5 CC1108 15.224- 11.837 16.984 1.0061.31 RNAIC ATOM 2763 C6 CC1108 14.801 - 13.066 17.303 1.0067.15 RNAIC TER 2764 CC1108 ATOM 2765 05* GD1051 13.368 11.108-58.535 1.0055.60 RNA2O ATOM 2766 C5* GD1051 14.100 12.302-58.210 1.0063.32 RNA2C ATOM 2767 C4* GD1051 13.550 13.505 -58.939 1.0061.69 RNA2C ATOM 2768 O4* GD1051 13.809 13.364 -60.359 1.0066.02 RNA2O ATOM 2769 C3* GD1051 12.043 13.659-58.835 1.0059.67 RNA2C ATOM 277003* GD1051 11.661 14.349 -57.659 1.0053.26 RNA2O ATOM 2771 C2* GD1051 11.684 14.404-60.113 1.0058.82 RNA2C ATOM 2772 02* GD1051 11.873 15.801 -60.015 1.0062.26 RNA2O ATOM 2773 CI* GD1051 12.691 13.815-61.102 1.0058.27 RNA2C ATOM 2774 N9 GD1051 12.147 12.672-61.833 1.0055.11 RNA2N ATOM 2775 C8 GD1051 12.505 11.352-61.693 1.0057.64 RNA2C ATOM 2776 N7 GD1051 11.830 10.552 -62.472 1.0063.74 RNA2N ATOM 2777 C5 GD1051 10.976 11.393-63.171 1.0059.62 RNA2C ATOM 2778 C6 GD1051 10.002 11.100-64.162 1.0054.61 RNA2C ATOM 277906 GD1051 9.687 9.999-64.634 1.0056.94 RNA2O ATOM 2780 NI GD1051 9.366 12.254 -64.606 1.0052.85 RNA2N ATOM 2781 C2 GD1051 9.629 13.525 -64.157 1.0048.26 RNA2C -122- ATOM 2782 N2 GD1051 8.910 14.509-64.707 1.0049.20 RNA2N ATOM 2783 N3 GD1051 10.531 13.811-63.237 1.0051.58 RNA2N ATOM 2784 C4 GD1051 11.163 12.707-62.791 1.0056.30 RNA2C ATOM 2785 P CD1052 10.243 14.024-56.983 1.0059.48 RNA2P ATOM 2786 O1P CD1052 10.050 12.549-57.013 1.0061.66 RNA2O ATOM 2787 O2P CD1052 10.183 14.741-55.688 1.0073.92 RNA2O ATOM 2788 O5* CD1052 9.194 14.690-57.976 1.0041.41 RNA2O ATOM 2789 C5* CD1052 9.295 16.081-58.307 1.0047.28 RNA2C ATOM 2790 C4* CD1052 8.298 16.442-59.376 1.0045.31 RNA2C ATOM 2791 O4* CD1052 8.683 15.855-60.645 1.0050.63 RNA2O ATOM 2792 C3* CD1052 6.892 15.933-59.137 1.0047.61 RNA2C ATOM 2793 O3* CD1052 6.174 16.759-58.247 1.0056.07 RNA2O ATOM 2794 C2* CD1052 6.301 15.896-60.540 1.0049.42 RNA2C ATOM 2795 O2* CD1052 5.816 17.144-60.990 1.0040.34 RNA2O ATOM 2796 CI* CD1052 7.518 15.487-61.371 1.0050.98 RNA2C ATOM 2797 NI CD1052 7.546 14.031-61.621 1.0053.95 RNA2N ATOM 2798 C2 CD1052 6.704 13.502-62.611 1.0053.59 RNA2C ATOM 2799 O2 CD1052 5.974 14.271-63.253 1.0052.10 RNA2O ATOM 2800 N3 CD1052 6.705 12.169-62.838 1.0059.04 RNA2N ATOM 2801 C4 CD1052 7.499 11.370-62.120 1.0065.70 RNA2C ATOM 2802 N4 CD1052 7.459 10.056-62.374 1.0066.17 RNA2N ATOM 2803 C5 CD1052 8.369 11.880-61.110 1.0059.37 RNA2C ATOM 2804 C6 CD1052 8.363 13.202-60.898 1.0055.97 RNA2C ATOM 2805 P UD1053 5.067 16.101-57.298 1.0063.43 RNA2P ATOM 2806 O1P UD1053 5.641 14.831-56.780 1.0062.31 RNA2O ATOM 2807 O2P UD1053 4.576 17.128-56.343 1.0074.13 RNA2O ATOM 2808 O5* UD1053 3.889 15.763-58.312 1.0057.11 RNA2O ATOM 2809 C5* UD1053 3.199 16.820-58.990 1.0048.12 RNA2C ATOM 2810 C4* UD1053 2.185 16.257-59.953 1.0050.31 RNA2C ATOM 2811 O4* UD1053 2.860 15.628-61.074 1.0049.75 RNA2O ATOM 2812 C3* UD1053 1.277 15.164-59.421 1.0050.89 RNA2C ATOM 2813 O3* UD1053 0.202 15.634-58.629 1.0056.33 RNA2O ATOM 2814 C2* UD1053 0.818 14.477-60.698 1.0050.72 RNA2C ATOM 2815 O2* UD1053 -0.225 15.175-61.357 1.0048.82 RNA2O ATOM 2816 CI* UD1053 2.091 14.528-61.540 1.0043.49 RNA2C ATOM 2817 NI UD1053 2.881 13.292-61.391 1.0042.34 RNA2N ATOM 2818 C2 UD1053 2.501 12.182-62.141 1.0040.65 RNA2C ATOM 2819 02 UD1053 1.564 12.193-62.926 1.0043.48 RNA2O ATOM 2820 N3 UD1053 3.258 11.057-61.935 1.0032.60 RNA2N ATOM 2821 C4 UD1053 4.329 10.920-61.079 1.0048.03 RNA2C ATOM 2822 04 UD1053 4.880 9.822-60.973 1.0058.30 RNA2O ATOM 2823 C5 UD1053 4.670 12.106-60.352 1.0043.77 RNA2C ATOM 2824 C6 UD1053 3.954 13.222-60.528 1.0044.26 RNA2C ATOM 2825 P i GD1054 -0.300 14.738-57.393 1.0063.07 RNA2P ATOM 2826 O1P GD1054 0.909 14.253-56.659 1.0056.57 RNA2O ATOM 2827 O2P GD1054 -1.342 15.504-56.670 1.0055.48 RNA2O ATOM 2828 05* GD1054 -0.993 13.484-58.088 1.0055.82 RNA2O ATOM 2829 C5* GD1054 -2.203 13.659-58.842 1.0063.34 RNA2C ATOM 2830 C4* GD1054 -2.607 12.376-59.540 1.0061.66 RNA2C ATOM 2831 04* GD1054 -1.612 11.993-60.529 1.0057.48 RNA2O ATOM 2832 C3* GD1054 -2.785 11.116-58.707 1.0058.52 RNA2C - 123- ATOM 283303* GD1054 -4.027 11.063-58.021 1.0050.20 RNA2O ATOM 2834 C2* GD1054 -2.702 10.021-59.766 1.0054.72 RNA2C ATOM 283502* GD1054 -3.915 9.849-60.469 1.0057.84 RNA2O ATOM 2836 CI* GD1054 -1.657 10.588-60.723 1.0042.15 RNA2C ATOM 2837 N9 GD1054 -0.347 10.004-60.453 1.0043.98 RNA2N ATOM 2838 C8 GD1054 0.686 10.525-59.707 1.0048.29 RNA2C ATOM 2839 N7 GD1054 1.715 9.721-59.624 1.0048.90 RNA2N ATOM 2840 C5 GD1054 1.340 8.607-60.367 1.0043.87 RNA2C ATOM 2841 C6 GD1054 2.037 7.396-60.634 1.0037.83 RNA2C ATOM 284206 GDI 054 3.167 7.050-60.252 1.0035.95 RNA2O ATOM 2843 NI GD1054 1.279 6.539-61.428 1.0042.56 RNA2N ATOM 2844 C2 GD1054 0.013 6.807-61.901 1.0045.28 RNA2C ATOM 2845 N2 GD1054 -0.567 5.854-62.647 1.0042.14 RNA2N ATOM 2846 N3 GD1054 -0.642 7.925-61.659 1.0040.97 RNA2N ATOM 2847 C4 GD1054 0.074 8.774-60.892 1.0045.06 RNA2C ATOM 2848 P ' GD1055 -4.174 10.115-56.729 1.0060.11 RNA2P ATOM 2849 O1P GD1055 -3.012 10.347-55.817 1.0052.31 RNA2O ATOM 2850 O2P GD1055 -5.562 10.287-56.226 1.0045.31 RNA2O ATOM 2851 05* GD1055 -4.016 8.633-57.297 1.0061.25 RNA2O ATOM 2852 C5* GD1055 -5.060 8.044-58.084 1.0049.39 RNA2C ATOM 2853 C4* GD1055 -4.631 6.705-58.643 1.0046.06 RNA2C ATOM 285404* GD1055 -3.395 6.848-59.392 1.0046.04 RNA2O ATOM 2855 C3* GD1055 -4.322 5.571-57.678 1.0046.58 RNA2C ATOM 2856 O3* GD1055 -5.478 4.904-57.197 1.0044.61 RNA2O ATOM 2857 C2* GD1055 -3.512 4.627-58.556 1.0050.61 RNA2C ATOM 2858 O2* GD1055 -4.337 3.844-59.397 1.0057.17 RNA2O ATOM 2859 CI* GD1055 -2.719 5.604-59.419 1.0037.93 RNA2C ATOM 2860 N9 GD1055 -1.364 5.764-58.905 1.0028.75 RNA2N ATOM 2861 C8 GD1055 -0.813 6.849-58.266 1.0028.74 RNA2C ATOM 2862 N7 GD1055 0.437 6.662-57.928 1.0031.82 RNA2N ATOM 2863 C5 GD1055 0.725 5.377-58.371 1.0024.53 RNA2C ATOM 2864 C6 GD1055 1.924 4.619-58.293 1.0028.90 RNA2C ATOM 286506 GD1055 3.010 4.943-57.807 1.0032.85 RNA2O ATOM 2866 NI GD1055 1.771 3.360-58.862 1.0026.15 RNA2N ATOM 2867 C2 GD1055 0.615 2.884-59.432 1.0032.58 RNA2C ATOM 2868 N2 GD1055 0.658 1.635-59.922 1.0028.69 RNA2N ATOM 2869 N3 GD1055 -0.505 3.580-59.514 1.0026.67 RNA2N ATOM 2870 C4 GD1055 -0.377 4.809-58.971 1.0028.85 RNA2C ATOM 2871 P i GD1056 -5.427 ' 1178-55.764 1.0041.37 RNA2P ATOM 2872 O1P GD1056 -5.088 5.212-54.752 1.0049.91 RNA2O ATOM 2873 O2P GD1056 -6.660 3.370-55.603 1.0041.24 RNA2O ATOM 287405* GD1056 -4.173 3.205-55.857 1.0031.72 RNA2O ATOM 2875 C5* GD1056 -4.288 1.915-56.458 1.0026.06 RNA2C ATOM 2876 C4* GD1056 -2.992 1.163-56.310 1.0030.23 RNA2C ATOM 287704* GD1056 -1.926 1.929-56.923 1.0033.12 RNA2O ATOM 2878 C3* GD1056 -2.520 0.944-54.886 1.0025.25 RNA2C ATOM 287903* GD1056 -3.091 -0.214-54.323 1.0032.82 RNA2O ATOM 2880 C2* GD1056 -1.015 0.792-55.044 1.0030.19 RNA2C ATOM 2881 O2* GD1056 -0.631 -0.515-55.418 1.0028.72 RNA2O ATOM 2882 CI* GD1056 -0.728 1.769-56.181 1.0029.85 RNA2C ATOM 2883 N9 GD1056 -0.326 3.081-55.682 1.0033.20 RNA2N - 124- SUBSTITUTE SHEET (RUUE2$ ATOM 2884 C8 GD1056 -1.142 4.165-55.453 1.0031.51 RNA2C ATOM 2885 N7 GD1056 -0.496 5.205-55.003 1.0040.50 RNA2N ATOM 2886 C5 GD1056 0.825 4.784-54.926 1.0037.25 RNA2C ATOM 2887 C6 GD1056 1.985 5.481-54.505 1.0045.50 RNA2C ATOM 288806 GD1056 2.078 6.654-54.106 1.0054.00 RNA2O ATOM 2889 NI GD1056 3.122 4.677-54.584 1.0042.27 RNA2N ATOM 2890 C2 GD1056 3.138 3.372-55.020 1.0038.28 RNA2C ATOM 2891 N2 GD1056 4.337 2.765-55.040 1.0033.41 RNA2N ATOM 2892 N3 GD1056 2.060 2.712-55.413 1.0035.91 RNA2N ATOM 2893 C4 GD1056 0.947 3.474-55.341 1.0031.74 RNA2C ATOM 2894 P AD1057 -3.445 - 0.241-52.765 1.0034.80 RNA2P ATOM 2895 O1P AD1057 -2.899 -1.503-52.213 1.0040.31 RNA2O ATOM 2896 O2P AD1057 -3.058 1.055-52.152 1.0039.35 RNA2O ATOM 289705* AD1057 -5.027 -0.331 -52.754 1.0019.58 RNA2O ATOM 2898 C5* AD1057 -5.823 0.724-53.304 1.0024.68 RNA2C ATOM 2899 C4* AD1057 -6.915 0.144-54.161 1.0026.68 RNA2C ATOM 2900 O4* AD1057 -6.359 -0.301-55.425 1.0040.11 RNA2O ATOM 2901 C3* AD1057 -7.560 -1.100-53.585 1.0030.27 RNA2C ATOM 2902 O3* AD1057 -8.559 -0.816-52.635 1.0035.52 RNA2O ATOM 2903 C2* AD1057 -8.090 -1.811 -54.820 1.0030.75 RNA2C ATOM 2904 O2* AD1057 -9.317 -1.270-55.268 1.0024.78 RNA2O ATOM 2905 CI* AD1057 -6.991 -1.506-55.834 1.0016.37 RNA2C ATOM 2906 N9 AD1057 -5.973 -2.559-55.883 1.0021.50 RNA2N ATOM 2907 C8 AD1057 -4.626 -2.445-55.613 1.0018.28 RNA2C ATOM 2908 N7 AD1057 -3.962 -3.566-55.754 1.0023.67 RNA2N ATOM 2909 C5 AD1057 -4.935 -4.484-56.140 1.0021.49 RNA2C ATOM 2910 C6 AD1057 -4.872 -5.852-56.447 1.0017.73 RNA2C ATOM 2911 N6 AD1057 -3.748 -6.569-56.412 1.0022.33 RNA2N ATOM 2912 NI AD1057 -6.019 -6.470-56.797 1.0029.29 RNA2N ATOM 2913 C2 AD1057 -7.150 -5.753-56.829 1.0030.01 RNA2C ATOM 2914 N3 AD1057 -7.337 -4.465-56.559 1.0024.69 RNA2N ATOM 2915 C4 AD1057 -6.177 -3.879-56.219 1.0018.45 RNA2C ATOM 2916 P UD1058 -8.746 - 1.807-51.399 1.0030.93 RNA2P ATOM 2917 O1P UD1058 -7.361 -2.213-50.993 1.0024.94 RNA2O ATOM 2918 O2P UD1058 -9.669 -1.203-50.402 1.0029.08 RNA2O ATOM 2919 O5* UD1058 -9.464 -3.068-52.042 1.0030.31 RNA2O ATOM 2920 C5* UD1058 -10.859 -3.043-52.331 1.0028.81 RNA2C ATOM 2921 C4* UD1058 -11.349 -4.440-52.592 1.0031.83 RNA2C ATOM 2922 O4* UD1058 -10.668 -4.953-53.765 1.0033.24 RNA2O ATOM 2923 C3* UD1058 -11.031 -5.471-51.520 1.0033.13 RNA2C ATOM 2924 O3* UD1058 -11.925 -5.479-50.425 1.0032.98 RNA2O ATOM 2925 C2* UD1058 -11.084 -6.772-52.299 1.0029.12 RNA2C ATOM 2926 O2* UD1058 -12.414 -7.204-52.513 1.0029.74 RNA2O ATOM 2927 CI* UD1058 -10.455 -6.348-53.622 1.0026.32 RNA2C ATOM 2928 NI UD1058 -9.008 -6.614-53.638 1.0021.34 RNA2N ATOM 2929 C2 UD1058 -8.608 -7.932-53.803 1.0024.87 RNA2C ATOM 2930 O2 UD1058 -9.402 -8.853 -53.938 1.0031.94 RNA2O ATOM 2931 N3 UD1058 -7.253 -8.136-53.799 1.008.92 RNA2N ATOM 2932 C4 UD1058 -6.273 -7.188-53.647 1.0022.44 RNA2C ATOM 2933 04 UD1058 -5.088 -7.533-53.685 1.0018.08 RNA2O ATOM 2934 C5 UD1058 -6.759 -5.848-53.482 1.0022.73 RNA2C -125- SUBSTITUTE SHEET (RϋJE26^ ATOM 2935 C6 UD1058 -8.080 -5.614-53.488 1.0018.95 RNA2C ATOM 2936 P GD1059 -11.432 ■ -6.089-49.022 1.0029.43 RNA2P ATOM 2937 O1P GD1059 -9.995 -5.757-48.812 1.0018.78 RNA2O ATOM 2938 O2P GD1059 -12.431 -5.724-47.993 1.0038.92 RNA2O ATOM 293905* GD1059 -11.490 -7.659-49.247 1.0034.42 RNA2O ATOM 2940 C5* GD1059 -12.729 -8.312-49.534 1.0029.33 RNA2C ATOM 2941 C4* GD1059 -12.525 -9.801 -49.573 1.0027.67 RNA2C ATOM 2942 O4* GD1059 -11.608 -10.126-50.645 1.0028.30 RNA2O ATOM 2943 C3* GD1059 -11.883 -10.411-48.339 1.0032.02 RNA2C ATOM 294403* GD1059 -12.840 -10.666-47.314 1.0037.54 RNA2O ATOM 2945 C2* GD1059 -11.260 -11.691-48.887 1.0027.34 RNA2C ATOM 2946 O2* GD1059 -12.207 -12.736-48.993 1.0021.26 RNA2O ATOM 2947 CI* GD1059 -10.838 -11.258-50.289 1.0018.26 RNA2C ATOM 2948 N9 GD1059 -9.425 - 10.920-50.414 1.0011.76 RNA2N ATOM 2949 C8 GD1059 -8.846 -9.686-50.262 1.0010.37 RNA2C ATOM 2950 N7 GD1059 -7.552 -9.700-50.455 1.0015.12 RNA2N ATOM 2951 C5 GD1059 -7.260 - 11.026-50.747 1.005.51 RNA2C ATOM 2952 C6 GD1059 -6.022 - 11.652-51.055 1.0015.78 RNA2C ATOM 2953 O6 GD1059 -4.892 - 11.145 -51.124 1.0017.40 RNA2O ATOM 2954 NI GD1059 -6.184- 13.009-51.300 1.0012.54 RNA2N ATOM 2955 C2 GD1059 -7.377 - 13.685-51.256 1.0023.87 RNA2C ATOM 2956 N2 GD1059 -7.326 - 14.997-51.540 1.0021.07 RNA2N ATOM 2957 N3 GD1059 -8.536- 13.119-50.962 1.0020.56 RNA2N ATOM 2958 C4 GD1059 -8.404 - 11.794-50.723 1.0017.53 RNA2C ATOM 2959 P UD1060 -12.363- 10.713-45.780 1.0031.30 RNA2P ATOM 2960 O1P UD1060 -13.473 -10.167-44.963 1.0029.83 RNA2O ATOM 2961 O2P UD1060 -11.840 -12.074-45.484 1.0037.29 RNA2O ATOM 2962 O5* UD1060 -11.129 -9.708-45.745 1.0025.29 RNA2O ATOM 2963 C5* UD1060 -10.735 -9.064-44.527 1.0022.54 RNA2C ATOM 2964 C4* UD1060 -9.378 -8.435-44.692 1.0022.65 RNA2C ATOM 296504* UD1060 -8.401 -9.481-44.882 1.0024.56 RNA2O ATOM 2966 C3* UD1060 -9.238 -7.481-45.870 1.0026.03 RNA2C ATOM 2967 O3* UD1060 -8.303 -6.454-45.522 1.0041.53 RNA2O ATOM 2968 C2* UD1060 -8.608 -8.361-46.946 1.0031.11 RNA2C ATOM 296902* UD1060 -7.808 -7.616-47.841 1.0045.38 RNA2O ATOM 2970 CI* UD1060 -7.735 -9.299-46.110 1.0026.61 RNA2C ATOM 2971 NI UD1060 -7.519- 10.632-46.690 1.0021.85 RNA2N ATOM 2972 C2 UD1060 -6.291 - 10.898-47.261 1.0023.55 RNA2C ATOM 2973 O2 UD1060 -5.402 - 10.063-47.355 1.0021.48 RNA2O ATOM 2974 N3 UD1060 -6.141 - 12.182-47.726 1.0025.97 RNA2N ATOM 2975 C4 UD1060 -7.076 - 13.199-47.691 1.0028.32 RNA2C ATOM 297604 UD1060 -6.778 - 14.311-48.139 1.0027.53 RNA2O ATOM 2977 C5 UD1060 -8.329 - 12.837-47.107 1.0018.41 RNA2C ATOM 2978 C6 UD1060 -8.507 - 11.600-46.642 1.0021.87 RNA2C ATOM 2979 P i UD1061 -8.630 -: 5.419-44.325 1.0028.91 RNA2P ATOM 2980 O1P UD1061 -8.173 -4.091-44.810 1.0033.68 RNA2O ATOM 2981 O2P UD1061 -10.037 -5.590-43.863 1.0015.62 RNA2O ATOM 298205* UD1061 -7.649 -5.888-43.161 1.0019.70 RNA2O ATOM 2983 C5* UD1061 -6.225 -5.745-43.301 1.0018.21 RNA2C ATOM 2984 C4* UD1061 -5.514 -6.526-42.225 1.0027.99 RNA2C ATOM 298504* UD1061 -5.894 -5.996-40.927 1.0036.85 RNA2O - 126- ATOM 2986 C3* UD1061 -5.800 -8.028-42.181 1.0029.80 RNA2C ATOM 298703* UD1061 -4.608 -8.696-41.772 1.0033.59 RNA2O ATOM 2988 C2* UD1061 -6.812 -8.151-41.043 1.0033.22 RNA2C ATOM 298902* UD1061 -6.748 -9.417-40.415 1.0027.78 RNA2O ATOM 2990 CI* UD1061 -6.313 -7.055-40.102 1.0042.74 RNA2C ATOM 2991 NI UD1061 -7.205 -6.543-39.046 1.0044.96 RNA2N ATOM 2992 C2 UD1061 -6.737 -6.649-37.742 1.0053.51 RNA2C ATOM 299302 UD1061 -5.650 -7.143-37.464 1.0044.65 RNA2O ATOM 2994 N3 UD1061 -7.579 -6.157-36.776 1.0060.76 RNA2N ATOM 2995 C4 UD1061 -8.811 -5.585-36.961 1.0051.80 RNA2C ATOM 299604 UD1061 -9.435 -5.195-35.977 1.0048.61 RNA2O ATOM 2997 C5 UD1061 -9.240 -5.508-38.333 1.0040.80 RNA2C ATOM 2998 C6 UD1061 -8.440 -5.979-39.307 1.0043.37 RNA2C ATOM 2999 P GD1062 -3.700 - 9.466-42.848 1.0033.56 RNA2P ATOM 3000 O1P GD1062 -3.835 -8.777-44.158 1.0035.31 RNA2O ATOM 3001 O2P GD1062 -2.353 -9.644-42.252 1.0021.04 RNA2O ATOM 3002 O5* GD1062 -4.367 -10.905-42.956 1.0030.74 RNA2O ATOM 3003 C5* GD1062 -5.563 -11.128-43.737 1.0036.95 RNA2C ATOM 3004 C4* GD1062 -5.583 -12.554-44.235 1.0030.45 RNA2C ATOM 3005 O4* GD1062 -4.531 -12.739-45.222 1.0026.47 RNA2O ATOM 3006 C3* GD1062 -5.264 -13.550-43.139 1.0020.89 RNA2C ATOM 3007 O3* GD1062 -6.428 -13.905-42.431 1.0031.67 RNA2O ATOM 3008 C2* GD1062 -4.625 -14.707-43.894 1.0023.56 RNA2C ATOM 3009 O2* GD1062 -5.589 -15.567-44.466 1.0018.76 RNA2O ATOM 3010 CI* GD1062 -3.854 -13.963-44.988 1.0016.90 RNA2C ATOM 3011 N9 GD1062 -2.473 - .13.642-44.620 1.0013.03 RNA2N ATOM 3012 C8 GD1062 -1.919- 12.387-44.523 1.0019.49 RNA2C ATOM 3013 N7 GD1062 -0.660 - ■12.404-44.173 1.0013.70 RNA2N ATOM 3014 C5 GD1062 -0.362 - .13.749-44.024 1.0014.04 RNA2C ATOM 3015 C6 GD1062 0.850- 14.379-43.651 1.0024.18 RNA2C ATOM 3016 O6 GD1062 1.933- 13.852-43.356 1.0029.04 RNA2O ATOM 3017 NI GD1062 0.723 - 15.765-43.634 1.0022.87 RNA2N ATOM 3018 C2 GD1062 -0.427 - ■16.456-43.927 1.0030.15 RNA2C ATOM 3019 N2 GD1062 -0.349 - ■17.795-43.849 1.0024.93 RNA2N ATOM 3020 N3 GD1062 -1.570- ■15.878-44.269 1.0030.88 RNA2N ATOM 3021 C4 GD1062 -1.466- ■14.531 -44.300 1.0016.88 RNA2C ATOM 3022 P i GD1063 -6.322 -1 14.242-40.874 1.0028.41 RNA2P ATOM 3023 O1P GD1063 -5.463 -13.199-40.266 1.0027.32 RNA2O ATOM 3024 O2P GD1063 -7.701 -14.468-40.367 1.0029.73 RNA2O ATOM 3025 O5* GD1063 -5.523 -15.617-40.821 1.0030.17 RNA2O ATOM 3026 C5* GD1063 -6.184 -16.864-41.087 1.0024.95 RNA2C ATOM 3027 C4* GD1063 -5.241 -18.011 -40.832 1.0020.87 RNA2C ATOM 3028 O4* GD1063 -4.075 -17.850-41.677 1.0027.19 RNA2O ATOM 3029 C3* GD1063 ' -4.659 -18.092-39.434 1.0026.89 RNA2C ATOM 3030 O3* GD1063 -5.539 -18.706-38.508 1.0040.50 RNA2O ATOM 3031 C2* GD1063 -3.373 -18.869-39.659 1.0023.40 RNA2C ATOM 3032 O2* GD1063 -3.601 -20.256-39.810 1.0029.18 RNA2O ATOM 3033 CI* GD1063 -2.919 -18.297-40.994 1.0021.30 RNA2C ATOM 3034 N9 GD1063 -2.022 - ■17.158-40.820 1.0018.48 RNA2N ATOM 3035 C8 GD1063 -2.309 - 15.827-41.016 1.0013.94 RNA2C ATOM 3036 N7 GD1063 -1.283- .15.044-40.798 1.0019.66 RNA2N - 127- SUBT ATOM 3037 C5 GD1063 -0.260 -15.909 -40.428 1.0017.05 RNA2C ATOM 3038 C6 GD1063 1.093 - ■ 15.646 -40.066 1.0024.81 RNA2C ATOM 3039 O6 GD1063 1.680 ■ -14.559-39.999 1.0027.63 RNA2O ATOM 3040 NI GD1063 1.776 ■ -16.819-39.756 1.0029.06 RNA2N ATOM 3041 C2 GD1063 1.234 - ■18.080-39.781 1.0024.76 RNA2C ATOM 3042 N2 GD1063 2.051 ■ -19.081 -39.433 1.0026.32 RNA2N ATOM 3043 N3 GD1063 -0.018 -18.340-40.119 1.0025.89 RNA2N ATOM 3044 C4 GD1063 -0.702 ■ -17.217-40.429 1.0024.85 RNA2C ATOM 3045 P CD1064 -5.606 -: 18.145-37.003 1 1.0033.12 RNA2P ATOM 3046 O1P CD1064 -5.740 -16.669 -37.090 1.0033.72 RNA2O ATOM 3047 O2P CD1064 -6.628 -18.934-36.261 1.0034.10 RNA2O ATOM 3048 O5* C D1064 -4.159 -18.476-36.424 1.0027.13 RNA2O ATOM 3049 C5* CD1064 -3.695 -19.826 -36.395 1.0016.79 RNA2C ATOM 3050 C4* CD1064 -2.235 -19.884-36.032 1.0025.70 RNA2C ATOM 3051 O4* CD1064 -1.436 -19.190-37.022 1.0029.89 RNA2O ATOM 3052 C3* CD1064 -1.813 -19.250 -34.720 1.0029.70 RNA2C ATOM 3053 O3* CD1064 -2.095 -20.085-33.611 1.0037.04 RNA2O ATOM 3054 C2* CD1064 -0.315 -19.047 -34.923 1.0030.06 RNA2C ATOM 3055 O2* CD1064 0.445 -20.216 -34.696 1.0028.38 RNA2O ATOM 3056 CI* CD1064 -0.251 -18.704-36.409 1.0030.33 RNA2C ATOM 3057 NI CD1064 -0.140- -17.251 -36.627 1.0020.71 RNA2N ATOM 3058 C2 CD1064 1.114- 16.655 -36.474 1.0024.44 RNA2C ATOM 3059 O2 CD1064 2.086 - 17.365 -36.175 1.0030.49 RNA2O ATOM 3060 N3 CD1064 1.237- ■ 15.325 -36.654 1.0026.69 RNA2N ATOM 3061 C4 CD1064 0.170- 14.591 -36.976 1.0020.50 RNA2C ATOM 3062 N4 CD1064 0.347 - ■ 13.279-37.141 1.0022.60 RNA2N ATOM 3063 C5 CD1064 -1.120- ■15.169-37.143 1.0010.11 RNA2C ATOM 3064 C6 CD1064 -1.229- ■ 16.492 -36.962 1.0023.85 RNA2C ATOM 3065 P UD1065 -2.513- 19.420-32.214 : 1.0035.56 RNA2P ATOM 3066 O1P UD1065 -3.615 -18.460-32.467 1.0026.06 RNA2O ATOM 3067 O2P UD1065 -2.716 -20.527-31.248 1.0043.50 RNA2O ATOM 3068 O5* UD1065 -1.209 -18.600-31.807 1.0027.70 RNA2O ATOM 3069 C5* UD1065 0.044 -19.282-31.609 1.0030.92 RNA2C ATOM 3070 C4* UD1065 1.168 -18.287-31.469 1.0030.67 RNA2C ATOM 3071 O4* UD1065 1.332 -17.559-32.713 1.0039.57 RNA2O ATOM 3072 C3* UD1065 0.951 -17.209 -30.423 1.0036.18 RNA2C ATOM 3073 O3* UD1065 1.285 -17.667-29.123 1.0036.24 RNA2O ATOM 3074 C2* UD1065 1.843 -16.076 -30.921 1.0038.21 RNA2C ATOM 3075 O2* UD1065 3.207 -16.224 -30.578 1.0034.14 RNA2O ATOM 3076 CI* UD1065 1.692 -16.216-32.437 1.0034.96 RNA2C ATOM 3077 NI UD1065 0.645 - ■ 15.327-32.968 1.0022.93 RNA2N ATOM 3078 C2 UD1065 1.028- 14.066-33.377 1.0024.04 RNA2C ATOM 3079 O2 UD1065 2.187- ■ 13.674-33.325 1.0020.47 RNA2O ATOM 3080 N3 UD1065 0.008 - ■ 13.276-33.849 1.0017.91 RNA2N ATOM 3081 C4 UD1065 -1.325- -13.612-33.954 1.0025.02 RNA2C ATOM 3082 O4 UD1065 -2.125 • -12.793 -34.424 1.0030.88 RNA2O ATOM 3083 C5 UD1065 -1.640- -14.934-33.511 1.0026.71 RNA2C ATOM 3084 C6 UD1065 -0.670 - ■ 15.727-33.046 1.0028.23 RNA2C ATOM 3085 P UD1066 0.342 -] 17.279-27.876 1.0035.54 RNA2P ATOM 3086 O1P UD1066 -1.089 -17.498-28.212 1.0019.51 RNA2O ATOM 3087 O2P UD1066 0.927 -17.960-26.692 1.0043.24 RNA2O — -128- ATOM 3088 O5* UD1066 0.552 -15.708-27.728 1.0032.79 RNA2O ATOM 3089 C5* UD1066 1.867 -15.163-27.509 1.0039.57 RNA2C ATOM 3090 C4* UD1066 1.853 -13.664-27.695 1.0041.26 RNA2C ATOM 3091 04* UD1066 1.606 -13.339-29.088 1.0050.01 RNA2O ATOM 3092 C3* UD1066 0.773 -12.909 -26.935 1.0046.81 RNA2C ATOM 3093 O3* UD1066 1.137 -12.653 -25.587 1.0047.16 RNA2O ATOM 3094 C2* UD1066 0.645 -11.626-27.743 1.0045.38 RNA2C ATOM 3095 O2* UD1066 1.671 -10.702 -27.422 1.0047.24 RNA2O ATOM 3096 CI* UD1066 0.848 -12.142-29.168 1.0044.66 RNA2C ATOM 3097 NI UD1066 -0.437 - -12.423 -29.835 1.0036.02 RNA2N ATOM 3098 C2 UD1066 -1.001- 11.401 -30.583 1.0031.01 RNA2C ATOM 3099 O2 UD1066 -0.450 - ■10.325 -30.752 1.0024.12 RNA2O ATOM 3100 N3 UD1066 -2.231 - ■11.687-31.131 1.0026.04 RNA2N ATOM 3101 C4 UD1066 -2.939 - ■ 12.872-31.028 1.0032.10 RNA2C ATOM 3102 O4 UD1066 -4.082 - ■12.941 -31.501 1.0032.26 RNA2O ATOM 3103 C5 UD1066 -2.276 - •13.895 -30.271 1.0027.27 RNA2C ATOM 3104 C6 UD1066 -1.080- ■13.644-29.712 1.0035.51 RNA2C ATOM 3105 P AD1067 0.011-12.695-24.442 1 1.0041.56 RNA2P ATOM 3106 O1P AD1067 -0.869 -13.868-24.667 1.0035.90 RNA2O ATOM 3107 O2P AD1067 0.710 -12.532-23.138 1.0061.37 RNA2O ATOM 3108 O5* AD1067 -0.877 -11.403-24.702 1.0037.80 RNA2O ATOM 3109 C5* AD1067 -2.175 -11.275-24.099 1.0033.78 RNA2C ATOM 3110 C4* AD1067 -2.689 -9.870 -24.284 1.0040.27 RNA2C ATOM 3111 O4* AD1067 -1.791 -8.952-23.617 1.0040.68 RNA2O ATOM 3112 C3* AD1067 -2.714 -9.402 -25.727 1.0040.11 RNA2C ATOM 3113 O3* AD1067 -3.918 -9.794 -26.362 1.0046.79 RNA2O ATOM 3114 C2* AD1067 -2.560 -7.892 -25.606 1.0033.18 RNA2C ATOM 3115 O2* AD1067 -3.785 -7.245-25.315 1.0034.55 RNA2O ATOM 3116 CI* AD1067 -1.637 -7.782 -24.394 1.0030.38 RNA2C ATOM 3117 N9 AD1067 -0.216 -7.636 -24.699 1.0018.52 RNA2N ATOM 3118 C8 AD1067 0.791 ■ -8.539 -24.462 1.0019.03 RNA2C ATOM 3119 N7 AD1067 1.987 -8.090 -24.769 1.0023.17 RNA2N ATOM 3120 C5 AD1067 1.748 ■ -6.814-25.262 1.0012.64 RNA2C ATOM 3121 C6 AD1067 2.605 ■ -5.811-25.748 1.0016.33 RNA2C ATOM 3122 N6 AD1067 3.934 -5.945-25.831 1.0021.10 RNA2N ATOM 3123 NI AD1067 2.046 -4.651 -26.154 1.0017.93 RNA2N ATOM 3124 C2 AD1067 0.714 • -4.518-26.077 1.0024.51 RNA2C ATOM 3125 N3 AD1067 -0.197 -5.388 -25.642 1.0023.41 RNA2N ATOM 3126 C4 AD1067 0.393 ■ -6.528-25.240 1.0022.32 RNA2C ATOM 3127 P 1 GD1068 -3.863-10.352-27.861 : 1.0037.45 RNA2P ATOM 3128 O1P GD1068 -2.775 -11.365-27.915 1.0032.87 RNA2O ATOM 3129 O2P GD1068 -5.247 -10.719-28.265 1.0030.61 RNA2O ATOM 3130 O5* GD1068 -3.399 -9.084 -28.697 1.0034.59 RNA2O ATOM 3131 C5* GD1068 -4.254 -7.938 -28.794 1.0032.91 RNA2C ATOM 3132 C4* GD1068 -3.550 -6.828 -29.521 1.0039.65 RNA2C ATOM 3133 O4* GD1068 -2.460 -6.334 -28.708 1.0034.36 RNA2O ATOM 3134 C3* GD1068 -2.908 -7.218 -30.840 1.0041.96 RNA2C ATOM 3135 O3* GD1068 -3.874 -7.194-31.893 1.0038.73 RNA2O ATOM 3136 C2* GD1068 -1.811 -6.168-30.989 1.0037.55 RNA2C ATOM 3137 O2* GD1068 -2.315 -4.944-31.487 1.0054.39 RNA2O ATOM 3138 CI* GD1068 -1.382 -5.951 -29.535 1.0022.83 RNA2C - - 129- SUBSTITUTE SHEET ATOM 3139 N9 GD1068 -0.226 -6.739-29.134 1.0020.42 RNA2N ATOM 3140 C8 GD1068 -0.246 -8.011-28.616 1.0022.08 RNA2C ATOM 3141 N7 GD1068 0.944 -8.464-28.328 1.0022.50 RNA2N ATOM 3142 C5 GD1068 1.803 -7.433-28.683 1.0010.90 RNA2C ATOM 3143 C6 GD1068 3.211 -7.347-28.595 1.0018.64 RNA2C ATOM 314406 GD1068 4.011 -8.196-28.176 1.0032.91 RNA2O ATOM 3145 NI GD1068 3.679 -6.123-29.060 1.0012.16 RNA2N ATOM 3146 C2 GD1068 2.894 -5.115-29.547 1.0013.74 RNA2C ATOM 3147 N2 GD1068 3.543 -4.013-29.960 1.0020.53 RNA2N ATOM 3148 N3 GD1068 1.575 -5.179-29.629 1.0016.63 RNA2N ATOM 3149 C4 GD1068 1.100 -6.360-29.184 1.0016.14 RNA2C ATOM 3150 P AD1069 -3.995 - 8.447-32.902 1.0027.21 RNA2P ATOM 3151 O1P AD1069 -4.082 -9.718-32.124 1.0034.28 RNA2O ATOM 3152 O2P AD1069 -5.070 -8.102-33.864 1.0029.02 RNA2O ATOM 3153 O5* AD1069 -2.601 -8.445 -33.661 1.0013.61 RNA2O ATOM 3154 C5* AD1069 -2.231 -7.337-34.472 1.0012.04 RNA2C ATOM 3155 C4* AD1069 -0.867 -7.557-35.055 1.0021.87 RNA2C ATOM 3156 O4* AD1069 0.149 -7.322-34.046 1.0032.63 RNA2O ATOM 3157 C3* AD1069 -0.590 -8.954-35.628 1.0035.90 RNA2C ATOM 3158 O3* AD1069 0.162 -8.819-36.833 1.0043.63 RNA2O ATOM 3159 C2* AD1069 0.352 -9.560-34.592 1.0035.57 RNA2C ATOM 3160 O2* AD1069 1.241 -10.526-35.127 1.0044.23 RNA2O ATOM 3161 CI* AD1069 1.127 -8.311-34.199 1.0042.00 RNA2C ATOM 3162 N9 AD1069 2.031 -8.358-33.054 1.0038.32 RNA2N ATOM 3163 C8 AD1069 2.071 -9.207-31.976 1.0030.76 RNA2C ATOM 3164 N7 AD1069 3.141 -9.059-31.233 1.0035.91 RNA2N ATOM 3165 C5 AD1069 3.827 -8.017-31.841 1.0033.30 RNA2C ATOM 3166 C6 AD1069 5.053 -7.392-31.552 1.0039.74 RNA2C ATOM 3167 N6 AD1069 5.850 -7.751-30.540 1.0050.68 RNA2N ATOM 3168 NI AD1069 5.443 -6.375-32.353 1.0041.06 RNA2N ATOM 3169 C2 AD1069 4.649 -6.022-33.371 1.0043.25 RNA2C ATOM 3170 N3 AD1069 3.483 -6.540-33.747 1.0036.03 RNA2N ATOM 3171 C4 AD1069 3.131 -7.548-32.935 1.0031.57 RNA2C ATOM 3172 P AD1070 -0.353 - 9.514-38.183 1.0039.29 RNA2P ATOM 3173 O1P AD1070 0.847 -9.589-39.057 1.0023.58 RNA2O ATOM 3174 O2P AD1070 -1.128 -10.747-37.873 1.0027.46 RNA2O ATOM 3175 O5* AD1070 -1.376 -8.452-38.783 1.0032.87 RNA2O ATOM 3176 C5* AD1070 -0.906 -7.233-39.388 1.0032.49 RNA2C ATOM 3177 C4* AD1070 -2.018 -6.594-40.179 1.0035.94 RNA2C ATOM 3178 O4* AD1070 -3.134 -6.304-39.296 1.0034.73 RNA2O ATOM 3179 C3* AD1070 -1.665 -5.292-40.885 1.0039.27 RNA2C ATOM 318003* AD1070 -2.329 -5.275-42.147 1.0042.75 RNA2O ATOM 3181 C2* AD1070 -2.248 -4.225-39.960 1.0039.48 RNA2C ATOM 318202* AD1070 -2.656 -3.052-40.635 1.0046.91 RNA2O ATOM 3183 CI* AD1070 -3.468 -4.935-39.379 1.0038.47 RNA2C ATOM 3184 N9 AD1070 -3.821 -4.467-38.038 1.0042.60 RNA2N ATOM 3185 C8 AD1070 -3.112 -4.646-36.878 1.0043.81 RNA2C ATOM 3186 N7 AD1070 -3.690 -4.133-35.822 1.0045.93 RNA2N ATOM 3187 C5 AD1070 -4.854 -3.570-36.318 1.0044.50 RNA2C ATOM 3188 C6 AD1070 -5.898 -2.873-35.697 1.0050.91 RNA2C ATOM 3189 N6 AD1070 -5.936 -2.617-34.390 1.0062.29 RNA2N ~ -130- SUBSTΪT ATOM 3190 NI AD1070 -6.915 -2.441-36.474 1.0049.05 RNA2N ATOM 3191 C2 AD1070 -6.870 -2.698-37.783 1.0037.67 RNA2C ATOM 3192 N3 AD1070 -5.940 -3.344-38.485 1.0040.26 RNA2N ATOM 3193 C4 AD1070 -4.946 -3.761-37.683 1.0042.22 RNA2C ATOM 3194 P GD1071 -1.684 - 4.476-43.382 1.0030.55 RNA2P ATOM 3195 O1P GD1071 -2.623 -4.642-44.520 1.0033.24 RNA2O ATOM 3196 O2P GD1071 -1.310 -3.114-42.932 1.0042.96 RNA2O ATOM 319705* GD1071 -0.331 -5.246-43.697 1.0021.65 RNA2O ATOM 3198 C5* GD1071 -0.333 -6.592-44.214 1.0029.38 RNA2C ATOM 3199 C4* GD1071 1.026 -6.907-44.779 1.0023.80 RNA2C ATOM 3200 O4* GD1071 1.238 -6.061-45.928 1.0028.20 RNA2O ATOM 3201 C3* GD1071 2.141 -6.557-43.811 1.0030.81 RNA2C ATOM 3202 O3* GD1071 2.441 -7.666-42.979 1.0041.31 RNA2O ATOM 3203 C2* GD1071 3.288 -6.132-44.719 1.0022.22 RNA2C ATOM 3204 O2* GD1071 4.080 -7.199-45.191 1.0028.60 RNA2O ATOM 3205 CI* GD1071 2.532 -5.498-45.883 1.0021.88 RNA2C ATOM 3206 N9 GD1071 2.369 -4.053-45.773 1.0020.68 RNA2N ATOM 3207 C8 GD1071 1.186 -3.366-45.636 1.0017.70 RNA2C ATOM 3208 N7 GD1071 1.347 -2.072-45.623 1.0024.21 RNA2N ATOM 3209 C5 GD1071 2.716 -1.895-45.742 1.0013.42 RNA2C ATOM 3210 C6 GD1071 3.478 -0.710-45.794 1.0024.45 RNA2C ATOM 3211 O6 GD1071 3.078 0.460-45.758 1.0034.15 RNA2O ATOM 3212 NI GD1071 4.841 -0.981 -45.904 1.0015.33 RNA2N ATOM 3213 C2 GD1071 5.395 -2.241-45.961 1.0023.28 RNA2C ATOM 3214 N2 GD1071 6.734 -2.306-46.052 1.0012.46 RNA2N ATOM 3215 N3 GD1071 4.686 -3.356-45.925 1.0019.68 RNA2N ATOM 3216 C4 GD1071 3.363 -3.109-45.817 1.0012.68 RNA2C ATOM 3217 P ■ CD1072 2.695 - ' 7.430-41.419 1.0033.36 RNA2P ATOM 3218 O1P CD1072 1.653 -6.490-40.920 1.0033.81 RNA2O ATOM 3219 O2P CD1072 2.864 -8.759-40.777 1.0035.75 RNA2O ATOM 3220 O5* CD1072 4.090 -6.677-41.393 1.0020.85 RNA2O ATOM 3221 C5* CD1072 5.294 -7.370-41.724 1.0018.04 RNA2C ATOM 3222 C4* CD1072 6.458 -6.420-41.676 1.0027.13 RNA2C ATOM 3223 O4* CD1072 6.309 -5.437-42.729 1.0037.39 RNA2O ATOM 3224 C3* CD1072 6.577 -5.591-40.408 1.0033.89 RNA2C ATOM 3225 O3* CD1072 7.216 -6.295-39.352 1.0027.21 RNA2O ATOM 3226 C2* CD1072 7.364 -4.376-40.882 1.0036.24 RNA2C ATOM 3227 O2* CD1072 8.753 -4.637-40.967 1.0040.82 RNA2O ATOM 3228 CI* CD1072 6.803 -4.182-42.291 1.0032.40 RNA2C ATOM 3229 NI CD1072 5.704 -3.196-42.347 1.0021.10 RNA2N ATOM 3230 C2 CD1072 6.015 ■ -1.860-42.594 1.0022.51 RNA2C ATOM 3231 O2 CD1072 7.206 -1.541-42.755 1.0032.30 RNA2O ATOM 3232 N3 CD1072 5.016 -0.947-42.647 1.0018.99 RNA2N ATOM 3233 C4 CD1072 3.750 ■ -1.327-42.456 1.0023.03 RNA2C ATOM 3234 N4 CD1072 2.795 -0.389-42.506 1.0021.64 RNA2N ATOM 3235 C5 CD1072 3.405 ■ -2.681 -42.204 1.0018.92 RNA2C ATOM 3236 C6 CD1072 4.404 ■ -3.575-42.160 1.0022.99 RNA2C ATOM 3237 P . AD1073 6.502 -i 6.360-37.915 1.0037.37 RNA2P ATOM 3238 O1P AD1073 6.300 -4.954-37.487 1.0030.80 RNA2O ATOM 3239 O2P AD1073 5.328 -7.287-37.972 1.0026.29 RNA2O ATOM 3240 O5* AD1073 7.614 -6.996-36.980 1.0033.33 RNA2O 1 - 131- SUBSTITUTE SHEET RULE26 ATOM 3241 C5* AD1073 8.842 -6.293-36.711 1.0045.87 RNA2C ATOM 3242 C4* AD1073 9.614 -7.024-35.651 1.0039.23 RNA2C ATOM 3243 O4* AD1073 8.804 -7.060-34.451 1.0042.33 RNA2O ATOM 3244 C3* AD1073 9.847 -8.484-35.996 1.0042.31 RNA2C ATOM 3245 O3* AD1073 11.022 -8.666-36.753 1.0046.57 RNA2O ATOM 3246 C2* AD1073 9.902 -9.161-34.638 1.0040.15 RNA2C ATOM 3247 O2* AD1073 11.169 -9.047-34.018 1.0050.42 RNA2O ATOM 3248 CI* AD1073 8.866 -8.350-33.866 1.0029.91 RNA2C ATOM 3249 N9 AD1073 7.532 -8.935-33.963 1.0024.96 RNA2N ATOM 3250 C8 AD1073 6.453 -8.438-34.648 1.0025.01 RNA2C ATOM 3251 N7 AD1073 5.373 -9.170-34.534 1.0031.09 RNA2N ATOM 3252 C5 AD1073 5.770 - 10.224-33.727 1.0016.48 RNA2C ATOM 3253 C6 AD1073 5.085 - 11.338 -33.237 1.0025.59 RNA2C ATOM 3254 N6 AD1073 3.804 - -11.589 -33.504 1.0028.23 RNA2N ATOM 3255 NI AD1073 5.765 - ■12.201 -32.456 1.0025.23 RNA2N ATOM 3256 C2 AD1073 7.053 - ■ 11.951 -32.200 1.0027.30 RNA2C ATOM 3257 N3 AD1073 7.811- ■10.937-32.608 1.0031.09 RNA2N ATOM 3258 C4 AD1073 7.099 - 10.097-33.375 1.0027.01 RNA2C ATOM 3259 P GD1074 11.030 ■ -9.753-37.924 1.0043.98 RNA2P ATOM 3260 O1P GD1074 9.978 -9.343-38.892 1.0047.14 RNA2O ATOM 3261 O2P GD1074 12.435 < -9.917-38.384 1.0036.10 RNA2O ATOM 3262 O5* GD1074 10.556 -11.084-37.192 1.0030.43 RNA2O ATOM 3263 C5* GD1074 11.408 -11.715-36.230 1.0029.08 RNA2C ATOM 3264 C4* GD1074 10.753 -12.951-35.675 1.0027.13 RNA2C ATOM 3265 O4* GD1074 9.559 -12.586-34.940 1.0025.79 RNA2O ATOM 3266 C3* GD1074 10.260 -13.964-36.689 1.0034.21 RNA2C ATOM 3267 O3* GD1074 11.289 -14.803-37.175 1.0042.20 RNA2O ATOM 3268 C2* GD1074 9.202 -14.730-35.908 1.0033.31 RNA2C ATOM 3269 02* GD1074 9.747 -15.738-35.080 1.0037.22 RNA2O ATOM 3270 CI* GD1074 8.598 -13.621 -35.049 1.0021.21 RNA2C ATOM 3271 N9 GD1074 7.387 - ■13.070-35.648 1.0027.34 RNA2N ATOM 3272 C8 GD1074 7.235 - 11.852-36.268 1.0027.08 RNA2C ATOM 3273 N7 GD1074 6.017- ■11.640-36.688 1.0025.47 RNA2N ATOM 3274 C5 GD1074 5.325 - 12.787-36.327 1.0019.99 RNA2C ATOM 3275 C6 GD1074 3.966 - 13.130 -36.504 1.0030.58 RNA2C ATOM 3276 06 GD1074 3.063 - 12.460-37.021 1.0035.90 RNA2O ATOM 3277 NI GD1074 3.687 - 14.396-35.992 1.0036.16 RNA2N ATOM 3278 C2 GD1074 4.597 - 15.219 -35.379 1.0034.56 RNA2C ATOM 3279 N2 GD1074 4.134- ■16.400-34.936 1.0034.63 RNA2N ATOM 3280 N3 GD1074 5.868 - 14.906-35.205 1.0031.20 RNA2N ATOM 3281 C4 GD1074 6.159- 13.683-35.695 1.0023.24 RNA2C ATOM 3282 P i CD1075 11.130- 15.471 -38.624 1.0045.43 RNA2P ATOM 3283 O1P CD1075 10.527 -14.447-39.520 1.0054.78 RNA2O ATOM 3284 O2P CD1075 12.430 -16.096-38.995 1.0041.18 RNA2O ATOM 3285 05* CD1075 10.046 -16.607-38.379 1.0033.77 RNA2O ATOM 3286 C5* CD1075 10.384 -17.767-37.609 1.0031.73 RNA2C ATOM 3287 C4* CD1075 9.233 ■ -18.737-37.587 1.0031.50 RNA2C ATOM 3288 04* CD1075 8.122 -18.137-36.879 1.0031.95 RNA2O ATOM 3289 C3* CD1075 8.653 ■ -19.112-38.940 1.0034.59 RNA2C ATOM 3290 03* CD1075 9.390 -20.130-39.596 1.0042.98 RNA2O ATOM 3291 C2* CD1075 7.239 • -19.539-38.581 1.0030.88 RNA2C -132- ATOM 3292 O2* CD1075 7.175 -20.852 -38.064 1.0024.97 RNA2O ATOM 3293 CI* CD1075 6.902 -18.546 -37.472 1.0031.01 RNA2C ATOM 3294 NI CD1075 6.223 • -17.355-38.013 1.0026.90 RNA2N ATOM 3295 C2 CD1075 4.831 ■ -17.388-38.173 1.0032.07 RNA2C ATOM 3296 O2 CD1075 4.206 • -18.407-37.825 1.0031.32 RNA2O ATOM 3297 N3 CD1075 4.204 • -16.313-38.700 1.0031.52 RNA2N ATOM 3298 C4 CD1075 4.908 - ■15.237-39.059 1.0024.70 RNA2C ATOM 3299 N4 CD1075 4.246 ■ -14.208-39.592 1.0023.21 RNA2N ATOM 3300 C5 CD1075 6.320 - ■15.169-38.892 1.0020.78 RNA2C ATOM 3301 C6 CD1075 6.932 - ■16.239-38.370 1.0026.55 RNA2C ATOM 3302 P CD1076 9.458-20.140-41.200 1 [.0041.54 RNA2P ATOM 3303 O1P CD1076 9.719 -18.749-41.663 1.0042.90 RNA2O ATOM 3304 O2P CD1076 10.362 i -21.241 -41.62. ! 1.0043.49 RNA2O ATOM 3305 O5* CD1076 7.973 -20.524-41.614 1.0036.12 RNA2O ATOM 3306 C5* CD1076 7.448 -21.808-41.272 1.0035.93 RNA2C ATOM 3307 C4* CD1076 6.024 -21.941 -41.742 1.0036.70 RNA2C ATOM 3308 04* CD1076 5.179 -21.022-41.003 1.0041.67 RNA2O ATOM 3309 C3* CD1076 5.735 -21.611-43.198 1.0033.47 RNA2C ATOM 3310 O3* CD1076 6.076 -22.654 -44.099 1.0041.74 RNA2O ATOM 3311 C2* CD1076 4.240 -21.334-43.160 1.0038.53 RNA2C ATOM 3312 O2* CD1076 3.483 -22.530-43.103 1.0031.60 RNA2O ATOM 3313 CI* CD1076 4.107 -20.590-41.831 1.0039.34 RNA2C ATOM 3314 NI CD1076 4.199- -19.124-42.018 1.0025.11 RNA2N ATOM 3315 C2 CD1076 3.048 - •18.421 -42.397 1.0028.28 RNA2C ATOM 3316 O2 CD1076 1.978- -19.045 -42.536 1.0022.07 RNA2O ATOM 3317 N3 CD1076 3.127- -17.083 -42.605 1.0027.17 RNA2N ATOM 3318 C4 CD1076 4.293 - •16.452-42.451 1.0027.03 RNA2C ATOM 3319 N4 CD1076 4.330- -15.136-42.681 1.0024.90 RNA2N ATOM 3320 C5 CD1076 5.475 - •17.140-42.056 1.0021.98 RNA2C ATOM 3321 C6 CD1076 5.384- •18.460-41.849 1.0026.59 RNA2C ATOM 3322 P AD1077 6.603 -22.281 -45.575 1 1.0039.40 RNA2P ATOM 3323 O1P AD1077 7.618 -21.198-45.455 1.0025.39 RNA2O ATOM 3324 O2P AD1077 6.965 -23.549 -46.255 1.0045.75 RNA2O ATOM 3325 O5* AD1077 5.308 -21.688-46.290 1.0035.32 RNA2O ATOM 3326 C5* AD1077 4.132 -22.496 -46.434 1.0030.36 RNA2C ATOM 3327 C4* AD1077 2.948 -21.659-46.863 1.0039.87 RNA2C ATOM 3328 O4* AD1077 2.657 -20.660 -45.852 1.0036.52 RNA2O ATOM 3329 C3* AD1077 3.067 -20.856-48.149 1.0035.06 RNA2C ATOM 3330 03* AD1077 2.842 -21.640-49.313 1.0033.77 RNA2O ATOM 3331 C2* AD1077 1.981 -19.801 -47.965 1.0041.16 RNA2C ATOM 3332 02* AD1077 0.677 -20.271 -48.264 1.0033.46 RNA2O ATOM 3333 CI* AD1077 2.078 -19.520 -46.466 1.0037.76 RNA2C ATOM 3334 N9 AD1077 2.924 ■ -18.352-46.211 1.0025.78 RNA2N ATOM 3335 C8 AD1077 4.243 - ■18.300-45.836 1.0018.19 RNA2C ATOM 3336 N7 AD1077 4.722 ■ -17.081 -45.756 1.0017.18 RNA2N ATOM 3337 C5 AD1077 3.639- ■16.275 -46.087 1.0018.35 RNA2C ATOM 3338 C6 AD1077 3.492 - .14.874 -46.208 1.0024.31 RNA2C ATOM 3339 N6 AD1077 4.486 ■ -13.996 -46.008 1.0025.10 RNA2N ATOM 3340 NI AD1077 2.277 ■ .14.401 -46.558 1.0022.28 RNA2N ATOM 3341 C2 AD1077 1.285 - •15.278-46.776 1.0017.11 RNA2C ATOM 3342 N3 AD1077 1.302- -16.604 -46.702 1.0022.31 RNA2N - - 133- ATOM 3343 C4 AD1077 2.522 - .17.044 -46.352 1.0017.88 RNA2C ATOM 3344 P UD1078 3.650-21.306-50.662 1 .0027.11 RNA2P ATOM 3345 O1P UD1078 5.104 -21.343 -50.374 1.0020.77 RNA2O ATOM 3346 O2P UD1078 3.091 -22.176-51.728 1.0043.45 RNA2O ATOM 3347 O5* UD1078 3.288 -19.785 -50.981 1.0030.32 RNA2O ATOM 3348 C5* UD1078 1.985 -19.408-51.478 1.0030.56 RNA2C ATOM 3349 C4* UD1078 1.896 -17.901-51.631 1.0032.53 RNA2C ATOM 3350 O4* UD1078 2.062 -17.283 -50.329 1.0027.97 RNA2O ATOM 3351 C3* UD1078 2.967 -17.244 -52.497 1.0036.01 RNA2C ATOM 3352 O3* UD1078 2.620 -17.183-53.871 1.0042.75 RNA2O ATOM 3353 C2* UD1078 2.990 -15.821-51.961 1.0036.74 RNA2C ATOM 3354 O2* UD1078 1.935 -15.045 -52.493 1.0040.26 RNA2O ATOM 3355 CI* UD1078 2.744 -16.048-50.472 1.0035.91 RNA2C ATOM 3356 NI UD1078 4.015- •16.102-49.729 1.0025.89 RNA2N ATOM 3357 C2 UD1078 4.637 - 14.892-49.423 1.0035.33 RNA2C ATOM 3358 O2 UD1078 4.167- ■ 13.800 -49.730 1.0030.93 RNA2O ATOM 3359 N3 UD1078 5.830- ■15.008-48.749 1.0028.65 RNA2N ATOM 3360 C4 UD1078 6.455 - 16.177-48.357 1.0030.34 RNA2C ATOM 3361 O4 UD1078 7.555- 16.119-47.795 1.0039.15 RNA2O ATOM 3362 C5 UD1078 5.749 - 17.376 -48.699 1.0025.89 RNA2C ATOM 3363 C6 UD1078 4.584 - 17.300 -49.355 1.0028.67 RNA2C ATOM 3364 P ' CD1079 2.674-18.503-54.775 1.0037.89 RNA2P ATOM 3365 O1P CD1079 2.944 -18.013-56.153 1.0039.80 RNA2O ATOM 3366 O2P CD1079 3.558 -19.539-54.176 1.0037.02 RNA2O ATOM 3367 05* CD1079 1.167 -18.996-54.704 1.0015.08 RNA2O ATOM 3368 C5* CD1079 0.145 -18.192-55.288 1.0023.37 RNA2C ATOM 3369 C4* CD1079 -1.208 -18.608-54.795 1.0019.59 RNA2C ATOM 3370 04* CD1079 -1.438 -18.079-53.467 1.0027.26 RNA2O ATOM 3371 C3* CD1079 -2.308 -17.995 -55.628 1.0031.62 RNA2C ATOM 3372 03* CD1079 -2.525 -18.767-56.789 1.0035.58 RNA2O ATOM 3373 C2* CD1079 -3.484 -17.941 -54.667 1.0027.16 RNA2C ATOM 3374 02* CD1079 -4.148 -19.180-54.551 1.0030.55 RNA2O ATOM 3375 CI* CD1079 -2.774 -17.609-53.357 1.0019.20 RNA2C ATOM 3376 NI CD1079 -2.738 - ■ 16.155 -53.087 1.0015.42 RNA2N ATOM 3377 C2 CD1079 -3.891 - 15.525 -52.594 1.0014.73 RNA2C ATOM 3378 02 CD1079 -4.922 - ■16.196-52.423 1.0022.43 RNA2O ATOM 3379 N3 CD1079 -3.853 - ■ 14.203 -52.319 1.0015.70 RNA2N ATOM 3380 C4 CD1079 -2.730 - 13.512 -52.513 1.0019.14 RNA2C ATOM 3381 N4 CD1079 -2.733 - ■ 12.219 -52.194 1.0018.52 RNA2N ATOM 3382 C5 CD1079 -1.550- 14.119-53.033 1.0014.27 RNA2C ATOM 3383 C6 CD1079 -1.598- 15.430-53.303 1.009.72 RNA2C ATOM 3384 P . AD1080 -2.665 -1 [8.025-58.200 1 1.0033.84 RNA2P ATOM 3385 O1P AD1080 -1.604 -16.982-58.302 1.0029.98 RNA2O ATOM 3386 O2P AD1080 -2.762 -19.085 -59.240 1.0051.18 RNA2O ATOM 3387 05* AD1080 -4.078 -17.315-58.069 1.0018.89 RNA2O ATOM 3388 C5* AD1080 -5.228 -18.109-57.802 1.0023.14 RNA2C ATOM 3389 C4* AD1080 -6.362 -17.256-57.316 1.0029.15 RNA2C ATOM 3390 04* AD1080 -6.077 -16.724-55.997 1.0031.88 RNA2O ATOM 3391 C3* AD1080 -6.704 -16.028-58.131 1.0027.12 RNA2C ATOM 3392 03* AD1080 -7.427 -16.344-59.312 .1.0035.45 RNA2O ATOM 3393 C2* AD1080 -7.520 -15.221 -57.129 1.0024.68 RNA2C -134- ATOM 339402* AD1080 -8.839 -15.710-57.002 1.0023.19 RNA2O ATOM 3395 CI* AD1080 -6.774 -15.502-55.826 1.0022.08 RNA2C ATOM 3396 N9 AD1080 -5.817- ■14.431 -55.545 1.0019.19 RNA2N ATOM 3397 C8 AD1080 -4.460 - 14.391 -55.773 1.0021.24 RNA2C ATOM 3398 N7 AD1080 -3.911- ■13.232-55.485 1.0017.04 RNA2N ATOM 3399 C5 AD1080 -4.974 - 12.465 -55.021 1.0010.07 RNA2C ATOM 3400 C6 AD1080 -5.061 - 11.132 -54.578 1.0015.82 RNA2C ATOM 3401 N6 AD1080 -4.019- 10.295 -54.529 1.0019.09 RNA2N ATOM 3402 NI AD1080 -6.271 - •10.680-54.183 1.0020.36 RNA2N ATOM 3403 C2 AD1080 -7.317 - 11.517 -54.229 1.0015.92 RNA2C ATOM 3404 N3 AD1080 -7.362 - 12.783 -54.626 1.0014.17 RNA2N ATOM 3405 C4 AD1080 -6.145- 13.200-55.023 1.009.63 RNA2C ATOM 3406 P UD1081 -7.413-15.312-60.548 1.0031.28 RNA2P ATOM 3407 O1P UD1081 -6.027 -14.791-60.717 1.008.76 RNA2O ATOM 3408 O2P UD1081 -8.089 -15.971-61.696 1.0035.73 RNA2O ATOM 3409 O5* UD1081 -8.356 -14.144-60.021 1.0018.56 RNA2O ATOM 3410 C5* UD1081 -9.643 -14.457-59.459 1.0022.44 RNA2C ATOM 3411 C4* UD1081 -10.276 -13.222-58.867 1.0034.63 RNA2C ATOM 3412 O4* UD1081 -9.471 -12.728-57.771 1.0031.00 RNA2O ATOM 3413 C3* UD1081 -10.406 -12.045-59.817 1.0037.02 RNA2C ATOM 3414 O3* UD1081 -11.605 -12.172-60.569 1.0043.64 RNA2O ATOM 3415 C2* UD1081 -10.429 -10.844-58.874 1.0032.75 RNA2C ATOM 3416 O2* UD1081 -11.714 -10.603-58.330 1.0030.48 RNA2O ATOM 3417 CI* UD1081 -9.499 -11.311-57.756 1.0021.25 RNA2C ATOM 3418 NI UD1081 -8.115- 10.826-57.857 1.008.85 RNA2N ATOM 3419 C2 UD1081 -7.839 -9.537-57.429 1.0018.01 RNA2C ATOM 3420 O2 UD1081 -8.706 -8.754-57.039 1.0020.38 RNA2O ATOM 3421 N3 UD1081 -6.515 -9.190-57.477 1.004.56 RNA2N ATOM 3422 C4 UD1081 -5.463 -9.977-57.902 1.0019.29 RNA2C ATOM 3423 O4 UD1081 -4.306 -9.560-57.785 1.0017.28 RNA2O ATOM 3424 C5 UD1081 -5.838- 11.273-58.364 1.008.37 RNA2C ATOM 3425 C6 UD1081 -7.118- 11.640-58.331 1.009.01 RNA2C ATOM 3426 P UD1082 -11.700 - 11.511-62.026 1.0037.21 RNA2P ATOM 3427 O1P UD1082 -10.555 -11.984-62.849 1.0030.04 RNA2O ATOM 3428 O2P UD1082 -13.101 -11.726-62.489 1.0036.07 RNA2O ATOM 3429 O5* UD1082 -11.463 -9.962-61.755 1.0048.61 RNA2O ATOM 3430 C5* UD1082 -12.470 -9.172-61.107 1.0049.13 RNA2C ATOM 3431 C4* UD1082 -12.043 -7.729-61.052 1.0045.78 RNA2C ATOM 3432 O4* UD1082 -11.006 -7.553-60.054 1.0041.16 RNA2O ATOM 3433 C3* UD1082 -11.417 -7.176-62.317 1.0045.00 RNA2C ATOM 3434 O3* UD1082 -12.349 -6.822-63.321 1.0044.91 RNA2O ATOM 3435 C2* UD1082 -10.633 -5.979-61.801 1.0041.47 RNA2C ATOM 3436 O2* UD1082 -11.449 -4.837-61.628 1.0038.13 RNA2O ATOM 3437 CI* UD1082 -10.147 -6.497-60.448 1.0034.17 RNA2C ATOM 3438 NI UD1082 -8.767 -6.998-60.524 1.0021.76 RNA2N ATOM 3439 C2 UD1082 -7.752 ■ -6.093-60.271 1.0027.58 RNA2C ATOM 3440 O2 UD1082 -7.961 -4.925-59.983 1.0039.33 RNA2O ATOM 3441 N3 UD1082 -6.482 -6.599-60.370 1.0017.32 RNA2N ATOM 3442 C4 UD1082 -6.125 -7.886-60.687 1.0019.81 RNA2C ATOM 3443 O4 UD1082 -4.925 -8.184-60.736 1.0021.01 RNA2O ATOM 3444 C5 UD1082 -7.228 ■ -8.767-60.933 1.0016.38 RNA2C - 135- ATOM 3445 C6 UD1082 -8.483 -8.304-60.843 1.0016.69 RNA2C ATOM 3446 P UD1083 -11.820 -6.597-64.817 1.0043.63 RNA2P ATOM 3447 O1P UD1083 -11.131 -7.845-65.255 1.0040.26 RNA2O ATOM 3448 O2P UD1083 -12.95C 1 -6.055-65.619 1.0045.21 RNA2O ATOM 3449 O5* UD1083 -10.714 -5.466-64.618 1.0033.40 RNA2O ATOM 3450 C5* UD1083 -9.461 -5.509-65.306 1.0021.92 RNA2C ATOM 3451 C4* UD1083 -8.508 -4.519-64.689 1.0033.84 RNA2C ATOM 3452 O4* UD1083 -7.824 -5.125-63.563 1.0030.68 RNA2O ATOM 3453 C3* UD1083 -7.392 -4.060-65.607 1.0039.61 RNA2C ATOM 3454 O3* UD1083 -7.851 -2.983-66.405 1.0047.78 RNA2O ATOM 3455 C2* UD1083 -6.301 -3.633-64.635 1.0038.07 RNA2C ATOM 3456 O2* UD1083 -6.517 -2.326-64.141 1.0048.19 RNA2O ATOM 3457 CI* UD1083 -6.486 -4.647-63.504 1.0032.72 RNA2C ATOM 3458 NI UD1083 -5.568 -5.793-63.608 1.0023.49 RNA2N ATOM 3459 C2 UD1083 -4.251 -5.604-63.225 1.0027.40 RNA2C ATOM 3460 02 UD1083 -3.823 -4.541-62.823 1.0042.53 RNA2O ATOM 3461 N3 UD1083 -3.447 -6.710-63.335 1.0031.74 RNA2N ATOM 3462 C4 UD1083 -3.809 -7.963-63.784 1.0030.45 RNA2C ATOM 3463 04 UD1083 -2.962 -8.863-63.823 1.0030.78 RNA2O ATOM 3464 C5 UD1083 -5.183 -8.081 -64.168 1.0019.97 RNA2C ATOM 3465 C6 UD1083 -5.995 -7.019-64.069 1.0027.83 RNA2C ATOM 3466 P AD1084 -7.438 - 2.912-67.949 1.0045.35 RNA2P ATOM 3467 O1P AD1084 -7.390 -4.295-68.485 1.0047.07 RNA2O ATOM 3468 O2P AD1084 -8.323 -1.906-68.587 1.0048.86 RNA2O ATOM 3469 05* AD1084 -5.952 -2.353-67.903 1.0030.12 RNA2O ATOM 3470 C5* AD1084 -5.051 -2.560-68.990 1.0025.41 RNA2C ATOM 3471 C4* AD1084 -3.717 -1.960-68.652 1.0029.72 RNA2C ATOM 3472 04* AD1084 -3.876 -0.534-68.496 1.0039.52 RNA2O ATOM 3473 C3* AD1084 -3.174 -2.444-67.326 1.0026.49 RNA2C ATOM 3474 03* AD1084 -2.405 -3.601-67.544 1.0036.34 RNA2O ATOM 3475 C2* AD1084 -2.346 -1.271-66.828 1.0033.86 RNA2C ATOM 3476 02* AD1084 -1.043 -1.267-67.373 1.0028.54 RNA2O ATOM 3477 CI* AD1084 -3.138 -0.086-67.379 1.0030.15 RNA2C ATOM 3478 N9 AD1084 -4.093 0.522-66.459 1.0028.36 RNA2N ATOM 3479 C8 AD1084 -5.439 0.258-66.342 1.0028.20 RNA2C ATOM 3480 N7 AD1084 -6.058 1.041 -65.494 1.0025.56 RNA2N ATOM 3481 C5 AD1084 -5.050 1.861 -65.004 1.0022.38 RNA2C ATOM 3482 C6 AD1084 -5.061 2.922-64.088 1.0027.67 RNA2C ATOM 3483 N6 AD1084 -6.165 3.359-63.482 1.0038.68 RNA2N ATOM 3484 NI AD1084 -3.884 3.530-63.815 1.0034.84 RNA2N ATOM 3485 C2 AD1084 -2.776 3.091-64.434 1.0037.58 RNA2C ATOM 3486 N3 AD1084 -2.641 2.106-65.322 1.0027.16 RNA2N ATOM 3487 C4 AD1084 -3.830 1.530-65.569 1.0029.13 RNA2C ATOM 3488 P . AD1085 -2.533 - 4.824-66.531 1.0033.05 RNA2P ATOM 3489 O1P AD1085 -3.976 -4.945-66.187 1.0026.54 RNA2O ATOM 3490 O2P AD1085 -1.809 -5.987-67.103 1.0037.42 RNA2O ATOM 3491 05* AD1085 -1.708 -4.311-65.275 1.0037.64 RNA2O ATOM 3492 C5* AD1085 -0.321 -3.983-65.415 1.0034.30 RNA2C ATOM 3493 C4* AD1085 0.137 -3.193-64.225 1.0040.98 RNA2C ATOM 3494 O4* AD1085 -0.509 -1.900-64.217 1.0045.08 RNA2O ATOM 3495 C3* AD1085 -0.209 -3.817-62.888 1.0033.48 RNA2C - 136- ATOM 349603* AD1085 0.816 -4.734 -62.538 1.0033.50 RNA2O ATOM 3497 C2* AD1085 -0.260 -2.614-61.955 1.0033.78 RNA2C ATOM 349802* AD1085 1.022 -2.252-61.488 1.0036.97 RNA2O ATOM 3499 CI* AD1085 -0.762 -1.506-62.885 1.0029.69 RNA2C ATOM 3500 N9 AD1085 -2.183 -1.205-62.769 1.0020.61 RNA2N ATOM 3501 C8 AD1085 -3.232 -1.910-63.299 1.0032.48 RNA2C ATOM 3502 N7 AD1085 -4.406 -1.388-63.038 1.0031.65 RNA2N ATOM 3503 C5 AD1085 -4.110 -0.263 -62.285 1.0023.98 RNA2C ATOM 3504 C6 AD1085 -4.922 0.724-61.710 1.0027.87 RNA2C ATOM 3505 N6 AD1085 -6.253 0.732-61.813 1.0035.25 RNA2N ATOM 3506 NI AD1085 -4.315 1.716-61.023 1.0023.17 RNA2N ATOM 3507 C2 AD1085 -2.975 1.709-60.936 1.0028.66 RNA2C ATOM 3508 N3 AD1085 -2.102 0.838-61.439 1.0029.00 RNA2N ATOM 3509 C4 AD1085 -2.742 -0.137-62.110 1.0024.43 RNA2C ATOM 3510 P AD1086 0.438 - 6.094-61.782 1.0032.76 RNA2P ATOM 3511 O1P AD1086 -0.961 -6.454-62.137 1.0017.94 RNA2O ATOM 3512 O2P AD1086 1.532 -7.068 -62.001 1.0030.14 RNA2O ATOM 3513 O5* AD1086 0.451 -5.671 -60.253 1.0042.21 RNA2O ATOM 3514 C5* AD1086 1.644 -5.155-59.645 1.0032.88 RNA2C ATOM 3515 C4* AD1086 1.288 -4.326 -58.440 1.0036.41 RNA2C ATOM 3516 O4* AD1086 0.612 -3.114-58.860 1.0029.39 RNA2O ATOM 3517 C3* AD1086 0.303 -4.967-57.481 1.0036.90 RNA2C ATOM 3518 O3* AD1086 0.922 -5.900 -56.613 1.0033.24 RNA2O ATOM 3519 C2* AD1086 -0.287 -3.768 -56.748 1.0042.63 RNA2C ATOM 3520 O2* AD1086 0.470 -3.347 -55.630 1.0053.18 RNA2O ATOM 3521 CI* AD1086 -0.267 -2.692 -57.839 1.0038.42 RNA2C ATOM 3522 N9 AD1086 -1.590 -2.432 -58.407 1.0027.17 RNA2N ATOM 3523 C8 AD1086 -2.195 -1.210-58.569 1.0027.28 RNA2C ATOM 3524 N7 AD1086 -3.431 -1.285-59.001 1.0032.05 RNA2N ATOM 3525 C5 AD1086 -3.644 -2.647-59.160 1.0025.72 RNA2C ATOM 3526 C6 AD1086 -4.765 -3.385 -59.572 1.0030.69 RNA2C ATOM 3527 N6 AD1086 -5.930 -2.832-59.910 1.0037.15 RNA2N ATOM 3528 NI AD1086 -4.650 -4.731-59.619 1.0026.67 RNA2N ATOM 3529 C2 AD1086 -3.484 -5.284-59.271 1.0027.74 RNA2C ATOM 3530 N3 AD1086 -2.360 -4.697 -58.860 1.0032.46 RNA2N ATOM 3531 C4 AD1086 -2.510 -3.363 -58.824 1.0028.26 RNA2C ATOM 3532 P GD1087 0.286 - ' 7.364-56.455 1.0031.77 RNA2P ATOM 3533 O1P GD1087 -0.973 -7.249 -55.682 1.0028.82 RNA2O ATOM 3534 O2P GD1087 0.266 -8.020 -57.788 1.0046.35 RNA2O ATOM 3535 O5* GD1087 1.337 -8.122-55.545 1.0032.87 RNA2O ATOM 3536 C5* GD1087 2.401 -8.899-56.109 1.0029.23 RNA2C ATOM 3537 C4* GD1087 3.449 -9.109.-55.061 1.0033.39 RNA2C ATOM 3538 O4* GD1087 4.062 -7.829 -54.802 1.0039.61 RNA2O ATOM 3539 C3* GD1087 2.847 -9.568 -53.742 1.0026.85 RNA2C ATOM 3540 O3* GD1087 2.937 -10.985-53.689 1.0026.33 RNA2O ATOM 3541 C2* GD1087 3.745 -8.914-52.696 1.0029.63 RNA2C ATOM 3542 O2* GD1087 4.887 -9.702-52.418 1.0030.88 RNA2O ATOM 3543 CI* GD1087 4.196 -7.635 -53.412 1.0031.58 RNA2C ATOM 3544 N9 GD1087 3.534 -6.370 -53.099 1.0024.38 RNA2N ATOM 3545 C8 GD1087 2.184 ■ -6.105-53.015 1.0013.22 RNA2C ATOM 3546 N7 GD1087 1.926 -4.837-52.821 1.006.56 RNA2N - -137- UBSTΪTUΪE SHEET RULE26 ATOM 3547 C5 GD1087 3.176 -4.240-52.743 1.0011.78 RNA2C ATOM 3548 C6 GD1087 3.536 -2.887-52.546 1.0026.38 RNA2C ATOM 3549 O6 GD1087 2.796 -1.905-52.394 1.0028.30 RNA2O ATOM 3550 NI GD1087 4.919 -2.723-52.537 1.0019.38 RNA2N ATOM 3551 C2 GD1087 5.836 -3.736-52.697 1.0026.46 RNA2C ATOM 3552 N2 GD1087 7.138 -3.390-52.661 1.0019.48 RNA2N ATOM 3553 N3 GD1087 5.509 -4.997-52.881 1.0020.61 RNA2N ATOM 3554 C4 GD1087 4.176 -5.176-52.894 1.0016.45 RNA2C ATOM 3555 P AD1088 1.639-1 [1.888-53.962 1.0030.91 RNA2P ATOM 3556 O1P AD1088 0.713 -11.203-54.900 1.0035.03 RNA2O ATOM 3557 O2P AD1088 2.152 -13.234-54.286 1.0039.93 RNA2O ATOM 3558 O5* AD1088 0.937 -11.965-52.543 1.0035.70 RNA2O ATOM 3559 C5* AD1088 1.728 -12.195-51.367 1.0040.71 RNA2C ATOM 3560 C4* AD1088 1.473 -11.114-50.352 1.0031.86 RNA2C ATOM 3561 O4* AD1088 0.051 -11.035-50.098 1.0031.43 RNA2O ATOM 3562 C3* AD1088 2.134 -11.354-49.008 1.0028.62 RNA2C ATOM 3563 O3* AD1088 2.454 -10.092-48.453 1.0022.01 RNA2O ATOM 3564 C2* AD1088 1.032 -12.007-48.192 1.0019.87 RNA2C ATOM 3565 02* AD1088 1.196 -11.783-46.811 1.0035.87 RNA2O ATOM 3566 CI* AD1088 -0.209 -11.301-48.739 1.0017.80 RNA2C ATOM 3567 N9 AD1088 -1.421 -12.106-48.687 1.008.11 RNA2N ATOM 3568 C8 AD1088 -2.654 ■ -11.733-48.221 1.0011.14 RNA2C ATOM 3569 N7 AD1088 -3.559 -12.675-48.317 1.0026.75 RNA2N ATOM 3570 C5 AD1088 ' -2.873 ■ -13.743-48.883 1.0015.31 RNA2C ATOM 3571 C6 AD1088 -3.272 ■ -15.045-49.241 1.0015.70 RNA2C ATOM 3572 N6 AD1088 -4.511- -15.516-49.067 1.0017.72 RNA2N ATOM 3573 NI AD1088 -2.343 • -15.856-49.789 1.009.16 RNA2N ATOM 3574 C2 AD1088 -1.099 - ■15.388-49.957 1.0014.79 RNA2C ATOM 3575 N3 AD1088 -0.603 • -14.189-49.657 1.0018.20 RNA2N ATOM 3576 C4 AD1088 -1.555 - -13.405-49.117 1.0014.12 RNA2C ATOM 3577 P GD1089 3.501 - 9.994-47.248 1.0027.70 RNA2P ATOM 3578 O1P GD1089 4.147 -11.322-47.068 1.0028.27 RNA2O ATOM 3579 O2P GD1089 2.776 -9.361-46.117 1.0025.52 RNA2O ATOM 3580 05* GD1089 4.606 -8.988-47.785 1.0022.53 RNA2O ATOM 3581 C5* GD1089 5.471 -9.357-48.871 1.0030.86 RNA2C ATOM 3582 C4* GD1089 5.959 -8.118-49.573 1.0024.73 RNA2C ATOM 3583 04* GD1089 4.810 -7.428-50.122 1.0031.53 RNA2O ATOM 3584 C3* GD1089 6.676 -7.119-48.676 1.0023.96 RNA2C ATOM 3585 03* GD1089 7.692 -6.491-49.437 1.0035.59 RNA2O ATOM 3586 C2* GD1089 5.581 -6.109-48.333 1.0026.26 RNA2C ATOM 3587 02* GD1089 6.055 -4.799-48.099 1.0039.73 RNA2O ATOM 3588 CI* GD1089 4.742 -6.120-49.602 1.0026.61 RNA2C ATOM 3589 N9 GD1089 3.339 -5.773-49.400 1.0022.30 RNA2N ATOM 3590 C8 GD1089 2.265 -6.629-49.311 1.0019.61 RNA2C ATOM 3591 N7 GD1089 1.123 -6.007-49.184 1.0020.16 RNA2N ATOM 3592 C5 GD1089 1.468 -4.661-49.171 1.0020.55 RNA2C ATOM 3593 C6 GD1089 0.653 -3.505-49.059 1.0026.65 RNA2C ATOM 3594 06 GD1089 -0.582 -3.435-48.934 1.0034.44 RNA2O ATOM 3595 NI GD1089 1.415 -2.339-49.098 1.0018.23 RNA2N ATOM 3596 C2 GD1089 2.782 -2.292-49.218 1.0022.47 RNA2C ATOM 3597 N2 GD1089 3.341 -1.065-49.215 1.0023.99 RNA2N -138- ATOM 3598 N3 GD1089 3.551 -3.365-49.325 1.0021.65 RNA2N ATOM 3599 C4 GD1089 2.832 ■ -4.504-49.293 1.0015.76 RNA2C ATOM 3600 P UD1090 9.177 -' 7.107-49.459 1.0046.88 RNA2P ATOM 3601 O1P UD1090 9.375 -7.944-48.246 1.0047.63 RNA2O ATOM 3602 O2P UD1090 9.376 -7.711-50.800 1.0046.50 RNA2O ATOM 3603 O5* UD1090 10.098 -5.811-49.333 1.0047.06 RNA2O ATOM 3604 C5* UD1090 11.428 -5.782-49.876 1.0048.58 RNA2C ATOM 3605 C4* UD1090 12.040 -4.407-49.703 1.0055.86 RNA2C ATOM 3606 O4* UD1090 11.307 -3.422-50.482 1.0058.42 RNA2O ATOM 3607 C3* UD1090 12.027 -3.835-48.296 1.0057.85 RNA2C ATOM 3608 O3* UD1090 13.074 -4.330-47.488 1.0054.72 RNA2O ATOM 3609 C2* UD1090 12.152 -2.336-48.538 1.0056.90 RNA2C ATOM 3610 O2* UD1090 13.486 -1.912-48.750 1.0055.53 RNA2O ATOM 3611 CI* UD1090 11.345 -2.164-49.823 1.0047.41 RNA2C ATOM 3612 NI UD1090 9.971 -1.713-49.552 1.0039.04 RNA2N ATOM 3613 C2 UD1090 9.769 - -0.350-49.369 1.0041.49 RNA2C ATOM 3614 O2 UD1090 10.675 0.475-49.415 1.0047.92 RNA2O ATOM 3615 N3 UD1090 8.468 0.014-49.123 1.0033.29 RNA2N ATOM 3616 C4 UD1090 7.371 • -0.820-49.033 1.0035.37 RNA2C ATOM 3617 O4 UD1090 6.255 -0.333-48.820 1.0043.33 RNA2O ATOM 3618 C5 UD1090 7.660 ■ -2.210-49.227 1.0026.33 RNA2C ATOM 3619 C6 UD1090 8.916 ■ -2.599-49.476 1.0031.79 RNA2C ATOM 3620 P ' GD1091 12.865 - 4.400-45.899 1.0063.03 RNA2P ATOM 3621 O1P GD1091 11.489 -4.915-45.629 1.0048.47 RNA2O ATOM 3622 O2P GD1091 14.047 -5.119-45.346 1.0063.48 RNA2O ATOM 3623 O5* GD1091 12.909 -2.874-45.434 1.0053.82 RNA2O ATOM 3624 C5* GD1091 14.160 -2.173-45.369 1.0060.37 RNA2C ATOM 3625 C4* GD1091 13.939 -0.687-45.231 1.0057.35 RNA2C ATOM 3626 O4* GD1091 13.057 -0.232-46.291 1.0051.52 RNA2O ATOM 3627 C3* GD1091 13.275 -0.168-43.964 1.0064.14 RNA2C ATOM 3628 O3* GD1091 14.165 -0.050-42.851 1.0071.95 RNA2O ATOM 3629 C2* GD1091 12.766 1.197-44.414 1.0059.80 RNA2C ATOM 3630 O2* GD1091 13.774 2.190-44.402 1.0067.83 RNA2O ATOM 3631 CI* GD1091 12.345 0.913-45.854 1.0048.17 RNA2C ATOM 3632 N9 GD1091 10.912 0.647-45.911 1.0035.24 RNA2N ATOM 3633 C8 GD1091 10.281 -0.571-45.991 1.0035.20 RNA2C ATOM 3634 N7 GD1091 8.979 ■ .0.474-45.954 1.0029.59 RNA2N ATOM 3635 C5 GD1091 8.739 0.890-45.858 1.0021.43 RNA2C ATOM 3636 C6 GD1091 7.518 1.604-45.771 1.0032.33 RNA2C ATOM 3637 O6 GD1091 6.364 1.159-45.749 1.0043.19 RNA2O ATOM 3638 NI GD1091 7.731 2.976-45.699 1.0028.62 RNA2N ATOM 3639 C2 GD1091 8.961 3.582-45.701 1.0039.37 RNA2C ATOM 3640 N2 GD1091 8.965 4.920-45.626 1.0034.96 RNA2N ATOM 3641 N3 GD1091 10.107 2.925-45.772 1.0032.50 RNA2N ATOM 3642 C4 GD1091 9.920 1.594-45.848 1.0025.53 RNA2C ATOM 3643 P ι CD1092 13.560 1 3.093-41.358 1.0080.57 RNA2P ATOM 3644 O1P CD1092 12.499 -0.941-41.171 1.0072.16 RNA2O ATOM 3645 O2P CD1092 14.702 0.146-40.409 1.0077.36 RNA2O ATOM 3646 O5* CD1092 12.841 1.520-41.356 1.0067.00 RNA2O ATOM 3647 C5* CD1092 13.608 2.728-41.517 1.0047.50 RNA2C ATOM 3648 C4* CD1092 12.721 3.950-41.413 1.0046.89 RNA2C - 139- UBSTITUTE SHEET (RULE26| ATOM 3649 O4* CD1092 11.785 3.999-42.524 1.0047.64 RNA2O ATOM 3650 C3* CD1092 11.825 4.069-40.193 1.0048.58 RNA2C ATOM 3651 O3* CD1092 12.485 4.523-39.029 1.0050.53 RNA2O ATOM 3652 C2* CD1092 10.775 5.069-40.650 1.0046.94 RNA2C ATOM 3653 O2* CD1092 11.196 6.411-40.524 1.0056.76 RNA2O ATOM 3654 CI* CD1092 10.610 4.694-42.122 1.0044.37 RNA2C ATOM 3655 NI CD1092 9.429 3.823-42.282 1.0040.91 RNA2N ATOM 3656 C2 CD1092 8.155 4.415-42.217 1.0043.01 RNA2C ATOM 3657 02 CD1092 8.072 5.647-42.083 1.0041.14 RNA2O ATOM 3658 N3 CD1092 7.056 3.632-42.298 1.0033.92 RNA2N ATOM 3659 C4 CD1092 7.188 2.312-42.444 1.0039.14 RNA2C ATOM 3660 N4 CD1092 6.075 1.577-42.496 1.0035.85 RNA2N ATOM 3661 C5 CD1092 8.469 1.685-42.538 1.0031.59 RNA2C ATOM 3662 C6 CD1092 9.552 2.471 -42.458 1.0035.03 RNA2C ATOM 3663 P GD1093 11.977 4.012-37.593 1.0051.96 RNA2P ATOM 3664 O1P GD1093 11.975 2.526-37.626 1.0048.41 RNA2O ATOM 3665 O2P GD1093 12.764 4.724-36.553 1.0064.77 RNA2O ATOM 3666 05* GD1093 10.458 4.492-37.515 1.0035.20 RNA2O ATOM 3667 C5* GD1093 10.122 5.886-37.581 1.0024.69 RNA2C ATOM 3668 C4* GD1093 8.630 6.056-37.704 1.0029.37 RNA2C ATOM 3669 04* GD1093 8.164 5.435-38.930 1.0034.30 RNA2O ATOM 3670 C3* GD1093 7.808 5.387-36.620 1.0033.91 RNA2C ATOM 3671 03* GD1093 7.738 6.175-35.452 1.0053.14 RNA2O ATOM 3672 C2* GD1093 6.454 5.194-37.289 1.0036.57 RNA2C ATOM 3673 02* GD1093 5.628 6.344-37.254 1.0023.38 RNA2O ATOM 3674 CI* GD1093 6.871 4.878-38.726 1.0033.38 RNA2C ATOM 3675 N9 GD1093 6.940 3.436-38.961 1.0031.32 RNA2N ATOM 3676 C8 GD1093 8.073 2.656-39.054 1.0027.97 RNA2C ATOM 3677 N7 GD1093 7.812 1.389-39.243 1.0030.70 RNA2N ATOM 3678 C5 GD1093 6.424 1.326-39.280 1.0027.66 RNA2C ATOM 3679 C6 GD1093 5.563 0.215-39.451 1.0030.04 RNA2C ATOM 3680 O6 GD1093 5.866 -0.977-39.608 1.0042.76 RNA2O ATOM 3681 NI GD1093 4.222 0.596-39.422 1.0021.84 RNA2N ATOM 3682 C2 GD1093 3.770 1.881-39.247 1.0013.29 RNA2C ATOM 3683 N2 GD1093 2.437 2.046-39.237 1.0019.33 RNA2N ATOM 3684 N3 GD1093 4.564 2.926-39.091 1.0016.91 RNA2N ATOM 3685 C4 GD1093 5.869 2.579-39.115 1.0023.30 RNA2C ATOM 3686 P UD1094 7.627 . 5.455-34.022 1.0046.64 RNA2P ATOM 3687 O1P UD1094 8.556 4.303-34.026 1.0032.38 RNA2O ATOM 3688 O2P UD1094 7.774 6.516-32.989 1.0056.93 RNA2O ATOM 3689 05* UD1094 6.124 4.934-33.989 1.0026.86 RNA2O ATOM 3690 C5* UD1094 5.051 5.877-33.932 1.0035.20 RNA2C ATOM 3691 C4* UD1094 3.735 5.172-33.742 1.0045.98 RNA2C ATOM 3692 04* UD1094 3.308 4.545-34.978 1.0050.88 RNA2O ATOM 3693 C3* UD1094 3.692 4.055-32.717 1.0039.85 RNA2C ATOM 3694 O3* UD1094 3.600 4.551-31.387 1.0048.03 RNA2O ATOM 3695 C2* UD1094 2.457 3.270-33.154 1.0040.06 RNA2C ATOM 3696 02* UD1094 1.243 3.843-32.701 1.0044.52 RNA2O ATOM 3697 CI* UD1094 2.527 3.400-34.678 1.0045.26 RNA2C ATOM 3698 NI UD1094 3.134 2.217-35.313 1,0038.99 RNA2N ATOM 3699 C2 UD1094 2.294 1.148-35.606 1.0029.79 RNA2C -140- ATOM 370002 UD1094 1.083 1.180-35.422 1.0031.88 RNA2O ATOM 3701 N3 UD1094 2.920 0.043-36.124 1.0017.61 RNA2N ATOM 3702 C4 UD1094 4.262 -0.105-36.384 1.0031.42 RNA2C ATOM 3703 O4 UD1094 4.679 -1.193-36.785 1.0023.03 RNA2O ATOM 3704 C5 UD1094 5.062 1.053-36.093 1.0028.82 RNA2C ATOM 3705 C6 UD1094 4.485 2.147-35.584 1.0023.80 RNA2C ATOM 3706 P AD1095 4.523 : 3.907-30.234 1.0043.63 RNA2P ATOM 3707 O1P AD1095 5.870 3.607-30.802 1.0036.61 RNA2O ATOM 3708 O2P AD1095 4.416 4.772-29.033 1.0064.56 RNA2O ATOM 3709 O5* AD1095 3.794 2.535-29.896 1.0028.91 RNA2O ATOM 3710 C5* AD1095 4.511 1.451-29.281 1.0029.01 RNA2C ATOM 3711 C4* AD1095 3.579 0.291-29.049 1.0027.64 RNA2C ATOM 3712 O4* AD1095 2.506 0.741-28.191 1.0038.10 RNA2O ATOM 3713 C3* AD1095 2.890 -0.216-30.302 1.0032.19 RNA2C ATOM 3714 O3* AD1095 3.698 -1.186-30.964 1.0040.82 RNA2O ATOM 3715 C2* AD1095 1.575 -0.772-29.769 1.0037.08 RNA2C ATOM 3716 O2* AD1095 1.705 -2.077-29.240 1.0037.59 RNA2O ATOM 3717 CI* AD1095 1.278 0.195-28.623 1.0027.61 RNA2C ATOM 3718 N9 AD1095 0.397 1.313-28.956 1.0026.65 RNA2N ATOM 3719 C8 AD1095 0.753 2.601-29.290 1.0020.45 RNA2C ATOM 3720 N7 AD1095 -0.273 3.404-29.463 1.0027.16 RNA2N ATOM 3721 C5 AD1095 -1.376 2.587-29.246 1.0016.61 RNA2C ATOM 3722 C6 AD1095 -2.765 2.837-29.271 1.0025.70 RNA2C ATOM 3723 N6 AD1095 -3.303 4.034-29.520 1.0029.59 RNA2N ATOM 3724 NI AD1095 -3.596 1.799-29.023 1.0028.34 RNA2N ATOM 3725 C2 AD1095 -3.060 0.599-28.761 1.0025.38 RNA2C ATOM 3726 N3 AD1095 -1.775 0.240-28.702 1.0028.20 RNA2N ATOM 3727 C4 AD1095 -0.977 1.292-28.955 1.0021.18 RNA2C ATOM 3728 P AD1096 3.829 - 1.151-32.569 1.0034.70 RNA2P ATOM 3729 O1P AD1096 4.017 0.256-32.992 1.0037.33 RNA2O ATOM 3730 O2P AD1096 4.838 -2.167-32.962 1.0024.34 RNA2O ATOM 3731 O5* AD1096 2.383 -1.617-33.047 1.0020.77 RNA2O ATOM 3732 C5* AD1096 1.913 -2.930-32.724 1.0019.81 RNA2C ATOM 3733 C4* AD1096 0.421 -3.021-32.910 1.0022.36 RNA2C ATOM 3734 O4* AD1096 -0.262 -2.200-31.934 1.0023.18 . RNA2O ATOM 3735 C3* AD1096 -0.119 -2.546-34.243 1.0023.44 RNA2C ATOM 3736 O3* AD1096 0.028 -3.536-35.249 1.0037.12 RNA2O ATOM 3737 C2* AD1096 -1.575 -2.237-33.914 1.0026.79 RNA2C ATOM 3738 O2* AD1096 -2.392 -3.387-33.889 1.0029.84 RNA2O ATOM 3739 CI* AD1096 -1.458 -1.686-32.493 1.0023.36 RNA2C ATOM 3740 N9 AD1096 -1.373 -0.228-32.496 1.0024.90 RNA2N ATOM 3741 C8 AD1096 -0.240 0.551-32.560 1.0030.09 RNA2C ATOM 3742 N7 AD1096 -0.485 1.838-32.573 1.0029.53 RNA2N ATOM 3743 C5 AD1096 -1.870 1.914-32.507 1.0021.47 RNA2C ATOM 3744 C6 AD1096 -2.751 3.005-32.479 1.0023.47 RNA2C ATOM 3745 N6 AD1096 -2.348 4.281-32.511 1.0030.56 RNA2N ATOM 3746 NI AD1096 -4.075 2.741 -32.411 1.0023.77 RNA2N ATOM 3747 C2 AD1096 -4.471 1.460-32.368 1.0024.81 RNA2C ATOM 3748 N3 AD1096 -3.736 0.349-32.383 1.0022.60 RNA2N ATOM 3749 C4 AD1096 -2.429 0.650-32.454 1.0013.49 RNA2C ATOM 3750 P CD1097 0.158 -: 3.087-36.781 1.0028.43 RNA2P -141- ATOM 3751 O1P CD1097 1.274 -2.107-36.889 1.0025.96 RNA2O ATOM 3752 O2P CD1097 0.208 -4.341 -37.575 1.0039.67 RNA2O ATOM 375305* CD1097 -1.234 -2.357 -37.037 1.0017.23 RNA2O ATOM 3754 C5* CD1097 -1.317 -1.078-37.691 1.0020.94 RNA2C ATOM 3755 C4* CD1097 -2.742 -0.584 -37.636 1.0029.32 RNA2C ATOM 375604* CD1097 -3.029 -0.045-36.315 1.0040.36 RNA2O ATOM 3757 C3* CD1097 -3.106 0.550-38.569 1.0029.37 RNA2C ATOM 375803* CD1097 -3.388 0.082 -39.870 1.0044.58 RNA2O ATOM 3759 C2* CD1097 -4.341 1.126-37.895 1.0033.92 RNA2C ATOM 376002* CD1097 -5.487 0.330-38.113 1.0032.32 RNA2O ATOM 3761 CI* CD1097 -3.945 1.037-36.423 1.0034.10 RNA2C ATOM 3762 NI CD1097 -3.265 2.289-36.012 1.0031.44 RNA2N ATOM 3763 C2 CD1097 -4.047 3.417-35.683 1.0027.94 RNA2C ATOM 376402 CD1097 -5.285 3.313-35.669 1.0029.21 RNA2O ATOM 3765 N3 CD1097 -3.427 4.588 -35.390 1.0030.98 RNA2N ATOM 3766 C4 CD1097 -2.090 4.658 -35.404 1.0044.95 RNA2C ATOM 3767 N4 CD1097 -1.519 5.838-35.133 1.0050.64 RNA2N ATOM 3768 C5 CD1097 -1.275 3.522-35.698 1.0039.09 RNA2C ATOM 3769 C6 CD1097 -1.897 2.370-35.988 1.0032.35 RNA2C ATOM 3770 P . D1098 -2.688 i 0.785-41.132 1 .0043.71 RNA2P ATOM 3771 O1P AD1098 -1.216 0.563-41.059 1.0024.08 RNA2O ATOM 3772 O2P AD1098 -3.449 0.343 -42.334 1.0056.53 RNA2O ATOM 377305* AD1098 -2.952 2.337 -40.908 1.0042.07 RNA2O ATOM 3774 C5* AD1098 -4.281 2.842 -40.702 1.0041.90 RNA2C ATOM 3775 C4* AD1098 -4.225 4.295 -40.292 1.0049.33 RNA2C ATOM 377604* AD1098 -3.523 4.414 -39.025 1.0047.73 RNA2O ATOM 3777 C3* AD1098 -3.462 5.219-41.229 1.0050.90 RNA2C ATOM 377803* AD1098 -4.263 5.645 -42.324 1.0054.47 RNA2O ATOM 3779 C2* AD1098 -3.057 6.363 -40.303 1.0047.39 RNA2C ATOM 378002* AD1098 -4.104 7.289 -40.085 1.0053.57 RNA2O ATOM 3781 CI* AD1098 -2.781 5.621 -38.995 1.0036.88 RNA2C ATOM 3782 N9 AD1098 -1.365 5.289-38.851 1.0028.68 RNA2N ATOM 3783 C8 AD1098 -0.744 4.078-39.051 1.0036.76 RNA2C ATOM 3784 N7 AD1098 0.560 4.120-38.906 1.0027.01 RNA2N ATOM 3785 C5 AD1098 0.813 5.442 -38.575 1.0032.11 RNA2C ATOM 3786 C6 AD1098 2.004 6.136-38.311 1.0039.08 RNA2C ATOM 3787 N6 AD1098 3.217 5.578 -38.364 1.0035.79 RNA2N ATOM 3788 NI AD1098 1.907 7.447 -37.996 1.0037.08 RNA2N ATOM 3789 C2 AD1098 0.692 8.013 -37.969 1.0035.02 RNA2C ATOM 3790 N3 AD1098 -0.498 7.470-38.214 1.0031.17 RNA2N ATOM 3791 C4 AD1098 -0.366 6.169-38.516 1.0035.12 RNA2C ATOM 3792 P i GD1099 -3.598 : 5.799-43.783 1.0057.31 RNA2P ATOM 3793 O1P GD1099 -3.062 4.481 -44.215 1.0060.32 RNA2O ATOM 3794 O2P GD1099 -4.589 6.508 -44.640 1.0060.85 RNA2O ATOM 379505* GD1099 -2.349 6.753 -43.537 1.0041.11 RNA2O ATOM 3796 C5* GD1099 -2.543 8.130-43.169 1.0050.07 RNA2C ATOM 3797 C4* GD1099 -1.216 8.782 -42.888 1.0047.05 RNA2C ATOM 379804* GD1099 -0.626 8.173-41.712 1.0046.92 RNA2O ATOM 3799 C3* GD1099 -0.174 8.588 -43.975 1.0054.47 RNA2C ATOM 380003* GD1099 -0.305 9.517-45.036 1.0055.05 RNA2O ATOM 3801 C2* GD1099 1.139 8.720-43.217 1.0048.61 RNA2C - 142- ATOM 380202* GD1099 1.553 10.057-43.029 1.0055.32 RNA2O ATOM 3803 CI* GD1099 0.781 8.073-41.878 1.0040.34 RNA2C ATOM 3804 N9 GD1099 1.140 6.659-41.891 1.0034.55 RNA2N ATOM 3805 C8 GD1099 0.293 5.577-41.965 1.0033.18 RNA2C ATOM 3806 N7 GD1099 0.926 4.437-42.047 1.0037.87 RNA2N ATOM 3807 C5 GD1099 2.270 4.787-42.007 1.0028.79 RNA2C ATOM 3808 C6 GD1099 3.437 3.978-42.083 1.0036.73 RNA2C ATOM 3809 O6 GD1099 3.519 2.747-42.210 1.0046.32 RNA2O ATOM 3810 NI GD1099 4.596 4.744-42.006 1.0030.92 RNA2N ATOM 3811 C2 GD1099 4.630 6.113-41.873 1.0040.47 RNA2C ATOM 3812 N2 GD1099 5.847 6.678-41.812 1.0023.42 RNA2N ATOM 3813 N3 GD1099 3.549 6.876-41.805 1.0031.10 RNA2N ATOM 3814 C4 GD1099 2.415 6.152-41.883 1.0028.17 RNA2C ATOM 3815 P CD1100 0.097 ! 9.071-46.522 1.0056.56 RNA2P ATOM 3816 O1P CD1100 -0.323 7.657-46.716 1.0063.87 RNA2O ATOM 3817 O2P CD1100 -0.407 10.115-47.447 1.0069.36 RNA2O ATOM 3818 O5* CD1100 1.688 9.106-46.507 1.0039.12 RNA2O ATOM 3819 C5* CD1100 2.380 10.337-46.298 1.0032.71 RNA2C ATOM 3820 C4* CD1100 3.863 10.098-46.207 1.0040.37 RNA2C ATOM 3821 O4* CD1100 4.155 9.281 -45.042 1.0045.57 RNA2O ATOM 3822 C3* CD1100 4.502 9.335-47.356 1.0048.34 RNA2C ATOM 3823 O3* CD1100 4.774 10.136-48.495 1.0058.69 RNA2O ATOM 3824 C2* CD1100 5.771 8.784-46.718 1.0042.72 RNA2C ATOM 3825 O2* CD1100 6.840 9.707-46.670 1.0045.27 RNA2O ATOM 3826 CI* CD1100 5.289 8.466-45.303 1.0036.28 RNA2C ATOM 3827 NI CD1100 4.897 7.048-45.234 1.0033.17 RNA2N ATOM 3828 C2 CD1100 5.910 6.083-45.177 1.0037.72 RNA2C ATOM 3829 O2 CD1100 7.090 6.461 -45.104 1.0037.78 RNA2O ATOM 3830 N3 CD1100 5.582 4.772-45.201 1.0034.10 RNA2N ATOM 3831 C4 CD1100 4.299 4.409-45.268 1.0036.21 RNA2C ATOM 3832 N4 CD1100 4.024 3.103-45.330 1.0035.52 RNA2N ATOM 3833 C5 CD1100 3.242 5.369-45.283 1.0032.04 RNA2C ATOM 3834 C6 CD1100 3.583 6.665-45.263 1.0033.05 RNA2C ATOM 3835 P UD1101 4.754 ! 9.460-49.951 1.0059.64 RNA2P ATOM 3836 O1P UD1101 3.464 8.731-50.077 1.0053.79 RNA2O ATOM 3837 O2P UD1101 5.117 10.490-50.957 1.0073.54 RNA2O ATOM 3838 O5* UD1101 5.931 8.390-49.894 1.0044.03 RNA2O ATOM 3839 C5* UD1101 7.275 8.809-49.652 1.0037.19 RNA2C ATOM 3840 C4* UD1101 8.197 7.620-49.625 1.0044.44 RNA2C ATOM 3841 O4* UD1101 7.844 6.748-48.520 1.0047.50 RNA2O ATOM 3842 C3* UD1101 8.140 6.710-50.836 1.0049.53 RNA2C ATOM 3843 O3* UD1101 8.892 7.203-51.930 1.0055.95 RNA2O ATOM 3844 C2* UD1101 8.681 5.396-50.286 1.0046.03 RNA2C ATOM 3845 O2* UD1101 10.091 5.371-50.196 1.0046.23 RNA2O ATOM 3846 CI* UD1101 8.097 5.396-48.875 1.0041.37 RNA2C ATOM 3847 NI UD1101 6.840 4.627-48.800 1.0033.41 RNA2N ATOM 3848 C2 UD1101 6.935 3.238-48.784 1.0034.44 RNA2C ATOM 384902 UD1101 8.011 2.640-48.812 1.0033.60 RNA2O ATOM 3850 N3 UD1101 5.730 2.575-48.737 1.0017.93 RNA2N ATOM 3851 C4 UD1101 4.466 3.143-48.705 1.0036.01 RNA2C ATOM 385204 UD1101 3.465 2.411 -48.702 1.0025.00 RNA2O 143- ATOM 3853 C5 UD1101 4.457 4.577-48.714 1.0024.85 RNA2C ATOM 3854 C6 UD1101 5.610 5.251-48.760 1.0026.88 RNA2C ATOM 3855 P CD1102 8.485 ( 5.763-53.418 1.0041.89 RNA2P ATOM 3856 O1P CD1102 7.001 6.821-53.510 1.0043.20 RNA2O ATOM 3857 O2P CD1102 9.312 7.542-54.372 1.0053.94 RNA2O ATOM 385805* CD1102 8.938 5.240-53.483 1.0038.14 RNA2O ATOM 3859 C5* CD1102 10.317 4.889-53.306 1.0037.05 RNA2C ATOM 3860 C4* CD1102 10.494 3.390-53.332 1.0045.27 RNA2C ATOM 3861 04* CD1102 9.855 2.793-52.168 1.0052.28 RNA2O ATOM 3862 C3* CD1102 9.872 2.637-54.498 1.0054.50 RNA2C ATOM 3863 03* CD1102 10.597 2.706-55.716 1.0057.12 RNA2O ATOM 3864 C2* CD1102 9.784 1.219-53.949 1.0052.66 RNA2C ATOM 386502* CD1102 11.017 0.522-54.000 1.0056.57 RNA2O ATOM 3866 CI* CD1102 9.401 1.482-52.493 1.0046.15 RNA2C ATOM 3867 NI CD1102 7.932 1.399-52.330 1.0028.20 RNA2N ATOM 3868 C2 CD1102 7.331 0.128-52.307 1.0022.69 RNA2C ATOM 386902 CD1102 8.053 -0.881-52.366 1.0035.31 RNA2O ATOM 3870 N3 CD1102 5.988 0.028-52.219 1.009.49 RNA2N ATOM 3871 C4 CD1102 5.246 1.129-52.135 1.0016.43 RNA2C ATOM 3872 N4 CD1102 3.922 0.979-52.052 1.0015.53 RNA2N ATOM 3873 C5 CD1102 5.825 2.433-52.133 1.0015.77 RNA2C ATOM 3874 C6 CD1102 7.158 2.521-52.229 1.0021.76 RNA2C ATOM 3875 P AD1103 9.806 : 2.525-57.105 1.0047.42 RNA2P ATOM 3876 O1P AD1103 8.514 3.264-57.011 1.0038.37 RNA2O ATOM 3877 O2P AD1103 10.747 2.818-58.216 1.0057.18 RNA2O ATOM 387805* AD1103 9.456 0.974-57.138 1.0048.19 RNA2O ATOM 3879 C5* AD1103 10.493 -0.015-56.995 1.0051.39 RNA2C ATOM 3880 C4* AD1103 9.894 -1.397-56.965 1.0045.50 RNA2C ATOM 3881 04* AD1103 8.978 -1.488-55.847 1.0045.01 RNA2O ATOM 3882 C3* AD1103 9.053 -1.764-58.178 1.0051.96 RNA2C ATOM 388303* AD1103 9.867 -2.246-59.243 1.0053.83 RNA2O ATOM 3884 C2* AD1103 8.095 -2.817-57.622 1.0048.46 RNA2C ATOM 388502* AD1103 8.635 -4.125-57.578 1.0047.52 RNA2O ATOM 3886 CI* AD1103 7.882 -2.316-56.192 1.0043.28 RNA2C ATOM 3887 N9 AD1103 6.646 -1.549-56.032 1.0030.89 RNA2N ATOM 3888 C8 AD1103 6.477 -0.189-55.914 1.0025.35 RNA2C ATOM 3889 N7 AD1103 5.222 0.179-55.797 1.0026.03 RNA2N ATOM 3890 C5 AD1103 4.519 -1.019-55.836 1.0017.17 RNA2C ATOM 3891 C6 AD1103 3.149 -1.314-55.759 1.0019.87 RNA2C ATOM 3892 N6 AD1103 2.193 -0.387-55.623 1.0016.79 RNA2N ATOM 3893 NI AD1103 2.784 -2.616-55.828 1.0026.16 RNA2N ATOM 3894 C2 AD1103 3.737 -3.548-55.965 1.0023.04 RNA2C ATOM 3895 N3 AD1103 5.055 -3.394-56.049 1.0030.58 RNA2N ATOM 3896 C4 AD1103 5.384 -2.090-55.977 1.0028.62 RNA2C ATOM 3897 P i CD1104 9.699 - 1.627-60.718 1.0044.57 RNA2P ATOM 3898 O1P CD1104 9.942 -0.162-60.644 1.0047.15 RNA2O ATOM 3899 O2P CD1104 10.506 -2.463-61.648 1.0047.11 RNA2O ATOM 390005* CD1104 8.160 -1.850-61.042 1.0036.26 RNA2O ATOM 3901 C5* CD1104 7.642 -3.172-61.211 1.0034.08 RNA2C ATOM 3902 C4* CD1104 6.144 -3.130-61.321 1.0033.02 RNA2C ATOM 390304* CD1104 5.569 -2.739-60.048 1.0035.45 RNA2O -144- Sϋδ STTTUTESHEETR ATOM 3904 C3* CD1104 5.595 -2.113-62.301 1.0036.26 RNA2C ATOM 3905 O3* CD1104 5.633 -2.561-63.643 1.0042.96 RNA2O ATOM 3906 C2* CD1104 4.183 -1.890-61.780 1.0035.20 RNA2C ATOM 3907 O2* CD1104 3.297 -2.916-62.185 1.0038.85 RNA2O ATOM 3908 CI* CD1104 4.408 -1.952-60.268 1.0031.46 RNA2C ATOM 3909 NI CD1104 4.636 -0.606-59.702 1.0026.13 RNA2N ATOM 3910 C2 CD1104 3.528 0.178-59.334 1.0024.36 RNA2C ATOM 3911 O2 CD1104 2.386 -0.295-59.447 1.0021.42 RNA2O ATOM 3912 N3 CD1104 3.735 1.428-58.865 1.0027.00 RNA2N ATOM 3913 C4 CD1104 4.981 1.900-58.745 1.0031.66 RNA2C ATOM 3914 N4 CD1104 5.140 3.147-58.292 1.0037.50 RNA2N ATOM 3915 C5 CD1104 6.120 1.119-59.087 1.0019.85 RNA2C ATOM 3916 C6 CD1104 5.906 -0.115-59.554 1.0026.62 RNA2C ATOM 3917 P CD1105 5.825 - 1.489-64.826 1.0042.78 RNA2P ATOM 3918 O1P CD1105 6.805 -0.460-64.381 1.0036.29 RNA2O ATOM 3919 O2P CD1105 6.074 -2.246-66.084 1.0051.04 RNA2O ATOM 3920 O5* CD1105 4.397 -0.802-64.932 1.0018.59 RNA2O ATOM 3921 C5* CD1105 3.253 -1.574-65.316 1.0029.02 RNA2C ATOM 3922 C4* CD1105 2.021 -0.711-65.320 1.0036.00 RNA2C ATOM 3923 O4* CD1105 1.741 -0.275-63.965 1.0045.01 RNA2O ATOM 3924 C3* CD1105 2.122 0.582-66.111 1.0043.97 RNA2C ATOM 3925 O3* CD1105 1.919 0.405-67.505 1.0050.57 RNA2O ATOM 3926 C2* CD1105 1.060 1.451-65.447 1.0042.61 RNA2C ATOM 3927 O2* CD1105 -0.259 1.147-65.873 1.0033.02 RNA2O ATOM 3928 CI* CD1105 1.225 1.048-63.983 1.0040.14 RNA2C ATOM 3929 NI CD1105 2.173 1.938-63.273 1.0034.85 RNA2N ATOM 3930 C2 CD1105 1.704 3.161 -62.765 1.0030.45 RNA2C ATOM 3931 O2 CD1105 0.516 3.473-62.939 1.0029.26 RNA2O ATOM 3932 N3 CD1105 2.558 3.975-62.106 1.0032.19 RNA2N ATOM 3933 C4 CD1105 3.836 3.622-61.956 1.0039.46 RNA2C ATOM 3934 N4 CD1105 4.644 4.466-61.298 1.0041.48 RNA2N ATOM 3935 C5 CD1105 4.346 2.391-62.471 1.0036.86 RNA2C ATOM 3936 C6. CD1105 3.488 1.587-63.114 1.0034.30 RNA2C ATOM 3937 P AD1106 2.559 1.463-68.538 1,0047.42 RNA2P ATOM 3938 O1P AD1106 3.960 1.743-68.117 1.0033.03 RNA2O ATOM 3939 O2P AD1106 2.297 0.944-69.905 1.0051.03 RNA2O ATOM 3940 05* AD1106 1.674 2.772-68.323 1.0038.12 RNA2O ATOM 3941 C5* AD1106 0.283 2.777-68.706 1.0043.96 RNA2C ATOM 3942 C4* AD1106 -0.340 4.129-68.452 1.0051.41 RNA2C ATOM 3943 04* AD1106 -0.379 4.381-67.026 1.0057.25 RNA2O ATOM 3944 C3* AD1106 0.391 5.331-69.029 1.0056.31 RNA2C ATOM 3945 O3* AD1106 0.086 5.559-70.396 1.0055.12 RNA2O ATOM 3946 C2* AD1106 -0.076 6.467-68.126 1.0056.95 RNA2C ATOM 3947 02* AD1106 -1.351 6.970-68.478 1.0057.32 RNA2O ATOM 3948 CI* AD1106 -0.169 5.761-66.776 1.0049.81 RNA2C ATOM 3949 N9 AD1106 1.065 5.896-66.003 1.0039.90 RNA2N ATOM 3950 C8 AD1106 2.098 4.994-65.902 1.0041.00 RNA2C ATOM 3951 N7 AD1106 3.070 5.388-65.116 1.0041.71 RNA2N ATOM 3952 C5 AD1106 2.652 6.635-64.672 1.0037.31 RNA2C ATOM 3953 C6 AD1106 -3.238 7.572-63.805 1.0036.44 RNA2C ATOM 3954 N6 AD1106 4.419 7.389-63.208 1.0040.12 RNA2N - -145- ATOM 3955 NI AD1106 2.563 8.720-63.570 1.0038.29 RNA2N ATOM 3956 C2 AD1106 1.380 8.904-64.178 1.0037.00 RNA2C ATOM 3957 N3 AD1106 0.726 8.097-65.014 1.0037.07 RNA2N ATOM 3958 C4 AD1106 1.423 6.965-65.219 1.0037.01 RNA2C ATOM 3959 P GD1107 1.186 6.251 -71.341 1.0060.89 RNA2P ATOM 3960 O1P GDI 107 2.513 5.650-71.037 1.0051.64 RNA2O ATOM 3961 O2P GD1107 0.665 6.218-72.732 1.0066.72 RNA2O ATOM 3962 O5* GD1107 1.226 7.763-70.838 1.0059.43 RNA2O ATOM 3963 C5* GD1107 0.098 8.639-71.043 1.0070.93 RNA2C ATOM 3964 C4* GD1107 0.341 9.984-70.392 1.0070.62 RNA2C ATOM 3965 O4* GD1107 0.347 9.841-68.945 1.0070.80 RNA2O ATOM 3966 C3* GD1107 1.673 10.648-70.701 1.0069.85 RNA2C ATOM 3967 O3* GD1107 1.703 11.337-71.937 1.0068.76 RNA2O ATOM 3968 C2* GD1107 1.852 11.589-69.519 1.0071.85 RNA2C ATOM 3969 O2* GD1107 1.134 12.799-69.666 1.0074.63 RNA2O ATOM 3970 CI* GD1107 1.278 10.751-68.377 1.0066.31 RNA2C ATOM 3971 N9 GDI 107 2.356 9.990-67.753 1.0061.03 RNA2N ATOM 3972 C8 GD1107 2.765 8.710-68.056 1.0064.56 RNA2C ATOM 3973 N7 GD1107 3.811 8.330-67.371 1.0062.08 RNA2N ATOM 3974 C5 GD1107 4.100 9.417-66.555 1.0059.12 RNA2C ATOM 3975 C6 GDI 107 5.134 9.600-65.598 1.0054.80 RNA2C ATOM 3976 O6 GD1107 6.035 8.812-65.270 1.0051.34 RNA2O ATOM 3977 NI GD1107 5.056 10.854-65.001 1.0050.79 RNA2N ATOM 3978 C2 GD1107 4.109 11.810-65.287 1.0054.33 RNA2C ATOM 3979 N2 GD1107 4.199 12.959-64.606 1.0051.64 RNA2N ATOM 3980 N3 GD1107 3.146 11.653-66.176 1.0049.03 RNA2N ATOM 3981 C4 GD1107 3.201 10.443-66.769 1.0058.09 RNA2C ATOM 3982 P i CD1108 3.118 11.599-72.654 1.0071.56 RNA2P ATOM 3983 O1P CD1108 3.923 10.353-72.579 1.0060.79 RNA2O ATOM 3984 O2P CD1108 2.828 12.209-73.977 1.0078.78 RNA2O ATOM 3985 O5* CD1108 3.837 12.677-71.723 1.0069.28 RNA2O ATOM 3986 C5* CD1108 3.274 13.992-71.536 1.0065.61 RNA2C ATOM 3987 C4* CD1108 4.139 14.809-70.605 1.0060.04 RNA2C ATOM 3988 O4* CD1108 4.193 14.171-69.304 1.0061.74 RNA2O ATOM 3989 C3* CD1108 5.598 14.965-71.001 1.0060.53 RNA2C ATOM 3990 O3* CD1108 5.901 15.783-72.134 1.0066.71 RNA2O ATOM 3991 C2* CD1108 6.282 15.272-69.677 1.0063.96 RNA2C ATOM 3992 O2* CD1108 6.155 16.631-69.306 1.0069.72 RNA2O ATOM 3993 CI* CD1108 5.457 14.420-68.706 1.0064.54 RNA2C ATOM 3994 NI CD1108 6.098 13.130-68.372 1.0061.20 RNA2N ATOM 3995 C2 CD1108 7.127 13.116-67.417 1.0059.89 RNA2C ATOM 3996 O2 CD1108 7.454 14.179-66.867 1.0054.39 RNA2O ATOM 3997 N3 CD1108 7.739 11.946-67.119 1.0060.31 RNA2N ATOM 3998 C4 CD1108 7.359 10.821-67.728 1.0062.68 RNA2C ATOM 3999 N4 CD1108 7.999 9.689-67.411 1.0063.03 RNA2N ATOM 4000 C5 CD1108 6.308 10.803-68.693 1.0064.65 RNA2C ATOM 4001 C6 CD1108 5.711 11.968-68.982 1.0064.25 RNA2C TER 4002 CD 1108 HET ATM 4003 CD CD 201 4.25C 1 -2.291 -5.7350.9177.47 CD HETATM 4004 CD CD 202 5.716 i 1.827 1.431 0.9132.35 CD HETATM4005 O HOH 205 7.540 -4.792 -0.436 1.0019.29 O - 146- HETATM 4006 O HOH 209 8.097 9.026 -9.315 1.00 27.99 O HETATM 4007 MG MG 210 7.174 1.073 -14.750 1.00 31.99 MG HETATM 4008 CD CD 211 3.380 6.488 -27.905 0.91 47.98 CD HETATM 4009 O HOH 213 -0.304 4.175 -0.867 1.00 38.63 O HETATM 4010 MG MG 214 -17.505 21.323 11.148 1.00 36.28 MG HETATM 4011 MG MG 215 -1.702 7.910 -11.196 1.00 23.07 MG HETATM 4012 O HOH 216 -3.510 9.209 -16.056 1.00 43.93 O HETATM 4013 O HOH 217 -4.416 -0.858 -2.563 1.00 53.29 O HETATM 4014 O HOH 218 6.288 -5.327 -3.385 1.00 23.44 O HETATM 4015 O HOH 221 -1.778 1.682 -3.132 1.00 35.80 O HETATM 4016 O HOH 222 -6.849 10.117 -5.442 1.00 24.81 O HETATM 4017 MG MG 223 14.745 i -5.902 12.250 1.00 36.97 MG HETATM 4018 MG MG 225 19.765 i -8.266 10.030 1.00 41.29 MG HETATM 4019 MG MG 226 4.983 5.583 -14.224 1.00 17.24 MG HETATM 4020 HG HG 227 10.163 10.934 -4.731 0.10 21.14 HG HETATM 4021 MG MG 228 0.368 -4.197 15.065 1.00 49.67 MG HETATM 4022 HG HG 230 -4.955 2.266 -15.287 0.41 65.01 HG HETATM 4023 O HOH 232 17.184 -8.123 12.078 1.00 46.90 O HETATM 4024 O HOH 233 5.132 -9.156 11.493 1.00 39.77 O HETATM 4025 O HOH 235 -2.182 2.520 -0.424 1.00 32.75 O HETATM 4026 O HOH 236 3.337 3.950 -2.832 1.00 22.74 O HETATM 4027 O HOH 237 -0.294 3.992 -4.949 1.0041.19 O HETATM 4028 O HOH 238 3.987 7.706 -7.271 1.00 22.33 O HETATM 4029 O HOH 239 -2.682 1.061 -25.220 1.00 28.52 O HETATM 4030 O HOH 241 -0.901 -1.716 11.637 1.00 34.24 O HETATM 4031 O HOH 243 13.905 -12.456 1.182 1.00 61.18 O HETATM 4032 O HOH 244 -6.595 6.151 4.226 1.00 33.67 O HETATM 4033 O HOH 245 -10.614 11.084 18.691 1.00 47.29 O HETATM 4034 O HOH 246 2.153 6.645 -5.263 1.00 42.17 O HETATM 4035 O HOH 254 1.596 7.517 -28.596 1.00 20.43 O HETATM 4036 O HOH 255 5.496 5.982 -27.129 1.00 15.56 O HETATM 4037 O HOH 256 5.082 7.342 -29.082 1.00 15.30 O HETATM 4038 MG MG 257 4.272 8.284 -11.053 1.00 18.63 MG HETATM 4039 O HOH 258 5.759 9.095 -9.332 1.00 22.95 O HETATM 4040 O HOH 259 5.439 8.750 -13.001 1.00 29.22 O HETATM 4041 O HOH 260 3.112 6.893 -9.834 1.00 15.63 O HETATM 4042 O HOH 261 2.565 9.752 -1 1.319 1.00 21.45 O HETATM 4043 O HOH 262 2.003 -1.889 -6.293 1.00 39.08 O HETATM 4044 O HOH 263 6.523 -2.887 -3.470 1.00 31.47 O HETATM 4045 O HOH 264 5.691 -4.152 -6.413 1.00 49.36 O HETATM 4046 O HOH 265 13.164 -1.037 -13.541 1.00 53.81 O HETATM 4047 O HOH 266 1.658 -4.440 -6.534 1.00 54.55 O HETATM 4048 O HOH 267 4.147 -0.985 -10.097 1.00 21.21 O HETATM 4049 O HOH 268 7.729 0.998 -17.041 1.00 32.76 O HETATM 4050 O HOH 269 9.473 0.412 -15.439 1.00 22.86 O HETATM 4051 O HOH 270 5.281 1.436 -15.928 1.00 30.01 O HETATM 4052 O HOH 271 5.086 -1.392 -12.878 1.00 29.98 O HETATM 4053 O HOH 272 5.284 18.973 -15.526 1.00 29.56 O HETATM 4054 MG MG 273 5.268 8.632 9.371 1.00 35.80 MG HETATM 4055 O HOH 274 4.009 8.265 7.258 1.00 21.81 O HETATM 4056 O HOH 275 6.536 8.905 7.475 1.00 34.86 O - 147- SUBSTITUTESHEEr HETATM 4057 O HOH 276 3.058 8.060 9.657 1.0031.13 O HETATM 4058 O HOH 277 5.081 6.362 8.463 1.0031.02 O HETATM 4059 O HOH 278 3.600 10.499 8.517 1.0050.03 O HETATM 4060 CD CD 302 0.011 -4.071-53.3800.9131.52 CD HETATM 4061 O HOH 305 1.845 2.702-51.597 1.0014.19 O HETATM 4062 CD CD 311 4.100 -9.327-24.111 0.9176.29 CD HETATM 4063 O HOH 313 -1.010 -7.500-47.833 1.0040.72 O HETATM 4064 MG MG 318 1.219 3.097-48.942 1.0017.48 MG HETATM 4065 O HOH 322 -10.157 -13.890-44.431 1.0041.81 O HETATM 4066 MG MG 326 2.778 -7.878-38.005 1.0011.66 MG HETATM 4067 O HOH 327 9.652 -2.170-38.994 1.0044.35 O HETATM 4068 HG HG 332 -7.089 -5.545 -35.0060.6082.38 HG HETATM 4069 O HOH 333 1.493- -12.458-57.479 1.0039.19 O HETATM 4070 O HOH 335 -4.211 7.242-62.792 1.0049.93 O HETATM 4071 O HOH 336 -7.759 -5.212-49.585 1.0035.75 O HETATM 4072 O HOH 338 -3.953 -6.679-45.543 1.0038.41 O HETATM 4073 O HOH 339 0.508 - ■10.010-44.801 1.0028.38 O HETATM 4074 O HOH 340 -8.610 1.401 -65.472 1.0031.42 O HETATM 4075 O HOH 343 5.058 - ■ 10.891-43.391 1.0029.07 O HETATM 4076 O HOH 345 5.817- ■19.070-33.612 1.0035.77 O HETATM 4077 O HOH 346 8.758 - ■14.281-46.244 1.0040.41 O HETATM 4078 HG HG 347 6.715- ■ 12.669 -48.448 0.2054.24 HG HETATM 4079 O HOH 349 5.113- ■ 13.530-54.095 1.0042.05 O HETATM 4080 O HOH 352 6.195 -6.263-57.438 1.0039.69 O HETATM 4081 O HOH 353 12.125 3.149-49.649 1.0038.23 O HETATM 4082 MG MG 354 11.145 i 8.122-61.981 1.0029.67 MG HETATM 4083 O HOH 355 10.792 7.517-64.576 1.0068.09 O HETATM 4084 O HOH 356 12.630 7.721-60.264 1.0042.56 O HETATM 4085 O HOH 357 13.374 7.731-62.491 1.0044.36 O HETATM 4086 O HOH 358 8.902 7.560-61.857 1.0047.98 O HETATM 4087 MG MG 360 6.237 6.431-66.914 1.0028.74 MG HETATM 4088 O HOH 361 6.408 4.325-65.550 1.0056.01 O HETATM 4089 O HOH 362 8.361 5.765-66.746 1.0036.18 O HETATM 4090 O HOH 363 4.653 5.030-68.186 1.0040.11 O HETATM 4091 O HOH 364 7.146 6.368-64.453 1.0050.71 O HETATM 4092 MG MG 365 4.856 8.795-57.034 1.0057.29 MG HETATM 4093 O HOH 367 5.981 7.693-58.709 1.0045.32 O HETATM 4094 O HOH 368 2.602 9.503-57.044 1.0034.21 O HETATM 4095 O HOH 369 -3.740 -7.741-49.878 1.0034.52 O HETATM 4096 O HOH 371 -4.630 -7.088-47.848 1.0047.42 O HETATM 4097 O HOH 372 -1.660 -6.106-49.542 1.0029.15 O HETATM 4098 O HOH 373 -6.163 -7.124-50.377 1.0043.85 O HETATM 4099 O HOH 374 -4.330 -5.161-49.766 1.0036.71 O HETATM 4100 MG MG 375 -4.006 -10.777-39.969 1.0019.68 MG HETATM 4101 O HOH 376 -3.858 ■ -12.278-36.949 1.0028.95 O HETATM 4102 O HOH 377 -2.097 ■ -12.249-40.683 1.0038.24 O HETATM 4103 O HOH 378 -5.782 ■ -11.177-38.567 1.0048.85 O HETATM 4104 O HOH 379 -3.396 -9.585-37.760 1.0053.51 O . HETATM 4105 MG MG 380 1.544 -10.560-40.973 1.0015.03 MG HETATM 4106 O HOH 381 0.239 -9.278-41.992 1.0024.23 O HETATM 4107 O HOH 382 3.079 - •11.151 -39.552 1.0029.52 O - 148- SUB i HETATM 4108 O HOH 383 2.890 - -11.254 -42.623 1.00 28.59 O HETATM 4109 O HOH 384 0.497 ■ -12.218 -40.320 1.00 24.46 O HETATM 4110 MG MG 385 4.975 -3.399 -36.540 1.00 26.05 MG HETATM 4111 O HOH 386 4.351 -3.722 -38.893 1.00 47.91 O HETATM 4112 O HOH 387 6.538 -3.279 -34.525 1.00 52.58 O HETATM 4113 O HOH 388 6.829 -2.324 -37.582 1.00 23.58 O HETATM 4114 O HOH 389 2.776 -4.208 -36.379 1.00 47.45 O HETATM 4115 CD CD 390 -0.220 -0.169 -45.971 1.00 66.34 CD HETATM 4116 O HOH 391 1.204 0.456 -48.678 1.00 26.12 O HETATM 4117 O HOH 392 -2.039 -0.298 -44.457 1.00 74.79 O HETATM 4118 O HOH 394 -2.332 -1.375 -46.858 1.00 55.72 O HETATM 4119 O HOH 395 0.735 -1.415 -41.666 1.00 23.21 O HETATM 4120 O HOH 396 -2.289 1.508 -46.080 1.00 38.73 O HETATM 412 I MG MG 397 -1.117 -10.966 -60.412 1.00 36.18 MG HETATM 4122 O HOH 399 -2.144 -9.538 -58.861 1.00 29.70 O HETATM 4123 O HOH 400 1.112 - ■10.642 -59.923 1.00 66.19 O HETATM 4124 O HOH 401 -3.291 -10.503 -60.904 1.00 35.31 O HETATM 4125 O HOH 402 -2.294 -12.413 -59.078 1.00 39.66 O HETATM 4126 O HOH 403 -1.467 -8.797 -61.459 1.00 53.05 O HETATM 4127 O HOH 404 -12.040 -30.139 -41.430 1.00 41.13 O HETATM 4128 O HOH 405 -2.445 ■ -24.982 -35.646 1.00 41.49 O HETATM 4129 O HOH 406 -12.232 -9.609 -53.785 1.00 19.82 O HETATM 4130 O HOH 407 -10.736 -14.577 -49.559 1.00 27.37 O HETATM 4131 O HOH 408 -18.946 -19.067 -62.962 1.00 48.41 O HETATM 4132 O HOH 409 -19.414 -10.463 -60.502 1.00 52.79 O HETATM 4133 O HOH 410 -6.651 • -19.456 -54.939 1.00 26.78 O HETATM 4134 O HOH 411 -2.899 ■ -18.491 -49.891 1.00 31.34 O HETATM 4135 O HOH 412 -4.041 ■ -25.738 -47.368 1.00 61.51 O HETATM 4136 CD CD 413 -13.027 8.492 10.933 0.10 33.43 CD HETATM 4137 CD CD 414 -11.592 5.003 -2.412 0.10 14.13 CD HETATM 4138 HG HG 415 -23.456 -2.491 -20.626 0.10 35.19 HG HETATM 4139 HG HG 416 -17.183 -2.624 -19.816 0.10 45.02 HG HETATM 4140 O HOH 418 -0.113 29.557 -9.189 1.00 36.18 O HETATM 4141 O HOH 419 -1.958 16.568 4.135 1.00 22.82 O HETATM 4142 O HOH 420 0.874 15.995 -1.216 1.00 36.22 O HETATM 4143 O HOH 421 -0.098 21.800 -5.101 1.00 35.12 O HETATM 4144 O HOH 422 -1.412 23.130 -2.906 1.00 36.67 O HETATM 4145 O HOH 423 -3.317 24.792 0.592 1.00 45.31 O HETATM 4146 O HOH 424 0.019 9.295 -10.598 1.00 36.37 O HETATM 4147 O HOH 425 -2.568 8.364 -13.958 1.00 50.92 O HETATM 4148 O HOH 426 -2.689 18.373 -24.066 1.00 34.21 O HETATM 4149 O HOH 427 7.170 6.156 -29.910 1.00 17.29 O HETATM 4150 O HOH 428 8.929 4.171 -22.749 1.00 41.67 O HETATM 4151 O HOH 429 12.036 0.863 -14.965 1.00 42.52 O HETATM 4152 O HOH 431 -1.202 8.279 12.504 1.00 41.33 O HETATM 4153 O HOH 432 8.485 7.265 7.104 1.00 46.57 O HETATM 4154 O HOH 434 . 4.018 10.172 4.758 1.00 37.32 O HETATM 4155 O HOH 435 18.225 -9.006 -2.120 1.00 60.80 O HETATM 4156 MG MG 437 11.760 1 -10.915 4.311 1.00 47.79 MG HETATM 4157 O HOH 438 12.113 -10.561 1.951 1.00 58.11 O HETATM 4158 O HOH 440 14.043 -10.435 3.845 1.00 43.62 O - - 149- HETATM 4159 O HOH 441 9.524 ■ -10.398 4.381 1.00 41.20 O HETATM 4160 O HOH 442 11.946 -13.321 4.538 1.00 65.98 O HETATM 4161 O HOH 443 12.227 -8.461 4.164 1.00 61.70 O HETATM 4162 O HOH 444 1.040 4.817 -2.689 1.00 32.93 O HETATM 4163 O HOH 445 4.226 0.914 2.202 1.00 3.57 O HETATM 4164 O HOH 446 6.340 -0.071 1.151 1.00 19.50 O HETATM 4165 O HOH 447 4.234 3.232 1.596 1.00 12.18 O HETATM 4166 HG 1 HG 448 -4.015 -8.066 -15.150 0.10 21.04 HG HETATM 4167 O HOH 450 -4.907 -3.163 -52.1 17 1.00 24.48 O HETATM 4168 HG 1 HG 451 -5.485 5.932 ■ -35.358 0.10 26.20 HG HETATM 4169 O HOH 452 -4.427 1.650 - -44.668 1.00 47.88 O HETATM 4170 O HOH 453 -6.126 -4.197 -47.630 1.00 40.28 O HETATM 4171 O HOH 454 -14.902 -5.184 -53.399 1.00 41.04 O HETATM 4172 O HOH 455 2.198 - ■ 31.615 -45.895 1.00 38.45 O HETATM 4173 O HOH 456 -0.111 -29.053 -48.914 1.00 37.64 O HETATM 4174 O HOH 457 5.023 - ■28.677 -39.390 1.00 42.30 O HETATM 4175 O HOH 459 -8.700 -0.565 ■ -36.045 1.00 32.85 O HETATM 4176 O HOH 460 -1.593 -4.423 ■ -51.572 1.00 28.40 O HETATM 4177 O HOH 461 -1.729 -3.181 -53.813 1.00 2.00 O HETATM 4178 O HOH 462 -1.294 -5.593 -53.672 1.00 22.25 O HETATM 4179 O HOH 463 0.388 -1.958 - ■53.133 1.00 27.43 O MASTER 320 0 35 8 7 0 3 12 4175 4 0 32 END 150- SUBSTΠUTESHE

Claims: Claims: 1. A method for identifying a potential modulator of ribosomal protein Ll l/GAR activity, comprising the steps of: a. using a three-dimensional structure of the Ll l/GAR complex as defined by atomic coordinates of the LI 1/GAR according to Table II; b. employing said three-dimensional structure to design or select said potential modulator; c. providing said potential modulator; and d. contacting said potential modulator with LI 1/GAR in the presence of an activity to determine the ability of said potential modulator to modulate said activity. 2. The method according to claim 1, wherein said potential modulator is designed de novo. 3. The method according to claim 1, wherein said potential modulator is designed from a known modulator. 4. The method according to claim 1, wherein said step of employing said three-dimensional structure to design or select said compound comprises the steps of: a. identifying chemical entities or fragments capable of associating with said LI 1/GAR; and b. assembling the identified chemical entities or fragments into a single molecule to provide the structure of said potential modulator. 5. The method according to claim 4, wherein said potential modulator is designed de novo. 6. The method according to claim 4, wherein said potential modulator is designed from a known modulator. 7. A method for screening Ll l/GAR-binding compounds comprising the steps of: a. incubating in vitro one or more compounds, a known Ll l/GAR binding activity and labeled RNA comprising GAR RNA; b. separating that fraction of said labeled RNA bound to said known LI 1/GAR binding activity from that fraction of said labeled RNA not bound to said known LI 1/GAR binding - 151- activity; and c. detecting labeled RNA, wherein a decrease in the level of said labeled RNA bound to said known LI 1/GAR binding activity in the presence of said one or more compounds indicates the binding of said one or more compounds to LI 1/GAR. 8. A method for screening LI 1/GAR-binding compounds comprising the steps of: a. incubating in vitro one or more compounds, a labeled known LI 1/GAR binding activity and an RNA comprising GAR RNA; b. separating that fraction of said labeled known Ll l/GAR binding activity bound to said RNA from that fraction of said labeled known LI 1/GAR binding ctivity not bound to said RNA; and c. detecting labeled known LI 1/GAR binding activity wherein a decrease in the level of said labeled known LI 1/GAR binding activity bound to said RNA in the presence of said one or more compounds indicates that said one or more compounds binds LI 1/GAR. 9. The method of either one of claims 7 or 8 wherein said known LI 1/GAR binding activity is an antibiotic. 10. The method of claim 9 wherein said antibiotic is thiostrepton. 11. The method of claim 9 wherein said antibiotic is micrococcin. 12. The method of claim 8 wherein said RNA comprising GAR RNA is contained within a ribosome. 13. The method of any one of claims 7 - 12 wherein a plurality of compounds is screened for LI 1/GAR binding in a plurality of separate, simultaneous assays. 14. A method for screening Ll l/GAR-binding compounds comprising the steps of: a. incubating in vitro one or more compounds with a translationally competent cell extract and a translatable RNA; b. detecting translation, wherein a decrease in the level of translation indicates binding of said one or more compounds to LI 1/GAR. - 152- SUBSTπUTESHEET R 15. The method of claim 14 wherein said translatable RNA encodes an enzyme and wherein said step of detecting translation comprises detecting the activity of said enzyme. 16. The method of claim 15 wherein said enzyme is luciferase. 17. The method of claim 14 wherein said translatable RNA is poly-U, and said step of detecting translation detects the incoφoration of labeled phenylalanine into polyphenylalanine. 18. The method of any one of claims 14-17 wherein said translationally competent cell extract comprises isolated ribosomes. 19. A method for screening LI 1/GAR-binding compounds comprising the steps of: a. incubating in vitro one or more compounds, isolated 70S ribosomes, isolated EF-G and gamma-labeled GTP; b. detecting GTP hydrolysis wherein a decrease in GTP hydrolysis indicates said one or more compounds binds LI 1/GAR. 20. A method for screening anti-bacterial compounds comprising the steps of: a. incubating in vitro one or more compounds, a known Ll l/GAR binding activity and labeled RNA comprising GAR RNA; b. separating that fraction of said labeled RNA bound to said known LI 1/GAR binding activity from that fraction of said labeled RNA not bound to said known LI 1/GAR binding activity; and c. detecting labeled RNA, wherein a decrease in the level of said labeled RNA bound to said known Ll l /GAR binding activity in the presence of said one or more compounds indicates that one or more of said compounds has anti-bacterial properties. 21. A method for screening anti-bacterial compounds comprising the steps of: a. incubating in vitro one or more compounds, a labeled known LI 1/GAR binding activity and an RNA comprising GAR RNA; b. separating that fraction of said labeled known LI 1/GAR binding activity bound to said RNA from that fraction of said labeled known LI 1/GAR binding activity not bound to said - 153- UBSTITUTE SHEET (RULE RNA; and c. detecting labeled known LI 1/GAR binding activity wherein a decrease in the level of said labeled known LI 1/GAR binding activity bound to said RNA in the presence of said one or more compounds indicates that said one or more compounds has anti-bacterial properties. 22. The method of either one of claims 20 or 21 wherein said known L 11/GAR binding activity is an antibiotic. 23. The method of claim 22 wherein said antibiotic is thiostrepton. 24. The method of claim 22 wherein said antibiotic is micrococcin. 25. The method of claim 21 wherein said RNA comprising GAR RNA is contained within a ribosome. 26. The method of any one of claims 20-25 wherein a plurality of compounds are screened for anti-bacterial properties in a plurality of separate simultaneous assays. 27. A method for screening anti-bacterial compounds comprising the steps of: a. incubating in vitro one or more compounds with a translationally competent cell extract and a translatable RNA; b. detecting translation, wherein a decrease in the level of translation indicates said one or more compounds has anti-bacterial properties. 28. The method of claim 27 wherein said translatable RNA encodes an enzyme and wherein said step of detecting translation comprises detecting the activity of said enzyme. 29. The method of claim 28 wherein said enzyme is luciferase. 30. The method of claim 29 wherein said translatable RNA is poly-U, and said step of detecting translation detects the incoφoration of labeled phenylalanine into polyphenylalanine. 31. The method of any one of claims 27-30 wherein said translationally competent cell extract comprises isolated ribosomes. 32. A method for screening anti-bacterial compounds comprising the steps of: a. incubating in vitro one or more compounds, isolated bacterial ribosomes, isolated EF-G - 154- SUBSTITUTE SHEET (RULE26} and gamma-labeled GTP; b. detecting GTP hydrolysis wherein a decrease in GTP hydrolysis indicates said one or more compounds has anti-bacterial properties. - 155-

Inventors: RAMAKRISHNAN VENKI, WIMBERLY BRIAN T, RAMAKRISHNAN, VENKI, WIMBERLY, BRIAN, T.
Applicants: RAMAKRISHNAN VENKI, UNIV UTAH, WIMBERLY BRIAN T, RAMAKRISHNAN, VENKI, THE UNIVERSITY OF UTAH, WIMBERLY, BRIAN, T.
Application year: 2000
Main classification: A61K
IPC codes: A61P31, C12Q1, G01N33